PS18	O
Most	O
carriers	O
of	O
autosomal	O
recessive	O
spinal	BP
muscular	IP
atrophy-8	IP
have	O
only	O
one	O
copy	O
of	O
SMN1-14	BG
because	O
of	O
SMN1	BG
gene-18	IG
deletions	O
or	O
gene	O
conversions	O
from	O
SMN1-24	BG
to	O
SMN2-26	BG
,	O
which	O
has	O
only	O
one	O
base	O
difference	O
in	O
coding	O
sequence	O
from	O
SMN1-38	BG
.	O

PS24	O
First	O
,	O
mutations	O
within	O
the	O
C	BG
-	IG
terminal	IG
SH2	IG
region-10	IG
of	O
Ras	BG
GTPase	IG
-	IG
activating	IG
protein-16	IG
in	O
a	O
subset	O
of	O
basal	BP
cell	IP
carcinomas-23	IP
were	O
demonstrated	O
.	O

PS28	O
Mutations	O
in	O
the	O
megalencephalic	O
leukoencephalopathy-5	BP
with	O
subcortical	O
cysts1	BG
gene-9	IG
have	O
been	O
found	O
as	O
causative	O
of	O
megalencephalic	O
leukoencephalopathy-17	BP
with	O
subcortical	O
cysts	O
in	O
60	O
-	O
70	O
%	O
of	O
affected	O
subjects	O
,	O
without	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS29	O
Sequence	O
analysis	O
for	O
megalencephalic	O
leukoencephalopathy-5	BP
with	O
subcortical	O
cysts1	BG
gene-9	IG
revealed	O
a	O
compound	O
heterozygosity	O
for	O
two	O
mutations	O
in	O
megalencephalic	O
leukoencephalopathy-19	BP
with	O
subcortical	O
cysts1	BG
gene-23	IG
,	O
inherited	O
from	O
healthy	O
non	O
consanguineous	O
parents	O
.	O

PS39	O
Heterologous	O
expression	O
of	O
Cx40	BG
-	IG
Q58L-6	IG
in	O
connexin	O
-	O
deficient	O
neuroblastoma-11	BP
cells	O
resulted	O
in	O
marked	O
reduction	O
of	O
junctional	O
conductance	O
and	O
diffuse	O
localization	O
of	O
immunoreactive	O
proteins	O
in	O
the	O
vicinity	O
of	O
the	O
plasma	O
membrane	O
without	O
formation	O
of	O
gap-36	BG
junctions	O
.	O

PS59	O
An	O
autoimmune	BP
disease-3	IP
and	O
a	O
dramatic	O
increase	O
in	O
total	O
serum	O
IgE-11	BG
concentration	O
are	O
observed	O
in	O
BN	O
rats	O
that	O
are	O
chronically	O
injected	O
with	O
HgCl2	O
.	O

PS63	O
Seropositive	O
rheumatoid	BP
arthritis-3	IP
is	O
genetically	O
linked	O
to	O
a	O
group	O
of	O
HLA	BG
-	IG
DRB1	IG
alleles-14	IG
sharing	O
a	O
sequence	O
motif	O
within	O
the	O
third	O
hypervariable	O
region	O
.	O

PS70	O
The	O
description	O
of	O
heterozygosis	O
and	O
Val-6	BG
/	O
Val-8	BG
homozygosis	O
in	O
7	O
patients	O
with	O
Multibacillary	O
leprosy	O
and	O
thrombosis-17	BP
corroborates	O
the	O
implication	O
of	O
anomalous	O
phenotype	O
expression	O
of	O
beta2GP1-26	BG
and	O
development	O
of	O
anti	BG
-	IG
beta2GP1	IG
antibodies-33	IG
,	O
with	O
consequent	O
thrombosis-37	BP
and	O
APS	O
.	O

PS80	O
One	O
macular	O
corneal	BP
dystrophy-4	IP
type	O
I	O
subject	O
was	O
associated	O
with	O
a	O
novel	O
S51X-13	BG
homozygous	O
mutation	BG
in	IG
carbohydrate	IG
sulfotransferase	IG
6-19	IG
,	O
while	O
the	O
other	O
two	O
macular	O
corneal	BP
dystrophy-27	IP
type	O
I	O
subjects	O
harbored	O
a	O
previously	O
reported	O
W232X	O
homozygous	O
mutation	O
.	O

PS94	O
Hemopoietic	BG
histocompatibility	IG
Ag-3	IG
are	O
noncodominantly	O
expressed	O
on	O
bone	O
marrow	O
stem	O
cells	O
and	O
other	O
normal	O
and	O
neoplastic-16	BP
cells	O
of	O
hemopoietic	O
origin	O
.	O

PS102	O
Although	O
most	O
patients	O
with	O
hypogonadotropic	BP
hypogonadism-6	IP
can	O
be	O
treated	O
by	O
delivery	O
of	O
exogenous	O
pulsatile	O
GnRH-15	BG
,	O
in	O
several	O
cases	O
,	O
patients	O
with	O
GNRHR	O
mutations	O
fail	O
to	O
respond	O
efficiently	O
to	O
GnRH-30	BG
treatment	O
.	O

PS103	O
In	O
previous	O
studies	O
of	O
light	O
-	O
induced	O
and	O
age	O
-	O
related	O
retinal	BP
degeneration-13	IP
between	O
the	O
BALB	O
/	O
cByJ-18	BG
/	O
cByJ-20	BG
/	O
cByJ-22	BG
(	O
BALB-24	BG
/	O
cByJ-26	BG
)	O
and	O
B6	O
(	O
Cg	O
)	O
-	O
Tyr-34	BG
(	O
c	BG
-	IG
2J-38	IG
)	O
/	O
J	O
(	O
B6a	O
)	O
albino	O
mouse	O
strains	O
,	O
retinal	O
degeneration	O
-	O
modifying	O
quantitative	O
trait	O
loci	O
(	O
QTLs	O
)	O
were	O
identified	O
.	O

PS107	O
Further	O
studies	O
on	O
MHC	BG
class	IG
I	IG
and	IG
II	IG
genotype-9	IG
and	O
phenotype	O
relation	O
in	O
colorectal	BP
cancer-15	IP
may	O
help	O
to	O
identify	O
trigger	O
mechanisms	O
for	O
tumourigenesis	O
,	O
involved	O
markers	O
and	O
possible	O
mechanisms	O
of	O
subsequent	O
immune	O
escape	O
.	O

PS133	O
To	O
determine	O
the	O
frequency	O
of	O
primary	O
collagen	BG
VI-8	IG
deficiency	O
in	O
congenital	BP
muscular	IP
dystrophy-13	IP
in	O
Japan	O
and	O
to	O
establish	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS152	O
The	O
association	O
of	O
HLA	BG
-	IG
DRB1	IG
*-7	IG
15	O
with	O
susceptibility	O
to	O
multiple	BP
sclerosis-13	IP
has	O
been	O
consistently	O
reported	O
although	O
its	O
effect	O
on	O
the	O
clinical	O
phenotype	O
is	O
still	O
controversial	O
.	O

PS164	O
Melancholic	O
depression-2	BP
according	O
to	O
DSM	O
-	O
IV	O
criteria	O
is	O
converted	O
into	O
a	O
mixture	O
of	O
basic	O
symptom	O
dimensions	O
and	O
this	O
mixture	O
is	O
investigated	O
for	O
its	O
possible	O
links	O
with	O
familial	O
depression-29	BP
,	O
time	O
needed	O
for	O
complete	O
recovery	O
,	O
plasma	O
vasopressin-38	BG
-	O
concentration	O
,	O
correlated	O
plasma	O
vasopressin-44	BG
-	O
and	O
cortisolconcentrations	O
,	O
and	O
features	O
of	O
temperament	O
and	O
character	O
.	O

PS165	O
the	O
other	O
is	O
a	O
subtype	O
with	O
an	O
above	O
-	O
normal	O
plasma	O
vasopressin-12	BG
concentration	O
,	O
an	O
anxious	O
-	O
retarded	O
phenotype	O
without	O
an	O
intensity	O
threshold	O
,	O
correlated	O
vasopressin	O
-	O
and	O
cortisol	O
-	O
concentration	O
,	O
low	O
pre	O
-	O
morbid	O
cooperativeness	O
and	O
a	O
positive	O
family	O
history	O
of	O
depression-44	BP
.	O

PS168	O
Our	O
findings	O
indicate	O
that	O
the	O
frequency	O
of	O
RET	BG
somatic	IG
mutations-10	IG
is	O
similar	O
in	O
Japanese	O
and	O
Chinese	O
sporadic	O
medullary	BP
thyroid	IP
carcinomas-20	IP
,	O
and	O
the	O
presence	O
or	O
absence	O
of	O
RET	BG
mutation-29	IG
does	O
not	O
correlate	O
with	O
the	O
differentiation	O
of	O
sporadic	O
medullary	BP
thyroid	IP
carcinomas-40	IP
.	O

PS176	O
To	O
evaluate	O
the	O
contribution	O
of	O
HLA	BG
-	IG
DM	IG
alleles-9	IG
to	O
susceptibility	O
to	O
systemic	BP
lupus	IP
erythematosus-15	IP
in	O
a	O
Caucasian	O
population	O
.	O

PS177	O
HLA	BG
-	IG
DMA-3	IG
and	O
DMB	BG
alleles-6	IG
were	O
studied	O
in	O
73	O
patients	O
with	O
systemic	BP
lupus	IP
erythematosus-15	IP
,	O
147	O
randomly	O
selected	O
controls	O
,	O
and	O
86	O
HLA-24	BG
-	O
DRB1-26	BG
genotype	O
matched	O
controls	O
by	O
oligotyping	O
of	O
polymerase	O
chain	O
reaction	O
amplified	O
genomic	O
DNA	O
with	O
sequence	O
-	O
specific	O
oligonucleotide	O
probes	O
.	O

PS179	O
After	O
stratification	O
of	O
patients	O
and	O
matched	O
controls	O
according	O
to	O
DRB1	BG
genotypes-11	IG
,	O
only	O
HLA	BG
-	IG
DMA	IG
*	IG
0104-18	IG
was	O
increased	O
in	O
systemic	BP
lupus	IP
erythematosus-24	IP
patients	O
negative	O
for	O
the	O
systemic	BP
lupus	IP
erythematosus-31	IP
susceptibility	O
HLA	BG
-	IG
DR	IG
alleles-36	IG
.	O

PS180	O
For	O
the	O
patients	O
and	O
controls	O
positive	O
for	O
HLA	BG
-	IG
DR	IG
allele	IG
-	IG
susceptibility-13	IG
for	O
systemic	BP
lupus	IP
erythematosus-17	IP
,	O
HLA	BG
-	IG
DMA	IG
*	IG
0103-23	IG
,	O
DMA	BG
*	IG
0104-27	IG
,	O
DMB	BG
*	IG
0102-31	IG
,	O
and	O
DMB	O
*	O
0103	O
alleles	O
tended	O
to	O
be	O
more	O
frequent	O
,	O
but	O
without	O
reaching	O
statistical	O
significance	O
.	O

PS183	O
Our	O
results	O
suggest	O
that	O
HLA	BG
-	IG
DMA	IG
*	IG
0104-9	IG
may	O
represent	O
a	O
novel	O
allele	O
of	O
susceptibility	O
to	O
systemic	BP
lupus	IP
erythematosus-20	IP
.	O

PS188	O
To	O
investigate	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Chinese	O
familial	O
and	O
sporadic	O
hypertrophic	BP
cardiomyopathy-14	IP
,	O
specific	O
exons	O
of	O
the	O
myosin	BG
binding	IG
protein	IG
-	IG
c	IG
gene-25	IG
(	O
MYBPC3-27	BG
)	O
were	O
screened	O
in	O
six	O
families	O
with	O
hypertrophic	BP
cardiomyopathy-36	IP
and	O
in	O
20	O
patients	O
with	O
sporadic	O
hypertrophic	BP
cardiomyopathy-44	IP
from	O
the	O
Anhui	O
Province	O
region	O
of	O
China	O
.	O

PS200	O
We	O
present	O
a	O
detailed	O
transcript	O
map	O
of	O
the	O
MCOLN1	BG
gene-10	IG
region	O
that	O
includes	O
the	O
genes	O
KIAA0521	O
,	O
neuropathy-18	BP
target	O
esterase-20	BG
,	O
a	O
novel	O
zinc	BG
finger	IG
gene-26	IG
,	O
and	O
two	O
novel	O
transcripts	O
in	O
addition	O
to	O
MCOLN1	O
.	O

PS203	O
More	O
than	O
140	O
different	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
Cu	BG
/	IG
Zn	IG
superoxide	IG
dismutase	IG
-	IG
1-17	IG
gene	O
in	O
patients	O
with	O
amyotrophic	BP
lateral	IP
sclerosis-24	IP
,	O
some	O
occurring	O
as	O
founder	O
mutations	O
.	O

PS223	O
In	O
the	O
last	O
few	O
years	O
,	O
a	O
very	O
active	O
line	O
of	O
research	O
took	O
place	O
after	O
the	O
first	O
identification	O
of	O
SCN5A-20	BG
mutations	O
associated	O
with	O
an	O
inherited	O
form	O
of	O
cardiac	O
arrhythmias-29	BP
and	O
sudden	O
death	O
,	O
the	O
LQT3	BG
variant-36	IG
of	O
the	O
long	O
QT	O
syndrome	O
.	O

PS245	O
The	O
previously	O
described	O
CRYBA1	BG
mutation	IG
deltaG91-6	IG
was	O
demonstrated	O
in	O
two	O
Chinese	O
families	O
with	O
distinct	O
phenotypes	O
of	O
congenital	O
cataract-18	BP
,	O
suggesting	O
a	O
lack	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS246	O
To	O
describe	O
the	O
disease	O
course	O
in	O
patients	O
with	O
vitelliform	O
macular	BP
dystrophy-11	IP
with	O
a	O
Best1	BG
mutation-15	IG
and	O
to	O
determine	O
the	O
association	O
between	O
Best1	BG
genotype-23	IG
and	O
visual	O
prognosis	O
.	O

PS247	O
Ataxia	O
with	O
oculomotor	O
apraxia-4	BP
type	O
2	O
is	O
an	O
autosomal	O
recessive	O
disease	O
due	O
to	O
mutations	O
in	O
the	O
senataxin	BG
gene-18	IG
,	O
causing	O
progressive	O
cerebellar	BP
ataxia-23	IP
with	O
peripheral	BP
neuropathy-26	IP
,	O
cerebellar	BP
atrophy-29	IP
,	O
occasional	O
oculomotor	O
apraxia-33	BP
and	O
elevated	O
alpha	BG
-	IG
feto	IG
-	IG
protein-40	IG
serum	O
level	O
.	O

PS250	O
We	O
have	O
assessed	O
these	O
requirements	O
by	O
clonal	O
analysis	O
of	O
the	O
V1-11	BG
to	O
V3	BG
env-14	IG
PCR	O
products	O
of	O
26	O
patients	O
infected	O
with	O
subtype	O
B	O
human	O
immunodeficiency-25	BP
virus	O
type	O
1	O
.	O

PS253	O
Recent	O
studies	O
have	O
reported	O
germline	O
mutations	O
in	O
GATA4	BG
gene-9	IG
in	O
some	O
types	O
of	O
congenital	BP
heart	IP
disease-16	IP
.	O

PS275	O
To	O
analyze	O
the	O
retinoblastoma	BG
susceptibility	IG
gene-6	IG
for	O
mutations	O
in	O
retinoblastoma-10	BP
patients	O
and	O
correlate	O
the	O
genotypes	O
the	O
phenotypes	O
.	O

PS298	O
In	O
this	O
study	O
143	O
spinal	BP
muscular	IP
atrophy-7	IP
patients	O
have	O
been	O
genotyped	O
for	O
the	O
presence	O
or	O
absence	O
of	O
the	O
SMNt-19	BG
,	O
SMNc-21	BG
and	O
neuronal	BG
apoptosis	IG
inhibitory	IG
protein	IG
genes-27	IG
,	O
and	O
the	O
data	O
correlated	O
with	O
quantifiable	O
clinical	O
variables	O
.	O

PS304	O
To	O
determine	O
the	O
association	O
of	O
TaqIB	BG
polymorphism-7	IG
with	O
HDL	BG
-	IG
C-11	IG
levels	O
among	O
Filipinos	O
with	O
cardiovascular	BP
risk-17	IP
factors	O
.	O

PS313	O
Thus	O
,	O
we	O
investigated	O
the	O
impact	O
of	O
several	O
Cytochrome	BG
P450-10	IG
polymorphisms	O
on	O
coronary	O
endothelial	O
function	O
in	O
patients	O
with	O
coronary	BP
artery	IP
disease-21	IP
.	O

PS336	O
The	O
stable	O
fractions	O
of	O
glycated-5	BP
hemoglobin-6	BG
,	O
particularly-8	BP
hemoglobinA-9	BG
(	O
1c-11	BG
)	O
,	O
and	O
glycated-15	BP
albumin-16	BG
were	O
measured	O
to	O
monitor	O
chronic	O
glycemic	O
control	O
.	O

PS359	O
The	O
present	O
study	O
was	O
undertaken	O
to	O
examine	O
this	O
association	O
in	O
our	O
cohort	O
of	O
Fuchs	O
corneal	BP
dystrophy-16	IP
patients	O
,	O
to	O
assess	O
the	O
significance	O
of	O
this	O
finding	O
,	O
and	O
to	O
investigate	O
the	O
candidacy	O
of	O
TCF4-33	BG
in	O
the	O
context	O
of	O
the	O
mapped	O
Fuchs	O
corneal	BP
dystrophy2-42	IP
locus	O
.	O

PS367	O
A	O
large	O
number	O
of	O
mutations	O
in	O
genes	O
coding	O
for	O
sarcomeric	O
proteins	O
,	O
ie	O
the	O
beta	BG
-	IG
myosin	IG
heavy	IG
chain	IG
,	IG
cardiac	IG
troponin	IG
T	IG
,	IG
cardiac	IG
troponinI	IG
,	IG
alpha	IG
-	IG
tropomyosin-30	IG
,	O
myosin	BG
-	IG
binding	IG
protein	IG
C-36	IG
,	O
and	O
essential	O
and	O
regulatory	O
myosin	BG
light	IG
chains-44	IG
in	O
patients	O
with	O
Hypertrophic	O
cardiomyopathy-49	BP
have	O
been	O
identified	O
.	O

PS383	O
p16-1	BG
expression	O
proved	O
not	O
to	O
be	O
a	O
suitable	O
surrogate	O
marker	O
of	O
human	O
papilloma-13	BP
virus	O
high	O
-	O
risk	O
infection	O
in	O
oral	O
lesions	O
,	O
in	O
particular	O
in	O
basaloid	O
squamous	O
cell	O
carcinoma	O
.	O

PS387	O
After	O
NF2	O
inactivation	O
,	O
additional	O
events	O
may	O
occur	O
and	O
are	O
related	O
to	O
greater	O
aggressiveness-14	BP
,	O
such	O
as	O
loss	O
of	O
1p	O
,	O
14q	O
,	O
10	O
q	O
and	O
9p	O
chromosomes	O
,	O
reactivation	O
of	O
telomerase-32	BG
,	O
inactivation	O
of	O
the	O
p16-37	BG
/	O
CDKN2A-39	BG
gene	O
.	O

PS392	O
We	O
identified	O
PTPN11-3	BG
mutations	O
in	O
blood	O
or	O
bone	O
marrow	O
specimens	O
from	O
77	O
newly	O
reported	O
patients	O
with	O
juvenile	O
myelomonocytic	O
leukemia-19	BP
or	O
Noonan	O
syndrome	O
/	O
MPD	O
(	O
n	O
=	O
8	O
)	O
.	O

PS397	O
Patients	O
with	O
heterozygous	O
familial	O
hypercholesterolemia-5	BP
are	O
characterized	O
by	O
higher	O
levels	O
of	O
LDLP	BG
cholesterol-13	IG
,	O
lower	O
level	O
of	O
HDLP	BG
cholesterol-19	IG
and	O
higher	O
triglycerides	O
in	O
the	O
serum	O
than	O
in	O
healthy	O
controls	O
.	O

PS400	O
Exons	O
3	O
-	O
4	O
were	O
analyzed	O
for	O
mutations	O
in	O
281	O
mental	BP
retardation-12	IP
patients	O
(	O
aged	O
13	O
months	O
-	O
27	O
years	O
old	O
,	O
144	O
males	O
-	O
137	O
females	O
)	O
consisting	O
of	O
88	O
patients	O
referred	O
for	O
Rett	O
syndrome	O
and	O
193	O
patients	O
referred	O
for	O
AS	O
-	O
like	O
and	O
Fragile	BG
-	IG
X-48	IG
-	O
like	O
Syndrome	O
-	O
like	O
types	O
of	O
mental	BP
retardation-57	IP
.	O

PS408	O
Furthermore	O
,	O
we	O
demonstrated	O
loss	O
of	O
heterozygosity	O
at	O
markers	O
on	O
chromosome	O
9p	O
flanking	O
the	O
CDKN2A	BG
locus-16	IG
in	O
a	O
primary	O
melanoma-20	BP
and	O
a	O
metastasis	O
from	O
the	O
proband	O
.	O

PS437	O
Each	O
variant	O
of	O
Multiple	O
endocrine	O
neoplasia-6	BP
type	O
2	O
results	O
from	O
a	O
different	O
RET	BG
gene-14	IG
mutation	O
,	O
with	O
a	O
good	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS446	O
WIDER	O
IMPLICATIONS	O
OF	O
THE	O
FINDINGS	O
:	O
This	O
study	O
confirms	O
yet	O
again	O
the	O
importance	O
of	O
aurora	BG
kinase	IG
C	IG
gene-18	IG
mutations	O
in	O
the	O
aetiology	O
of	O
macrozoospermia-24	BP
.	O

PS450	O
To	O
clarify	O
the	O
role	O
of	O
alpha	BG
1	IG
-	IG
antitrypsin-9	IG
deficiency	O
in	O
the	O
acute	O
vasculitic	O
process	O
as	O
well	O
as	O
in	O
progression	O
of	O
the	O
disease	O
,	O
we	O
studied	O
84	O
patients	O
with	O
either	O
C	BG
-	IG
ANCA-33	IG
or	O
P	BG
-	IG
ANCA-37	IG
vasculitis-38	BP
with	O
special	O
reference	O
to	O
:	O
(	O
a	O
)	O
the	O
alpha	BG
1	IG
-	IG
antitrypsin	IG
gene-52	IG
,	O
(	O
b	O
)	O
the	O
phenotypic	O
variants	O
and	O
(	O
c	O
)	O
the	O
serum	O
levels	O
during	O
both	O
acute	O
illness	O
and	O
remission	O
.	O

PS452	O
These	O
results	O
indicate	O
:	O
(	O
a	O
)	O
a	O
high	O
incidence	O
of	O
the	O
phenotypicZ	BG
gene-14	IG
of	O
alpha	BG
1	IG
-	IG
antitrypsin-19	IG
in	O
systemic	O
vasculitis-22	BP
irrespective	O
of	O
the	O
type	O
of	O
autoantibodies	O
;	O

PS454	O
The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
the	O
Nppa-14	BG
and	O
Nppb	BG
genes-17	IG
in	O
the	O
development	O
of	O
hypertension-22	BP
in	O
the	O
SHR	O
.	O

PS463	O
Moreover	O
,	O
Gdnf	BG
-	IG
/	IG
-	IG
knockout	IG
mutant-8	IG
mice	O
display	O
congenital	BP
intestinal	IP
aganglionosis-13	IP
and	O
renal	BP
agenesis-16	IP
,	O
a	O
phenotype	O
very	O
similar	O
to	O
the	O
Ret	BG
-	IG
/	IG
-	IG
mouse-28	IG
.	O

PS469	O
Syncytium	O
-	O
inducing	O
,	O
CXCR4-5	BG
-	O
tropic	O
human	O
immunodeficiency-9	BP
virus	O
type	O
1	O
isolates	O
did	O
have	O
higher	O
relative	O
fitness	O
values	O
than	O
non	O
-	O
syncytium	O
-	O
inducing	O
,	O
CCR5	BG
-	IG
tropic	IG
human	IG
immunodeficiency	IG
virus	IG
type	IG
1-34	IG
isolates	O
,	O
as	O
determined	O
by	O
dual	O
virus	O
competitions	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
,	O
but	O
increases	O
in	O
fitness	O
during	O
disease	O
were	O
not	O
solely	O
powered	O
by	O
a	O
gradual	O
switch	O
in	O
coreceptor	O
usage	O
.	O

PS474	O
Apparent	O
mineralocorticoid	O
excess	O
AS	O
A	O
CAUSE	O
OF	O
HYPERTENSION	O
:	O
The	O
mutations	O
in	O
the	O
11	O
beta	O
-	O
Hydroxysteroid	O
dehydrogenase2	BG
gene-19	IG
,	O
together	O
with	O
those	O
currently	O
being	O
sought	O
by	O
us	O
for	O
other	O
kindreds	O
with	O
Apparent	O
mineralocorticoid	O
excess	O
,	O
establishes	O
Apparent	O
mineralocorticoid	O
excess	O
as	O
a	O
monogenic	O
cause	O
of	O
human	O
hypertension-47	BP
and	O
will	O
provide	O
insight	O
into	O
the	O
structure	O
-	O
function	O
relationships	O
of	O
this	O
important	O
enzyme	O
.	O

PS479	O
All	O
patients	O
with	O
MEN2-4	BG
have	O
medullary	O
thyroid	BP
carcinoma-8	IP
.	O

PS485	O
Mutations	O
in	O
the	O
cationic	O
trypsinogen	O
(	O
protease	O
,	O
serine	O
,	O
1	O
(	O
trypsin-13	BG
1	O
)	O
;	O
PRSS1-17	BG
)	O
gene	O
are	O
causally	O
associated	O
with	O
recurrent	O
acute	O
and	O
chronic	O
pancreatitis-28	BP
.	O

PS489	O
Genotype	O
-	O
phenotype	O
correlations	O
did	O
not	O
suggest	O
any	O
significant	O
difference	O
in	O
the	O
age	O
of	O
onset	O
,	O
severity	O
of	O
disease	O
,	O
or	O
pancreatic	BP
endocrine	IP
insufficiency-24	IP
in	O
patients	O
with	O
or	O
without	O
mutated	O
SPINK1-31	BG
and	O
irrespective	O
of	O
the	O
allelic	O
status	O
of	O
N34S	BG
SPINK1-40	IG
.	O

PS508	O
To	O
investigate	O
the	O
relation	O
of	O
HLA	BG
-	IG
DR	IG
alleles-9	IG
to	O
the	O
development	O
of	O
rheumatoid	BP
arthritis-15	IP
and	O
the	O
correlations	O
between	O
HLA	BG
-	IG
DR	IG
alleles-23	IG
and	O
clinical	O
manifestations	O
of	O
patients	O
with	O
rheumatoid	BP
arthritis-31	IP
in	O
Taiwan	O
.	O

PS509	O
The	O
HLA	BG
-	IG
DRB1	IG
alleles-5	IG
were	O
studied	O
in	O
144	O
patients	O
with	O
rheumatoid	BP
arthritis-13	IP
and	O
154	O
healthy	O
controls	O
using	O
polymerase	O
chain	O
reaction	O
/	O
sequence	O
specific	O
oligonucleotide	O
probe	O
methods	O
.	O

PS516	O
Each	O
variant	O
of	O
Multiple	O
endocrine	O
neoplasia-6	BP
type	O
2	O
results	O
from	O
different	O
RET	BG
gene-13	IG
mutation	O
,	O
with	O
a	O
good	O
genotype	O
phenotype	O
correlation	O
.	O

PS524	O
However	O
,	O
Hemoglobin	BG
H-4	IG
disease	O
may	O
occur	O
from	O
interactions	O
between	O
alpha	O
(	O
0	O
)	O
-	O
thalassemia	O
with	O
non	O
-	O
deletional	O
mutations	O
(	O
alpha	BG
(	IG
T	IG
)	IG
alpha-27	IG
or	O
alpha	BG
(	IG
T	IG
)-32	IG
)	O
or	O
with	O
abnormal-36	BP
hemoglobins-37	BG
such	O
as	O
Hb-40	BG
Constant	O
Spring	O
,	O
Hb	BG
Pakse-45	IG
,	O
Hb	BG
Quong	IG
Sze-49	IG
,	O
and	O
Hb	BG
Pak	IG
Num	IG
Po-55	IG
.	O

PS545	O
In	O
14	O
of	O
23	O
spinal	BP
muscular	IP
atrophy-7	IP
patients	O
with	O
two	O
SMN1-11	BG
copies	O
,	O
at	O
least	O
one	O
intact	O
SMN1-18	BG
copy	O
was	O
sequenced	O
,	O
which	O
excludes	O
a	O
5q	O
-	O
spinal	O
muscular	O
atrophy	O
and	O
suggests	O
the	O
existence	O
of	O
further	O
gene	O
(	O
s	O
)	O
responsible	O
for	O
approximately	O
4	O
%	O
-	O
5	O
%	O
of	O
phenotypes	O
indistinguishable	O
from	O
spinal	BP
muscular	IP
atrophy-55	IP
.	O

PS549	O
One	O
exception	O
is	O
the	O
identification	O
of	O
rare	O
heterozygous	O
mutations	O
of	O
the	O
FOXP2	BG
gene-13	IG
in	O
a	O
monogenic	O
syndrome	O
characterised	O
by	O
impaired	O
sequencing	O
of	O
articulatory	O
gestures	O
,	O
disrupting	O
speech	O
(	O
developmental	O
verbal	O
dyspraxia-31	BP
,	O
DVD	O
)	O
,	O
as	O
well	O
as	O
multiple	O
deficits	O
in	O
expressive	O
and	O
receptive	O
language	O
.	O

PS553	O
Extracellular	O
missense	O
mutations	O
and	O
in	O
-	O
frame	O
deletions	O
expressed	O
defective	O
FAS	BG
protein-12	IG
,	O
failed	O
to	O
bind	O
FAS	BG
ligand-18	IG
,	O
and	O
exhibited	O
dominant	O
-	O
negative	O
interference	O
with	O
FAS-27	BG
-	O
mediated	O
apoptosis-30	BP
.	O

PS569	O
In	O
conclusion	O
,	O
the	O
molecular	O
and	O
pathological	O
classification	O
of	O
hepatocellular	BP
adenomas-11	IP
permits	O
the	O
identification	O
of	O
strong	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
suggests	O
that	O
adenomas	O
with	O
beta	BG
-	IG
catenin-28	IG
activation	O
have	O
a	O
higher	O
risk	O
of	O
malignant	BP
transformation-36	IP
.	O

PS583	O
Triple	O
A	O
syndrome	O
,	O
also	O
known	O
as	O
Allgrove	O
syndrome	O
,	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
three	O
cardinal	O
symptoms	O
:	O
adrenal	BP
insufficiency-24	IP
due	O
to	O
ACTH-27	BG
insensitivity	O
,	O
achalasia	O
and	O
alacrima-32	BP
.	O

PS584	O
Our	O
data	O
give	O
new	O
insights	O
into	O
the	O
understanding	O
of	O
the	O
mechanisms	O
linking	O
invasion	O
and	O
E	BG
-	IG
cadherin-17	IG
mutations	O
in	O
diffuse	O
gastric	BP
cancer-22	IP
.	O

PS587	O
We	O
sought	O
to	O
determine	O
whether	O
plasma	O
H	O
(	O
e	O
)	O
concentration	O
or	O
methylenetetrahydrofolate	BG
reductase	IG
genotype-15	IG
would	O
be	O
more	O
strongly	O
associated	O
with	O
carotid	O
plaque	O
area	O
,	O
a	O
potential	O
intermediate	O
phenotype	O
of	O
atherosclerosis-31	BP
.	O

PS598	O
These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
the	O
DRD2	BG
gene-11	IG
in	O
obesity-13	BP
,	O
as	O
measured	O
by	O
percent	O
body	O
fat	O
as	O
well	O
as	O
by	O
weight	O
and	O
body	O
mass	O
index	O
.	O

PS602	O
The	O
breast	BP
cancer-3	IP
susceptibility	O
gene	O
BRCA2-6	BG
on	O
chromosome	O
13q12	O
-	O
13	O
has	O
recently	O
been	O
identified	O
.	O

PS605	O
Recent	O
studies	O
have	O
suggested	O
that	O
the	O
phenotype	O
in	O
BRCA1	BG
families-10	IG
with	O
respect	O
to	O
the	O
ratio	O
of	O
breast	O
to	O
ovarian	O
cancer-20	BP
varies	O
with	O
the	O
location	O
of	O
the	O
BRCA1	BG
mutation-28	IG
.	O

PS616	O
X	O
-	O
linked	O
hypophosphatemic	BP
rickets-5	IP
results	O
from	O
mutations	O
in	O
the	O
PHEX	BG
gene-12	IG
.	O

PS629	O
PTPN11-1	BG
mutations	O
are	O
the	O
only	O
genetic	BP
abnormalities-7	IP
reported	O
so	O
far	O
in	O
some	O
patients	O
with	O
NL	O
/	O
multiple	O
giant	O
cell	O
lesionsS	O
and	O
in	O
one	O
individual	O
with	O
LEOPARD	O
syndrome	O
and	O
multiple	O
giant	O
cell	O
lesions	O
.	O

PS642	O
In	O
conclusion	O
,	O
troponin	BG
-	IG
T	IG
mutations-7	IG
were	O
responsible	O
for	O
3	O
%	O
of	O
the	O
hypertrophic	BP
cardiomyopathy-16	IP
cases	O
in	O
our	O
study	O
population	O
.	O

PS644	O
Indeed	O
,	O
more	O
than	O
40	O
heterozygous	O
NKX2	BG
-	IG
5	IG
germline	IG
mutations-11	IG
have	O
been	O
observed	O
in	O
individuals	O
with	O
Congenital	BP
heart	IP
disease-20	IP
,	O
and	O
these	O
are	O
spread	O
along	O
the	O
coding	O
region	O
,	O
with	O
many	O
shown	O
to	O
impact	O
protein	O
function	O
.	O

PS650	O
Simple	O
linear	O
regression	O
analysis	O
showed	O
a	O
correlation	O
between	O
pretreatment	O
phenylalanine	O
concentrations	O
and	O
predicted	O
phenylalanine	BG
hydroxylase-15	IG
activity	O
in	O
29	O
Japanese	O
phenylketonuria-20	BP
patients	O
.	O

PS662	O
In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
prevalence	O
and	O
phenotype	O
/	O
genotype	O
correlation	O
of	O
connexin	BG
gene	IG
family	IG
variants-18	IG
in	O
a	O
cohort	O
of	O
children	O
with	O
nonsyndromic	O
hearing	BP
loss-27	IP
.	O

PS669	O
This	O
article	O
summarizes	O
the	O
present	O
knowledge	O
,	O
recent	O
developments	O
,	O
and	O
common	O
pitfalls	O
in	O
the	O
diagnosis	O
,	O
classification	O
,	O
and	O
genetics	O
of	O
hyperphenylalaninemia-23	BP
,	O
including	O
tetrahydrobiopterin-26	BG
(	O
BH4-28	BG
)	O
deficiency	O
.	O

PS673	O
Receptor	BG
tyrosine	IG
kinase-3	IG
single	O
nucleotide	O
polymorphisms	O
are	O
associated	O
with	O
the	O
Hirschsprung	BP
'-12	IP
s	O
disease	O
.	O

PS677	O
Recently	O
,	O
significant	O
improvements	O
in	O
methods	O
for	O
detection	O
of	O
mutations	O
have	O
paved	O
the	O
way	O
for	O
an	O
alternative	O
system	O
for	O
classification	BP
of-21	IP
Phenylalanine	BG
hydroxylase	IG
deficiency-24	IP
,	O
which	O
is	O
based	O
solely	O
on	O
Phenylalanine	BG
hydroxylase-32	IG
genotypes	O
.	O

PS678	O
Susceptibility	O
to	O
multiple	BP
sclerosis-4	IP
has	O
been	O
consistently	O
associated	O
with	O
the	O
Human	BG
Leukocyte	IG
Antigen-13	IG
-	O
DRB11501	O
genotype	O
,	O
however	O
effects	O
on	O
disease	O
severity	O
and	O
clinical	O
outcome	O
have	O
varied	O
in	O
different	O
populations	O
.	O

PS684	O
On	O
the	O
basis	O
of	O
an	O
analysis	O
of	O
published	O
cases	O
,	O
we	O
propose	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
increased	BP
seizure	IP
activity-21	IP
with	O
missense	O
TCF4-24	BG
mutations	O
.	O

PS707	O
We	O
reasoned	O
that	O
dominant	O
-	O
negative	O
effects	O
might	O
be	O
stronger	O
in	O
familial	BP
cancer-13	IP
cases	O
associated	O
with	O
germline	BG
TP53-18	IG
mutations	O
,	O
where	O
mutant	O
alleles	O
coexist	O
with	O
the	O
wild	O
-	O
type	O
allele	O
since	O
conception	O
.	O

PS732	O
The	O
results	O
of	O
studies	O
,	O
focused	O
on	O
the	O
correlation	O
between	O
tumour	O
genotype	O
and	O
the	O
histopathological	O
type	O
of	O
tumour	O
,	O
involving	O
cases	O
of	O
both	O
RET-24	BG
/	O
Papillary	O
thyroid	O
carcinoma	O
and	O
Trk	O
rearrangements	O
in	O
Papillary	O
thyroid	BP
carcinoma-35	IP
,	O
are	O
not	O
unequivocal	O
.	O

PS733	O
In	O
general	O
,	O
it	O
is	O
assumed	O
that	O
oncogenic	O
Trk	BG
sequences-10	IG
are	O
typical	O
for	O
the	O
spontaneous	O
type	O
of	O
Papillary	BP
thyroid	IP
carcinoma-20	IP
.	O

PS741	O
To	O
describe	O
the	O
clinical	O
phenotype	O
of	O
the	O
complete	O
type	O
of	O
X	O
-	O
linked	O
congenital	BP
stationary	IP
night	IP
blindness-17	IP
(	O
CSNB1-19	BG
)	O
with	O
different	O
types	O
of	O
mutations	O
in	O
the	O
NYX	BG
gene-29	IG
.	O

PS775	O
We	O
set	O
up	O
a	O
new	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
-	O
based	O
protocol	O
to	O
screen	O
patients	O
with	O
autosomal	O
dominant	O
hereditary	O
spastic	BP
paraplegia-23	IP
for	O
mutations	O
in	O
SPG4-27	BG
.	O

PS782	O
these	O
microdeletions	O
involve	O
recurrent	O
loss	O
of	O
three	O
non	O
-	O
overlapping	O
regions	O
designated	O
as	O
AZFa-14	BG
,	O
AZFb-16	BG
and	O
AZFc-18	BG
,	O
associated	O
with	O
spermatogenic	BP
failure-23	IP
.	O

PS785	O
We	O
identified	O
a	O
probable	O
causative	O
novel	O
myocilin	BG
gene-8	IG
missense	O
mutation	O
,	O
Gly326Ser	O
,	O
in	O
one	O
Popen	O
-	O
angle	O
glaucoma-19	BP
case	O
and	O
found	O
a	O
consistent	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
eight	O
of	O
his	O
relatives	O
.	O

PS795	O
Clinical	O
findings	O
include	O
:	O
developmental	BP
delay-6	IP
,	O
severe	O
behavioural	BP
disturbances-10	IP
,	O
growth	O
-	O
pubertal	O
retardation	O
,	O
congenital	O
conductive	O
mild	O
hearing	O
loss	O
,	O
growth	BG
hormone	IG
deficiency-25	IP
,	O
compensate	O
hypothyroidism-28	BP
,	O
dysmorphic	O
facial	O
features	O
,	O
excessive	O
joint	BP
hypermobility-36	IP
,	O
brachymetaphalangy	O
,	O
abnormal	O
dermatoglyphics	O
and	O
a	O
history	O
of	O
neonatal	BP
laryngomalacia-47	IP
,	O
hypotonia-49	BP
and	O
umbilical	O
hernia	O
.	O

PS808	O
These	O
results	O
indicate	O
the	O
presence	O
of	O
anti	BG
-	IG
R7V	IG
antibodies-10	IG
in	O
our	O
study	O
population	O
with	O
human	O
immunodeficiency-17	BP
virus	O
infection	O
.	O

PS811	O
The	O
finding	O
of	O
the	O
same	O
mutation	O
in	O
all	O
available	O
patients	O
,	O
together	O
with	O
the	O
previous	O
reports	O
of	O
the	O
disease	O
,	O
strongly	O
suggested	O
that	O
position	O
161	O
of	O
the	O
KRT9	BG
gene-29	IG
also	O
represents	O
a	O
mutation	O
"	O
hotspot	O
"	O
for	O
epidermolytic	BP
palmoplantar	IP
keratoderma-40	IP
.	O

PS819	O
From	O
initial	O
analyses	O
of	O
whole	O
exome	O
sequencing	O
data	O
,	O
we	O
identified	O
mutations	O
in	O
the	O
solute	O
carrier	O
organic	O
anion	BG
transporter	IG
family-20	IG
,	O
member	O
2A1	BG
(	IG
SLCO2A1	IG
)	IG
gene-27	IG
,	O
encoding	O
prostaglandin	O
transporter	O
,	O
in	O
3	O
of	O
the	O
Pachydermoperiostosis-37	BP
patients	O
.	O

PS820	O
We	O
found	O
that	O
SLCO2A1-4	BG
is	O
a	O
novel	O
gene	O
responsible	O
for	O
Pachydermoperiostosis-11	BP
.	O

PS829	O
Recently	O
,	O
different	O
point	O
mutations	O
and	O
base	O
pair	O
deletions	O
have	O
been	O
identified	O
in	O
the	O
rhodopsin	BG
gene-16	IG
in	O
a	O
proportion	O
of	O
patients	O
with	O
autosomal	O
dominant	O
retinitis	BP
pigmentosa-26	IP
,	O
providing	O
convincing	O
evidence	O
for	O
allelic	O
genetic	O
heterogeneity	O
in	O
this	O
disease	O
.	O

PS830	O
Since	O
the	O
identification	O
of	O
the	O
ATRX	BG
gene-7	IG
(	O
synonyms	O
XNP	O
,	O
XH2	O
)	O
in	O
1995	O
,	O
it	O
has	O
been	O
shown	O
to	O
be	O
the	O
disease	O
gene	O
for	O
numerous	O
forms	O
of	O
syndromal	O
X	O
-	O
linked	O
mental	BP
retardation-35	IP
[	O
X	O
-	O
linked	O
alpha	O
thalassemia	O
/	O
mental	O
retardation	O
(	O
ATR	BG
-	IG
X-48	IG
)	O
syndrome	O
,	O
Carpenter	O
syndrome	O
,	O
Juberg	O
-	O
Marsidi	O
syndrome	O
,	O
Smith	O
-	O
Fineman	O
-	O
Myers	O
syndrome	O
,	O
X	O
-	O
linked	O
mental	BP
retardation-71	IP
with	O
spastic	BP
paraplegia-74	IP
]	O
.	O

PS835	O
MIBI	O
scintigraphy	O
has	O
been	O
shown	O
to	O
be	O
a	O
non	O
-	O
invasive	O
cost	O
-	O
effective	O
in	O
vivo	O
assay	O
of	O
ATP	BG
-	IG
binding	IG
cassette	IG
transporters-23	IG
associated	O
with	O
multidrug	O
resistance	O
in	O
cancer-29	BP
,	O
including	O
P	BG
-	IG
glycoprotein-34	IG
,	O
multidrug	BG
-	IG
resistant	IG
protein	IG
1-40	IG
and	O
breast	BG
cancer	IG
resistant	IG
protein-45	IG
.	O

PS846	O
This	O
study	O
shows	O
an	O
association	O
between	O
IL23R-7	BG
and	O
all	O
subphenotypes	O
of	O
Crohn	O
'	O
s	O
disease	O
with	O
a	O
smaller	O
effect	O
on	O
ulcerative	O
colitis-22	BP
.	O

PS848	O
The	O
absence	O
of	O
platelet	BG
surface	IG
glycoprotein	IG
IIb	IG
-	IG
IIIa	IG
complexes-10	IG
confirmed	O
the	O
clinical	O
diagnosis	O
of	O
Glanzmann	O
'	O
s	O
thrombasthenia-19	BP
.	O

PS851	O
None	O
of	O
the	O
patients	O
with	O
DLPIII	O
had	O
tuberous	O
or	O
palmar	O
xanthomas-11	BP
characteristic	O
of	O
classically	O
defined	O
type	BG
III	IG
hyperlipoproteinemia-18	IG
.	O

PS878	O
Analysis	O
of	O
the	O
killer	BG
cell	IG
immunoglobulin	IG
-	IG
like	IG
receptor-9	IG
genotype	O
in	O
correlation	O
with	O
the	O
corresponding	O
killer	BG
cell	IG
immunoglobulin	IG
-	IG
like	IG
receptor	IG
-	IG
L	IG
profile-24	IG
,	O
revealed	O
a	O
decreased	O
frequency	O
of	O
stimulatory	O
2DS1-32	BG
/	O
C2-34	BG
mismatch	O
both	O
in	O
anemia-38	BP
and	O
myelosysplastic	O
syndromes	O
.	O

PS896	O
Here	O
we	O
present	O
a	O
mutation	O
analysis	O
and	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
study	O
on	O
the	O
gene	BG
encoding	IG
otoferlin-18	IG
,	O
responsible	O
for	O
the	O
DFNB9	O
subtype	O
of	O
prelingual	BP
hearing-27	IP
impairment	O
.	O

PS906	O
We	O
report	O
on	O
nine	O
patients	O
of	O
European	O
origin	O
affected	O
by	O
the	O
cblE-12	BG
type	O
of	O
homocystinuria-15	BP
.	O

PS908	O
Using	O
this	O
approach	O
,	O
we	O
sought	O
for	O
the	O
minor	O
histocompatibility	O
antigens	O
recognized	O
by	O
a	O
HLA	BG
-	IG
DRB1	IG
*-18	IG
1501	O
-	O
restricted	O
T	O
-	O
cell	O
clone	O
,	O
isolated	O
from	O
a	O
multiple	O
myeloma-31	BP
patient	O
during	O
a	O
strong	O
graft	O
-	O
versus	O
-	O
tumor	O
effect	O
associated	O
with	O
acute	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
grade	O
3	O
.	O

PS909	O
The	O
phenotype	O
of	O
surviving	O
offspring	O
was	O
determined	O
by	O
zoxazolamine	O
paralysis-10	BP
time	O
and	O
hepatic-13	BP
aryl	BG
hydrocarbon	IG
hydroxylase-16	IG
activity	O
measurements	O
.	O

PS913	O
To	O
investigate	O
the	O
expression	O
of	O
pepsinogen	BG
A3-7	IG
encoding	O
genes	O
in	O
the	O
gastric	O
mucosa	O
of	O
normal	O
controls	O
and	O
subjects	O
with	O
atrophic	O
gastritis-21	BP
and	O
gastric	O
cancer-24	BP
.	O

PS916	O
Unexpressed	O
pepsinogen	BG
A3	IG
encoding	IG
genes-5	IG
can	O
be	O
shown	O
in	O
many	O
cases	O
of	O
atrophic	O
gastritis-14	BP
and	O
gastric	O
cancer-17	BP
,	O
but	O
rarely	O
in	O
healthy	O
controls	O
and	O
subjects	O
with	O
superficial	O
gastritis-28	BP
.	O

PS921	O
To	O
investigate	O
the	O
association	O
of	O
tumor	BG
necrosis	IG
factor-8	IG
microsatellite	O
alleles	O
with	O
the	O
pathogenesis	O
of	O
rheumatoid	BP
arthritis-16	IP
in	O
Taiwan	O
.	O

PS924	O
The	O
phenotypic	O
frequency	O
of	O
tumor	BG
necrosis	IG
factora3	IG
-	IG
e1-9	IG
was	O
significantly	O
lower	O
in	O
DR4	O
(	O
+	O
)	O
rheumatoid	BP
arthritis-19	IP
patients	O
than	O
in	O
DR4	O
(	O
+	O
)	O
controls	O
,	O
while	O
a	O
negative	O
linkage	O
disequilibrium	O
was	O
noted	O
between	O
tumor	BG
necrosis	IG
factora3	IG
-	IG
e1-41	IG
and	O
HLA	BG
-	IG
DR4-45	IG
.	O

PS953	O
We	O
have	O
found	O
that	O
VCX	BG
-	IG
A-7	IG
is	O
retained	O
in	O
all	O
patients	O
with	O
normal	O
intelligence	O
and	O
is	O
deleted	O
in	O
all	O
patients	O
with	O
mental	BP
retardation-24	IP
.	O

PS954	O
We	O
have	O
found	O
that	O
VCX	BG
-	IG
A-7	IG
is	O
retained	O
in	O
all	O
patients	O
with	O
normal	O
intelligence	O
and	O
is	O
deleted	O
in	O
all	O
patients	O
with	O
mental	BP
retardation-24	IP
.	O

PS955	O
To	O
study	O
the	O
cardiac	O
troponin	BG
T-6	IG
(	O
TNNT2-8	BG
)	O
gene	O
mutation	O
in	O
Chinese	O
patients	O
with	O
hypertrophic	BP
cardiomyopathy-17	IP
and	O
to	O
analyze	O
the	O
correlation	O
between	O
the	O
genotype	O
and	O
phenotype	O
.	O

PS959	O
We	O
investigated	O
the	O
association	O
between	O
Xeroderma	BG
pigmentosum	IG
group	IG
G-9	IG
/	O
ERCC5-11	BG
polymorphisms	O
and	O
risk	O
of	O
squamous	BP
cell	IP
carcinoma-18	IP
of	O
the	O
head	O
and	O
neck	O
.	O

PS963	O
These	O
findings	O
suggest	O
that	O
genetic	O
variation	O
in	O
Xeroderma	BG
pigmentosum	IG
group	IG
G-11	IG
/	O
ERCC5-13	BG
may	O
not	O
affect	O
the	O
risk	O
of	O
squamous	BP
cell	IP
carcinoma-22	IP
of	O
the	O
head	O
and	O
neck	O
,	O
although	O
rs4150351	BG
C	IG
variant	IG
genotypes-33	IG
were	O
associated	O
with	O
an	O
increased	O
expression	O
of	O
Xeroderma	BG
pigmentosum	IG
group	IG
G-44	IG
/	O
ERCC5	BG
mRNA-47	IG
and	O
nonsignificantly	O
decreased	O
risk	O
of	O
squamous	BP
cell	IP
carcinoma-55	IP
of	O
the	O
head	O
and	O
neck	O
.	O

PS965	O
Parameters	O
associated	O
with	O
higher	O
random	O
C	O
-	O
peptide	O
were	O
lower-10	BP
hemoglobin	BG
A1C-12	IG
,	O
older	O
age	O
of	O
onset	O
,	O
higher	O
frequency	O
of	O
HLA	BG
DR3	IG
genotype-24	IG
,	O
and	O
responsiveness	O
to	O
a	O
mixed	O
-	O
meal	O
tolerance	O
test	O
.	O

PS973	O
Disruption	O
of	O
peroxisome	BG
proliferator-4	IG
activated	O
receptor	BG
-	IG
gamma-8	IG
in	O
myeloid	O
cells	O
impairs	O
alternative	O
macrophage	O
activation	O
,	O
and	O
predisposes	O
these	O
animals	O
to	O
development	O
of	O
diet	O
-	O
induced	O
obesity-27	BP
,	O
insulin	BG
resistance-30	IP
,	O
and	O
glucose	O
intolerance	O
.	O

PS974	O
Using	O
the	O
T	BG
-	IG
bet-5	IG
-	O
deficient	O
(	O
T	O
-	O
bet	O
(	O
-	O
/	O
-	O
)	O
)	O
murine	O
model	O
of	O
asthma-21	BP
and	O
the	O
natural	O
murine	O
pathogen	O
Mycoplasma	O
pulmonis	O
,	O
we	O
provide	O
a	O
mechanistic	O
explanation	O
for	O
this	O
correlation	O
.	O

PS981	O
Genotype	O
-	O
phenotype	O
correlation	O
studies	O
suggest	O
that	O
mutations	O
in	O
the	O
beta	BG
-	IG
myosin	IG
heavy	IG
chain	IG
gene-16	IG
are	O
associated	O
with	O
more	O
extensive	O
hypertrophy	O
and	O
a	O
higher	O
risk	O
of	O
sudden	BP
cardiac	IP
death-30	IP
as	O
compared	O
to	O
mutations	O
in	O
genes	O
coding	O
for	O
other	O
sarcomeric	O
proteins	O
,	O
such	O
as	O
myosin	BG
binding	IG
protein	IG
-	IG
C-49	IG
and	O
cardiac	BG
troponin	IG
T-53	IG
.	O

PS997	O
Our	O
findings	O
support	O
that	O
homozygous	O
genotype	O
of	O
methylene	BG
tetrahydrofolate	IG
reductase-10	IG
is	O
a	O
genetic	O
risk	O
factor	O
for	O
coronary	BP
artery	IP
disease-19	IP
.	O

PS999	O
PURPOSE	BG
Heat	IG
-	IG
shock	IG
protein	IG
27-6	IG
,	O
encoded	O
by	O
HSPB1-10	BG
,	O
plays	O
crucial	O
roles	O
in	O
tumorigenesis	O
and	O
cell	O
survival	O
and	O
is	O
reported	O
to	O
be	O
an	O
independent	O
prognosis	O
marker	O
for	O
cancer-30	BP
.	O

PS1010	O
Moreover	O
,	O
we	O
systematically	O
evaluated	O
all	O
case	O
reports	O
of	O
sporadic	O
non	O
-	O
autoimmune	BP
hyperthyroidism-14	IP
for	O
evidence	O
of	O
an	O
association	O
of	O
the	O
clinical	O
course	O
with	O
the	O
in	O
vitro	O
activity	O
of	O
the	O
mutated	BG
TSH	IG
receptor-33	IG
.	O

PS1023	O
To	O
date	O
we	O
have	O
identified	O
65	O
missense	O
mutations	O
in	O
the	O
GALNS	BG
gene-12	IG
from	O
Mucopolysaccharidosis-14	BP
IVA	O
patients	O
,	O
but	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
has	O
remained	O
unclear	O
.	O

PS1033	O
During	O
the	O
past	O
decade	O
,	O
more	O
than	O
100	O
mutations	O
in	O
11	O
causal	O
gene	O
coding	O
for	O
sarcomeric	O
proteins	O
,	O
the	O
gamma	O
subunit	O
of	O
AMP	BG
-	IG
activated	IG
protein	IG
kinase-27	IG
and	O
triplet	O
-	O
repeat	O
syndromes	O
and	O
in	O
mitochondrial	O
DNA	O
,	O
have	O
been	O
identified	O
in	O
patients	O
with	O
hypertrophic	BP
cardiomyopathy-45	IP
.	O

PS1041	O
In	O
our	O
country	O
,	O
the	O
genetic	O
diagnosis	O
of	O
adult	O
patients	O
with	O
hereditary	O
hypokalaemic	BP
tubulopathies-14	IP
should	O
include	O
a	O
screening	O
of	O
A204T	O
mutation	O
in	O
the	O
CLCNKB	BG
gene-25	IG
.	O

PS1049	O
The	O
assumed	O
weak	O
association	O
of	O
the	O
TT	O
-	O
genotype	O
of	O
the	O
CD14	BG
promoter-13	IG
polymorphism	O
with	O
myocardial	BP
infarction-17	IP
could	O
not	O
be	O
not	O
established	O
in	O
a	O
well	O
-	O
defined	O
group	O
of	O
young	O
patients	O
with	O
a	O
high	O
genetic	O
risk	O
.	O

PS1070	O
The	O
histogram	O
of	O
the	O
combined	O
population	O
cohort	O
showed	O
a	O
bimodal	O
distribution	O
of	O
thiopurine	BG
methyltransferase-14	IG
activity	O
,	O
with	O
no	O
subject	O
having	O
low-21	BP
thiopurine	BG
methyltransferase	IG
activity-24	IP
(	O
<	O
5	O
units	O
)	O
.	O

PS1076	O
Pure	O
tone	O
audiograms	O
of	O
63	O
unrelated	O
probands	O
with	O
GJB2-9	BG
-	O
associated	O
hearing	BP
loss-13	IP
having	O
15	O
different	O
mutations	O
were	O
obtained	O
and	O
evaluated	O
for	O
correlation	O
between	O
the	O
degree	O
of	O
hearing	BP
loss-29	IP
and	O
genotypes	O
.	O

PS1081	O
The	O
purpose	O
of	O
this	O
study	O
to	O
assess	O
for	O
PAX6-9	BG
mutation	O
in	O
two	O
unrelated	O
families	O
with	O
classic	BP
hereditary	IP
aniridia-18	IP
from	O
the	O
Arabian	O
Peninsula	O
.	O

PS1083	O
The	O
factors	O
that	O
whether	O
and	O
how	O
genes	O
involving	O
lipid	O
metabolism	BG
including	IG
lipoprotein	IG
lipase-13	IG
and	O
apolipoprotein	BG
CII-16	IG
influence	O
occurrence	O
of	O
acute	O
attack	O
of	O
pancreatitis-23	BP
and	O
chronic	O
pancreatitis-26	BP
is	O
not	O
clear	O
.	O

PS1094	O
It	O
was	O
suspected	O
that	O
the	O
patient	O
was	O
suffering	O
from	O
chondrodysplasia-10	BP
punctata	O
because	O
of	O
a	O
loss	O
of	O
the	O
arylsulfatase	BG
E-19	IG
gene	O
.	O

PS1105	O
Studying	O
the	O
20	O
exons	O
of	O
the	O
RET	BG
gene-8	IG
by	O
a	O
combination	O
of	O
denaturating	O
gradient	O
gel	O
electrophoresis	O
and	O
single	O
strand	O
conformation	O
polymorphism	O
in	O
a	O
large	O
series	O
of	O
Hirschsprung	BP
disease-28	IP
patients	O
(	O
45	O
sporadic	O
cases	O
and	O
35	O
familial	O
forms	O
)	O
,	O
we	O
found	O
mutations	O
of	O
the	O
RET	BG
gene-46	IG
in	O
50	O
%	O
of	O
familial	O
Hirschsprung	BP
disease-53	IP
,	O
regardless	O
of	O
the	O
length	O
of	O
the	O
aganglionic	O
segment	O
.	O

PS1121	O
The	O
phenotype	O
/	O
genotype	O
correlation	O
demonstrates	O
the	O
broad	O
phenotypic	O
range	O
of	O
low	O
-	O
level	O
45	O
,	O
X	O
mosaicism	O
with	O
the	O
resultant	O
short	BP
stature-23	IP
and	O
external	O
female	O
phenotype	O
,	O
despite	O
the	O
presence	O
of	O
SRY-33	BG
in	O
a	O
high	O
proportion	O
of	O
cells	O
in	O
various	O
tissues	O
.	O

PS1123	O
The	O
study	O
failed	O
to	O
show	O
the	O
influence	O
of	O
any	O
particular	O
apolipoprotein	BG
E	IG
genotype-13	IG
on	O
disease	O
severity	O
,	O
with	O
specifically	O
apolipoprotein	BG
E	IG
epsilon4-22	IG
being	O
no	O
more	O
common	O
in	O
the	O
milder	O
spinal	BP
muscular	IP
atrophy-32	IP
forms	O
and	O
apolipoprotein	BG
E	IG
epsilon2-37	IG
not	O
over	O
represented	O
in	O
type	O
I	O
spinal	BP
muscular	IP
atrophy-46	IP
.	O

PS1129	O
The	O
polymorphisms	O
of	O
TFRC	O
in	O
424G	O
/	O
A	O
and	O
-	O
5184C	O
/	O
T	O
sites	O
were	O
not	O
associated	O
with	O
susceptibility	O
to	O
IgA-21	BG
nephropathy-22	BP
,	O
but	O
associated	O
with	O
density	O
of	O
immunofluorescence	O
of	O
IgA-31	BG
in	O
mesangium	O
in	O
our	O
large	O
population	O
based	O
Chinese	O
patients	O
.	O

PS1137	O
All	O
six	O
patients	O
with	O
mutation	O
P30L	O
,	O
V281L	O
,	O
or	O
P453S-11	BG
(	O
homozygous	O
or	O
compound	O
heterozygous	O
)	O
had	O
nonclassic	O
Congenital	BP
adrenal	IP
hyperplasia-22	IP
.	O

PS1138	O
In	O
conclusion	O
,	O
UGT1A1-4	BG
polymorphisms	O
modulate	O
the	O
hepatic	O
metabolism	O
of	O
the	O
carcinogenic	O
intermediate	O
of	O
2	O
-	O
amino	O
-	O
1	O
-	O
methyl	O
-	O
6	O
-	O
phenylimidazo	O
[	O
4	O
,	O
5	O
-	O
f	O
]	O
pyridine	O
and	O
may	O
determine	O
the	O
level	O
of	O
its	O
exposure	O
and	O
potentially	O
influence	O
the	O
risk	O
of	O
cancer-48	BP
through	O
dietary	O
exposure	O
to	O
HCAs	O
.	O

PS1150	O
However	O
,	O
Cystic	BG
fibrosisTR-4	IG
messenger	O
ribonucleic	O
acid	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
electrophysiological	O
properties	O
or	O
Shwachman	O
scores	O
obtained	O
from	O
Cystic	BP
fibrosis-22	IP
patients	O
.	O

PS1164	O
Mutations	O
in	O
the	O
dysferlin	BG
gene-5	IG
on	O
chromosome	O
2p13	O
cause	O
distinct	O
phenotypes	O
of	O
muscular	BP
dystrophy-14	IP
:	O
limb	O
-	O
girdle	O
muscular	BP
dystrophy-20	IP
type	O
2B	O
,	O
Miyoshi	O
myopathy	O
,	O
and	O
distal	O
anterior	O
compartment	O
myopathy-31	BP
,	O
which	O
are	O
known	O
by	O
the	O
term	O
'	O
dysferlinopathy	O
'	O
.	O

PS1169	O
Loci	O
on	O
chromosome	O
4	O
near	O
Lv	O
and	O
on	O
chromosome	O
6	O
near	O
Tnfr1-12	BG
are	O
associated	O
with	O
resistance	O
to	O
coccidioidomycosis-18	BP
in	O
mice	O
.	O

PS1171	O
These	O
results	O
suggest	O
that	O
a	O
locus	O
near	O
Lv-8	BG
is	O
responsible	O
for	O
early	BP
resistance-13	IP
to	O
coccidioidomycosis	O
but	O
not	O
for	O
modulating	O
the	O
interleukin	BG
-	IG
10-23	IG
and	O
interleukin	BG
-	IG
4-27	IG
responses	O
.	O

PS1178	O
In	O
addition	O
to	O
the	O
discovery	O
of	O
X	O
-	O
linked	O
recessive	O
hypomorphic	O
mutations	O
in	O
NFkappaB-14	BG
essential	O
modulator	O
as	O
the	O
cause	O
of	O
anhidrotic	O
ectodermal	BP
dysplasia-23	IP
with	O
immunodeficiency	O
,	O
autosomal	O
-	O
dominant	O
hypermorphic	O
mutations	O
in	O
inhibitor	BG
of	IG
nuclear	IG
factor	IG
kappaB-37	IG
alpha	O
have	O
been	O
described	O
recently	O
.	O

PS1183	O
We	O
previously	O
reported	O
linkage	O
of	O
the	O
locus	O
for	O
central	O
areolar	O
choroidal	BP
dystrophy-12	IP
in	O
this	O
family	O
to	O
an	O
interval	O
of	O
approximately	O
5	O
cM	O
on	O
chromosome	O
17p13	O
flanked	O
by	O
polymorphic	O
markers	O
D17S1810	O
and	O
CHLC	BG
GATA7B03-33	IG
.	O

PS1188	O
Junctional	O
epidermolysis	O
bullosa	O
with	O
pyloric	BP
atresia-6	IP
is	O
an	O
autosomal	O
recessive	O
disorder	O
resulting	O
from	O
mutations	O
in	O
the	O
genes	O
encoding	O
alpha	BG
6	IG
beta	IG
4	IG
integrin-23	IG
(	O
ITGA6-25	BG
and	O
ITGB4-27	BG
)	O
.	O

PS1203	O
By	O
using	O
matrices	O
of	O
correlation	O
coefficients	O
we	O
tested	O
the	O
genetic	O
effect	O
of	O
a	O
variant	O
within	O
the	O
gene	O
encoding	O
the	O
beta3	BG
-	IG
subunit-22	IG
of	O
heterotrimeric	BG
G	IG
-	IG
proteins-27	IG
(	O
Gbeta3-29	BG
-	O
C825T	O
polymorphism	O
)	O
on	O
posttransplant	O
hypertension-36	BP
and	O
kidney	BP
allograft	IP
function-40	IP
.	O

PS1206	O
We	O
determined	O
the	O
nucleotide	O
sequence	O
of	O
the	O
Melanocortin	BG
4	IG
receptor	IG
gene-11	IG
in	O
500	O
probands	O
with	O
severe	O
childhood	O
obesity-18	BP
.	O

PS1222	O
Since	O
the	O
discovery	O
of	O
these	O
genes	O
,	O
studies	O
have	O
been	O
performed	O
in	O
which	O
the	O
pathological	O
characteristics	O
of	O
familial	BP
cancers-19	IP
arising	O
in	O
patients	O
with	O
germline	O
BRCA1-25	BG
and	O
BRCA2	BG
mutation-28	IG
have	O
been	O
examined	O
.	O

PS1223	O
A	O
distinct	O
pathological	O
phenotype	O
of	O
high	O
-	O
grade	O
,	O
oestrogen	O
receptor	O
-	O
negative	O
breast	BP
cancer-15	IP
,	O
often	O
with	O
medullary	O
features	O
,	O
has	O
been	O
consistently	O
described	O
for	O
BRCA1	BG
cancers-28	IG
.	O

PS1231	O
The	O
identification	O
of	O
the	O
SMN1	BG
gene-6	IG
as	O
determinant	O
of	O
Spinal	BP
muscular	IP
atrophy-12	IP
opened	O
new	O
alternatives	O
to	O
study	O
the	O
disease	O
.	O

PS1239	O
We	O
investigated	O
the	O
molecular	O
determinant	O
of	O
a	O
mild	O
form	O
of	O
retinopathy-11	BP
in	O
association	O
with	O
a	O
subtle	O
splicing	O
modulation	O
of	O
MYO7A	BG
mRNA-21	IG
.	O

PS1244	O
Two	O
syndromes	O
with	O
early	O
-	O
onset	O
protein	O
-	O
losing	O
nephropathy-10	BP
can	O
be	O
distinguished	O
according	O
to	O
the	O
type	O
of	O
WT1-19	BG
mutation	O
.	O

PS1256	O
We	O
report	O
a	O
further	O
patient	O
with	O
a	O
recurrent	O
polyalanine	O
stretch	O
elongation	O
within	O
TBX1-13	BG
and	O
for	O
the	O
first	O
time	O
link	O
TBX1-20	BG
cytoplasmatic	O
protein	O
aggregation	O
to	O
congenital	BP
heart	IP
defects-27	IP
.	O

PS1266	O
Our	O
study	O
suggests	O
that	O
the	O
genotypes	BG
C-7	IG
and	O
Val-9	BG
/	O
Val-11	BG
,	O
which	O
are	O
more	O
frequent	O
in	O
smoking	O
-	O
related	O
lung	O
cancer-22	BP
,	O
are	O
closely	O
related	O
with	O
high-28	BP
aryl	BG
hydrocarbon	IG
hydroxylase-31	IG
inducibility	O
and	O
high	O
non	O
-	O
induced	O
aryl	BG
hydrocarbon	IG
hydroxylase	IG
activity-41	IP
,	O
respectively	O
.	O

PS1275	O
The	O
growth	BG
hormone1-3	IG
genotype	O
therefore	O
constitutes	O
a	O
risk	O
factor	O
for	O
hypertension-11	BP
that	O
interacts	O
with	O
stature	O
.	O

PS1284	O
Nearly	O
70	O
%	O
of	O
all	O
of	O
the	O
known	O
cTnT	O
mutations	O
that	O
cause	O
familial	O
hypertrophic	BP
cardiomyopathy-15	IP
fall	O
within	O
the	O
TNT1-19	BG
region	O
that	O
is	O
critical	O
to	O
cTn-25	BG
-	O
Tm-27	BG
binding	O
.	O

PS1290	O
Our	O
results	O
support	O
previous	O
findings	O
about	O
participation	O
of	O
mutations	O
of	O
NOD2-11	BG
and	O
ICAM	BG
-	IG
1	IG
genes-16	IG
in	O
inflammatory	BP
bowel	IP
disease-20	IP
.	O

PS1293	O
This	O
review	O
provides	O
an	O
update	O
on	O
genotype	O
-	O
phenotype	O
correlation	O
for	O
human	BG
desmoplakin	IG
mutations-14	IG
as	O
well	O
as	O
an	O
overview	O
of	O
desmoplakin-21	BG
abnormalities	O
in	O
other	O
conditions	O
,	O
including	O
autoimmune	BP
blistering-29	IP
diseases	O
,	O
epithelial	O
malignancies-33	BP
and	O
blood	O
vessel	O
morphogenesis	O
.	O

PS1298	O
To	O
investigate	O
the	O
changes	O
of	O
insulin	BG
resistance-7	IP
and	O
soluble	O
intercellular	BG
adhesion	IG
molecule	IG
-	IG
1-14	IG
in	O
normotensive	O
adolescents	O
with	O
a	O
family	O
history	O
of	O
hypertension-23	BP
and	O
to	O
analyse	O
the	O
related	O
factors	O
.	O

PS1306	O
Clinically	O
,	O
hyper	O
IgD-4	BG
was	O
also	O
found	O
significantly	O
associated	O
with	O
arthritis-11	BP
(	O
OR	O
=	O
18	O
)	O
.	O

PS1321	O
Some	O
patients	O
with	O
the	O
infantile	O
form	O
of	O
carnitine	O
palmitoyltransferase	BG
2-10	IG
deficiency	O
present	O
with	O
acute	O
encephalopathy-15	BP
,	O
but	O
others	O
do	O
not	O
develop	O
encephalopathy-22	BP
.	O

PS1338	O
The	O
highest	O
correlation	O
was	O
found	O
between	O
fibrillin	BG
-	IG
1-9	IG
missense	O
mutations	O
,	O
which	O
manifested	O
as	O
ectopia	BP
lentis-17	IP
,	O
skeletal	O
major	O
and	O
skin	O
minor	O
criteria	O
,	O
and	O
two	O
out	O
of	O
four	O
clustered	O
phenotypes	O
.	O

PS1343	O
Genotype	O
-	O
phenotype	O
correlation	O
study	O
found	O
30	O
min	O
and	O
60	O
min	O
glucose	O
of	O
the	O
oral	O
glucose	O
tolerance	O
test	O
were	O
higher	O
in	O
polycystic	BP
ovary-23	IP
syndrome	O
patients	O
with	O
rs11225161	BG
risk	IG
allele	IG
A-30	IG
.	O

PS1360	O
Hepatocellular	BP
carcinoma-2	IP
was	O
observed	O
only	O
in	O
fumarylacetoacetate	BG
hydrolase-8	IG
-	O
negative	O
regions	O
.	O

PS1380	O
Here	O
,	O
we	O
examined	O
the	O
contribution	O
of	O
a	O
4	O
-	O
bp	O
insertion	O
/	O
deletion	O
polymorphism	O
(	O
rs10680577	O
)	O
within	O
the	O
distal	O
promoter	O
of	O
EGLN2-24	BG
to	O
the	O
risk	O
of	O
hepatocelluar	BP
carcinoma-30	IP
in	O
Chinese	O
populations	O
.	O

PS1382	O
Genetic	O
variations	O
in	O
or	O
adjacent	O
to	O
the	O
Calcitonin	BG
gene-9	IG
may	O
be	O
associated	O
with	O
primary	O
Osteoarthritis-15	BP
development	O
.	O

PS1394	O
In	O
particular	O
,	O
case	O
-	O
control	O
studies	O
have	O
recently	O
shown	O
association	O
between	O
hemoglobin	BG
C-14	IG
and	O
resistance	O
to	O
severe	O
malaria-19	BP
in	O
Mali	O
and	O
to	O
clinical	O
malaria	O
in	O
Burkina	O
Faso	O
.	O

PS1401	O
Mucolipidosis-1	BP
II	BG
alpha	IG
/	IG
beta	IG
and	IG
III	IG
alpha	IG
/	IG
beta-10	IG
are	O
autosomal	O
recessive	O
diseases	O
caused	O
by	O
a	O
deficiency	O
of	O
alpha	O
and	O
/	O
or	O
beta	O
subunits	O
of	O
the	O
enzyme	BG
N	IG
-	IG
acetylglucosamine	IG
-	IG
1	IG
-	IG
phosphotransferase-35	IG
,	O
which	O
is	O
encoded	O
by	O
the	O
GNPTAB	BG
gene-43	IG
.	O

PS1403	O
Primary	O
pigmented	O
nodular	O
adrenocortical	O
disease	O
,	O
a	O
rare	O
cause	O
of	O
corticotropin-11	BG
-	O
independent	O
Cushing	O
syndrome	O
,	O
can	O
be	O
part	O
of	O
Carney	O
complex	O
,	O
an	O
autosomal	O
dominant	O
multiple	O
neoplasia-28	BP
syndrome	O
characterized	O
by	O
spotty	O
skin	O
pigmentation-34	BP
,	O
cardiac	O
myxomas	O
,	O
and	O
endocrine	O
tumors	O
or	O
be	O
isolated	O
(	O
i	O
)	O
.	O

PS1406	O
Besides	O
patients	O
with	O
atypical	O
Cystic	O
fibrosis	O
,	O
there	O
are	O
large	O
numbers	O
of	O
so	O
-	O
called	O
monosymptomatic	O
diseases	O
such	O
as	O
various	O
forms	O
of	O
obstructive	BP
azoospermia-24	IP
,	O
idiopathic	O
pancreatitis	O
or	O
disseminated	O
bronchiectasis-30	BP
associated	O
with	O
Cystic	BG
fibrosisTR-34	IG
mutations	O
uncharacteristic	O
for	O
Cystic	O
fibrosis	O
.	O

PS1408	O
In	O
several	O
DFNA12	BG
families-4	IG
mutations	O
in	O
TECTA	O
,	O
the	O
gene	O
encoding	O
alpha	BG
-	IG
tectorin-14	IG
,	O
were	O
shown	O
to	O
cause	O
hearing	BP
impairment-21	IP
with	O
different	O
phenotypes	O
depending	O
on	O
the	O
location	O
of	O
the	O
mutation	O
.	O

PS1410	O
The	O
protective	O
effect	O
of	O
carotenoids	O
on	O
bladder	BP
cancer-8	IP
seemed	O
to	O
be	O
influenced	O
by	O
N	BG
-	IG
acetyltransferase	IG
-	IG
1	IG
genotype-19	IG
,	O
N	BG
-	IG
acetyltransferase	IG
-	IG
2-25	IG
phenotype	O
and	O
cytochrome	BG
P4501A2-29	IG
phenotype	O
;	O

PS1412	O
We	O
investigated	O
the	O
role	O
of	O
R353Q	O
polymorphism	O
in	O
the	O
F7	BG
gene-11	IG
in	O
139	O
Indian	O
families	O
with	O
coronary	BP
artery	IP
disease-19	IP
,	O
comprising	O
of	O
222	O
affected	O
subjects	O
,	O
105	O
unaffected	O
subjects	O
and	O
126	O
affected	O
sibling	O
pairs	O
.	O

PS1415	O
Absence	O
of	O
Alpha	BG
-	IG
1	IG
antitrypsin-6	IG
in	O
Null	O
mutations	O
results	O
in	O
more	O
severe	O
emphysema-14	BP
as	O
compared	O
to	O
ZZ	O
and	O
SZ	O
.	O

PS1416	O
Subjects	O
with	O
Null	O
mutations	O
should	O
be	O
considered	O
a	O
subgroup	O
at	O
particularly	O
high	O
risk	O
of	O
emphysema-15	BP
within	O
Alpha	BG
-	IG
1	IG
antitrypsin	IG
deficiency-21	IP
.	O

PS1425	O
Hence	O
,	O
the	O
expression	O
of	O
BAG	BG
-	IG
1-8	IG
was	O
closely	O
associated	O
with	O
the	O
sensitivity	O
to	O
platinum	O
-	O
based	O
chemotherapeutics	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer-26	BP
patients	O
.	O

PS1441	O
Although	O
the	O
relationship	O
between	O
the	O
location	O
of	O
APC-8	BG
mutations	O
and	O
dental	BP
abnormalities-12	IP
remains	O
controversial	O
,	O
this	O
case	O
supports	O
the	O
hypothesis	O
that	O
a	O
mutation	O
at	O
around	O
codon	O
1556	O
of	O
APC-29	BG
is	O
closely	O
associated	O
with	O
dental	O
abnormality	O
and	O
osteomas-37	BP
.	O

PS1451	O
Variations	O
and	O
haplotypes	O
of	O
the	O
chymotrypsin	BG
C-7	IG
gene	O
in	O
Chinese	O
patients	O
with	O
chronic	O
pancreatitis-14	BP
and	O
control	O
subjects	O
with	O
genotype	O
-	O
phenotype	O
correlation	O
were	O
investigated	O
.	O

PS1454	O
Imatinib	O
,	O
an	O
inhibitor	O
of	O
the	O
Bcr	BG
-	IG
Abl	IG
tyrosine	IG
kinase-11	IG
,	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
Philadelphia	O
chromosome	O
-	O
positive	O
chronic	BP
myeloid	IP
leukemia-27	IP
.	O

PS1465	O
We	O
have	O
analysed	O
collagen	BG
VI-5	IG
expression	O
in	O
14	O
Ullrich	O
congenital	BP
muscular	IP
dystrophy-12	IP
patients	O
.	O

PS1469	O
Of	O
the	O
66	O
breakpoints	O
,	O
90	O
%	O
were	O
located	O
in	O
Alu-11	BG
elements	O
,	O
revealing	O
Alu-15	BG
-	O
mediated	O
recombination	O
as	O
the	O
major	O
mechanism	O
for	O
large	BP
germline-25	IP
deletions	O
of	O
the	O
Von	BG
Hippel	IG
-	IG
Lindau	IG
disease	IG
gene-34	IG
,	O
which	O
lies	O
in	O
a	O
region	O
of	O
high	O
Alu-43	BG
density	O
.	O

PS1470	O
We	O
not	O
only	O
noted	O
the	O
association	O
of	O
renal	BP
cell	IP
carcinomas-10	IP
with	O
retention	O
of	O
the	O
HSPC300	BG
gene-16	IG
,	O
but	O
also	O
observed	O
a	O
significant	O
correlation	O
between	O
retention	O
of	O
HSPC300	O
and	O
the	O
development	O
of	O
retinal	BP
angiomas-33	IP
(	O
AR	O
)	O
.	O

PS1472	O
We	O
report	O
a	O
9	O
-	O
year	O
-	O
old	O
British	O
Chinese	O
girl	O
with	O
progressive	O
osseous	O
heteroplasia-15	BP
resulting	O
from	O
a	O
de	O
novo	O
missense	O
mutation	O
(	O
W281R	O
)	O
in	O
the	O
GNAS1	BG
gene-29	IG
.	O

PS1479	O
This	O
results	O
in	O
deficient	O
cortisol	O
,	O
increased	O
ACTH-8	BG
,	O
adrenal	BP
hyperplasia-11	IP
and	O
increased	O
adrenal	O
androgen	O
secretion	O
.	O

PS1484	O
One	O
hundred	O
high	O
tension	O
glaucoma-5	BP
patients	O
patients	O
and	O
controls	O
were	O
screened	O
for	O
Optineurin	BG
gene-14	IG
mutations	O
by	O
direct	O
sequencing	O
using	O
an	O
ABI	O
prism	O
310	O
/	O
3100	O
Avant	O
genetic	O
analyzer	O
.	O

PS1491	O
The	O
clinical	O
feature	O
in	O
patients	O
with	O
congenital-7	BP
factor	BG
VII	IG
deficiency-10	IP
is	O
in	O
part	O
dependent	O
on	O
the	O
underlying	O
genetic	O
defect	O
,	O
but	O
the	O
mechanisms	O
influencing	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

PS1513	O
Exclusion	O
of	O
TIGR	BG
gene-4	IG
mutations	O
in	O
Polish	O
patients	O
with	O
primary	O
open	O
angle	O
glaucoma-13	BP
means	O
that	O
they	O
probably	O
have	O
mutations	O
in	O
other	O
genes	O
,	O
what	O
paves	O
the	O
way	O
to	O
the	O
studies	O
on	O
other	O
loci	O
that	O
predispose	O
to	O
primary	O
open	O
angle	O
glaucoma-40	BP
.	O

PS1535	O
The	O
tyrosinase	BG
gene-3	IG
is	O
known	O
to	O
be	O
essential	O
for	O
melanization	O
and	O
has	O
been	O
shown	O
to	O
rescue	O
pigmentation-17	BP
in	O
albino	O
mice	O
.	O

PS1539	O
Mutation	O
of	O
the	O
non	BG
-	IG
muscle	IG
myosin	IG
heavy	IG
chain	IG
type	IG
II	IG
-	IG
A-13	IG
results	O
in	O
MYH9	O
-	O
related	O
hereditary	O
macrothrombocytopenia-20	BP
,	O
including	O
four	O
autosomal	O
dominant	O
platelet	O
disorders	O
:	O
May	O
-	O
Hegglin	O
anomaly	O
,	O
Sebastian	O
,	O
Fechtner	O
and	O
Epstein	BG
syndrome-39	IG
.	O

PS1544	O
In	O
contrast	O
,	O
PKP1-4	BG
is	O
not	O
expressed	O
in	O
the	O
heart	O
,	O
which	O
accounts	O
for	O
the	O
lack	O
of	O
cardiomyopathy-18	BP
in	O
patient	O
1	O
.	O

PS1549	O
We	O
identified	O
two	O
novel	O
Paired	BG
Box	IG
gene	IG
6-8	IG
mutations	O
in	O
families	O
with	O
severe	O
aniridia-14	BP
.	O

PS1556	O
Complete	BP
azoospermia-2	IP
factor	O
region	O
c	O
deletions	O
,	O
including	O
BPY2-9	BG
,	O
CDY1-11	BG
and	O
DAZ	BG
genes-14	IG
,	O
were	O
identified	O
in	O
24	O
men	O
.	O

PS1570	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
is	O
a	O
group	O
of	O
autosomal	O
recessive	O
disorders	O
mainly	O
due	O
to	O
defects	O
in	O
the	O
steroid	BG
21	IG
-	IG
hydroxylase-20	IG
(	O
CYP21-22	BG
)	O
gene	O
.	O

PS1580	O
In	O
some	O
families	O
of	O
lamellar	O
ichthyosis	O
,	O
transglutaminase	O
1	O
gene	O
mutations	O
were	O
identified	O
as	O
causative	O
genetic	O
defects	O
and	O
transglutaminase	BG
1-20	IG
is	O
thought	O
to	O
be	O
one	O
of	O
the	O
candidate	O
molecules	O
for	O
non	O
-	O
bullous	O
congenital	BP
ichthyosiform	IP
erythroderma-36	IP
.	O

PS1581	O
Two	O
families	O
with	O
mottled	O
pigmentation-5	BP
carried	O
the	O
P25L	O
mutation	O
in	O
KRT5-11	BG
,	O
commonly	O
associated	O
with	O
this	O
subtype	O
.	O

PS1585	O
Five	O
germline	O
mutations	O
in	O
the	O
glial	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
gene	O
,	O
one	O
of	O
the	O
RET-19	BG
ligands	O
,	O
have	O
been	O
detected	O
in	O
Hirschsprung	BP
disease-27	IP
patients	O
.	O

PS1614	O
Plasma	O
calcitonin-2	BG
is	O
a	O
sensitive	O
and	O
specific	O
marker	O
for	O
the	O
presence	O
of	O
Medullary	O
thyroid	BP
carcinoma-15	IP
.	O

PS1618	O
We	O
examined	O
transmission	O
of	O
HLA	BG
-	IG
DQB1	IG
alleles-8	IG
in	O
225	O
African	O
American	O
families	O
with	O
at	O
least	O
one	O
offspring	O
with	O
sarcoidosis-20	BP
.	O

PS1619	O
Furthermore	O
,	O
all	O
Spinal	BP
muscular	IP
atrophy-6	IP
type	O
I	O
patients	O
had	O
one	O
copy	O
of	O
H4F5-14	BG
.	O

PS1622	O
Three	O
hereditary	O
forms	O
of	O
multiple	O
endocrine	O
neoplasia-7	BP
type	O
2	O
have	O
been	O
identified	O
:	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2A-18	IG
,	O
multiple	O
endocrine	O
neoplasia-22	BP
type	O
2B	O
,	O
and	O
familial	O
Medullary	O
thyroid	BP
carcinoma-30	IP
.	O

PS1631	O
Any	O
Juvenile	O
polyposis	O
patient	O
with	O
a	O
SMAD4	BG
mutation-8	IG
is	O
,	O
therefore	O
,	O
at	O
risk	O
for	O
the	O
visceral	O
manifestations	O
of	O
hemorrhagic	O
telangiectasia	O
and	O
any	O
hemorrhagic	BP
telangiectasia-25	IP
patient	O
with	O
SMAD4	BG
mutation-29	IG
is	O
at	O
risk	O
for	O
early	O
onset	O
gastrointestinal	BP
cancer-37	IP
.	O

PS1636	O
Specifically	O
,	O
Stat4-3	BG
-	O
deficient	O
New	O
Zealand	O
mixed	O
mice	O
develop	O
accelerated	O
nephritis-12	BP
and	O
increased	O
mortality	O
in	O
the	O
absence	O
of	O
high	O
levels	O
of	O
autoantibodies	O
including	O
anti	BG
-	IG
dsDNA	IG
Abs-28	IG
,	O
and	O
in	O
the	O
presence	O
of	O
relatively	O
reduced	O
levels	O
of	O
IFN	BG
-	IG
gamma-41	IG
.	O

PS1639	O
Clinicopathological	O
characteristics	O
of	O
breast	BP
carcinomas-5	IP
originating	O
from	O
BRCA1	BG
/	IG
2	IG
heterozygotes-11	IG
were	O
consistent	O
with	O
those	O
already	O
reported	O
and	O
not	O
different	O
from	O
those	O
observed	O
in	O
BRCA1	BG
/	IG
2	IG
mutation-28	IG
(	O
-	O
)	O
breast	BP
cancer-33	IP
patients	O
.	O

PS1672	O
We	O
confirmed	O
the	O
association	O
of	O
BSN-6	BG
and	O
MST1-8	BG
with	O
inflammatory	BP
bowel	IP
disease-12	IP
susceptibility	O
,	O
either	O
in	O
the	O
adult	O
or	O
the	O
early	O
-	O
onset	O
cohorts	O
.	O

PS1673	O
A	O
10	O
-	O
cM	O
multipoint	O
,	O
non	O
-	O
parametric	O
,	O
autosomal	O
genome	O
-	O
wide	O
scan	O
of	O
schizophrenia-17	BP
was	O
performed	O
in	O
Merlin-21	BG
.	O

PS1689	O
This	O
study	O
sought	O
correlation	O
between	O
plasma	O
levels	O
of	O
soluble	O
endothelial	BG
protein	IG
C	IG
receptor-13	IG
and	O
disease	O
manifestation	O
/	O
severity	O
,	O
with	O
a	O
focus	O
on	O
lupus	O
nephritis-25	BP
.	O

PS1690	O
In	O
81	O
systemic	BP
lupus	IP
erythematosus-5	IP
patients	O
(	O
evaluated	O
cross	O
-	O
sectionally	O
and	O
longitudinally	O
)	O
and	O
59	O
healthy	O
controls	O
,	O
levels	O
of	O
soluble	O
endothelial	BG
protein	IG
C	IG
receptor-26	IG
and	O
soluble	O
E	BG
-	IG
selectin-31	IG
were	O
assessed	O
by	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
circulating	O
endothelial	O
cells	O
isolated	O
by	O
immunomagnetic	O
separation	O
,	O
and	O
endothelial	BG
protein	IG
C	IG
receptor	IG
gene-55	IG
polymorphisms	O
determined	O
.	O

PS1694	O
The	O
results	O
suggest	O
that	O
soluble	O
E	BG
-	IG
selectin-8	IG
and	O
soluble	BG
endothelial	IG
protein	IG
C	IG
receptor-14	IG
are	O
not	O
equivalent	O
end	O
points	O
of	O
vasculopathy-21	BP
and	O
endothelial	O
perturbation	O
in	O
systemic	BP
lupus	IP
erythematosus-28	IP
.	O

PS1698	O
The	O
recombinant	O
inbred	O
strains	O
were	O
produced	O
as	O
a	O
model	O
system	O
for	O
genetic	O
and	O
correlation	O
analysis	O
of	O
spontaneous	O
hypertension-18	BP
and	O
other	O
risk	O
factors	O
of	O
cardiovascular	BP
disease-25	IP
such	O
as	O
insulin	BG
resistance-29	IP
and	O
dyslipidemia	O
.	O

PS1710	O
Each	O
variant	O
of	O
Multiple	O
endocrine	O
neoplasia-6	BP
type	O
2	O
results	O
from	O
a	O
different	O
RET	BG
gene-14	IG
mutation	O
,	O
with	O
a	O
good	O
genotype	O
-	O
phenotype	O
correlation	O
with	O
regard	O
to	O
aggressiveness-27	BP
of	O
medullary	O
thyroid	BP
carcinoma-31	IP
,	O
time	O
of	O
onset	O
of	O
medullary	BP
thyroid	IP
carcinoma-39	IP
and	O
the	O
presence	O
or	O
absence	O
of	O
other	O
endocrine	O
tumours	O
.	O

PS1713	O
The	O
rate	O
of	O
mutation	O
detection	O
is	O
higher	O
in	O
the	O
PKD2	BG
gene-11	IG
but	O
the	O
global	O
efficacy	O
of	O
the	O
technique	O
is	O
very	O
low	O
as	O
PKD2-23	BG
represents	O
only	O
15	O
%	O
of	O
Autosomal	O
dominant	O
polycystic	BP
kidney-32	IP
disease	O
patients	O
.	O

PS1722	O
Wiskott	O
-	O
Aldrich	O
Syndrome	O
Protein	O
is	O
a	O
regulator	O
of	O
actin-10	BG
polymerization	O
in	O
hematopoietic	O
cells	O
with	O
well	O
-	O
defined	O
functional	O
domains	O
that	O
are	O
involved	O
in	O
cell	O
signaling	O
and	O
cell	O
locomotion	O
,	O
immune	O
synapse	O
formation	O
,	O
and	O
apoptosis-36	BP
.	O

PS1723	O
Classic	O
Wiskott	O
-	O
Aldrich	O
Syndrome	O
occurs	O
when	O
Wiskott	O
-	O
Aldrich	O
Syndrome	O
Protein	O
is	O
absent	O
,	O
X	O
-	O
linked	O
thrombocytopenia-19	BP
when	O
mutated	O
Wiskott	O
-	O
Aldrich	O
Syndrome	O
Protein	O
is	O
expressed	O
and	O
X	O
-	O
linked	O
neutropenia-33	BP
when	O
missense	O
mutations	O
occur	O
in	O
the	O
Cdc42	BG
-	IG
binding	IG
site-43	IG
.	O

PS1727	O
These	O
include	O
the	O
dominantly	O
inherited	O
cancer-6	BP
syndromes	O
multiple	O
endocrine	O
neoplasia-10	BP
types	O
2A	O
and	O
2B	O
(	O
MEN	O
2A	O
and	O
MEN	O
2B	O
)	O
and	O
familial	O
medullary	O
thyroid	BP
carcinoma-26	IP
,	O
as	O
well	O
as	O
some	O
cases	O
of	O
familial	O
Hirschsprung	BG
disease-36	IG
(	O
HSCR1-38	BG
)	O
.	O

PS1731	O
To	O
evaluate	O
the	O
genotypic	O
and	O
phenotypic	O
correlations	O
of	O
Bietti	O
'	O
s	O
crystalline	BP
dystrophy-13	IP
in	O
patients	O
with	O
the	O
CYP4V2	BG
gene-19	IG
by	O
mutation	O
screening	O
and	O
clinical	O
and	O
electrophysiological	O
assessment	O
.	O

PS1733	O
Bietti	O
'	O
s	O
crystalline	BP
dystrophy-5	IP
patients	O
with	O
homozygous	O
IVS6	BG
-	IG
8del17bp-11	IG
/	O
insGC-13	BG
or	O
compound	O
heterozygous	O
IVS6	BG
-	IG
8del17bp-19	IG
/	O
insGC-21	BG
and	O
IVS8	BG
-	IG
2A-25	IG
>	O
G	O
mutations	O
appeared	O
to	O
have	O
more	O
severe	O
disease	O
phenotype	O
based	O
on	O
electrophysiological	O
testing	O
.	O

PS1736	O
To	O
perform	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
study	O
in	O
an	O
X	O
-	O
linked	O
congenital	BP
idiopathic	IP
nystagmus-16	IP
pedigree	O
(	O
pedigree	O
1	O
)	O
and	O
to	O
assess	O
the	O
allelic	O
variance	O
of	O
the	O
FRMD7	BG
gene-31	IG
in	O
congenital	BP
idiopathic	IP
nystagmus-35	IP
.	O

PS1738	O
We	O
demonstrate	O
that	O
other	O
congenital	BP
nystagmus	IP
genes-7	IP
exist	O
besides	O
FRMD7-10	BG
.	O

PS1740	O
While	O
FRMD7	BG
mutations-3	IG
may	O
be	O
found	O
in	O
some	O
cases	O
of	O
X	O
-	O
linked	O
congenital	BP
idiopathic	IP
nystagmus-16	IP
,	O
the	O
diagnostic	O
yield	O
is	O
low	O
.	O

PS1748	O
ZNF804A-1	BG
is	O
one	O
of	O
the	O
strongest	O
candidate	O
genes	O
for	O
schizophrenia-10	BP
,	O
yet	O
its	O
function	O
and	O
role	O
in	O
disease	O
pathophysiology	O
are	O
largely	O
unknown	O
.	O

PS1756	O
We	O
examined	O
the	O
clinical	O
features	O
of	O
the	O
first	O
Italian	O
FAmyotrophic	BP
lateral	IP
sclerosis-12	IP
with	O
the	O
Leu144Phe	BG
SOD1	IG
mutation-17	IG
.	O

PS1764	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
entire	O
c	BG
-	IG
KIT	IG
sequence-12	IG
from	O
cutaneous	O
biopsies	O
of	O
50	O
children	O
with	O
mastocytosis-20	BP
(	O
ages	O
0	O
-	O
16	O
years	O
)	O
.	O

PS1769	O
Hormone	O
-	O
sensitive	O
lipase-4	BG
,	O
a	O
key	O
enzyme	O
in	O
fatty	O
acid	O
mobilization	O
from	O
lipid	O
stores	O
,	O
is	O
expressed	O
in	O
the	O
liver	O
and	O
decreased	BP
hepatic-24	IP
insulin-25	BG
sensitivity	O
has	O
been	O
reported	O
in	O
our	O
Hormone	O
-	O
sensitive	O
lipase-35	BG
null	O
mouse	O
model	O
.	O

PS1780	O
We	O
have	O
analysed	O
60	O
families	O
with	O
a	O
history	O
of	O
breast	O
and	O
/	O
or	O
ovarian	O
cancer-15	BP
for	O
germline	O
mutations	O
in	O
BRCA1-20	BG
.	O

PS1781	O
To	O
report	O
the	O
appearance	O
of	O
an	O
unusual	O
vortex	O
pattern	O
of	O
corneal	O
deposits	O
in	O
two	O
patients	O
with	O
the	O
R555W	O
mutation	O
in	O
the	O
transforming	O
growth	O
factor	O
beta	O
-	O
induced	O
gene	O
(	O
TGFB1-30	BG
)	O
associated	O
with	O
granular	O
corneal	BP
dystrophy-36	IP
.	O

PS1783	O
In	O
spite	O
of	O
the	O
strict	O
phenotype	O
-	O
genotype	O
correlation	O
reported	O
for	O
the	O
TGFB1-13	BG
-	O
associated	O
corneal	BP
dystrophies-17	IP
,	O
atypical	O
clinical	O
findings	O
may	O
be	O
produced	O
by	O
previously	O
identified	O
,	O
conserved	O
mutations	O
.	O

PS1795	O
The	O
SNPs	O
tagging	O
the	O
PTGER4-5	BG
,	O
NKX2	BG
-	IG
3-9	IG
,	O
ZNF365-11	BG
,	O
IFNG-13	BG
,	O
PSMG1-15	BG
,	O
and	O
HLA-18	BG
area	O
were	O
associated	O
with	O
ulcerative	BP
colitis-24	IP
.	O

PS1799	O
Triple	O
A	O
syndrome	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
alacrima	O
,	O
achalasia	O
,	O
ACTH-15	BG
-	O
resistant	O
adrenal	BP
insufficiency-19	IP
,	O
autonomic	O
dysfunction	O
,	O
and	O
neurodegeneration	O
.	O

PS1804	O
Mutations	O
in	O
the	O
cone	O
-	O
rod	O
homeobox	BG
gene-8	IG
are	O
associated	O
with	O
cone	O
-	O
rod	O
dystrophy	O
,	O
Leber	O
congenital	O
amaurosis	O
,	O
and	O
,	O
in	O
rare	O
cases	O
,	O
retinitis	BP
pigmentosa-28	IP
.	O

PS1818	O
This	O
evidence	O
suggests	O
that	O
the	O
NR2A	BG
(	IG
GRIN2A	IG
)	IG
gene-10	IG
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
schizophrenia-19	BP
and	O
disease	O
phenotypes	O
.	O

PS1835	O
To	O
investigate	O
association	O
of	O
mutation	O
in	O
WNK4	BG
gene-8	IG
with	O
essential	O
hypertension-11	BP
and	O
to	O
analyze	O
the	O
expression	O
of	O
WNK4	BG
gene-19	IG
.	O

PS1844	O
In	O
this	O
study	O
,	O
we	O
screened	O
the	O
entire	O
coding	O
region	O
of	O
the	O
polycystic	BP
kidney-14	IP
disease	O
type	O
1	O
and	O
PKD2	BG
genes-20	IG
in	O
17	O
Finnish	O
families	O
with	O
Autosomal	O
dominant	O
polycystic	BP
kidney-29	IP
disease	O
via	O
long	O
-	O
range	O
polymerase	O
chain	O
reaction	O
,	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
,	O
and	O
direct	O
sequencing	O
.	O

PS1850	O
To	O
analyze	O
the	O
mutational	O
spectrum	O
of	O
steroid	BG
21	IG
-	IG
hydroxylase-10	IG
(	O
CYP21-12	BG
)	O
and	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
patients	O
with	O
congenital	BP
adrenal	IP
hyperplasia-25	IP
registered	O
in	O
the	O
Middle	O
European	O
Society	O
for	O
Pediatric	O
Endocrinology	O
congenital	BP
adrenal	IP
hyperplasia-37	IP
database	O
,	O
and	O
to	O
design	O
a	O
reliable	O
and	O
rational	O
approach	O
for	O
CYP21	BG
mutation-50	IG
detection	O
in	O
Middle	O
European	O
populations	O
.	O

PS1857	O
By	O
using	O
PCR	O
/	O
SSCP	O
and	O
DNA	O
sequencing	O
,	O
all	O
exons	O
of	O
phenylalanine	BG
hydroxylase	IG
gene-15	IG
in	O
the	O
185	O
unrelated	O
patients	O
with	O
phenylketonuria-22	BP
from	O
Northern	O
China	O
were	O
studied	O
.	O

PS1872	O
The	O
analysis	O
of	O
somatic	BG
Neurofibromatosis	IG
type	IG
1	IG
gene-8	IG
mutations	O
in	O
neurofibromas	O
from	O
Neurofibromatosis-13	BP
type	O
1	O
patients	O
revealed	O
that	O
each	O
neurofibroma-20	BP
results	O
from	O
an	O
individual	O
second	O
hit	O
mutation	O
,	O
indicating	O
that	O
factors	O
that	O
influence	O
somatic	O
mutation	O
rates	O
may	O
be	O
regarded	O
as	O
potential	O
modifiers	O
of	O
Neurofibromatosis-44	BP
type	O
1	O
.	O

PS1874	O
Lissencephaly-1	BP
caused	O
by	O
LIS1	O
or	O
DCX	O
mutation	O
frequently	O
results	O
in	O
West	O
syndrome	O
,	O
while	O
lissencephaly	O
due	O
to	O
ARX	BG
mutation-19	IG
is	O
associated	O
with	O
the	O
most	O
severe	O
form	O
of	O
epilepsy	O
but	O
never	O
results	O
in	O
West	O
syndrome	O
nor	O
infantile	O
spasms	O
.	O

PS1892	O
The	O
percentage	O
of	O
retinitis-4	BP
pigmentosa	BG
GTPase	IG
regulator	IG
mutations-8	IG
identified	O
is	O
17	O
%	O
(	O
5	O
/	O
29	O
)	O
in	O
our	O
genetically	O
well	O
-	O
defined	O
population	O
.	O

PS1898	O
However	O
,	O
in	O
stratification	O
analyses	O
,	O
we	O
found	O
a	O
significant	O
association	O
of	O
XPF	BG
-	IG
rs1799801-15	IG
with	O
a	O
reduced	O
cancer-19	BP
risk	O
in	O
Caucasian	O
populations	O
.	O

PS1914	O
HMedullary	O
thyroid	BP
carcinoma-3	IP
in	O
the	O
era	O
of	O
RET-8	BG
analysis	O
presents	O
with	O
a	O
smaller	O
primary	O
tumor	O
,	O
lower	O
preoperative	O
serum	O
calcitonin-20	BG
levels	O
,	O
and	O
lower	O
rates	O
of	O
lymph	O
node	O
metastasis	O
.	O

PS1919	O
The	O
molecular	O
clones	O
pSPeiav19-4	BG
and	O
p19-6	BG
/	O
wenv17-8	BG
of	O
equine	O
infectious	O
anemia-12	BP
virus	O
differ	O
in	O
env-16	BG
and	O
long	O
terminal	O
repeats	O
and	O
produce	O
viruses	O
(	O
equine	O
infectious	O
anemia-27	BP
virus	O
(	O
19	O
)	O
and	O
equine	O
infectious	O
anemia-35	BP
virus	O
(	O
17	O
)	O
,	O
respectively	O
)	O
of	O
dramatically	O
different	O
virulence	O
phenotypes	O
.	O

PS1931	O
Up	O
to	O
date	O
17	O
constitutively	O
activating	O
TSH	BG
receptor-8	IG
mutations	O
have	O
been	O
reported	O
in	O
24	O
families	O
with	O
familial	O
non	O
-	O
autoimmune	BP
hyperthyroidism-21	IP
.	O

PS1938	O
This	O
family	O
confirms	O
that	O
ataxia-5	BP
,	O
ophthalmoparesis	O
and	O
sensory	O
peripheral	O
neuropathy-11	BP
are	O
the	O
salient	O
features	O
of	O
the	O
SCA2-18	BG
phenotype	O
.	O

PS1948	O
These	O
results	O
demonstrate	O
an	O
association	O
between	O
the	O
Rsa	BG
I-9	IG
genotype	O
and	O
the	O
phenotype	O
of	O
cytochrome	BG
P4502E1-16	IG
in	O
our	O
samples	O
,	O
and	O
the	O
data	O
are	O
compatible	O
with	O
the	O
assumption	O
that	O
cytochrome	BG
P4502E1	IG
c1	IG
/	IG
c1	IG
genotype-35	IG
is	O
a	O
susceptibility	O
factor	O
for	O
certain	O
cancers-42	BP
in	O
Chinese	O
.	O

PS1952	O
Normal	O
stature	O
was	O
frequent	O
in	O
SOS1-6	BG
mutations	O
,	O
hypertrophic	BP
cardiomyopathy-10	IP
in	O
RAF1-12	BG
,	O
and	O
developmental	BP
delay-16	IP
in	O
RAF1-18	BG
,	O
BRAF-20	BG
,	O
or	O
SHOC2-23	BG
mutations	O
.	O

PS1953	O
Defective	O
steroid	BP
synthesis-3	IP
due	O
to	BG
21	IG
-	IG
hydroxylase	IG
deficiency-9	IP
is	O
the	O
most	O
common	O
form	O
of	O
congenital	BP
adrenal	IP
hyperplasia-18	IP
.	O

PS1955	O
Other	O
well	O
-	O
established	O
associations	O
include	O
CYP2B6	BG
alleles-8	IG
and	O
efavirenz	O
central	O
nervous	O
system	O
side	O
effects	O
,	O
UGT1A1	BG
alleles-18	IG
and	O
atazanavir	O
-	O
associated	O
hyperbilirubinemia-23	BP
and	O
HLA	BG
class	IG
II	IG
allele	IG
HLA	IG
-	IG
DRB	IG
*-32	IG
0101	O
and	O
nevirapine	O
-	O
associated	O
hypersensitivity	O
.	O

PS1959	O
More	O
than	O
20	O
Hereditary	O
spastic	BP
paraplegia-6	IP
loci	O
and	O
10	O
spastic	O
paraplegia	O
genes	O
have	O
been	O
identified	O
to	O
date	O
,	O
including	O
the	O
genes	O
responsible	O
for	O
the	O
two	O
most	O
frequent	O
forms	O
of	O
autosomal	O
dominant	O
spastic	BP
paraplegia-33	IP
,	O
encoding	O
spastin	O
(	O
spastic	BP
paraplegia-39	IP
genes4	O
)	O
and	O
atlastin-43	BG
(	O
spastic	BG
paraplegia	IG
genes3A-47	IG
)	O
,	O
respectively	O
.	O

PS1963	O
To	O
search	O
for	O
mutations	O
in	O
F10	BG
gene-7	IG
giving	O
rise	O
to	O
severe	O
Factor	BG
X	IG
deficiency-14	IP
and	O
to	O
study	O
the	O
contribution	O
of	O
thrombin-21	BG
generation	O
and	O
thromboelastometry	O
as	O
a	O
tool	O
for	O
evaluation	O
of	O
hemostasis-31	BP
.	O

PS1980	O
In	O
addition	O
,	O
heterozygosity	O
for	O
mutations	O
in	O
the	O
Dihydropyrimidine	BG
dehydrogenase	IG
gene-11	IG
increases	O
the	O
risk	O
of	O
toxicity	O
in	O
cancer-18	BP
patients	O
treated	O
with	O
this	O
drug	O
.	O

PS1983	O
Although	O
glial	O
lineages	O
are	O
very	O
heterogeneous	O
with	O
respect	O
to	O
position	O
,	O
time	O
of	O
differentiation	O
,	O
and	O
lineage	O
tree	O
,	O
they	O
all	O
express	O
and	O
require	O
two	O
homologous	O
genes	O
,	O
glial	O
cell	O
deficient	O
/	O
glial	O
cell	O
missing	O
and	O
glide2-37	BG
,	O
that	O
act	O
in	O
concert	O
,	O
with	O
glial	BP
cell	IP
deficient-47	IP
/	O
glial	O
cell	O
missing	O
constituting	O
the	O
major	O
glial	O
-	O
promoting	O
factor	O
.	O

PS1995	O
single	O
nucleotide	O
polymorphism	O
at	O
8q24	O
makes	O
diabetes	O
a	O
risk	O
factor	O
of	O
colorectal	BP
cancer-13	IP
via	O
insulin	BG
growth	IG
factor	IG
2	IG
receptor-19	IG
,	O
especially	O
in	O
genetically	O
non	O
-	O
risk	O
allele	O
cases	O
.	O

PS2021	O
However	O
,	O
congenital	BP
abnormalities-4	IP
are	O
expected	O
in	O
both	O
unbalanced	O
forms	O
of	O
the	O
translocation	O
,	O
including	O
mental	BP
retardation-17	IP
,	O
which	O
could	O
be	O
explained	O
by	O
the	O
gene	O
dosage	O
variation	O
of	O
P2RX2-29	BG
.	O

PS2027	O
With	O
the	O
discovery	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
the	O
FOXP3	BG
gene-12	IG
in	O
patients	O
with	O
Autoimmune	BP
enteropathy-17	IP
,	O
a	O
dramatic	O
advance	O
in	O
the	O
understanding	O
of	O
Autoimmune	O
enteropathy	O
was	O
made	O
.	O

PS2039	O
Analysis	O
of	O
a	O
large	O
patient	O
population	O
demonstrates	O
a	O
phenotype	O
-	O
genotype	O
correlation	O
:	O
classic	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
occurs	O
when	O
Wiskott	O
-	O
Aldrich	O
syndromeP	O
is	O
absent	O
,	O
X	O
-	O
linked	O
thrombocytopenia-31	BP
when	O
mutated	O
Wiskott	O
-	O
Aldrich	O
syndromeP	O
is	O
expressed	O
,	O
and	O
X	O
-	O
linked	O
neutropenia-45	BP
when	O
missense	O
mutations	O
occur	O
in	O
the	O
Cdc42	BG
-	IG
binding	IG
site-55	IG
.	O

PS2042	O
No	O
influence	O
of	O
Mannan	O
-	O
binding	O
lectin2	BG
genotype-8	IG
on	O
the	O
incidence	O
of	O
duodenal	BP
ulcer-14	IP
or	O
gastritis-16	BP
was	O
found	O
.	O

PS2044	O
Mutations	O
in	O
the	O
GH	BG
receptor	IG
gene-6	IG
cause	O
congenital-8	BP
GH	BG
insensitivity-10	IP
,	O
a	O
genetic	O
disorder	O
characterized	O
by	O
severe	O
growth	O
retardation	O
associated	O
with	O
high	O
serum	O
concentration	O
of	O
GH-26	BG
and	O
low	O
serum	O
levels	O
of	O
IGF	BG
-	IG
I-34	IG
.	O

PS2045	O
Mutations	O
in	O
the	O
GH	BG
receptor	IG
gene-6	IG
cause	O
congenital-8	BP
GH	BG
insensitivity-10	IP
,	O
a	O
genetic	O
disorder	O
characterized	O
by	O
severe	O
growth	O
retardation	O
associated	O
with	O
high	O
serum	O
concentration	O
of	O
GH-26	BG
and	O
low	O
serum	O
levels	O
of	O
IGF	BG
-	IG
I-34	IG
.	O

PS2048	O
Glycemic	O
and	O
glycosylated-3	BP
hemoglobin-4	BG
(	O
Hb	BG
A	IG
(	IG
1c	IG
)-10	IG
)	O
levels	O
are	O
associated	O
with	O
RH	O
phenotype	O
.	O

PS2059	O
To	O
report	O
the	O
spectrum	O
of	O
the	O
CYP1B1	BG
mutation-8	IG
in	O
Kuwaiti	O
patients	O
with	O
primary	O
congenital	O
glaucoma-15	BP
.	O

PS2117	O
Sixty	O
-	O
five	O
unrelated	O
anti	BG
-	IG
La	IG
antibody-8	IG
-	O
negative	O
systemic	BP
lupus	IP
erythematosus-13	IP
patients	O
,	O
37	O
of	O
them	O
with	O
and	O
28	O
without	O
anti	BG
-	IG
Ro	IG
antibodies-26	IG
,	O
were	O
included	O
.	O

PS2122	O
Multiple	O
endocrine	O
neoplasia-3	BP
type	O
2a	O
results	O
from	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
RET	BG
proto	IG
-	IG
oncogene-17	IG
.	O

PS2125	O
Patients	O
with	O
a	O
D631Y	BG
RET-5	IG
mutation	O
typically	O
present	O
with	O
pheochromocytoma-10	BP
and	O
medullary	O
thyroid	BP
carcinoma-14	IP
appears	O
to	O
occur	O
with	O
a	O
later	O
onset	O
than	O
reported	O
with	O
other	O
RET	BG
mutations-27	IG
.	O

PS2137	O
RET-1	BG
is	O
a	O
candidate	O
gene	O
for	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-10	IP
due	O
to	O
its	O
role	O
in	O
the	O
development	O
of	O
the	O
intrinsic	O
innervation	O
and	O
ganglia	O
of	O
the	O
smooth	O
musculature	O
and	O
the	O
association	O
of	O
RET	BG
variants-33	IG
with	O
another	O
motility	O
disorder	O
(	O
Hirschsprung	O
'	O
s	O
disease	O
)	O
.	O

PS2162	O
Antinuclear	BP
antibody-2	IP
,	O
antithyroid	BG
peroxidase-5	IG
and	O
anti	BG
-	IG
aquaporin	IG
-	IG
4-11	IG
assays	O
and	O
HLA	BG
-	IG
DRB1-16	IG
genotyping	O
were	O
performed	O
in	O
198	O
MS	O
patients	O
and	O
188	O
controls	O
.	O

PS2179	O
Polymorphic	O
changes	O
modulating	O
the	O
acetylation	O
capacity	O
of	O
the	O
N	BG
-	IG
acetyltransferase-11	IG
genes	O
have	O
been	O
implicated	O
in	O
the	O
risk	O
of	O
developing	O
cancer-21	BP
.	O

PS2207	O
Nine	O
families	O
with	O
Autosomal	O
dominant	O
hereditary	O
spastic	BP
paraplegia-8	IP
were	O
linked	O
to	O
the	O
SPG4	BG
locus-14	IG
at	O
2p21-16	BG
-	O
p24-18	BG
.	O

PS2216	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
investigate	O
if	O
bilirubin-10	BG
and	O
UGT1A1	BG
*	IG
28-14	IG
are	O
protective	O
against	O
ischemic	O
stroke-19	BP
in	O
a	O
prospective	O
case	O
-	O
referent	O
setting	O
.	O

PS2217	O
Inactivation	BP
of	IP
the-3	IP
adenomatous	BG
polyposis	IG
coli	IG
gene	IG
product-8	IG
initiates	O
colorectal	O
tumorigenesis	O
.	O

PS2223	O
It	O
will	O
be	O
generalized	O
into	O
the	O
airways	O
of	O
cystic	O
fibrosis	O
patients	O
with	O
hope	O
that	O
normal	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-20	IG
will	O
reverse	O
the	O
physiological	O
defect	O
in	O
cystic	BP
fibrosis-28	IP
cells	O
.	O

PS2228	O
The	O
angiotensin	BG
converting	IG
enzyme-4	IG
insertion	O
deletion	O
polymorphism	O
has	O
been	O
associated	O
with	O
much	O
cardiovascular	O
pathology	O
,	O
including	O
posttransplantation	BP
hypertension-18	IP
.	O

PS2229	O
We	O
investigated	O
the	O
influence	O
of	O
the	O
angiotensin	BG
converting	IG
enzyme-9	IG
insertion	O
deletion	O
polymorphism	O
polymorphism	O
on	O
posttransplantation	BP
hypertension-16	IP
.	O

PS2244	O
A	O
bivariate	O
segregation	O
analysis	O
of	O
genetic	O
hemochromatosis-7	BP
with	O
serum	O
ferritin-10	BG
concentration	O
was	O
undertaken	O
to	O
examine	O
the	O
pleiotropic	O
effect	O
of	O
the	O
hemochromatosis	O
locus	O
on	O
each	O
of	O
the	O
two	O
phenotypes	O
,	O
in	O
an	O
ascertained	O
sample	O
of	O
families	O
from	O
Brittany	O
,	O
France	O
.	O

PS2246	O
OBJECTIVES	O
:	O
To	O
investigate	O
the	O
clinical	O
manifestations	O
associated	O
with	O
the	O
mutation	O
spectrums	O
of	O
the	O
human	BG
cytochrome	IG
P450-17	IG
(	O
CYP1B1-19	BG
)	O
and	O
myocilin-22	BG
genes	O
in	O
South	O
Korean	O
patients	O
with	O
primary	O
congenital	O
glaucoma-31	BP
.	O

PS2259	O
Sixty	O
German	O
families	O
with	O
three	O
or	O
more	O
cases	O
of	O
breast	O
/	O
ovarian	O
cancer-13	BP
with	O
at	O
least	O
two	O
cases	O
diagnosed	O
under	O
the	O
age	O
of	O
60	O
were	O
screened	O
for	O
mutations	O
by	O
SSCP-30	BG
/	O
CSGE-32	BG
and	O
subsequent	O
direct	O
sequencing	O
.	O

PS2277	O
The	O
fetal	O
hemoglobin-3	BG
(	O
HbF-5	BG
)	O
levels	O
and	O
betaS	BG
-	IG
globin	IG
gene-12	IG
haplotypes	O
of	O
125	O
sickle	O
cell	O
anemia-18	BP
patients	O
from	O
Brazil	O
were	O
investigated	O
.	O

PS2300	O
The	O
pyrin	BG
protein-3	IG
is	O
expressed	O
solely	O
in	O
neutrophiles	O
white	O
blood	O
cells	O
which	O
are	O
found	O
in	O
large	O
numbers	O
in	O
the	O
inflammatory	O
sites	O
during	O
Familial	O
Mediterranean	O
fever-25	BP
attacks	O
.	O

PS2303	O
The	O
Multiple	BG
endocrine	IG
neoplasia	IG
type	IG
1	IG
gene-7	IG
encodes	O
menin	O
,	O
a	O
protein	O
involved	O
in	O
many	O
cell	O
functions	O
,	O
such	O
as	O
transcription	O
,	O
genome	O
stability	O
,	O
cell	O
cycling	O
and	O
apoptosis-29	BP
.	O

PS2310	O
We	O
,	O
therefore	O
,	O
analyzed	O
94	O
unrelated	O
families	O
from	O
Germany	O
with	O
inherited	O
medullary	O
thyroid	BP
carcinoma-15	IP
for	O
mutation	O
of	O
the	O
ret	BG
protooncogene-21	IG
.	O

PS2322	O
Sequencing	O
did	O
not	O
reveal	O
any	O
TRPM6-6	BG
or	O
TRPM7	BG
gene-9	IG
mutations	O
in	O
the	O
female	O
Hypomagnesemia	O
with	O
secondary	O
hypocalcemia-17	BP
patient	O
with	O
an	O
X	O
;	O
9	O
translocation	O
.	O

PS2334	O
Low	O
dosages	O
of	O
calcineurin	O
inhibitors	O
were	O
used	O
in	O
our	O
center	O
,	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
incidence	O
of	O
Posttransplantation	BP
diabetes-22	IP
mellitus	O
between	O
the	O
CsA	O
and	O
Tac	BG
groups-29	IG
;	O

PS2356	O
A	O
comparable	O
correlation	O
was	O
obtained	O
when	O
Zidovudine	BP
resistance-8	IP
was	O
analyzed	O
only	O
relative	O
to	O
the	O
T215Y-15	BG
/	O
F-17	BG
mutation	O
.	O

PS2360	O
A	O
comparable	O
correlation	O
was	O
obtained	O
when	O
Zidovudine	BP
resistance-8	IP
was	O
analyzed	O
only	O
relative	O
to	O
the	O
T215Y-15	BG
/	O
F-17	BG
mutation	O
.	O

PS2373	O
Adenylosuccinate	BG
lyase	IG
deficiency-3	IP
is	O
a	O
selectively	O
neuronopathic	O
disorder	O
with	O
psychomotor	BP
retardation-11	IP
and	O
epilepsy-13	BP
as	O
leading	O
traits	O
.	O

PS2375	O
Adenylosuccinate	BG
lyase	IG
deficiency-3	IP
is	O
a	O
selectively	O
neuronopathic	O
disorder	O
with	O
psychomotor	BP
retardation-11	IP
and	O
epilepsy-13	BP
as	O
leading	O
traits	O
.	O

PS2385	O
PRPF8-1	BG
mutations	O
should	O
be	O
suspected	O
in	O
patients	O
with	O
autosomal	O
dominant	O
retinitis	O
pigmentosa-12	BP
and	O
variable	O
expressivity	O
.	O

PS2390	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
/	O
X	O
-	O
linked	O
spastic	BP
paraplegia-10	IP
(	O
PMD	O
/	O
SPG2-14	BG
)	O
comprises	O
a	O
spectrum	O
of	O
diseases	O
that	O
range	O
from	O
severe	O
to	O
quite	O
mild	O
.	O

PS2395	O
We	O
conclude	O
that	O
NOS1-4	BG
variants	O
are	O
present	O
in	O
patients	O
with	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-14	IP
yet	O
show	O
no	O
significant	O
statistical	O
association	O
with	O
the	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-26	IP
phenotype	O
,	O
suggesting	O
at	O
best	O
an	O
adjuvant	O
role	O
for	O
NOS1-36	BG
in	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-41	IP
.	O

PS2444	O
however	O
,	O
the	O
visual	O
evolution	O
in	O
patients	O
with	O
mutations	O
in	O
GUCY2D-11	BG
and	O
cone	BG
-	IG
rod	IG
homeobox-16	IG
remained	O
stable	O
,	O
while	O
individuals	O
with	O
mutations	O
in	O
the	O
RPE65	BG
gene-27	IG
showed	O
progressive	BP
visual	IP
loss-31	IP
.	O

PS2459	O
Recurrent	BG
R162W	IG
mutation	IG
ofkeratin	IG
9-5	IG
has	O
been	O
reported	O
in	O
multiple	O
families	O
with	O
epidermolytic	BP
hyperkeratosis-14	IP
-	O
type	O
hereditary	O
palmoplantar	BP
keratoderma-19	IP
.	O

PS2460	O
We	O
have	O
previously	BP
reported	IP
haploinsufficiency-5	IP
for	O
Sonic	BG
Hedgehog-8	IG
(	O
SHH-10	BG
)	O
as	O
a	O
cause	O
for	O
Holoprosencephaly	O
.	O

PS2462	O
Contemporary	O
hormonal	O
therapy	O
with	O
third	O
-	O
generation	O
aromatase	O
inhibitors	O
for	O
estrogen	BG
-	IG
receptor-13	IG
-	O
positive	O
breast	BP
cancers-17	IP
in	O
postmenopausal	O
women	O
is	O
still	O
facing	O
the	O
challenge	O
of	O
interpatient	O
variability	O
in	O
therapeutic	O
response	O
and	O
intensity	O
of	O
adverse	O
effects	O
.	O

PS2476	O
Oral	O
denopamine	O
,	O
atropine	O
or	O
cilostazol	O
all	O
increase	O
ICa	BG
-	IG
L-11	IG
,	O
and	O
for	O
this	O
reason	O
may	O
be	O
effective	O
in	O
reducing	O
episodes	O
of	O
ventricular	BP
fibrillation-25	IP
.	O

PS2478	O
Recent	O
studies	O
have	O
suggested	O
that	O
a	O
phosphodiester	O
-	O
linked	O
structure	O
on	O
O	O
-	O
mannose	O
is	O
also	O
important	O
for	O
the	O
laminin-20	BG
-	O
binding	O
activity	O
and	O
that	O
mutations	O
in	O
other	O
causative	O
genes	O
of	O
alpha	O
-	O
dystroglycanopathy-34	BP
,	O
such	O
as	O
fukutin-38	BG
(	O
originally	O
identified	O
as	O
the	O
gene	O
responsible	O
for	O
Fukuyama	O
-	O
type	O
congenital	BP
muscular	IP
dystrophy-52	IP
)	O
and	O
LARGE	O
,	O
disrupt	O
the	O
post	O
-	O
phosphoryl	O
structure	O
.	O

PS2486	O
The	O
three	O
stop	O
codon	O
mutants	O
and	O
one	O
of	O
the	O
splice	O
mutants	O
had	O
phenotypes	O
indistinguishable	O
from	O
the	O
Pde6b-17	BG
(	O
rd1-19	BG
)	O
mouse	O
in	O
rapidity	O
of	O
onset	O
of	O
retinal	BP
degeneration-28	IP
,	O
suggesting	O
that	O
they	O
are	O
null	O
alleles	O
.	O

PS2487	O
We	O
studied	O
28	O
individuals	O
from	O
a	O
four	O
-	O
generation	O
Chilean	O
family	O
(	O
ADC54-13	BG
)	O
including	O
13	O
affected	O
individuals	O
with	O
cataracts-20	BP
,	O
microcornea	O
and	O
/	O
or	O
corneal	O
opacity	O
.	O

PS2493	O
In	O
these	O
studies	O
,	O
we	O
also	O
summarized	O
the	O
distribution	O
of	O
HLA	BG
-	IG
DR	IG
antigens-14	IG
in	O
patients	O
with	O
insulin-18	BG
-	O
dependent	O
diabetes	BP
mellitus-22	IP
who	O
presented	O
autoimmune	BP
disorders-26	IP
other	O
than	O
islet	O
cell	O
autoantibodies	O
.	O

PS2495	O
Neuropathologic	O
features	O
in	O
6	O
individuals	O
included	O
frontotemporal	BP
lobar	IP
degeneration-9	IP
with	O
ubiquitin-11	BG
-	O
positive	O
neuronal	O
cytoplasmic	O
and	O
intranuclear	O
inclusions	O
(	O
FTLD	O
-	O
U	O
with	O
NII	O
)	O
.	O

PS2514	O
We	O
studied	O
64	O
nonsmall	O
cell	O
lung	O
cancer-7	BP
patients	O
and	O
37	O
healthy	O
controls	O
of	O
Turkish	O
origin	O
for	O
L	BG
-	IG
myc	IG
gene	IG
polymorphism-21	IG
.	O

PS2517	O
Our	O
results	O
suggested	O
that	O
L	BG
-	IG
myc	IG
gene-8	IG
polymorphism	O
was	O
not	O
a	O
suitable	O
prognostic	O
marker	O
of	O
metastatic	O
development	O
in	O
Turkish	O
nonsmall	O
cell	O
lung	O
cancer-24	BP
patients	O
.	O

PS2518	O
Nevertheless	O
,	O
the	O
influence	O
of	O
gene	O
content	O
of	O
the	O
marker	O
chromosome	O
,	O
particularly	O
the	O
three	O
gamma	BG
-	IG
aminobutyric	IG
acid	IG
-	IG
A	IG
receptor	IG
subunit	IG
genes-24	IG
,	O
may	O
represent	O
the	O
link	O
between	O
epilepsy	O
,	O
mental	BP
retardation-34	IP
,	O
and	O
pervasive	O
developmental	O
disorder	O
.	O

PS2523	O
Our	O
results	O
suggest	O
the	O
absence	O
of	O
an	O
association	O
between	O
the	O
beta	BG
-	IG
fibrinogen	IG
gene	IG
-	IG
148C-16	IG
/	O
T	O
polymorphism	O
and	O
susceptibility	O
to	O
coronary	BP
artery	IP
disease-25	IP
and	O
the	O
possibility	O
that	O
-	O
455G	O
/	O
A	O
polymorphism	O
(	O
in	O
particular	O
,	O
allele	O
A	O
)	O
increases	O
susceptibility	O
to	O
this	O
disease	O
in	O
the	O
Chinese	O
population	O
.	O

PS2527	O
A	O
comprehensive	O
gene	O
-	O
based	O
association	O
study	O
was	O
performed	O
using	O
14	O
tagging	O
single	O
-	O
nucleotide	O
polymorphism	O
of	O
SLC30A8-18	BG
in	O
Han	O
Chinese	O
subjects	O
with	O
normal	O
glucose	O
tolerance	O
,	O
impaired	BP
glucose	IP
regulation-30	IP
,	O
and	O
type	O
2	O
diabetes	O
(	O
n	O
=	O
521	O
)	O
.	O

PS2531	O
Interestingly	O
,	O
this	O
correlation	O
and	O
a	O
link	O
between	O
MYH7-9	BG
mutations	O
and	O
a	O
higher	O
degree	O
of	O
mitral	BP
valve	IP
regurgitation-18	IP
held	O
true	O
for	O
both	O
Hypertrophic	BP
cardiomyopathy-24	IP
and	O
dilated	BP
cardiomyopathy-27	IP
,	O
indicating	O
that	O
the	O
gene	O
affected	O
by	O
a	O
mutation	O
may	O
determine	O
the	O
magnitude	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
both	O
Hypertrophic	BP
cardiomyopathy-49	IP
and	O
dilated	BP
cardiomyopathy-52	IP
.	O

PS2532	O
Germline	O
mutations	O
in	O
four	O
human	O
mismatch	O
repair	O
genes	O
(	O
MSH2-10	BG
,	O
MLH1-12	BG
,	O
PMS1-14	BG
,	O
and	O
PMS2	O
)	O
have	O
been	O
reported	O
to	O
cause	O
hereditary	O
non	O
-	O
polyposis	O
colon	O
cancer-29	BP
syndrome	O
.	O

PS2540	O
Maternal	O
alloantibodies	O
against	O
HPA	BG
-	IG
1a-6	IG
can	O
cross	O
placenta	O
,	O
opsonize	O
foetal	O
platelets	O
,	O
and	O
induce	O
neonatal	BP
alloimmune	IP
thrombocytopenia-19	IP
.	O

PS2542	O
We	O
investigated	O
the	O
association	O
of	O
the	O
intron	O
4	O
polymorphism	O
of	O
the	O
endothelial	BG
nitric	IG
oxide	IG
synthase-15	IG
gene	O
with	O
coronary	BP
artery	IP
disease-20	IP
.	O

PS2545	O
The	O
endothelial	BG
nitric	IG
oxide	IG
synthase	IG
intron	IG
4	IG
polymorphism-8	IG
may	O
be	O
a	O
marker	O
of	O
multi	O
-	O
vessel	O
coronary	BP
artery	IP
disease-19	IP
in	O
African	O
Americans	O
and	O
Caucasians	O
.	O

PS2554	O
Mutations	O
in	O
the	O
genes	O
for	O
endoglin-6	BG
and	O
for	O
activin	BG
A	IG
receptor	IG
type	IG
II	IG
-	IG
like	IG
kinase	IG
1-17	IG
have	O
been	O
identified	O
to	O
cause	O
haemorrhagic	BP
teleangiectasia-24	IP
.	O

PS2565	O
Because	O
invasiveness	O
is	O
partially	O
dictated	O
by	O
the	O
proteins	O
these	O
tumors	O
secrete	O
we	O
used	O
SILAC	O
to	O
characterize	O
the	O
secretomes	O
of	O
four	O
glioblastoma-21	BP
cell	O
lines	O
(	O
LN18-25	BG
,	O
T98-27	BG
,	O
U118-29	BG
and	O
U87-31	BG
)	O
.	O

PS2571	O
In	O
recent	O
years	O
,	O
a	O
candidate	O
gene	O
for	O
HLA-9	BG
-	O
linked	O
hemochromatosis-12	BP
,	O
HFE	O
,	O
has	O
been	O
cloned	O
,	O
and	O
a	O
single	O
G	O
-	O
to	O
-	O
A	O
mutation	O
resulting	O
in	O
a	O
cysteine	O
-	O
to	O
-	O
tyrosine	O
substitution	O
(	O
C282Y	O
)	O
has	O
been	O
identified	O
in	O
up	O
to	O
80	O
%	O
of	O
study	O
patients	O
with	O
type	O
1	O
hereditary	O
hemochromatosis-56	BP
.	O

PS2577	O
The	O
ability	O
of	O
the	O
olfactory	O
system	O
to	O
detect	O
chemicals	O
at	O
sub	O
-	O
nanomolar	O
concentrations	O
is	O
explained	O
by	O
a	O
plethora-19	BP
of	O
amplification	O
devices	O
,	O
including	O
the	O
coupling	O
of	O
receptors	O
to	O
second	O
messenger	O
generation	O
through	O
GTP	BG
-	IG
binding	IG
proteins-37	IG
.	O

PS2580	O
As	O
in	O
all	O
other	O
forms	O
of	O
dystrophic	O
epidermolysis	BP
bullosa-9	IP
,	O
the	O
molecular	O
pathology	O
involves	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
anchoring	O
fibril	O
protein	O
,	O
type	BG
VII	IG
collagen-27	IG
(	O
COL7A1-29	BG
)	O
,	O
but	O
there	O
is	O
no	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
epidermolysis	BP
bullosa	IP
pruriginosa-44	IP
.	O

PS2589	O
There	O
was	O
a	O
significant	O
correlation	O
between	O
Epidermal	BG
growth	IG
factor	IG
receptor	IG
Sp1	IG
-	IG
216	IG
G-14	IG
/	O
T-16	BG
polymorphism	O
and	O
treatment	O
response	O
to	O
chemoradiation	O
in	O
locally	O
advanced	O
rectal	BP
cancer-27	IP
.	O

PS2601	O
Genotyping	O
/	O
haplotyping	O
in	O
the	O
three	O
-	O
generation	O
family	O
with	O
hypochondroplasia-11	BP
showed	O
that	O
FGFR1-14	BG
,	O
FGFR2-16	BG
and	O
fibroblast	BG
growth	IG
factor	IG
receptor	IG
3	IG
genes-23	IG
were	O
not	O
linked	O
to	O
the	O
hypochondroplasia	O
phenotype	O
in	O
this	O
family	O
,	O
thus	O
further	O
confirming	O
the	O
genetic	O
heterogeneity	O
of	O
hypochondroplasia-42	BP
.	O

PS2630	O
In	O
the	O
elevated	O
red	O
cell	O
ferritin	O
group	O
,	O
21	O
individuals	O
had	O
associated	O
normal	O
plasma	O
ferritin-15	BG
,	O
and	O
23	O
had	O
increased	BP
plasma-21	IP
ferritin-22	BG
.	O

PS2635	O
The	O
higher	O
RR	O
found	O
for	O
the	O
same	O
genotype	O
in	O
distinct	O
populations	O
confirmed	O
that	O
cytochrome	BG
P450	IG
2E1	IG
enzyme-17	IG
is	O
one	O
of	O
several-21	BP
Nasopharyngeal	BG
carcinoma	IG
susceptibility	IG
genes-25	IG
and	O
that	O
the	O
RsaI-29	BG
minus	O
variant	O
is	O
one	O
mutation	O
that	O
affects	O
phenotype	O
.	O

PS2638	O
glycyl	BG
-	IG
tRNA	IG
synthetase-4	IG
(	O
GARS-6	BG
)	O
,	O
dynactin	BG
1-10	IG
(	O
dynactin	BG
1-13	IG
)	O
,	O
small	BG
heat	IG
shock	IG
27	IG
kDa	IG
protein	IG
1-22	IG
(	O
HSPB1-24	BG
)	O
,	O
small	BG
heat	IG
shock	IG
22	IG
kDa	IG
protein	IG
8-33	IG
(	O
HSPB8-35	BG
)	O
,	O
Berardinelli	O
-	O
Seip	O
congenital	BP
lipodystrophy-42	IP
(	O
BSCL2	O
)	O
and	O
senataxin	O
.	O

PS2660	O
Since	O
gliomas-2	BP
have	O
regions	O
of	O
diminished	O
oxygenation	O
,	O
and	O
have	O
clinical	O
resistance	O
to	O
chemotherapy	O
,	O
the	O
relationship	O
between	O
phenotypic	O
resistance	O
to	O
chemotherapy	O
after	O
hypoxic	O
exposure	O
and	O
expression	O
of	O
drug	O
resistance	O
genes	O
was	O
investigated	O
in	O
glioma-35	BP
cell	O
lines	O
(	O
U373	BG
MG-40	IG
,	O
PFAT	BG
-	IG
MT-44	IG
)	O
.	O

PS2679	O
This	O
indicates	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
nephropathy-9	BP
within	O
this	O
family	O
cannot	O
be	O
attributed	O
to	O
the	O
LMX1B	BG
genotype-19	IG
.	O

PS2680	O
This	O
indicates	O
that	O
the	O
incidence	O
and	O
severity	O
of	O
nephropathy-9	BP
within	O
this	O
family	O
cannot	O
be	O
attributed	O
to	O
the	O
LMX1B	BG
genotype-19	IG
.	O

PS2686	O
We	O
screened	O
four	O
Italian	O
children	O
with	O
hyperprolinemia-7	BP
presenting	O
epilepsy	O
,	O
mental	BP
retardation-12	IP
,	O
and	O
behavioral	BP
disorders-16	IP
for	O
proline	BG
dehydrogenase	IG
gene-20	IG
mutations	O
,	O
and	O
attempted	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS2699	O
We	O
studied	O
angiotensin	BG
-	IG
converting	IG
enzyme-6	IG
and	O
chymase	BG
-	IG
1-10	IG
polymorphisms	O
in	O
patients	O
with	O
systolic	O
heart	BP
failure-17	IP
and	O
the	O
correlation	O
with	O
clinical	O
status	O
and	O
left	O
ventricular	O
function	O
.	O

PS2725	O
More	O
recently	O
,	O
recessive	O
RYR1	BG
mutations-6	IG
have	O
been	O
described	O
in	O
few	O
congenital	BP
myopathy-13	IP
patients	O
with	O
variable	O
pathology	O
,	O
including	O
multi	O
-	O
minicores	O
.	O

PS2734	O
Since	O
the	O
isolation	O
of	O
the	O
gene	O
responsible	O
for	O
steroid	BG
21	IG
-	IG
hydroxylase-12	IG
deficiency	O
(	O
involved	O
in	O
about	O
90	O
%	O
of	O
the	O
cases	O
of	O
Congenital	BP
adrenal	IP
hyperplasia-26	IP
)	O
in	O
1984	O
,	O
knowledge	O
of	O
the	O
specific	O
mutations	O
that	O
cause	O
the	O
different	O
forms	O
of	O
Congenital	BP
adrenal	IP
hyperplasia-44	IP
has	O
grown	O
rapidly	O
.	O

PS2745	O
We	O
determined	O
the	O
indices	O
of	O
left	O
ventricular	O
hypertrophy	O
in	O
patients	O
with	O
beta	BG
-	IG
beta	IG
-	IG
myosin	IG
heavy	IG
chain-18	IG
mutations	O
associated	O
with	O
high	O
,	O
moderate	O
,	O
and	O
low	O
incidence	O
of	O
sudden	BP
cardiac	IP
death-32	IP
.	O

PS2747	O
Autosomal	O
-	O
recessive	O
agammaglobulinemia-4	BP
is	O
a	O
rare	O
and	O
heterogeneous	O
disorder	O
,	O
characterized	O
by	O
early	O
-	O
onset	O
infections	O
,	O
profound	O
hypogammaglobulinemia-20	BP
of	O
all	O
immunoglobulin	BG
isotypes-24	IG
and	O
absence	O
of	O
circulating	O
B	O
lymphocytes	O
.	O

PS2751	O
There	O
are	O
,	O
however	O
,	O
controversial	O
reports	O
that	O
tumour	BG
necrosis	IG
factor	IG
-	IG
alpha	IG
promoter-14	IG
polymorphism	O
may	O
be	O
an	O
independent	O
marker	O
of	O
susceptibility	O
and	O
severity	O
of	O
Rheumatoid	BP
arthritis-27	IP
.	O

PS2754	O
We	O
suggest	O
that	O
tumour	BG
necrosis	IG
factor	IG
-	IG
alpha	IG
-	IG
308	IG
promoter-11	IG
polymorphism	O
is	O
not	O
a	O
genetic	O
risk	O
factor	O
for	O
Rheumatoid	BP
arthritis-21	IP
susceptibility	O
and	O
severity	O
.	O

PS2766	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
gene	O
fusions	O
involving	O
the	O
ETS	BG
gene	IG
family-13	IG
in	O
Japanese	O
prostate	BP
cancer-17	IP
.	O

PS2770	O
Accordingly	O
,	O
siRNA	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
SIPA1-10	BG
exerted	O
significant	O
effects	O
on	O
clonogenicity	O
,	O
adherence	O
and	O
migration	O
in	O
aggressive	BP
melanoma	IP
models-23	IP
.	O

PS2788	O
The	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
NTRK1-7	BG
and	O
WNK1-9	BG
/	O
HSN2-11	BG
typically	O
consisted	O
of	O
congenital	BP
insensitivity	IP
to	IP
pain-18	IP
and	O
anhidrosis	O
,	O
and	O
early	O
-	O
onset	O
ulcero	O
-	O
mutilating	O
sensory	O
neuropathy-30	BP
,	O
respectively	O
.	O

PS2798	O
A	O
Japanese	O
family	O
with	O
cold	O
-	O
induced	O
myotonia	O
and	O
weakness-10	BP
was	O
diagnosed	O
as	O
having	O
Paramyotonia	O
congenita	O
of	O
von	BG
Eulenburg-19	IG
.	O

PS2804	O
We	O
treated	O
the	O
primary	O
adipocytes	O
with	O
high	O
glucose	O
plus	O
insulin-10	BG
because	O
of	O
a	O
close	O
relation	O
between	O
insulin	BG
resistance-18	IP
and	O
obesity-20	BP
.	O

PS2835	O
We	O
investigated	O
32	O
hepatitis	BG
C	IG
virus	IG
reverse	IG
transcriptase-8	IG
-	O
polymerase	O
chain	O
reaction	O
positive	O
hepatocellular	BP
carcinoma-15	IP
cases	O
and	O
18	O
morphologically	O
normal	O
hepatic	O
tissues	O
distant	O
to	O
tumors	O
(	O
MNT	O
)	O
for	O
the	O
correlation	O
between	O
hepatitis	BG
C	IG
virus	IG
-	IG
NS3P-37	IG
,	O
p53-39	BG
,	O
p21-41	BG
(	O
waf-43	BG
)	O
,	O
mdm2-46	BG
,	O
p21ras-48	BG
and	O
c	BG
-	IG
erbB2-52	IG
and	O
DNA	O
content	O
by	O
immunohistochemistry	O
and	O
image	O
analysis	O
.	O

PS2844	O
Although	O
the	O
patients	O
with	O
TSC2-5	BG
mutations	O
tend	O
to	O
exhibit	O
relatively	O
severe	O
mental	BP
retardation-13	IP
in	O
comparison	O
to	O
those	O
with	O
TSC1	BG
mutations-20	IG
,	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
could	O
not	O
yet	O
be	O
established	O
.	O

PS2847	O
Autosomal	O
dominant	O
Centronuclear	O
myopathy-4	BP
is	O
due	O
to	O
mutations	O
in	O
the	O
large	O
GTPase	BG
dynamin	IG
2-14	IG
,	O
a	O
mechanochemical	O
enzyme	O
regulating	O
cytoskeleton	O
and	O
membrane	O
trafficking	O
in	O
cells	O
.	O

PS2850	O
Current	O
methods	O
for	O
the	O
molecular	O
diagnosis	O
of	O
the	O
21	O
-	O
hydroxylase-11	BG
deficiency	O
variant	O
of	O
congenital	BP
adrenal	IP
hyperplasia-17	IP
use	O
cumbersome	O
combinations	O
of	O
Southern	O
blotting	O
and	O
polymerase	O
chain	O
reaction	O
.	O

PS2851	O
The	O
clinical	O
manifestations	O
of	O
GSD	BG
III-6	IG
are	O
represented	O
by	O
hepatomegaly-10	BP
,	O
hypoglycemia-12	BP
,	O
hyperlipidemia-14	BP
,	O
short	BP
stature-17	IP
and	O
,	O
in	O
a	O
number	O
of	O
subjects	O
,	O
cardiomyopathy-26	BP
and	O
myopathy-28	BP
.	O

PS2858	O
HLA	BG
alleles-2	IG
were	O
only	O
the	O
markers	O
of	O
hemochromatosis-8	BP
allele	O
(	O
H	O
)	O
and	O
were	O
not	O
implicated	O
in	O
other	O
iron	O
overload	O
.	O

PS2860	O
The	O
common	O
clinical	O
features	O
observed	O
in	O
patients	O
with	O
dup	O
(	O
X	O
)	O
(	O
q28-14	BG
)	O
are	O
severe	O
ID	O
,	O
infantile	O
hypotonia-21	BP
,	O
mild	O
dysmorphic	O
features	O
and	O
a	O
history	O
of	O
recurrent	O
infections	O
,	O
and	O
methyl	O
CpG	O
binding	O
protein	O
2	O
duplication	O
syndrome	O
is	O
now	O
recognized	O
as	O
a	O
clinical	O
entity	O
.	O

PS2865	O
The	O
lack	O
of	O
genotype	O
and	O
phenotype	O
correlation	O
and	O
issues	O
of	O
predictive	O
genetic	O
testing	O
within	O
Frontotemporal	O
dementia	O
families	O
are	O
the	O
subject	O
of	O
case	O
3	O
,	O
and	O
case	BG
4-27	IG
shows	O
how	O
normal	O
aging	O
language	O
difficulties	O
and	O
cognitive	BP
changes-36	IP
can	O
be	O
misinterpreted	O
when	O
a	O
family	O
history	O
of	O
dementia	O
is	O
present	O
.	O

PS2873	O
Although	O
we	O
did	O
not	O
find	O
any	O
new	O
mutations	O
,	O
our	O
results	O
may	O
be	O
consistent	O
with	O
the	O
presence	O
of	O
yet	O
-	O
unidentified	O
mutations	O
of	O
CYP2C19-24	BG
that	O
causes	O
decreased-27	BP
CYP2C19	BG
activity-29	IP
in	O
the	O
Tanzanian	O
population	O
.	O

PS2874	O
Apolipoprotein	BG
E-2	IG
-	O
deficient	O
mice	O
on	O
6	O
inbred	O
genetic	O
backgrounds	O
were	O
compared	O
for	O
atherosclerosis-14	BP
lesion	O
size	O
in	O
the	O
aortic	O
root	O
in	O
2	O
independent	O
studies	O
.	O

PS2877	O
In	O
conclusion	O
,	O
this	O
meta	O
-	O
analysis	O
provides	O
strong	O
evidence	O
that	O
cytochrome	BG
P450	IG
1A1-14	IG
T3801C	O
polymorphism	O
is	O
not	O
associated	O
with	O
breast	BP
cancer-22	IP
risk	O
.	O

PS2897	O
Myopia-1	BP
was	O
associated	O
with	O
BBS3-5	BG
and	O
BBS4-7	BG
,	O
but	O
not	O
BBS2-11	BG
.	O

PS2905	O
Our	O
results	O
show	O
no	O
effect	O
of	O
the	O
apolipoprotein	BG
E	IG
genotype-10	IG
on	O
the	O
severity	O
of	O
multiple	O
sclerosis-16	BP
measured	O
by	O
multiple	O
sclerosisSS	O
,	O
as	O
a	O
recently	O
published	O
meta	O
-	O
analysis	O
has	O
noticed	O
.	O

PS2909	O
A	O
recent	O
study	O
found	O
a	O
high	O
prevalence	O
of	O
a	O
missense	O
mutation	O
(	O
S135L	O
)	O
in	O
the	O
gene	O
for	O
galactose	BG
1	IG
-	IG
phosphate	IG
uridyltransferase-23	IG
in	O
black	O
children	O
with	O
galactosemia-28	BP
(	O
J	O
Pediatr	O
1996	O
;	O
128	O
:	O
89	O
-	O
95	O
)	O
.	O

PS2926	O
To	O
identify	O
novel	O
or	O
rare	O
rhodopsin	BG
gene-7	IG
mutations	O
in	O
patients	O
with	O
autosomal	O
dominant	O
retinitis	BP
pigmentosa-15	IP
and	O
description	O
of	O
their	O
clinical	O
phenotype	O
.	O

PS2933	O
A	O
generalizable	O
genetic	O
scoring	O
algorithm	O
based	O
on	O
seven	O
HLA	BG
class	IG
I	IG
and	IG
coreceptor	IG
markers-14	IG
is	O
highly	O
predictive	O
of	O
viremia-19	BP
and	O
immunodeficiency	O
in	O
HIV	O
-	O
1	O
-	O
infected	O
adolescents	O
.	O

PS2938	O
To	O
study	O
cardiac	O
troponin	BG
T-5	IG
(	O
TNNT2-7	BG
)	O
gene	O
mutations	O
in	O
Chinese	O
patients	O
with	O
hypertrophic	BP
cardiomyopathy-16	IP
and	O
analyze	O
the	O
correlation	O
between	O
the	O
genotype	O
and	O
phenotype	O
.	O

PS2940	O
This	O
study	O
did	O
not	O
find	O
any	O
hypertrophic	BP
cardiomyopathy-8	IP
-	O
caused	O
mutations	O
in	O
TNNT2	BG
gene-14	IG
,	O
a	O
result	O
different	O
from	O
the	O
reported	O
rates	O
of	O
TNNT2	BG
gene-25	IG
mutation	O
ranging	O
from	O
10	O
%	O
to	O
20	O
%	O
in	O
other	O
nations	O
,	O
suggesting	O
that	O
TNNT2	BG
gene-41	IG
is	O
not	O
a	O
susceptible	O
gene	O
for	O
hypertrophic	BP
cardiomyopathy-49	IP
in	O
Chinese	O
population	O
.	O

PS2952	O
To	O
elucidate	O
the	O
relationships	O
between	O
morphological	O
phenotype	O
and	O
genetic	O
profile	O
,	O
we	O
screened	O
19	O
oligodendrogliomas	O
(	O
WHO	O
grade	O
II	O
)	O
and	O
23	O
low	O
-	O
grade	O
diffuse	O
astrocytomas-27	BP
(	O
WHO	O
grade	O
II	O
)	O
for	O
TP53	BG
mutations-35	IG
and	O
loss	O
of	O
heterozygosity	O
on	O
1p	O
and	O
19q	O
.	O

PS2978	O
We	O
extended	O
our	O
investigations	O
of	O
Crumbs	BG
homologue	IG
1-8	IG
in	O
these	O
retinal	BP
dystrophies-12	IP
,	O
and	O
identified	O
nine	O
novel	O
Crumbs	BG
homologue	IG
1	IG
sequence	IG
variants-22	IG
.	O

PS2982	O
In	O
apical	O
hypertrophic	BP
cardiomyopathy-4	IP
,	O
a	O
positive	O
genotype	O
was	O
found	O
less	O
frequently	O
than	O
in	O
nonapical	O
hypertrophic	BP
cardiomyopathy-17	IP
,	O
and	O
it	O
was	O
most	O
often	O
involving	O
MYBPC3-25	BG
and	O
MYH7	BG
genes-28	IG
.	O

PS2992	O
While	O
the	O
etiopathology	O
remains	O
unsolved	O
,	O
a	O
disruption	O
in	O
the	O
endocrine	O
/	O
autocrine	O
-	O
paracrine	O
prostatic	O
homeostasis	O
,	O
involving	O
steroid	BG
hormones-21	IG
,	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
Benign	O
prostatic	BP
hyperplasia-30	IP
.	O

PS3008	O
Our	O
results	O
highlight	O
the	O
critical	O
role	O
of	O
nonmuscle	O
myosin	BG
heavy	IG
chain	IG
IIA-12	IG
in	O
the	O
development	O
of	O
focal	BP
segmental	IP
glomerulosclerosis-19	IP
.	O

PS3031	O
Digital	O
photographs	O
of	O
45	O
individuals	O
with	O
PHOX2B-7	BG
-	O
confirmed	O
Congenital	BP
central	IP
hypoventilation-12	IP
syndrome	O
,	O
and	O
45	O
matched	O
controls	O
were	O
analyzed	O
for	O
17	O
linear	O
and	O
6	O
angular	O
measurements	O
,	O
and	O
9	O
derived	O
indices	O
.	O

PS3034	O
We	O
present	O
here	O
,	O
the	O
clinical	O
and	O
radiographic	O
details	O
along	O
with	O
,	O
results	O
of	O
mutational	O
analysis	O
of	O
the	O
carbonic	BG
anhydrase	IG
2	IG
gene-22	IG
in	O
an	O
individual	O
clinically	O
diagnosed	O
with	O
renal	BP
tubular	IP
acidosis-31	IP
,	O
osteopetrosis-33	BP
and	O
mental	BP
retardation-36	IP
and	O
his	O
family	O
members	O
to	O
establish	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS3038	O
In	O
the	O
same	O
apo	O
(	O
a	O
)	O
phenotypes	O
,	O
the	O
patients	O
with	O
diabetic	BP
retinopathy-14	IP
had	O
higher	O
Lp-17	BG
(	O
a	O
)	O
concentrations	O
than	O
those	O
without	O
diabetic	BP
retinopathy-26	IP
.	O

PS3040	O
In	O
vitro	O
sulfadoxine	O
and	O
pyrimethamine	BP
resistance-6	IP
has	O
been	O
associated	O
with	O
point	O
mutations	O
in	O
the	O
dihydropteroate	BG
synthase-16	IG
and	O
dihydrofolate	BG
reductase	IG
domains-20	IG
,	O
respectively	O
,	O
but	O
the	O
in	O
vivo	O
relevance	O
of	O
these	O
point	O
mutations	O
has	O
not	O
been	O
well	O
established	O
.	O

PS3052	O
Our	O
objective	O
was	O
to	O
investigate	O
TDP	BG
-	IG
43	IG
plasma-9	IG
levels	O
in	O
patients	O
with	O
amyotrophic	BP
lateral	IP
sclerosis-16	IP
.	O

PS3056	O
In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
TDP	BG
-	IG
43	IG
plasma-11	IG
levels	O
may	O
have	O
potential	O
as	O
a	O
marker	O
for	O
amyotrophic	BP
lateral	IP
sclerosis-22	IP
.	O

PS3063	O
Recent	O
studies	O
investigating	O
the	O
association	O
of	O
DNA	O
variants	O
in	O
the	O
metabotropic	BG
glutamate	IG
receptor	IG
gene-14	IG
(	O
GRM3-16	BG
)	O
with	O
schizophrenia-19	BP
susceptibility	O
revealed	O
conflicting	O
results	O
.	O

PS3090	O
Four	O
different	O
forms	O
of	O
isolated	O
methylmalonic	O
aciduria	O
have	O
been	O
described	O
:	O
mut	O
methylmalonic	O
aciduria-14	BP
associated	O
with	O
defects	O
in	O
the	O
methylmalonyl	BG
-	IG
CoA	IG
mutase-23	IG
apoenzyme	O
,	O
and	O
phenotypically	O
divided	O
into	O
two	O
subtypes	O
mut	O
-	O
and	O
mut0-35	BG
methylmalonic	O
aciduria-37	BP
,	O
and	O
three	O
different	O
defects	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
active	O
form	O
of	O
the	O
cofactor	O
adenosylcobalamin	O
,	O
termed	O
cbl-57	BG
methylmalonic	O
aciduria-59	BP
,	O
and	O
classified	O
into	O
three	O
different	O
complementation	O
groups	O
cblA-68	BG
,	O
cblB-70	BG
,	O
and	O
cblH-73	BG
associated	O
with	O
defects	O
in	O
the	O
methylmalonic	BG
aciduriaA	IG
and	IG
methylmalonic	IG
aciduriaB	IG
genes-84	IG
and	O
with	O
an	O
unidentified	O
protein	O
,	O
respectively	O
.	O

PS3105	O
In	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
rs17375018	O
in	O
ulcerative	O
colitis-10	BP
,	O
clinical	O
severity	O
was	O
associated	O
with	O
the	O
prevalence	O
of	O
the	O
G	BG
allele-22	IG
showed	O
a	O
trend	O
to	O
mild	O
activity	O
.	O

PS3111	O
But	O
few	O
H63D	BG
homozygotes-4	IG
with	O
clinical	O
manifestations	O
of	O
hereditary	O
haemochromatosis-10	BP
have	O
been	O
reported	O
.	O

PS3112	O
Additionally	O
,	O
we	O
sequenced	O
the	O
HFE	BG
gene-7	IG
of	O
H63D	BG
homozygotes-10	IG
with	O
haemochromatosis-12	BP
.	O

PS3114	O
But	O
few	O
H63D	BG
homozygotes-4	IG
with	O
clinical	O
manifestations	O
of	O
hereditary	O
haemochromatosis-10	BP
have	O
been	O
reported	O
.	O

PS3115	O
Additionally	O
,	O
we	O
sequenced	O
the	O
HFE	BG
gene-7	IG
of	O
H63D	BG
homozygotes-10	IG
with	O
haemochromatosis-12	BP
.	O

PS3118	O
forkhead	BG
box	IG
protein	IG
01A	IG
fragment-5	IG
determination	O
in	O
serum	O
with	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
mass	O
spectrometry	O
might	O
be	O
a	O
promising	O
approach	O
for	O
early	O
detection	O
of	O
colon	BP
carcinoma-29	IP
or	O
for	O
the	O
development	O
of	O
targeted	O
therapies	O
.	O

PS3129	O
GJB2-1	BG
-	O
associated	O
hearing	BP
loss-5	IP
was	O
linked	O
with	O
progressive	O
hearing	BP
loss-11	IP
or	O
with	O
recurrent	O
sudden	O
sensorineural	O
hearing	BP
loss-18	IP
in	O
three	O
of	O
15	O
cases	O
being	O
analysed	O
retrospectively	O
.	O

PS3130	O
We	O
extended	O
the	O
phenotypic	O
spectrum	O
of	O
GJB2-7	BG
-	O
related	O
disease	O
and	O
recommend	O
GJB2	O
mutation	O
screening	O
also	O
in	O
cases	O
of	O
progressive	O
hearing	BP
loss-22	IP
,	O
and	O
recurrent	O
SSNhearing	O
loss	O
.	O

PS3132	O
GJB2-1	BG
-	O
associated	O
hearing	BP
loss-5	IP
was	O
linked	O
with	O
progressive	O
hearing	BP
loss-11	IP
or	O
with	O
recurrent	O
sudden	O
sensorineural	O
hearing	BP
loss-18	IP
in	O
three	O
of	O
15	O
cases	O
being	O
analysed	O
retrospectively	O
.	O

PS3133	O
We	O
extended	O
the	O
phenotypic	O
spectrum	O
of	O
GJB2-7	BG
-	O
related	O
disease	O
and	O
recommend	O
GJB2	O
mutation	O
screening	O
also	O
in	O
cases	O
of	O
progressive	O
hearing	BP
loss-22	IP
,	O
and	O
recurrent	O
SSNhearing	O
loss	O
.	O

PS3134	O
In	O
this	O
study	O
,	O
we	O
determined	O
the	O
GSTM1-8	BG
and	O
GSTT1-10	BG
genotypes	O
in	O
104	O
family	O
members	O
representing	O
19	O
Korean	O
Hereditary	O
non	O
-	O
polyposis	O
colorectal	BP
cancers-24	IP
carrying	O
hMLH1-26	BG
/	O
hMSH2-28	BG
mutation	O
,	O
and	O
investigated	O
the	O
influence	O
of	O
GSTM1-36	BG
and	O
GSTT1-38	BG
geno	O
-	O
/	O
phenotype	O
status	O
on	O
both	O
age	O
at	O
diagnosis	O
of	O
CRC	O
and	O
cancer-52	BP
occurrence	O
.	O

PS3151	O
Seven	O
different	O
missense	O
mutations	O
in	O
exons	O
1	O
and	O
3	O
varied	O
in	O
their	O
biological	O
consequences	O
from	O
a	O
minimal	O
VHL	BG
2-19	IG
phenotype	O
with	O
pheochromocytoma-22	BP
only	O
to	O
a	O
full	O
VHL	BG
2-28	IG
phenotype	O
with	O
RCC	O
and	O
pancreatic	BP
lesion-34	IP
.	O

PS3154	O
Expression	O
studies	O
of	O
the	O
wild	O
type	O
and	O
mutant	O
forms	O
of	O
UCP2-11	BG
should	O
clarify	O
the	O
functional	O
consequences	O
these	O
polymorphisms	O
may	O
have	O
on	O
energy	O
metabolism	O
and	O
body	BP
weight	IP
regulation-27	IP
.	O

PS3164	O
To	O
screen	O
MYBPC3	BG
gene-4	IG
mutations	O
in	O
Chinese	O
patients	O
with	O
Hypertrophic	O
cardiomyopathy-11	BP
,	O
and	O
analyze	O
the	O
correlation	O
between	O
the	O
genotype	O
and	O
the	O
phenotype	O
.	O

PS3165	O
Compared	O
with	O
what	O
was	O
reported	O
abroad	O
,	O
the	O
MYBPC3	BG
gene-10	IG
is	O
a	O
common	O
pathogenic	O
gene	O
responsible	O
for	O
Hypertrophic	BP
cardiomyopathy-19	IP
in	O
Chinese	O
patients	O
,	O
and	O
the	O
phenotypes	O
of	O
these	O
two	O
mutations	O
in	O
their	O
respective	O
families	O
may	O
have	O
their	O
own	O
clinical	O
characteristics	O
.	O

PS3171	O
Compared	O
to	O
mainstream	BG
MEN	IG
1-5	IG
,	O
MEN	BG
1Burin-8	IG
is	O
characterized	O
by	O
a	O
high	O
prevalence	O
of	O
prolactin-16	BG
-	O
secreting	O
pituitary	BP
adenomas-20	IP
,	O
late	O
-	O
onset	O
of	O
hyperparathyroidism-26	BP
and	O
rare	O
pancreatic	O
involvement	O
.	O

PS3173	O
Compared	O
to	O
mainstream	BG
MEN	IG
1-5	IG
,	O
MEN	BG
1Burin-8	IG
is	O
characterized	O
by	O
a	O
high	O
prevalence	O
of	O
prolactin-16	BG
-	O
secreting	O
pituitary	BP
adenomas-20	IP
,	O
late	O
-	O
onset	O
of	O
hyperparathyroidism-26	BP
and	O
rare	O
pancreatic	O
involvement	O
.	O

PS3180	O
Furthermore	O
,	O
we	O
observed	O
an	O
interesting	O
correlation	O
between	O
Na	O
(	O
+	O
)	O
,	O
K	BG
(	IG
+	IG
)	IG
-	IG
ATPase-19	IG
activity	O
and	O
mood	O
that	O
may	O
relate	O
to	O
both	O
unipolar	O
depression-29	BP
and	O
bipolar	BP
disorder-32	IP
.	O

PS3181	O
Pharmaceuticals	O
that	O
increase	O
Na	O
(	O
+	O
)	O
,	O
K	BG
(	IG
+	IG
)	IG
-	IG
ATPase-14	IG
activity	O
or	O
block	O
endogenous	O
Na	O
(	O
+	O
)	O
,	O
K	BG
(	IG
+	IG
)	IG
-	IG
ATPase-29	IG
inhibition	O
may	O
provide	O
effective	O
treatment	O
for	O
depressive	BP
disorders-37	IP
and	O
preclude	O
depression-40	BP
in	O
susceptible	O
individuals	O
.	O

PS3211	O
One	O
child	O
had	O
high	O
serum	O
total	O
cholesterol	O
level	O
,	O
5	O
had	O
low	O
serum	O
high	BG
density	IG
lipoprotein	IG
cholesterol-17	IG
level	O
and	O
all	O
other	O
children	O
had	O
normal	O
serum	O
total	O
cholesterol	O
,	O
Low	BG
density	IG
lipoprotein	IG
cholesterol	IG
,	IG
high	IG
density	IG
lipoprotein	IG
cholesterol-37	IG
and	O
triglyceride	O
levels	O
from	O
children	O
with	O
hyperhomocysteinemia-44	BP
and	O
/	O
or	O
high	O
plasma	O
thiobarbituric	O
acid	O
reactive	O
system	O
levels	O
.	O

PS3214	O
In	O
the	O
present	O
study	O
we	O
have	O
undertaken	O
mutational	O
and	O
haplotype	O
analysis	O
of	O
ABCA4-13	BG
in	O
three	O
mixed	O
pedigrees	O
segregating	O
different	O
retinal	BP
dystrophies-21	IP
.	O

PS3216	O
In	O
the	O
present	O
study	O
we	O
have	O
undertaken	O
mutational	O
and	O
haplotype	O
analysis	O
of	O
ABCA4-13	BG
in	O
three	O
mixed	O
pedigrees	O
segregating	O
different	O
retinal	BP
dystrophies-21	IP
.	O

PS3230	O
Both	O
the	O
haplotype	O
distribution	O
and	O
the	O
mutational	O
spectrum	O
of	O
the	O
phenylalanine	BG
hydroxylase-12	IG
gene	O
has	O
been	O
defined	O
for	O
the	O
Chilean	O
phenylketonuria-20	BP
population	O
.	O

PS3237	O
A	O
cohort	O
of	O
606	O
Israeli	O
inflammatory	O
bowel	O
disease	O
patients	O
(	O
453	O
with	O
Crohn	O
'	O
s	O
disease	O
[	O
CD	O
]	O
and	O
153	O
with	O
ulcerative	BP
colitis-24	IP
[	O
UC	O
]	O
)	O
and	O
528	O
ethnically	O
matched	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
null	O
variants	O
of	O
glutathione	BG
S	IG
-	IG
transferaseM1-45	IG
and	O
glutathione	BG
S	IG
-	IG
transferaseT1-50	IG
.	O

PS3238	O
Comparing	O
inflammatory	BP
bowel	IP
disease-4	IP
patients	O
(	O
both	O
CD	O
and	O
UC	O
)	O
to	O
healthy	O
controls	O
revealed	O
a	O
pattern	O
of	O
lower	O
glutathione	BG
S	IG
-	IG
transferaseM1-23	IG
-	O
null	O
and	O
higher	O
glutathione	BG
S	IG
-	IG
transferaseT1-31	IG
-	O
null	O
frequencies	O
,	O
which	O
reached	O
significance	O
in	O
Arab	O
Moslem	O
patients	O
.	O

PS3240	O
To	O
better	O
characterize	O
the	O
genetic	O
and	O
clinical	O
spectrum	O
of	O
Familial	O
hemophagocytic	O
lymphohistiocytosis5	O
,	O
we	O
analyzed	O
a	O
cohort	O
of	O
185	O
patients	O
with	O
suspected	O
Familial	O
hemophagocytic	O
lymphohistiocytosis-25	BP
for	O
mutations	O
in	O
STXBP2-29	BG
.	O

PS3243	O
It	O
also	O
points	O
to	O
a	O
pronounced	O
influence	O
of	O
additional	O
factors	O
,	O
such	O
as	O
modifier	O
pathways	O
or	O
exogenous	O
effects	O
apart	O
from	O
the	O
CD95-22	BG
pathway	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	BP
lymphoproliferative-29	IP
syndrome	O
.	O

PS3246	O
The	O
frequency	O
of	O
different	O
Neurofibromatosis	O
type	O
1	O
mutation	O
types	O
in	O
a	O
cohort	O
of	O
published	O
and	O
unpublished	O
cases	O
with	O
Neurofibromatosis	BG
type	IG
1-21	IG
/	O
NFNS-23	BG
/	O
WS-25	BG
and	O
Pulmonary	BP
stenosis-28	IP
was	O
examined	O
.	O

PS3250	O
The	O
expression	O
of	O
CYP2D6-4	BG
in	O
bladder	O
mucosa	O
suggests	O
that	O
this	O
enzyme	O
could	O
be	O
involved	O
in	O
the	O
local	O
production	O
of	O
a	O
proximate	O
carcinogen	O
in	O
this	O
tissue	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
bladder	BP
cancer-33	IP
in	O
man	O
.	O

PS3253	O
Since	O
there	O
is	O
a	O
close	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Phenylketonuria-11	BP
,	O
determining	O
the	O
phenylalanine	BG
hydroxylase	IG
genotype-17	IG
can	O
be	O
extremely	O
important	O
for	O
therapy	O
as	O
well	O
as	O
prognosis	O
.	O

PS3260	O
We	O
studied	O
six	O
subjects	O
of	O
Japanese	O
origin	O
whose	O
major	O
abnormality	O
was	O
persistent	O
hyperthyrotropinemia-13	BP
by	O
genetic	O
sequence	O
analysis	O
of	O
the	O
TSHR	BG
gene-21	IG
.	O

PS3268	O
The	O
results	O
of	O
this	O
retrospective	O
study	O
suggest	O
that	O
tailoring	O
Mitomycin	O
C	O
therapy	O
to	O
individual	O
patients	O
with	O
superficial	O
bladder	O
cancer-19	BP
on	O
the	O
basis	O
of	O
NAD	BG
(	IG
P	IG
)	IG
H	IG
:	IG
Quinone	IG
oxidoreductase	IG
-	IG
1-33	IG
genotype	O
status	O
is	O
unlikely	O
to	O
be	O
of	O
clinical	O
benefit	O
.	O

PS3289	O
The	O
ryanodine	BG
receptor-3	IG
is	O
mutated	O
in	O
a	O
number	O
of	O
Malignant	O
hyperthermia-11	BP
pedigrees	O
,	O
some	O
members	O
of	O
which	O
also	O
have	O
central	O
core	O
disease	O
,	O
an	O
inherited	O
myopathy-26	BP
closely	O
associated	O
with	O
Malignant	BP
hyperthermia-31	IP
.	O

PS3296	O
Alstrom	O
syndrome	O
is	O
a	O
monogenic	O
form	O
of	O
infancy	O
-	O
onset	O
obesity-11	BP
and	O
insulin	BP
resistance-14	IP
,	O
caused	O
by	O
ALMS1-18	BG
mutations	O
.	O

PS3303	O
Mutations	O
in	O
the	O
CLN8	BG
gene-5	IG
underlie	O
Northern	O
epilepsy-8	BP
(	O
progressive	BP
epilepsy-11	IP
with	O
mental	BP
retardation-14	IP
[	O
EPMR	O
]	O
,	O
OMIM	O
600143	O
)	O
and	O
a	O
subset	O
of	O
Turkish	O
variant	O
late	O
infantile	O
NCL	O
,	O
but	O
the	O
pathogenetic	O
mechanisms	O
have	O
remained	O
elusive	O
.	O

PS3316	O
To	O
determine	O
the	O
mutations	O
in	O
the	O
CYP21A2	BG
gene-8	IG
in	O
Greek	O
-	O
Cypriots	O
with	O
congenital	BP
adrenal	IP
hyperplasia-16	IP
and	O
attempt	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS3317	O
Molecular	O
analysis	O
was	O
performed	O
by	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
and	O
direct	O
sequencing	O
of	O
PCR	O
products	O
of	O
the	O
CYP21A2	BG
gene-21	IG
in	O
32	O
congenital	BP
adrenal	IP
hyperplasia-26	IP
patients	O
.	O

PS3326	O
The	O
signs	O
suggest	O
a	O
developmental	BP
field	IP
defect-7	IP
(	O
disturbance	O
of	O
laterality	O
)	O
either	O
as	O
a	O
newly	O
recognised	O
pattern	O
of	O
Rubinstein-20	BG
-	O
Taybi	O
syndrome	O
,	O
or	O
alternatively	O
a	O
novel	O
contiguous	O
gene	O
syndrome	O
.	O

PS3331	O
These	O
data	O
imply	O
that	O
the	O
origin	O
of	O
common	O
up	O
-	O
regulating	O
variants	O
of	O
Th	BG
-	IG
2-16	IG
signalling	O
,	O
involving	O
STAT6-20	BG
,	O
promotes	O
asthma-23	BP
and	O
allergy	O
in	O
developed	O
countries	O
,	O
whereas	O
in	O
developing	O
countries	O
it	O
protects	O
against	O
parasitic	O
worm	O
infections	O
.	O

PS3337	O
To	O
determine	O
whether	O
the	O
genotype	O
could	O
be	O
distinguished	O
on	O
the	O
basis	O
of	O
the	O
phenotype	O
,	O
we	O
analysed	O
height	O
,	O
arm	O
span	O
,	O
and	O
skeletal	O
radiographs	O
from	O
23	O
patients	O
with	O
achondroplasia	O
and	O
the	O
G380R	O
mutation	O
of	O
fibroblast	BG
growth	IG
factor	IG
receptor	IG
3-40	IG
and	O
eight	O
with	O
hypochondroplasia-44	BP
and	O
the	O
N540K	O
mutation	O
.	O

PS3339	O
This	O
study	O
included	O
56	O
patients	O
with	O
X	O
-	O
linked	O
agammaglobulinemia-10	BP
,	O
with	O
or	O
without	O
a	O
positive	O
family	O
history	O
,	O
who	O
were	O
diagnosed	O
on	O
the	O
basis	O
of	O
their	O
clinical	O
features	O
,	O
low	O
peripheral	O
B	O
-	O
cell	O
count	O
,	O
and	O
low	O
immunoglobulin-40	BG
levels	O
.	O

PS3345	O
Therefore	O
,	O
the	O
SDF	BG
-	IG
1	IG
genotype-7	IG
of	O
729	O
human	O
immunodeficiency-11	BP
virus	O
type	O
1	O
-	O
infected	O
individuals	O
pooled	O
from	O
3	O
distinct	O
cohorts	O
was	O
determined	O
.	O

PS3346	O
Because	O
no	O
difference	O
in	O
survival	O
was	O
observed	O
after	O
diagnosis	O
according	O
to	O
AIDS	O
-	O
'	O
87	O
,	O
the	O
association	O
of	O
the	O
SDF1	BG
-	IG
3	IG
'	IG
A	IG
/	IG
3	IG
'	IG
A-29	IG
genotype	O
with	O
the	O
accelerated	O
progression	O
of	O
late	O
-	O
stage	O
human	O
immunodeficiency-40	BP
virus	O
type	O
1	O
disease	O
appears	O
to	O
be	O
explained	O
for	O
the	O
most	O
part	O
by	O
the	O
loss	O
of	O
CD4-57	BG
(	O
+	O
)	O
T	O
lymphocytes	O
.	O

PS3350	O
In	O
humans	O
,	O
the	O
Crumbs	BG
homolog	IG
-	IG
1-8	IG
gene	O
is	O
mutated	O
in	O
progressive	O
types	O
of	O
autosomal	O
recessive	O
retinitis	BP
pigmentosa-19	IP
and	O
Leber	O
congenital	BP
amaurosis-23	IP
.	O

PS3355	O
Mutations	O
in	O
the	O
gene	BG
COL17A1-5	IG
coding	O
for	O
type	BG
XVII	IG
collagen-10	IG
cause	O
non	O
-	O
Herlitz	O
junctional	BP
epidermolysis	IP
bullosa-17	IP
(	O
non	O
-	O
Herlitz	O
junctional	BP
epidermolysis	IP
bullosa-24	IP
)	O
.	O

PS3	O
patients	O
with	O
the	O
nondeletional	O
type	O
of	O
hemoglobin	BG
H-8	IG
disease	O
had	O
more	O
symptoms	O
at	O
a	O
younger	O
age	O
,	O
more	O
severe	O
hemolytic	BP
anemia-21	IP
,	O
more	BP
growth	IP
deficiency-25	IP
,	O
more	O
dysmorphic	O
facial	O
features	O
,	O
larger	BP
spleens-33	IP
,	O
larger	BP
livers-36	IP
,	O
and	O
higher	O
serum	O
ferritin-41	BG
levels	O
and	O
required	O
more	O
transfusions	O
than	O
patients	O
with	O
deletional-50	BP
hemoglobin	BG
H	IG
disease-53	IG
.	O

PS23	O
However	O
,	O
analyses	O
of	O
larger	O
sample	O
numbers	O
and	O
the	O
detection	O
of	O
additional	O
polymorphisms	O
that	O
affect	O
gene	O
expression	O
are	O
needed	O
before	O
we	O
can	O
conclude	O
that	O
N	BG
-	IG
methyl	IG
-	IG
D	IG
-	IG
aspartate	IG
receptor-32	IG
expression	O
and	O
serum	O
levels	O
of	O
d	O
-	O
serine	O
,	O
if	O
involved	O
in	O
schizophrenia-45	BP
pathophysiology	O
,	O
are	O
independent	O
and	O
additive	O
events	O
.	O

PS45	O
Although	O
several	O
congenital	O
adrenal	O
hyperplasia	O
causing	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
CYP21	BG
gene-14	IG
of	O
patients	O
with	O
21OH	O
deficiency	O
,	O
genotyping	O
of	O
the	O
21OH	BG
locus-25	IG
is	O
quite	O
complex	O
because	O
of	O
the	O
high	O
frequency	O
of	O
gene	O
conversion	O
and	O
the	O
presence	O
of	O
multiple	O
mutations	O
on	O
single	O
congenital	BP
adrenal	IP
hyperplasia-47	IP
alleles	O
.	O

PS161	O
SERPING1	BG
gene-2	IG
investigation	O
was	O
performed	O
by	O
exon	O
sequencing	O
followed	O
by	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
genomic	O
rearrangement	O
analysis	O
in	O
all	O
known	O
Danish	O
Hereditary	O
angioedema	BP
families-26	IP
.	O

PS239	O
The	O
results	O
of	O
haplotype	O
analysis	O
further	O
suggested	O
that	O
haplotypes	O
CAC	O
and	O
CGA	O
of	O
excision	O
repair	O
cross	O
-	O
complementing	O
complementation	O
group	O
2	O
/	O
xeroderma-23	BP
pigmentosum	O
D	O
,	O
TC	O
of	O
Excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
1-36	IG
and	O
CACTC-38	BG
of	O
excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
2	IG
/	IG
xeroderma	IG
pigmentosum	IG
D-51	IG
and	O
Excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
1-60	IG
were	O
significantly	O
associated	O
with	O
high	O
levels	O
of	O
DNA	O
adducts	O
compared	O
with	O
their	O
most	O
common	O
haplotypes	O
.	O

PS389	O
The	O
RYR1	BG
gene-3	IG
encodes	O
the	O
skeletal	BG
muscle	IG
isoform	IG
ryanodine	IG
receptor-10	IG
and	O
is	O
fundamental	O
to	O
the	O
process	O
of	O
excitation	O
-	O
contraction	O
coupling	O
and	O
skeletal	O
muscle	BP
calcium-25	IP
homeostasis	O
.	O

PS1	O
In	O
patients	O
with	O
nondeletional	O
type	O
of	O
hemoglobin	BG
H	IG
disease-9	IP
,	O
the	O
Constant	O
Spring	O
variant	O
was	O
the	O
majority	O
of	O
the	O
disease	O
.	O

PS2	O
Twenty	O
-	O
one	O
percent	O
of	O
children	O
with	O
hemoglobin	BG
H	IG
disease-10	IG
had	O
growth	BG
deficiency-13	IG
.	O

PS5	O
The	O
age	O
of	O
onset	O
of	O
down	O
-	O
regulation	O
of	O
lactase-10	BG
activity	O
in	O
children	O
with	O
C	O
/	O
C	O
-	O
13910	O
genotype	O
was	O
between	O
3	O
and	O
5	O
years	O
and	O
keeping	O
10	O
U	O
/	O
g	O
protein	BG
lactase-34	IG
activity	O
as	O
cut	O
off	O
,	O
adult	O
-	O
type	O
hypolactasia-43	BP
was	O
evident	O
in	O
all	O
the	O
individuals	O
>	O
8	O
years	O
of	O
age	O
for	O
this	O
genotype	O
.	O

PS19	O
Using	O
SMN	BG
gene-3	IG
dosage	O
analysis	O
,	O
we	O
determined	O
the	O
copy	O
numbers	O
of	O
SMN1-13	BG
and	O
SMN2-15	BG
in	O
the	O
general	O
population	O
as	O
well	O
as	O
in	O
spinal	BP
muscular	IP
atrophy-26	IP
patients	O
and	O
carriers	O
.	O

PS20	O
SMN2	O
copy	O
number	O
was	O
increased	O
to	O
three	O
or	O
four	O
in	O
a	O
subset	O
of	O
SMN1-14	BG
deletion	O
/	O
conversion	O
carriers	O
,	O
and	O
in	O
most	O
spinal	BP
muscular	IP
atrophy-25	IP
patients	O
with	O
a	O
milder	O
phenotype	O
.	O

PS21	O
Lynch	O
syndrome	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
MSH2-9	BG
,	O
MLH1-11	BG
,	O
MSH6-13	BG
,	O
and	O
PMS2-16	BG
mismatch	O
repair	O
genes	O
and	O
leads	O
to	O
a	O
high	O
risk	O
of	O
colorectal	O
and	O
endometrial	BP
cancer-30	IP
.	O

PS22	O
We	O
previously	O
reported	O
a	O
reduction	O
of	O
D	O
-	O
serine	O
serum	O
levels	O
in	O
schizophrenia-13	BP
,	O
supporting	O
the	O
disease	O
hypothesis	O
of	O
N	BG
-	IG
methyl	IG
-	IG
D	IG
-	IG
aspartate	IG
receptor-27	IG
-	O
mediated	O
hypo	O
-	O
neurotransmission	O
.	O

PS25	O
This	O
hypothesis	O
explains	O
the	O
phenotypic	O
overlap	O
of	O
Aicardi	O
-	O
Goutieres	O
syndrome	O
with	O
congenital	O
infection	O
and	O
some	O
aspects	O
of	O
systemic	BP
lupus	IP
erythematosus-21	IP
,	O
where	O
a	O
similar	BG
interferon	IG
alpha-27	IG
-	O
mediated	O
innate	O
immune	O
response	O
is	O
triggered	O
by	O
viral	O
and	O
host	O
nucleic	O
acids	O
respectively	O
.	O

PS26	O
Pseudoxanthoma	O
elasticum	O
is	O
a	O
heritable	O
connective	O
tissue	O
disorder	O
caused	O
by	O
mutations	O
in	O
an	O
ABC	BG
(	IG
ATP	IG
-	IG
Binding	IG
Cassette	IG
)	IG
transporter	IG
gene-22	IG
(	O
ABCC6-24	BG
)	O
,	O
which	O
manifests	O
with	O
cutaneous	O
,	O
ophthalmologic	O
,	O
and	O
cardiovascular	BP
findings-36	IP
.	O

PS27	O
Genotype	O
-	O
phenotype	O
correlations	O
are	O
well	O
documented	O
for	O
overall	BP
Neurofibromatosis-10	IP
2	O
disease	O
severity	O
but	O
have	O
not	O
been	O
definitively	O
evaluated	O
for	O
specific	O
types	O
of	O
non	BG
-	IG
VIII	IG
nerve	IG
tumors-28	IG
.	O

PS31	O
Although	O
most	O
of	O
the	O
patients	O
with	O
Acrodermatitis-7	BP
enteropathica	O
carry	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
,	O
some	O
of	O
them	O
have	O
either	O
no	O
SLC39A4-22	BG
mutation	O
or	O
only	O
a	O
monoallelic	O
mutation	O
.	O

PS32	O
In	O
cases	O
unexplained	O
by	O
current	O
genetic	O
analyses	O
,	O
the	O
most	O
plausible	O
molecular	O
causes	O
could	O
be	O
a	O
dysregulation	O
of	O
the	O
SLC39A4	BG
gene-21	IG
transcription	O
-	O
-	O
involving	O
either	O
metal	O
response	O
elements	O
or	O
a	O
modifier	O
gene	O
-	O
-	O
or	O
the	O
existence	O
of	O
another	O
putative	O
Acrodermatitis-42	BP
enteropathica	O
gene	O
.	O

PS34	O
The	O
most	O
prominent	O
candidate	O
gene	O
was	O
CRLF1-7	BG
,	O
recently	O
found	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cold	O
-	O
induced	O
sweating-21	BP
syndrome	O
type	O
1	O
.	O

PS35	O
Comparison	O
of	O
the	O
mutation	O
spectra	O
of	O
Crisponi	O
syndrome	O
and	O
cold	O
-	O
induced	O
sweating-13	BP
syndrome	O
type	O
1	O
suggests	O
that	O
neither	O
the	O
type	O
nor	O
the	O
location	O
of	O
the	O
CRLF1-27	BG
mutations	O
points	O
to	O
a	O
phenotype	O
/	O
genotype	O
correlation	O
that	O
would	O
account	O
for	O
the	O
most	O
severe	O
phenotype	O
in	O
Crisponi	O
syndrome	O
.	O

PS36	O
Affected	O
individuals	O
in	O
the	O
family	O
with	O
the	O
PY	O
motif	O
mutation	O
,	O
P62R-12	BG
,	O
had	O
a	O
high	O
prevalence	O
of	O
patent	BP
ductus	IP
arteriosus-21	IP
but	O
had	O
only	O
mild	O
abnormalities	O
of	O
facial	O
features	O
and	O
no	O
apparent	O
hand	O
anomalies	O
,	O
a	O
phenotype	O
different	O
from	O
that	O
associated	O
with	O
the	O
five	O
basic	O
domain	O
mutations	O
.	O

PS38	O
Our	O
goal	O
was	O
to	O
explore	O
whether	O
nucleotide	O
substitutions	O
in	O
genes	O
coding	O
for	O
connexin	BG
proteins-14	IG
would	O
associate	O
with	O
clinical	O
cases	O
of	O
Progressive	O
familial	BP
heart	IP
block-24	IP
type	O
I	O
and	O
if	O
so	O
,	O
to	O
establish	O
a	O
genotype	O
-	O
cell	O
phenotype	O
correlation	O
for	O
that	O
mutation	O
.	O

PS40	O
This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
germ	O
line	O
mutation	O
in	O
a	O
connexin	BG
gene-14	IG
that	O
associates	O
with	O
inherited	O
ventricular	O
arrhythmias-20	BP
and	O
emphasizes	O
the	O
importance	O
of	O
Cx40	O
in	O
normal	O
propagation	O
in	O
the	O
specialized	O
conduction	O
system	O
.	O

PS43	O
mutations	O
and	O
high	O
level	O
of	O
fetal-6	BP
hemoglobin-7	BG
.	O

PS46	O
A	O
random	O
sequence	O
analysis	O
,	O
performed	O
on	O
31	O
out	O
of	O
81	O
exons	O
showing	O
a	O
normal	O
SSCP	O
pattern	O
,	O
shows	O
the	O
method	O
to	O
be	O
highly	O
sensitive	O
:	O
no	O
sequence	O
variant	O
was	O
detected	O
,	O
thus	O
confirming	O
the	O
validity	O
of	O
this	O
non	O
-	O
radioactive	O
DNA	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
in	O
characterising	O
the	O
CYP21	BG
gene-52	IG
in	O
patients	O
with	O
steroid	BG
21OH	IG
deficiency-58	IP
.	O

PS47	O
Notwithstanding	O
the	O
complete	O
characterisation	O
of	O
all	O
exons	O
and	O
exon	O
/	O
intron	O
junctions	O
of	O
the	O
CYP21	BG
gene-16	IG
,	O
no	O
complete	O
genotype	O
/	O
phenotype	O
correlation	O
was	O
found	O
in	O
the	O
panel	O
of	O
patients	O
analysed	O
,	O
thus	O
suggesting	O
that	O
characterisation	O
of	O
congenital	BP
adrenal	IP
hyperplasia-40	IP
alleles	O
must	O
be	O
extended	O
to	O
outside	O
the	O
coding	O
region	O
of	O
the	O
CYP21	BG
gene-53	IG
,	O
most	O
probably	O
into	O
the	O
promoter	O
region	O
.	O

PS48	O
We	O
investigated	O
the	O
contribution	O
of	O
variants	O
of	O
tumour	BG
necrosis	IG
factor-10	IG
-	O
alpha	O
and	O
MDR1	BG
genes-15	IG
in	O
the	O
predisposition	O
and	O
response	O
to	O
medical	O
therapy	O
in	O
a	O
large	O
pediatric	O
cohort	O
of	O
patients	O
with	O
Crohn	O
disease	O
and	O
ulcerative	BP
colitis-36	IP
.	O

PS51	O
In	O
our	O
pediatric	O
cohort	O
,	O
the	O
promoter	O
-	O
308A	O
polymorphism	O
of	O
tumour	BG
necrosis	IG
factor	IG
-	IG
alpha-16	IG
but	O
not	O
the	O
MDR1	BG
gene-21	IG
is	O
significantly	O
involved	O
in	O
the	O
predisposition	O
to	O
both	O
Crohn	O
disease	O
and	O
ulcerative	O
colitis-34	BP
.	O

PS52	O
We	O
have	O
identified	O
a	O
large	O
kindred	O
with	O
multiple	O
endocrine	O
neoplasia-10	BP
2A	O
due	O
to	O
a	O
mutation	O
at	O
RET	O
codon	O
609	O
that	O
results	O
in	O
a	O
cysteine	O
to	O
serine	O
substitution	O
,	O
a	O
mutation	O
previously	O
identified	O
in	O
only	O
one	O
case	O
in	O
the	O
literature	O
.	O

PS53	O
Transfection	O
experiments	O
using	O
human	O
neuroblastoma-5	BP
cells	O
showed	O
that	O
the	O
mutant	BG
RET-11	IG
,	O
unlike	O
the	O
wild	BG
-	IG
type	IG
receptor-18	IG
,	O
is	O
constitutively	O
phosphorylated	O
in	O
the	O
absence	O
of	O
ligand	O
,	O
and	O
thus	O
resembles	O
other	O
previously	O
characterized	O
multiple	O
endocrine	O
neoplasia-37	BP
2A	O
mutations	O
.	O

PS54	O
The	O
identification	O
of	O
a	O
new	O
mutation	O
causing	O
a	O
multiple	O
endocrine	BG
neoplasia	IG
2A-12	IG
phenotype	O
that	O
features	O
pheochromocytoma-16	BP
and	O
the	O
surprising	O
absence	O
of	O
clinically	O
apparent	O
medullary	O
thyroid	BP
cancer-26	IP
has	O
significant	O
implications	O
for	O
carriers	O
of	O
this	O
mutation	O
and	O
provides	O
further	O
insights	O
into	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
multiple	O
endocrine	O
neoplasia-48	BP
2A	O
.	O

PS55	O
We	O
have	O
performed	O
loss	O
of	O
heterozygosity	O
studies	O
on	O
a	O
series	O
of	O
24	O
Portuguese	O
primary	O
neuroblastomas-15	BP
using	O
6	O
polymorphic	O
markers	O
located	O
at	O
chromosome	O
9p21	O
spanning	O
the	O
p16-26	BG
/	O
MTS1-28	BG
/	O
CDKN2-30	BG
,	O
p15-32	BG
/	O
MTS2-34	BG
/	O
CDKN2B-36	BG
,	O
and	O
the	O
interferon	BG
alpha-41	IG
and	O
beta	BG
genes-44	IG
.	O

PS56	O
This	O
result	O
suggests	O
the	O
presence	O
of	O
at	O
least	O
one	O
other	O
tumor	O
suppressor	O
gene	O
at	O
9p21	O
,	O
apart	O
from	O
the	O
p16-20	BG
and	O
p15	BG
genes-23	IG
,	O
which	O
may	O
be	O
of	O
importance	O
to	O
the	O
development	O
of	O
neuroblastoma-34	BP
.	O

PS58	O
This	O
correlation	O
is	O
reminiscent	O
of	O
that	O
observed	O
in	O
fat	O
/	O
fat	O
mice	O
,	O
whose	O
phenotype	O
,	O
also	O
characterized	O
by	O
obesity-20	BP
,	O
is	O
caused	O
by	O
a	O
null	O
mutation	O
in	O
the	O
carboxypeptidase	BG
E-31	IG
gene	O
.	O

PS60	O
In	O
contrast	O
,	O
LEW-4	BG
rats	O
do	O
not	O
develop	O
the	O
characteristic	O
glomerulonephritis-11	BP
and	O
are	O
very	O
"	O
low	O
IgE-17	BG
responders	O
"	O
.	O

PS61	O
No	O
correlation	O
was	O
found	O
between	O
the	O
peak	O
total	O
IgE-9	BG
level	O
and	O
autoimmune	BP
disease-13	IP
based	O
on	O
IgG-16	BG
deposition	O
in	O
spleen	O
and	O
/	O
or	O
kidney	O
.	O

PS64	O
We	O
later	O
investigated	O
the	O
possible	O
association	O
of	O
the	O
apo-9	BG
(	O
a	O
)	O
pentanucleotide	O
polymorphism	O
with	O
serum	O
lipid	O
levels	O
in	O
two	O
samples	O
from	O
Corsica	O
(	O
France	O
)	O
:	O
one	O
comprises	O
patients	O
or	O
individuals	O
with	O
high	O
risk	O
of	O
future	O
coronary	BP
heart	IP
disease-40	IP
and	O
the	O
other	O
is	O
a	O
control	O
sample	O
.	O

PS66	O
Phenotypic	O
variability	O
exists	O
in	O
Autosomal	O
recessive	O
polycystic	BP
kidney-8	IP
disease	O
,	O
even	O
among	O
families	O
with	O
supposedly	O
homozygous	O
mutations	O
in	O
the	O
PKHD1	BG
gene-21	IG
.	O

PS69	O
Multibacillary	O
leprosy	O
may	O
be	O
manifested	O
with	O
antiphospholipid	BP
antibodies-8	IP
,	O
among	O
which	O
anti	BG
-	IG
beta2GP1-14	IG
.	O

PS71	O
To	O
analyze	O
the	O
genetic	O
alterations	O
of	O
the	O
MEN1	BG
gene-9	IG
occurring	O
in	O
Italian	O
patients	O
we	O
performed	O
mutational	O
screening	O
by	O
Denaturant	O
Gradient	O
Gel	O
Electrophoresis	O
followed	O
by	O
sequencing	O
of	O
exons	O
2	O
-	O
10	O
of	O
the	O
MEN1	BG
gene-34	IG
in	O
27	O
Italian	O
Multiple	O
endocrine	O
neoplasia-40	BP
type	O
1	O
families	O
and	O
in	O
five	O
sporadic	O
cases	O
.	O

PS72	O
Our	O
findings	O
add	O
new	O
information	O
to	O
the	O
diversity	O
of	O
mutations	O
occurring	O
in	O
the	O
MEN1	BG
gene-15	IG
and	O
confirm	O
that	O
the	O
mutational	O
screening	O
of	O
Multiple	O
endocrine	O
neoplasia-25	BP
type	O
1	O
is	O
a	O
useful	O
approach	O
to	O
detect	O
individuals	O
at	O
higher	O
risk	O
of	O
developing	O
Multiple	O
endocrine	O
neoplasia-42	BP
type	O
1	O
-	O
associated	O
tumors	O
.	O

PS73	O
The	O
PCR	O
-	O
RFLP	O
technique	O
was	O
applied	O
to	O
analyze	O
the	O
correlation	O
between	O
the	O
polymorphisms	O
of	O
natural	BP
resistance-17	IP
-	O
associated	O
macrophage	BG
protein1	IG
gene-22	IG
and	O
immune	O
function	O
[	O
value	O
of	O
Polymorphonuclear	O
Leukocytes	O
obtained	O
by	O
Nitroblue	O
Tetrazolium	O
Reduction	O
and	O
effect	O
of	O
Cytotoxin	O
in	O
Monocyte	O
]	O
and	O
production	O
performance	O
in	O
165	O
Large	O
White	O
pigs	O
.	O

PS74	O
This	O
study	O
examined	O
novel	O
mutations	O
in	O
the	O
ABCC6	BG
gene-9	IG
in	O
our	O
cohort	O
of	O
76	O
German	O
Pseudoxanthoma-16	BP
elasticum	O
patients	O
and	O
54	O
unaffected	O
or	O
not	O
yet	O
affected	O
relatives	O
with	O
a	O
view	O
to	O
expanding	O
the	O
known	O
mutational	O
spectrum	O
of	O
the	O
gene	O
.	O

PS75	O
Pseudomona	BG
aeruginosa-2	IG
strains	O
isolated	O
from	O
the	O
sputum	O
of	O
cystic	BP
fibrosis-10	IP
patients	O
are	O
frequently	O
difficult	O
to	O
type	O
by	O
conventional	O
typing	O
methods	O
.	O

PS76	O
In	O
addition	O
,	O
the	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
is	O
required	O
for	O
natural	BP
killer-14	IP
cell	O
function	O
by	O
participating	O
in	O
the	O
formation	O
of	O
immunologic	O
synapses	O
and	O
facilitating	O
the	O
nuclear	O
translocation	O
of	O
nuclear	O
factor	O
for	O
activated	O
T	O
cell	O
and	O
nuclear	BG
factor	IG
-	IG
kappaB-41	IG
.	O

PS78	O
(	O
18	O
)	O
F	O
-	O
DOPA	O
PET	O
is	O
a	O
sensitive	O
and	O
specific	O
imaging	O
modality	O
for	O
the	O
detection	O
and	O
staging	O
of	O
pheochromocytomas-21	BP
and	O
paragangliomas	O
in	O
different	O
genotypes	O
,	O
including	O
von	O
Hippel	O
Lindau	O
syndrome	O
-	O
,	O
SDHB-35	BG
-	O
,	O
and	O
SDHD-39	BG
-	O
mutation	O
carriers	O
,	O
and	O
in	O
patients	O
with	O
no	O
germline	O
mutation	O
.	O

PS79	O
Genetic	O
examination	O
identified	O
that	O
two	O
Avellino	O
corneal	O
dystrophy	O
subjects	O
were	O
associated	O
with	O
homozygous	O
R124H	BG
mutation-15	IG
of	O
TGFBI-17	BG
,	O
and	O
four	O
lattice	O
corneal	BP
dystrophy-23	IP
type	O
I	O
subjects	O
were	O
all	O
associated	O
with	O
R124C	O
heterozygous	O
mutation	O
.	O

PS84	O
Hematological	O
parameters	O
of	O
the	O
patient	O
were	O
compared	O
with	O
those	O
observed	O
for	O
a	O
Thai	O
boy	O
who	O
demonstrated	O
features	O
of	O
erythrocytosis-19	BP
and	O
microcytosis	O
caused	O
by	O
homozygous	O
hemoglobin	BG
Tak-26	IG
with	O
thalassemia	O
and	O
with	O
those	O
of	O
pure	O
carriers	O
of	O
hemoglobin	BG
Tak-37	IG
thalassemia	O
in	O
our	O
series	O
.	O

PS87	O
This	O
study	O
provides	O
a	O
mutation	O
spectrum	O
of	O
CYP1B1-8	BG
causing	O
primary	O
congenital	O
glaucoma-12	BP
in	O
Indian	O
populations	O
that	O
has	O
implications	O
in	O
devising	O
molecular	O
diagnostics	O
for	O
rapid	O
screening	O
.	O

PS89	O
NIPBL-1	BG
,	O
SMC1A-3	BG
,	O
and	O
SMC3-6	BG
mutation	O
-	O
positive	O
patients	O
were	O
equally	O
likely	O
to	O
have	O
Congenital	BP
heart	IP
disease-18	IP
,	O
although	O
the	O
number	O
of	O
SMC1A-24	BG
and	O
SMC3-26	BG
mutation	O
-	O
positive	O
patients	O
were	O
small	O
in	O
comparison	O
.	O

PS92	O
However	O
,	O
the	O
function	O
of	O
menin-6	BG
,	O
the	O
product	O
of	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene-16	IG
,	O
remains	O
to	O
be	O
established	O
.	O

PS96	O
Crisponi	O
syndrome	O
and	O
cold	O
-	O
induced	O
sweating-7	BP
syndrome	O
type	O
1	O
are	O
disorders	O
caused	O
by	O
mutations	O
in	O
CRLF1-17	BG
.	O

PS97	O
To	O
evaluate	O
a	O
potential	O
genotype	O
/	O
phenotype	O
correlation	O
and	O
whether	O
Crisponi	O
syndrome	O
and	O
cold	O
-	O
induced	O
sweating-17	BP
syndrome	O
type	O
1	O
represent	O
two	O
allelic	O
diseases	O
or	O
manifestations	O
at	O
different	O
ages	O
of	O
the	O
same	O
disorder	O
,	O
we	O
carried	O
out	O
a	O
detailed	O
clinical	O
analysis	O
of	O
19	O
patients	O
carrying	O
mutations	O
in	O
CRLF1-48	BG
.	O

PS99	O
Although	O
we	O
could	O
not	O
identify	O
any	O
nucleotide	O
alteration	O
in	O
DYRK1A-10	BG
and	O
KCNJ6-12	BG
in	O
our	O
cohort	O
study	O
for	O
150	O
patients	O
with	O
mental	BP
retardation-22	IP
with	O
/	O
without	O
epilepsy	O
,	O
this	O
study	O
underscores	O
the	O
clinical	O
importance	O
of	O
Down	O
syndromeCR	O
not	O
only	O
for	O
Down	O
syndrome	O
but	O
also	O
for	O
developmental	O
disorders	O
.	O

PS100	O
The	O
characteristics	O
of	O
P450c17-4	BG
deficiency	O
include	O
46	O
,	O
XY	O
disorder	O
of	O
sex	O
development	O
,	O
hypertension-15	BP
,	O
hypokalemia-17	BP
,	O
and	O
lack	O
of	O
pubertal	O
development	O
.	O

PS101	O
Careful	O
examination	O
of	O
long	O
-	O
term	O
follow	O
-	O
ups	O
in	O
two	O
of	O
our	O
patients	O
suggested	O
to	O
us	O
that	O
estrogen	O
treatment	O
in	O
P450c17-22	BG
-	O
deficient	O
patients	O
might	O
worsen	O
the	O
enzymatic	O
defect	O
,	O
leading	O
to	O
aggravation	O
of	O
the	O
hypertension-37	BP
.	O

PS106	O
Expression	O
of	O
phenotype	O
-	O
related	O
parameters	O
for	O
MHC	BG
class	IG
I-10	IG
and	O
class	O
II	O
as	O
well	O
as	O
CD45-17	BG
and	O
carcinoembryonic	BG
antigen-20	IG
were	O
investigated	O
immunohistochemically	O
in	O
a	O
series	O
of	O
93	O
colorectal	BP
cancers-30	IP
.	O

PS109	O
Complete	O
analysis	O
of	O
the	O
CYP21	BG
gene-6	IG
was	O
performed	O
in	O
56	O
unrelated	O
French	O
women	O
with	O
symptomatic	O
nonclassical	O
congenital	BP
adrenal	IP
hyperplasia-19	IP
.	O

PS110	O
To	O
study	O
the	O
relationship	O
between	O
clinical	O
manifestations	O
in	O
systemic	BP
lupus	IP
erythematosus-11	IP
with	O
polymorphisms	O
in	O
suggested	O
susceptibility	O
genes	O
encoding	O
FcgammaRIIa-19	BG
,	O
FcgammaRIIIa-21	BG
,	O
FcgammaRIIIb-23	BG
,	O
CRP-25	BG
and	O
IL	BG
-	IG
1Ra-29	IG
.	O

PS116	O
There	O
are	O
some	O
systemic	O
diseases	O
which	O
can	O
also	O
affect	O
the	O
heart	O
,	O
for	O
example	O
triosephosphate	BG
isomerase	IG
deficiency-17	IP
,	O
hereditary	O
haemochromatosis-20	BP
,	O
CD	O
36	O
defect	O
or	O
propionic	BP
acidaemia-27	IP
.	O

PS117	O
Human	BG
immunodeficiency	IG
virus	IG
type	IG
1-5	IG
-	O
infected	O
individuals	O
who	O
remain	O
asymptomatic	O
despite	O
prolonged	O
infection	O
present	O
a	O
unique	O
opportunity	O
to	O
understand	O
virologic	O
and	O
immunologic	O
factors	O
involved	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

PS118	O
The	O
effects	O
of	O
the	O
observed	O
genetic	O
variations	O
on	O
LTR	O
transcription	O
were	O
studied	O
by	O
transient	O
transfection	O
of	O
an	O
LTR	O
-	O
driven	O
luciferase	BG
reporter	IG
gene-23	IG
and	O
by	O
infection	O
with	O
a	O
full	O
-	O
length	O
recombinant	O
Human	O
immunodeficiency-34	BP
virus	O
type	O
1	O
containing	O
a	O
luciferase-40	BG
reporter	O
(	O
HIVHXBLTRluc	O
)	O
.	O

PS119	O
Denatured	BG
hemoglobin	IG
and	IG
tritiated	IG
elastin-5	IG
were	O
used	O
as	O
substrates	O
for	O
protease-11	BG
and	O
elastase-13	BG
assays	O
.	O

PS120	O
There	O
was	O
no	O
significant	O
correlation	O
between	O
neutrophil	BG
protease-8	IG
or	O
elastase-10	BG
activity	O
and	O
age	O
,	O
smoking	O
,	O
degree	O
of	O
airway	O
obstruction	O
,	O
diffusing	O
capacity	O
,	O
lung	O
elastic	O
recoil	O
,	O
or	O
radiologic	O
presence	O
of	O
emphysema-33	BP
in	O
patients	O
with	O
M	O
and	O
MS	O
antitrypsin	O
.	O

PS122	O
Lower	O
amounts	O
of	O
triglycerides	O
,	O
total	O
cholesterol	O
,	O
low	BG
-	IG
density	IG
lipoprotein	IG
cholesterol	IG
,	IG
and	IG
high	IG
-	IG
density	IG
lipoprotein	IG
cholesterol-20	IG
were	O
seen	O
in	O
thalassemia-24	BP
intermedia	O
patients	O
compared	O
with	O
thalassemia-29	BP
major	O
patients	O
and	O
healthy	O
individuals	O
.	O

PS123	O
Inherited	O
susceptibility	O
to	O
a	O
wide	O
variety	O
of	O
neoplasias-8	BP
(	O
Li	O
-	O
Fraumeni	O
syndrome	O
)	O
,	O
has	O
been	O
shown	O
in	O
studies	O
of	O
one	O
cancer-23	BP
-	O
prone	O
family	O
,	O
to	O
have	O
an	O
intriguing	O
association	O
with	O
an	O
aberrant	O
c	BG
-	IG
raf	IG
-	IG
1	IG
gene-41	IG
and	O
inheritance	O
of	O
a	O
radioresistant	O
phenotype	O
in	O
their	O
non	O
-	O
cancerous	O
skin	O
fibroblasts	O
.	O

PS124	O
Although	O
the	O
contention	O
that	O
the	O
qualitative	O
topoisomerase	BG
II-8	IG
abnormalities	O
observed	O
here	O
may	O
be	O
associated	O
with	O
malfunction	O
is	O
highly	O
speculative	O
,	O
these	O
findings	O
may	O
be	O
relevant	O
to	O
the	O
mechanism	O
of	O
oncogenesis-30	BP
,	O
not	O
only	O
in	O
this	O
family	O
,	O
but	O
with	O
raf	O
and	O
ras-42	BG
type	O
oncogenes	O
.	O

PS128	O
Since	O
80	O
-	O
100	O
%	O
of	O
hemochromatosis-7	BP
patients	O
of	O
European	O
origin	O
are	O
homozygous	O
for	O
a	O
cysteine	O
to	O
tyrosine	O
exchange	O
in	O
the	O
HFE	BG
gene-23	IG
at	O
codon	O
282	O
,	O
genetic	O
screening	O
might	O
be	O
useful	O
.	O

PS129	O
Thus	O
,	O
since	O
Autosomal	O
recessive	O
spastic	BP
ataxia-7	IP
of	O
Charlevoix	O
-	O
Saguenay	O
shows	O
the	O
clinical	O
diversity	O
,	O
the	O
SACS	BG
gene-19	IG
should	O
be	O
analyzed	O
not	O
only	O
in	O
typical	O
cases	O
as	O
Quebec	O
patients	O
but	O
also	O
in	O
atypical	O
cases	O
as	O
non	O
-	O
Quebec	O
patients	O
.	O

PS130	O
Body	O
mass	O
index	O
,	O
waist	O
circumference	O
,	O
blood	O
pressure	O
,	O
plasma	O
insulin-12	BG
,	O
triglyceride	O
,	O
HDL	BG
-	IG
cholesterol-18	IG
levels	O
,	O
insulin	BG
resistance-22	IP
and	O
beta	O
-	O
cell	O
function	O
had	O
high	O
estimates	O
of	O
heritability	O
.	O

PS131	O
There	O
was	O
significant	O
familial	O
aggregation	O
of	O
T2DM-7	BG
and	O
related	O
phenotypes	O
including	O
obesity-12	BP
,	O
hypertension-14	BP
and	O
dyslipidaemia-16	BP
.	O

PS132	O
The	O
question	O
of	O
the	O
cell	O
of	O
origin	O
,	O
illustrated	O
by	O
the	O
evidence	O
of	O
tumor	O
-	O
derived	O
multipotent	O
progenitors	O
,	O
by	O
the	O
animal	O
models	O
of	O
gliomas-25	BP
,	O
and	O
by	O
lineage	O
markers	O
such	O
as	O
Olig1	BG
/	IG
2-35	IG
markers	O
,	O
remains	O
unsolved	O
.	O

PS134	O
We	O
performed	O
immunohistochemistry	O
for	O
collagen-5	BG
VI	O
in	O
muscles	O
from	O
362	O
Japanese	O
patients	O
with	O
congenital	BP
muscular	IP
dystrophy-16	IP
,	O
and	O
directly	O
sequenced	O
the	O
three	O
collagen	BG
VI	IG
genes-25	IG
,	O
COL6A1-27	BG
,	O
COL6A2-29	BG
,	O
and	O
COL6A3-32	BG
,	O
in	O
patients	O
found	O
to	O
have	O
collagen	BG
VI	IG
deficiency-41	IP
.	O

PS136	O
Among	O
these	O
patients	O
,	O
five	O
had	O
complete	BP
deficiency-8	IP
and	O
29	O
had	O
sarcolemma	O
-	O
specific	O
collagen	BG
VI-16	IG
deficiency	O
.	O

PS137	O
Primary	O
collagen	BG
VI-3	IG
deficiency	O
is	O
the	O
second	O
most	O
common	O
congenital	BP
muscular	IP
dystrophy-12	IP
after	O
Fukuyama	O
type	O
congenital	BP
muscular	IP
dystrophy-18	IP
in	O
Japan	O
.	O

PS142	O
We	O
searched	O
MEDLINE	O
and	O
EMBASE	O
databases	O
for	O
all	O
published	O
studies	O
related	O
to	O
circulating	O
levels	O
and	O
polymorphisms	O
of	O
Insulin	BG
-	IG
like	IG
growth	IG
factor	IG
1-23	IG
and	O
IGF	BG
-	IG
binding	IG
protein	IG
3-29	IG
and	O
cancer-31	BP
risk	O
.	O

PS145	O
In	O
conclusion	O
,	O
circulating	O
levels	O
of	O
Insulin	BG
-	IG
like	IG
growth	IG
factor	IG
1-12	IG
,	O
IGF	BG
-	IG
binding	IG
protein	IG
3-18	IG
and	O
IGF	BG
-	IG
binding	IG
protein	IG
3	IG
A	IG
-	IG
202C-27	IG
play	O
a	O
crucial	O
role	O
in	O
carcinogenesis	O
and	O
could	O
serve	O
as	O
susceptibility	O
biomarkers	O
for	O
cancer-41	BP
development	O
.	O

PS147	O
These	O
findings	O
suggest	O
that	O
loss	O
of	O
heterozygosity	O
genotyping	O
may	O
be	O
another	O
independent	O
prognostic	O
indicator	O
in	O
gastric	O
carcinoma	O
,	O
that	O
loss	O
of	O
heterozygosity	BG
-	IG
H-24	IG
,	O
particularly	O
the	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
6	O
,	O
could	O
be	O
associated	O
with	O
an	O
unfavorable	O
prognosis	O
,	O
while	O
the	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
22	O
may	O
be	O
related	O
to	O
the	O
histologic	O
progression	O
of	O
gastric	BP
carcinoma-60	IP
.	O

PS150	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
the	O
CYP2D6	BG
*	IG
10-14	IG
C188T	O
polymorphism	O
and	O
the	O
tardive	O
dyskinesia	O
occurrence	O
in	O
216	O
Chinese	O
schizophrenic	O
patients	O
(	O
113	O
patients	O
with	O
tardive	BP
dyskinesia-32	IP
and	O
103	O
patients	O
without	O
tardive	BP
dyskinesia-38	IP
)	O
and	O
explored	O
the	O
correlation	O
between	O
the	O
tardive	O
dyskinesia	O
severity	O
assessed	O
by	O
the	O
Abnormal	O
Involuntary	O
Movement	O
Scale	O
and	O
each	O
C188T	O
genotype	O
in	O
the	O
113	O
tardive	BP
dyskinesia-64	IP
patients	O
.	O

PS153	O
HLA	BG
-	IG
DRB1-3	IG
typing	O
was	O
performed	O
by	O
PCR	O
-	O
SSP	O
in	O
380	O
patients	O
with	O
sporadic	O
multiple	BP
sclerosis-17	IP
and	O
1088	O
unrelated	O
healthy	O
controls	O
.	O

PS154	O
The	O
AIB1	BG
gene-3	IG
was	O
isolated	O
upon	O
microdissection	O
of	O
the	O
homogeneously	O
staining	O
regions	O
observed	O
in	O
breast	BP
cancer-16	IP
cell	O
lines	O
.	O

PS155	O
These	O
properties	O
could	O
be	O
of	O
important	O
biological	O
significance	O
in	O
breast	O
and	O
ovarian	O
cancerigenesis-13	BP
,	O
and	O
we	O
were	O
,	O
therefore	O
,	O
interested	O
in	O
determining	O
whether	O
the	O
amplification	O
of	O
the	O
AIB1	BG
gene-30	IG
was	O
associated	O
with	O
a	O
particular	O
phenotype	O
or	O
subgroup	O
in	O
these	O
tumors	O
.	O

PS157	O
The	O
eukaryotic	BG
glyoxalase-3	IG
system	O
consists	O
of	O
two	O
enzymatic	O
components	O
,	O
glyoxalase	BG
I-12	IG
(	O
lactoylglutathione	BG
lyase-15	IG
)	O
and	O
glyoxalase	BG
II-19	IG
(	O
hydroxyacylglutathione	BG
hydrolase-22	IG
)	O
.	O

PS159	O
Hereditary	O
angioedema-2	BP
is	O
a	O
genetically	O
heterogeneous	O
disease	O
with	O
more	O
than	O
200	O
different	O
mutations	O
in	O
the	O
SERPING1	BG
gene-17	IG
.	O

PS162	O
The	O
disease	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
TYMP	O
gene	O
encoding	O
thymidine	BG
phosphorylasethymine	IG
phosphorylase-14	IG
.	O

PS163	O
After	O
selecting	O
patients	O
who	O
fulfilled	O
the	O
clinical	O
criteria	O
for	O
mitochondrial	O
neurogastrointestinal	O
encephalomyopathy	O
and	O
had	O
severe	O
thymidine	BG
phosphorylase	IG
deficiency-18	IP
in	O
the	O
buffy	O
coat	O
(	O
<	O
10	O
%	O
of	O
normal	O
activity	O
)	O
,	O
we	O
reviewed	O
their	O
medical	O
records	O
and	O
laboratory	O
studies	O
.	O

PS166	O
Despite	O
advances	O
in	O
the	O
understanding	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
multiple	O
endocrine	O
neoplasia-15	BP
type	O
2A	O
and	O
2B	O
,	O
and	O
familial	O
medullary	O
thyroid	BP
carcinoma-25	IP
,	O
the	O
frequency	O
and	O
prognostic	O
relevance	O
of	O
RET	BG
protooncogene	IG
mutations-35	IG
in	O
sporadic	O
medullary	BP
thyroid	IP
carcinomas-40	IP
remain	O
controversial	O
.	O

PS167	O
To	O
study	O
somatic	O
mutations	O
in	O
the	O
RET	BG
protooncogene-8	IG
in	O
Japanese	O
and	O
Chinese	O
sporadic	O
medullary	BP
thyroid	IP
carcinomas-16	IP
and	O
to	O
analyze	O
comparatively	O
the	O
correlation	O
between	O
RET-24	BG
mutation	O
and	O
tumor	O
differentiation	O
,	O
we	O
investigated	O
somatic	O
mutations	O
in	O
the	O
RET	O
protooncogene	O
in	O
20	O
Japanese	O
and	O
20	O
Chinese	O
sporadic	O
medullary	BP
thyroid	IP
carcinomas-47	IP
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
.	O

PS170	O
Previous	O
studies	O
have	O
suggested	O
that	O
the	O
highly	O
variable	O
metabolic	O
phenotypes	O
of	O
phenylalanine	BG
hydroxylase	IG
deficiency-14	IP
correlate	O
with	O
phenylalanine	BG
hydroxylase-18	IG
genotypes	O
.	O

PS171	O
Our	O
data	O
indicate	O
that	O
the	O
phenylalanine	BG
hydroxylase	IG
-	IG
mutation	IG
genotype-10	IG
is	O
the	O
main	O
determinant	O
of	O
metabolic	O
phenotype	O
in	O
most	O
patients	O
with	O
phenylalanine	BG
hydroxylase	IG
deficiency-24	IP
.	O

PS172	O
In	O
the	O
present	O
study	O
,	O
the	O
classification	O
of	O
105	O
phenylalanine	BG
hydroxylase-11	IG
mutations	O
may	O
allow	O
the	O
prediction	O
of	O
the	O
biochemical	O
phenotype	O
in	O
>	O
10	O
,	O
000	O
genotypes	O
,	O
which	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
hyperphenylalaninemia-36	BP
in	O
newborns	O
.	O

PS173	O
As	O
literature	O
review	O
suggests	O
that	O
this	O
type	O
may	O
be	O
more	O
common	O
in	O
Arabs	O
,	O
cascade	O
genetic	O
screening	O
of	O
early	O
onset	O
of	O
autosomal	O
recessive	O
-	O
osteopetrosis-25	BP
in	O
patients	O
of	O
Arabic	O
ancestry	O
may	O
preferably	O
start	O
with	O
the	O
CLCN7	BG
gene-37	IG
rather	O
than	O
the	O
TCIRG	O
gene	O
as	O
is	O
routinely	O
done	O
in	O
clinical	O
laboratories	O
.	O

PS174	O
Identifying	O
a	O
mutation	O
in	O
the	O
CLCN7	BG
gene-7	IG
in	O
a	O
patient	O
with	O
early	O
onset	O
of	O
autosomal	O
recessive	O
-	O
osteopetrosis-18	BP
may	O
also	O
guide	O
therapeutic	O
decisions	O
including	O
the	O
option	O
of	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

PS178	O
There	O
was	O
a	O
significant	O
presence	O
of	O
HLA	BG
-	IG
DMA	IG
*	IG
0103-11	IG
,	O
DMA	BG
*-14	IG
0104	O
,	O
and	O
DMB	O
*	O
0102	O
in	O
the	O
systemic	BP
lupus	IP
erythematosus-25	IP
patients	O
compared	O
with	O
the	O
randomly	O
selected	O
controls	O
.	O

PS182	O
This	O
is	O
the	O
first	O
study	O
evaluating	O
the	O
influence	O
of	O
HLA	BG
-	IG
DM-12	IG
in	O
a	O
Caucasian	O
systemic	BP
lupus	IP
erythematosus-18	IP
population	O
.	O

PS184	O
However	O
,	O
therapeutically	O
active	O
doses	O
of	O
500	O
mg	O
bear	O
the	O
risk	O
of	O
hypoglycaemia-13	BP
,	O
and	O
a	O
tolbutamide	O
-	O
derived	O
parameter	O
based	O
on	O
a	O
single	O
plasma	O
or	O
urine	O
concentration	O
reflecting	O
CYP2C9-30	BG
activity	O
accurately	O
is	O
lacking	O
.	O

PS186	O
An	O
analysis	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
is	O
consistent	O
with	O
a	O
more	O
common	O
frequency	O
of	O
pulmonary	BP
arteriovenous	IP
malformations-19	IP
in	O
patients	O
with	O
endoglin	O
mutations	O
than	O
in	O
patients	O
with	O
ACVRL1	BG
mutations-30	IG
in	O
our	O
collective	O
.	O

PS187	O
Due	O
to	O
these	O
significant	O
genetic	O
differences	O
in	O
the	O
subgroups	O
of	O
Lofgren	O
and	O
non	O
-	O
Lofgren	O
sarcoidosis	O
patients	O
,	O
we	O
conclude	O
that	O
the	O
genotyping	O
of	O
these	O
two	O
loci	O
(	O
-	O
308	O
TNF	BG
-	IG
alpha	IG
promoter	IG
polymorphism-35	IG
and	O
HLA	BG
-	IG
DR-39	IG
)	O
may	O
be	O
of	O
prognostic	O
value	O
for	O
the	O
course	O
of	O
disease	O
in	O
sarcoidosis-52	BP
.	O

PS189	O
No	O
mutations	O
of	O
MYBPC3-4	BG
were	O
detected	O
in	O
any	O
of	O
the	O
sporadic	O
hypertrophic	BP
cardiomyopathy-13	IP
patients	O
.	O

PS190	O
In	O
contrast	O
to	O
previous	O
reports	O
,	O
the	O
V896M	O
mutation	O
may	O
be	O
a	O
disease	O
-	O
causing	O
mutation	O
in	O
China	O
,	O
and	O
exon	O
27	O
of	O
MYBPC3-24	BG
may	O
be	O
a	O
mutational	O
hotspot	O
in	O
Fhypertrophic	BP
cardiomyopathy-32	IP
patients	O
.	O

PS191	O
However	O
,	O
mutations	O
of	O
MYBPC3-5	BG
were	O
not	O
prevalent	O
among	O
Shypertrophic	BP
cardiomyopathy-11	IP
patients	O
.	O

PS194	O
In	O
series	O
I	O
,	O
analysis	O
of	O
selected	O
density	O
fractions	O
from	O
35	O
coronary	O
heart	O
disease	O
patients	O
demonstrated	O
that	O
although	O
most	O
of	O
the	O
apo-22	BG
was	O
present	O
in	O
the	O
Lp	BG
density	IG
range-29	IG
,	O
apo-31	BG
was	O
consistently	O
found	O
in	O
both	O
the	O
VLDL-38	BG
and	O
IDL-40	BG
fractions	O
as	O
well	O
.	O

PS196	O
The	O
effects	O
on	O
indices	O
of	O
disease	O
severity	O
and	O
activity	O
of	O
HLA	BG
DR4-12	IG
and	O
DR1-14	BG
,	O
the	O
DRB1	BG
*	IG
04	IG
subtypes-20	IG
,	O
and	O
the	O
polymorphism	O
in	O
the	O
rheumatoid	BP
arthritis-28	IP
susceptibility	O
sequence	O
were	O
examined	O
.	O

PS197	O
The	O
high	O
risk	O
conferred	O
by	O
the	O
HVR3	BG
susceptibility-8	IG
sequence	O
,	O
present	O
in	O
76	O
%	O
,	O
was	O
confirmed	O
,	O
but	O
24	O
%	O
of	O
the	O
patients	O
with	O
long	O
-	O
standing	O
seropositive	O
erosive	O
rheumatoid	BP
arthritis-32	IP
lacked	O
this	O
sequence	O
.	O

PS201	O
Both	O
sibs	O
are	O
homozygous	O
for	O
the	O
E325K	BG
mutation-8	IG
,	O
the	O
same	O
genotype	O
that	O
was	O
found	O
in	O
the	O
most	O
severe	O
form	O
of	O
alpha	O
-	O
NAGA	O
deficiency	O
presenting	O
as	O
infantile	O
neuroaxonal	BP
dystrophy-30	IP
.	O

PS202	O
The	O
clinical	O
heterogeneity	O
among	O
the	O
11	O
known	O
individuals	O
with	O
alpha	BG
-	IG
NAGA-12	IG
deficiency	O
is	O
extreme	O
,	O
with	O
a	O
'	O
non	O
-	O
disease	O
'	O
(	O
two	O
cases	O
)	O
and	O
infantile	O
neuroaxonal	BP
dystrophy-31	IP
(	O
two	O
cases	O
)	O
at	O
the	O
opposite	O
sides	O
of	O
the	O
clinical	O
spectrum	O
.	O

PS207	O
Whereas	O
the	O
influence	O
of	O
other	O
polymorphisms	O
of	O
methionine	O
metabolism-9	BP
was	O
not	O
confirmed	O
,	O
the	O
present	O
study	O
supports	O
the	O
previously	O
made	O
observation	O
that	O
the	O
Tc2	BG
genotype-25	IG
contributes	O
to	O
X	O
-	O
linked	O
adrenoleukodystrophy	O
phenotype	O
generation	O
.	O

PS210	O
Lactacidosis	O
,	O
hypoglycemia-3	BP
,	O
elevated	O
serum	BG
transaminases-7	IG
and	O
conjugated	O
bilirubin	O
are	O
common	O
signs	O
of	O
mitochondrial	O
hepatopathy	O
.	O

PS211	O
A	O
combination	O
of	O
lactacidosis-4	BP
,	O
liver	O
involvement	O
,	O
and	O
Fanconi	O
type	O
renal	O
tubulopathy	O
is	O
common	O
when	O
the	O
complex	O
III	BG
assembly	IG
factor	IG
BCS1L-22	IG
harbors	O
mutations	O
,	O
the	O
most	O
severe	O
disease	O
with	O
consistent	O
genotype	O
-	O
phenotype	O
correlation	O
being	O
the	O
GRACILE	O
syndrome	O
.	O

PS212	O
Mutation	O
detection	O
is	O
complex	O
due	O
to	O
the	O
large	O
size	O
of	O
Neurofibromatosis	BG
type	IG
1	IG
gene-14	IG
,	O
the	O
presence	O
of	O
pseudogenes	O
and	O
the	O
great	O
variety	O
of	O
lesions	O
.	O

PS213	O
Fifteen	O
sequence	O
variants	O
likely	O
to	O
represent	O
non	O
-	O
pathogenic	O
polymorphisms	O
were	O
observed	O
at	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
locus-18	IG
.	O

PS219	O
We	O
conducted	O
a	O
three	O
-	O
stage	O
case	O
-	O
control	O
study	O
of	O
congenital	BP
heart	IP
disease-14	IP
in	O
Chinese	O
to	O
test	O
our	O
hypothesis	O
by	O
genotyping	O
miR	BG
-	IG
196a2	IG
rs11614913-26	IG
and	O
three	O
other	O
pre	BG
-	IG
miRNA	IG
SNPs-33	IG
(	O
miR	BG
-	IG
146a	IG
rs2910164-38	IG
,	O
miR	BG
-	IG
149	IG
rs2292832-43	IG
,	O
and	O
miR	BG
-	IG
499	IG
rs3746444-49	IG
)	O
in	O
1	O
,	O
324	O
congenital	O
heart	O
disease	O
cases	O
and	O
1	O
,	O
783	O
non	O
-	O
congenital	O
heart	O
disease	O
controls	O
.	O

PS222	O
This	O
is	O
the	O
first	O
study	O
to	O
indicate	O
that	O
miR	BG
-	IG
196a2	IG
rs11614913-12	IG
plays	O
a	O
role	O
in	O
sporadic	O
congenital	BP
heart	IP
disease-20	IP
susceptibility	O
.	O

PS224	O
X	O
-	O
linked	O
retinitis	BP
pigmentosa-5	IP
accounts	O
for	O
10	O
-	O
25	O
%	O
of	O
RP	BG
families-14	IG
and	O
causes	O
the	O
most	O
severe	O
form	O
of	O
the	O
disease	O
in	O
terms	O
of	O
onset	O
and	O
progression	O
.	O

PS225	O
Although	O
three	O
different	O
loci	O
(	O
RP3-6	BG
,	O
RP2-8	BG
and	O
RP15-10	BG
)	O
have	O
been	O
proposed	O
on	O
the	O
short	O
arm	O
of	O
the	O
X	O
-	O
chromosome	O
by	O
linkage	O
analysis	O
,	O
RP3-28	BG
represents	O
the	O
disease	O
locus	O
in	O
the	O
majority	O
of	O
X	O
-	O
linked	O
retinitis-40	BP
pigmentosa	O
families	O
.	O

PS226	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
associations	O
of	O
four	O
selected	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
rs8126	O
T	BG
>	IG
C-19	IG
,	O
rs710100	BG
G	IG
>	IG
A-24	IG
,	O
rs1052912	BG
G	IG
>	IG
A-29	IG
and	O
rs1052823	BG
G-32	IG
>	O
T	O
)	O
in	O
the	O
microRNA	O
-	O
binding	O
sites	O
of	O
the	O
3	O
'	O
untranslated	O
region	O
with	O
squamous	BP
cell	IP
carcinoma-51	IP
of	O
the	O
head	O
and	O
neck	O
risk	O
in	O
1077	O
patients	O
with	O
squamous	BP
cell	IP
carcinoma-64	IP
of	O
the	O
head	O
and	O
neck	O
and	O
1073	O
cancer	O
-	O
free	O
controls	O
in	O
a	O
non	O
-	O
Hispanic	O
White	O
population	O
.	O

PS227	O
In	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
analysis	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
64	O
squamous	BP
cell	IP
carcinoma-17	IP
of	O
the	O
head	O
and	O
neck	O
patients	O
,	O
the	O
rs8126	BG
CC	IG
genotype-28	IG
was	O
associated	O
with	O
reduced	O
expression	O
of	O
TNFAIP2	BG
messenger	IG
RNA-37	IG
.	O

PS229	O
The	O
dendrogram	O
developed	O
by	O
randomly	O
amplified	O
polymorphic	O
DNA	O
,	O
simple	O
sequence	O
repeat	O
and	O
cytochrome	BG
P450	IG
gene-16	IG
based	O
primers	O
analyses	O
revealed	O
that	O
the	O
genotypes	O
are	O
grouped	O
in	O
different	O
clusters	O
according	O
to	O
high	BP
calcium-32	IP
(	O
300	O
-	O
450	O
mg	O
/	O
100	O
g	O
)	O
,	O
medium	O
calcium	O
(	O
200	O
-	O
300	O
mg	O
/	O
100	O
g	O
)	O
and	O
low	BP
calcium-56	IP
(	O
100	O
-	O
200	O
mg	O
/	O
100	O
g	O
)	O
.	O

PS230	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
due	O
to	O
21	O
-	O
hydroxylase-8	BG
deficiency	O
(	O
21OHD	O
)	O
occurs	O
worldwide	O
.	O

PS234	O
Several	O
parameters	O
were	O
recorded	O
following	O
inoculation	O
such	O
as	O
parasitemia-9	BP
,	O
body	O
temperature	O
,	O
standard	O
hematological	O
parameters	O
,	O
gametocytemia	O
,	O
rosette	O
formation	O
,	O
autoagglutination	O
,	O
as	O
well	O
as	O
HRPI-28	BG
and	O
PfEMP3-30	BG
expression	O
.	O

PS237	O
Excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
1-8	IG
and	O
excision	O
repair	O
cross	O
-	O
complementing	O
complementation	O
group	O
2	O
/	O
xeroderma-19	BP
pigmentosum	O
D	O
participate	O
in	O
the	O
nucleotide	O
excision	O
repair	O
pathway	O
that	O
removes	O
Benzo	O
[	O
a	O
]	O
pyrene	O
diol	O
epoxide	O
-	O
DNA	O
adducts	O
;	O

PS238	O
Therefore	O
,	O
we	O
assayed	O
for	O
levels	O
of	O
in	O
vitro	O
Benzo	O
[	O
a	O
]	O
pyrene	O
diol	O
epoxide	O
-	O
induced	O
DNA	O
adducts	O
and	O
genotypes	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
of	O
the	O
nucleotide	O
excision	O
repair	O
genes	O
Excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
1-41	IG
(	O
rs3212986-43	BG
and	O
rs11615-45	BG
)	O
and	O
excision	O
repair	O
cross	O
-	O
complementing	O
complementation	O
group	O
2	O
/	O
xeroderma-57	BP
pigmentosum	O
D	O
(	O
rs13181	O
,	O
rs1799793	O
and	O
rs238406	O
)	O
in	O
707	O
healthy	O
non	O
-	O
Hispanic	O
whites	O
.	O

PS240	O
Our	O
findings	O
suggest	O
that	O
the	O
genotypes	O
and	O
haplotypes	O
of	O
Excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
1-17	IG
and	O
excision	BG
repair	IG
cross	IG
-	IG
complementing	IG
complementation	IG
group	IG
2-26	IG
/	O
xeroderma-28	BP
pigmentosum	O
D	O
may	O
have	O
an	O
effect	O
on	O
in	O
vitro	O
Benzo	O
[	O
a	O
]	O
pyrene	O
diol	O
epoxide	O
-	O
induced	O
DNA	O
adduct	O
levels	O
.	O

PS242	O
It	O
can	O
therefore	O
be	O
seen	O
that	O
the	O
majority	O
of	O
plaques	O
(	O
70	O
%	O
)	O
,	O
considered	O
a	O
risk	O
for	O
future	O
stroke-21	BP
due	O
to	O
altered	O
carotid	O
Doppler	O
tests	O
,	O
does	O
not	O
differ	O
greatly	O
by	O
the	O
homozygote	BG
allele	IG
Apo	IG
E	IG
-	IG
3	IG
/	IG
E	IG
-	IG
3-44	IG
commonly	O
found	O
in	O
the	O
blood	O
of	O
the	O
so	O
-	O
called	O
"	O
normal	O
"	O
population	O
.	O

PS244	O
When	O
the	O
polycystic	BP
ovary-4	IP
syndrome	O
population	O
was	O
analyzed	O
,	O
a	O
significant	O
statistical	O
difference	O
was	O
found	O
when	O
relating	O
the	O
group	O
with	O
the	O
highest	O
androgenemia	O
level	O
with	O
the	O
presence	O
of	O
A2	O
/	O
A2	O
genotype	O
of	O
CYP	BG
17	IG
gene-36	IG
,	O
and	O
a	O
higher	O
level	O
of	O
circulating	O
androgen	O
was	O
found	O
in	O
PCO	O
women	O
carrying	O
the	O
216	O
-	O
allele	O
of	O
CYP11alpha	BG
gene-57	IG
(	O
that	O
did	O
not	O
reach	O
statistical	O
significance	O
)	O
.	O

PS251	O
Combining	O
the	O
previously	O
described	O
11	O
/	O
25	O
and	O
net	O
charge	O
rules	O
for	O
the	O
V3	BG
genotype-15	IG
improved	O
the	O
prediction	O
of	O
human	O
immunodeficiency-21	BP
virus	O
type	O
1	O
coreceptor	O
usage	O
.	O

PS255	O
We	O
screened	O
germline	O
mutations	O
in	O
the	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
the	O
GATA4	BG
gene-17	IG
in	O
486	O
congenital	BP
heart	IP
disease-22	IP
patients	O
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
,	O
and	O
confirmed	O
the	O
mutations	O
by	O
sequencing	O
.	O

PS256	O
Nine	O
distinct	O
mutations	O
including	O
one	O
small	O
deletion	O
mutation	O
(	O
46delS	O
)	O
,	O
two	O
small	O
insertion	O
mutations	O
(	O
118	O
-	O
119insA	O
and	O
125	O
-	O
126insAA	O
)	O
,	O
and	O
six	O
non	O
-	O
synonymous	O
mutations	O
(	O
A6V-34	BG
,	O
P163S-36	BG
,	O
E359K-38	BG
,	O
P407Q-40	BG
,	O
S429T	O
and	O
A442V	O
)	O
were	O
identified	O
in	O
12	O
of	O
the	O
486	O
patients	O
(	O
nine	O
with	O
ventricular	BP
septal	IP
defect-59	IP
,	O
two	O
with	O
Tetralogy	O
of	O
Fallot	O
,	O
and	O
one	O
with	O
endocardial	O
cushion	O
defect	O
)	O
.	O

PS259	O
In	O
both	O
lakes	O
with	O
species	BP
pairs-6	IP
,	O
limnetics	O
and	O
benthics	O
differed	O
in	O
their	O
composition	O
of	O
Major	BG
Histocompatibility	IG
Complex	IG
alleles-19	IG
,	O
and	O
limnetics	O
had	O
fewer	O
Major	BG
Histocompatibility	IG
Complex	IG
alleles-28	IG
per	O
individual	O
than	O
benthics	O
.	O

PS260	O
Chronic	O
administration	O
of	O
typical	O
antipsychotic	O
agents	O
,	O
which	O
mainly	O
act	O
on	O
the	O
dopamine	BG
receptors-14	IG
,	O
implicates	O
a	O
role	O
of	O
dopamine	O
system	O
on	O
the	O
susceptibility	O
of	O
tardive	BP
dyskinesia-27	IP
.	O

PS261	O
In	O
the	O
present	O
study	O
,	O
the	O
association	O
between	O
a	O
functional	O
Val158Met	BG
polymorphism	IG
of	IG
Catechol	IG
-	IG
O	IG
-	IG
methyltransferase-18	IG
gene	O
and	O
tardive	O
dyskinesia	O
occurrence	O
and	O
tardive	O
dyskinesia	O
severity	O
was	O
investigated	O
in	O
299	O
Chinese	O
schizophrenic	O
patients	O
with	O
long	O
-	O
term	O
antipsychotic	O
treatment	O
(	O
tardive	BP
dyskinesia-43	IP
:	O
166	O
,	O
non	O
-	O
tardive	O
dyskinesia	O
:	O
133	O
)	O
.	O

PS263	O
Among	O
tardive	BP
dyskinesia-3	IP
patients	O
,	O
we	O
found	O
no	O
significant	O
correlation	O
between	O
Catechol	BG
-	IG
O	IG
-	IG
methyltransferase-16	IG
genotypes	O
and	O
the	O
total	O
scores	O
of	O
abnormal	O
involuntary	O
movement	O
scale	O
.	O

PS264	O
We	O
concluded	O
that	O
this	O
Catechol	BG
-	IG
O	IG
-	IG
methyltransferase-9	IG
polymorphism	O
might	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
susceptibility	O
of	O
tardive	BP
dyskinesia-22	IP
nor	O
on	O
the	O
severity	O
of	O
tardive	BP
dyskinesia-29	IP
.	O

PS265	O
Here	O
,	O
we	O
report	O
on	O
a	O
family	O
with	O
a	O
novel	O
GJB2-11	BG
mutation	O
causing	O
a	O
syndrome	O
of	O
focal	O
palmoplantar	BP
keratoderma-19	IP
with	O
severe	O
progressive	O
sensorineural	O
hearing	O
impairment	O
,	O
a	O
phenotype	O
reminiscent	O
of	O
Vohwinkel	O
syndrome	O
.	O

PS267	O
Selective	O
PCR	O
-	O
sequencing	O
of	O
UL97	O
(	O
protein	O
kinase	O
;	O
PK-11	BG
)	O
and	O
UL54	O
(	O
DNA	O
polymerase	O
;	O
definition	O
of	O
the	O
clinical	O
relationship	O
between	O
novel	O
UL54-26	BG
)	O
regions	O
important	O
for	O
antiviral	O
sensitivity	O
,	O
identified	O
the	O
majority	O
(	O
6	O
/	O
8	O
)	O
of	O
resistant	O
strains	O
through	O
detection	O
of	O
mutations	O
known	O
to	O
confer	O
antiviral	BP
resistance-53	IP
.	O

PS268	O
A	O
combination	O
of	O
phenotypic	O
and	O
genotypic	O
assays	O
is	O
recommended	O
for	O
complete	O
analysis	O
of	O
CMV	O
antiviral	BP
resistance-16	IP
,	O
as	O
well	O
as	O
further	O
definition	O
of	O
the	O
clinical	O
relationship	O
between	O
novel	O
UL54-29	BG
mutations	O
and	O
antiviral	BP
resistance-33	IP
.	O

PS269	O
Chromosomal	O
deletions	O
of	O
10q	O
and	O
candidate	O
genes	O
such	O
as	O
PTEN-10	BG
and	O
DMBT1-12	BG
have	O
been	O
thoroughly	O
investigated	O
in	O
glioblastomas-18	BP
but	O
few	O
data	O
specifically	O
address	O
oligodendrogliomas-24	BP
.	O

PS270	O
In	O
this	O
study	O
,	O
39	O
pure	O
oligodendrogliomas-7	BP
were	O
investigated	O
for	O
loss	O
of	O
heterozygosity	O
on	O
10q-15	BG
,	O
PTEN	BG
mutations-18	IG
,	O
and	O
DMBT1	BG
homozygous-22	IG
deletions	O
.	O

PS272	O
The	O
degree	O
of	O
Axillary	O
osmidrosis	O
in	O
Japanese	O
subjects	O
was	O
associated	O
with	O
the	O
genotype	O
of	O
the	O
ABCC11	BG
gene-17	IG
as	O
well	O
as	O
wet	BP
earwax-22	IP
type	O
.	O

PS273	O
Twenty	O
-	O
three	O
unrelated	O
,	O
Italian	O
Primary	O
hyperoxaluria-8	BP
type	O
1	O
patients	O
were	O
studied	O
,	O
20	O
of	O
which	O
were	O
grouped	O
according	O
to	O
severe	O
form	O
of	O
Primary	O
hyperoxaluria-26	BP
type	O
1	O
,	O
adult	O
form	O
(	O
group	O
B	O
)	O
,	O
and	O
mild	O
to	O
moderate	O
decrease	O
in	O
renal	O
function	O
(	O
group	O
C	O
)	O
.	O

PS274	O
we	O
examined	O
the	O
influence	O
of	O
the	O
androgen	BG
receptor	IG
gene-9	IG
(	O
AR-11	BG
)	O
CAG	O
microsatellite	O
(	O
AR	O
-	O
CAG	O
)	O
repeat	O
polymorphism	O
and	O
X	O
-	O
chromosome	O
inactivation	O
(	O
XCI	O
)	O
pattern	O
on	O
ovarian	O
reserve	O
markers	O
(	O
follicle	BG
stimulating	IG
hormone-38	IG
(	O
FSH-40	BG
)	O
and	O
antral	O
follicle	O
count	O
on	O
menstrual	O
cycle	O
day	O
3	O
-	O
5	O
)	O
and	O
disease	O
etiology	O
in	O
patients	O
with	O
polycystic	BP
ovarian-61	IP
syndrome	O
or	O
premature	O
ovarian	BP
failure-66	IP
(	O
POF	O
)	O
.	O

PS277	O
However	O
a	O
positive	O
correlation	O
between	O
location	O
of	O
the	O
mutations	O
in	O
certain	O
domains	O
of	O
the	O
retinoblastoma	BG
protein-16	IG
and	O
disease	O
severity	O
was	O
observed	O
.	O

PS278	O
Here	O
we	O
investigate	O
for	O
the	O
first	O
time	O
genetic	O
variations	O
in	O
the	O
XYLT	BG
-	IG
genes-14	IG
and	O
serum	BG
Xylosyltransferase	IG
I-18	IG
activities	O
and	O
their	O
implication	O
in	O
osteoarthritis-24	BP
.	O

PS279	O
Denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
was	O
used	O
for	O
the	O
screening	O
of	O
the	O
XYLT	BG
-	IG
genes-16	IG
in	O
49	O
osteoarthritis-19	BP
patients	O
.	O

PS284	O
We	O
investigated	O
gene	O
expression	O
profiles	O
between	O
and	O
within	O
distinct	O
multiple	O
endocrine	BG
neoplasia2-12	IG
subtypes	O
through	O
whole	O
-	O
genome	O
microarray	O
analysis	O
in	O
tumors	O
induced	O
by	O
NIH	O
-	O
3T3	O
cells	O
transformed	O
with	O
defined	O
RET	BG
-	IG
multiple	IG
endocrine	IG
neoplasia2A-35	IG
(	O
C609Y-37	BG
,	O
C634R-39	BG
)	O
,	O
multiple	O
endocrine	O
neoplasia2B-44	BP
,	O
(	O
A883F	O
,	O
M918T	O
)	O
,	O
and	O
familial	O
medullary	O
thyroid	BP
carcinoma-56	IP
(	O
Y791F	O
)	O
mutations	O
.	O

PS285	O
By	O
contrast	O
,	O
no	O
obvious	O
alterations	O
were	O
observed	O
among	O
individual	O
multiple	O
endocrine	BG
neoplasia2B-13	IG
and	O
multiple	O
endocrine	BG
neoplasia2A-17	IG
type	O
mutations	O
,	O
or	O
between	O
multiple	O
endocrine	O
neoplasia2A	O
and	O
familial	O
medullary	O
thyroid	BP
carcinoma-30	IP
.	O

PS286	O
Intriguingly	O
,	O
RET	O
-	O
multiple	O
endocrine	O
neoplasia2A	O
/	O
familial	O
medullary	O
thyroid	O
carcinoma	O
-	O
specific	O
tumors	O
were	O
characterized	O
by	O
a	O
considerable	O
number	O
of	O
genes	O
involved	O
in	O
the	O
host	O
antitumor	O
immune	O
response	O
via	O
stimulation	O
of	O
natural	O
killer	O
/	O
T	O
-	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
cytotoxicity	O
,	O
which	O
were	O
completely	O
absent	O
in	O
RET-52	BG
-	O
multiple	O
endocrine	O
neoplasia2B	O
related	O
cancers-58	BP
.	O

PS287	O
QPCR	O
on	O
tumors	O
versus	O
cultured	O
NIH	O
-	O
RET	O
cell	O
lines	O
demonstrated	O
that	O
they	O
are	O
largely	O
attributed	O
to	O
the	O
host	O
innate	O
immune	O
system	O
,	O
whereas	O
expression	O
of	O
CX3CL1-27	BG
involved	O
in	O
leukocyte	O
recruitment	O
is	O
exclusively	O
RET	O
-	O
multiple	O
endocrine	O
neoplasia2A	O
/	O
familial	O
medullary	O
thyroid	BP
carcinoma-43	IP
tumor	O
cell	O
dependent	O
.	O

PS288	O
In	O
correlation	O
,	O
massive	O
inflammatory	O
infiltrates	O
were	O
apparent	O
only	O
in	O
tumors	O
carrying	O
multiple	O
endocrine	O
neoplasia-15	BP
type	O
2A	O
/	O
familial	O
medullary	O
thyroid	BP
carcinoma-22	IP
mutations	O
,	O
suggesting	O
that	O
RET	BG
-	IG
multiple	IG
endocrine	IG
neoplasia2B	IG
receptors-32	IG
specifically	O
counteract	O
immune	O
infiltration	O
by	O
preventing	O
chemokine	O
expression	O
,	O
which	O
may	O
contribute	O
to	O
the	O
different	O
clinical	O
outcome	O
of	O
both	O
subtypes	O
.	O

PS289	O
This	O
study	O
provides	O
the	O
strongest	O
and	O
most	O
direct	O
evidence	O
that	O
mutagen	O
sensitivity	O
is	O
highly	O
heritable	O
,	O
thereby	O
validating	O
the	O
use	O
of	O
mutagen	O
sensitivity	O
as	O
a	O
cancer	BG
susceptibility	IG
factor-28	IG
.	O

PS290	O
To	O
explore	O
the	O
UL139	BG
gene-5	IG
polymorphism	O
of	O
human	O
cytomegalovirus	O
,	O
and	O
the	O
relationship	O
between	O
polymorphisms	O
of	O
human	BG
cytomegalovirus	IG
UL139	IG
ORF-20	IG
and	O
Hirschsprung	BP
'-23	IP
s	O
disease	O
.	O

PS292	O
Individuals	O
with	O
congenital	BP
central	IP
hypoventilation-5	IP
syndrome	O
have	O
characteristic	O
variants	O
in	O
the	O
PHOX2B	BG
gene-13	IG
(	O
primarily	O
polyalanine	O
expansion	O
mutations	O
)	O
.	O

PS293	O
Because	O
sympathetic	O
innervation	O
has	O
been	O
hypothesized	O
to	O
affect	O
the	O
development	O
of	O
dermatoglyphic	O
pattern	O
types	O
,	O
we	O
hypothesized	O
that	O
individuals	O
with	O
PHOX2B-21	BG
-	O
confirmed	O
congenital	BP
central	IP
hypoventilation-26	IP
syndrome	O
would	O
have	O
characteristic	O
dermatoglyphic	O
patterning	O
and	O
that	O
the	O
dermatoglyphic	O
phenotype	O
would	O
be	O
related	O
to	O
the	O
disease	O
-	O
defining	O
PHOX2B	BG
genotype-47	IG
.	O

PS294	O
Dermatoglyphic	O
pattern	O
type	O
frequency	O
,	O
left	O
/	O
right	O
symmetry	O
,	O
and	O
genotype	O
/	O
phenotype	O
correlation	O
were	O
assessed	O
for	O
33	O
individuals	O
with	O
PHOX2B-22	BG
-	O
confirmed	O
congenital	BP
central	IP
hypoventilation-27	IP
syndrome	O
and	O
compared	O
with	O
published	O
control	O
data	O
.	O

PS295	O
These	O
results	O
represent	O
the	O
first	O
report	O
describing	O
specific	O
dermatoglyphic	O
patterning	O
in	O
congenital	BP
central	IP
hypoventilation-14	IP
syndrome	O
and	O
suggest	O
a	O
relationship	O
between	O
PHOX2B-21	BG
and	O
the	O
expression	O
of	O
dermatoglyphic	O
pattern	O
types	O
.	O

PS296	O
An	O
expanded	O
congenital	BP
central	IP
hypoventilation-5	IP
syndrome	O
data	O
set	O
to	O
include	O
the	O
full	O
spectrum	O
of	O
PHOX2B-15	BG
mutations	O
is	O
necessary	O
to	O
further	O
delineate	O
the	O
role	O
of	O
PHOX2B-25	BG
in	O
dermatoglyphic	O
patterning	O
.	O

PS297	O
A	O
Japanese	BG
girl	IG
(	IG
glucose	IG
phosphate	IG
isomerase	IG
Fukuoka	IG
)-9	IG
had	O
an	O
episode	O
of	O
prolonged	O
neonatal	O
jaundice	O
and	O
at	O
3	O
years	O
of	O
age	O
was	O
admitted	O
due	O
to	O
acute	O
hemolytic	O
crisis	O
occurring	O
with	O
upper	O
respiratory	BP
tract	IP
infection-35	IP
.	O

PS299	O
Although	O
a	O
significant	O
correlation	O
was	O
observed	O
between	O
the	O
presence	O
or	O
absence	O
of	O
the	O
neuronal	BG
apoptosis	IG
inhibitory	IG
protein	IG
gene-18	IG
and	O
the	O
severity	O
of	O
the	O
clinical	O
phenotype	O
in	O
spinal	BP
muscular	IP
atrophy-29	IP
patients	O
generally	O
,	O
there	O
was	O
no	O
difference	O
in	O
age	O
of	O
onset	O
or	O
survival	O
in	O
type	O
I	O
patients	O
with	O
the	O
neuronal	BG
apoptosis	IG
inhibitory	IG
protein	IG
+	IG
or	IG
neuronal	IG
apoptosis	IG
inhibitory	IG
protein	IG
-	IG
genotype-60	IG
.	O

PS303	O
To	O
determine	O
the	O
phenotype	O
and	O
frequency	O
of	O
Cholesteryl	BG
Ester	IG
Transfer	IG
Protein-11	IG
(	O
TaqIB-13	BG
)	O
polymorphism	O
among	O
Filipinos	O
with	O
cardiovascular	BP
risk-20	IP
factors	O
.	O

PS305	O
Cholesteryl	BG
Ester	IG
Transfer	IG
Protein-4	IG
(	O
TaqIB-6	BG
)	O
Polymorphisms	O
exist	O
among	O
Filipinos	O
with	O
cardiovascular	BP
risk-14	IP
factors	O
.	O

PS306	O
Polymorphisms	O
in	O
the	O
N	BG
-	IG
Acetyltransferase	IG
2	IG
gene-8	IG
result	O
in	O
a	O
slow	O
acetylator	O
phenotype	O
,	O
which	O
has	O
been	O
associated	O
with	O
various	O
cancers-22	BP
and	O
neurodegenerative	O
diseases	O
.	O

PS309	O
Two	O
children	O
had	O
palate	IP
in	O
addition	O
to	O
distichiasis	O
,	O
but	O
without	O
the	O
previously	O
reported	O
association	O
with	O
the	O
Pierre	BG
-	IG
Robin	IG
sequence-21	IG
.	O

PS310	O
As	O
FOXC2-2	BG
/	O
FKLH14-4	BG
mutations	O
were	O
found	O
to	O
underlie	O
distichiasis	O
-	O
lymphedema-12	BP
syndrome	O
and	O
diverse	O
hereditary	O
lymphedema	O
conditions	O
,	O
this	O
gene	O
was	O
examined	O
by	O
sequence	O
analysis	O
.	O

PS314	O
We	O
determined	O
Cytochrome	BG
P4504A11	IG
F434S-5	IG
,	O
Cytochrome	BG
P4502C9	IG
I359L-9	IG
,	O
Cytochrome	BG
P4502C9	IG
G144C-13	IG
and	O
Cytochrome	BG
P450-16	IG
2J2	O
promotor	O
-	O
50G	O
>	O
T	O
polymorphisms	O
in	O
734	O
patients	O
with	O
coronary	BP
artery	IP
disease-30	IP
undergoing	O
percutaneous	O
coronary	O
intervention	O
.	O

PS315	O
The	O
Cytochrome	BG
P450	IG
2C9-4	IG
and	O
Cytochrome	BG
P450-7	IG
2J2	O
polymorphisms	O
did	O
not	O
show	O
any	O
correlation	O
with	O
coronary	O
vasoconstriction	O
,	O
hypertension-19	BP
,	O
diabetes	BP
mellitus-22	IP
,	O
blood	O
pressure	O
or	O
cholesterol	O
.	O

PS318	O
Expansion	O
of	O
the	O
trinucleotide	O
repeat	O
(	O
CAG	O
)	O
n	O
in	O
the	O
first	O
exon	O
of	O
the	O
androgen	BG
receptor	IG
gene-18	IG
is	O
associated	O
with	O
a	O
rare	O
motor	O
neuron	O
disorder	O
,	O
X	O
-	O
linked	O
spinal	O
and	O
bulbar	O
muscular	BP
atrophy-35	IP
.	O

PS320	O
suggesting	O
that	O
proteolipid	BG
protein	IG
1	IG
gene-6	IG
splicing	O
abnormalities	O
,	O
potentially	O
caused	O
by	O
undetected	O
intronic	O
mutations	O
,	O
are	O
either	O
not	O
involved	O
or	O
are	O
very	O
rarely	O
implicated	O
in	O
the	O
Pelizaeus	O
-	O
Merzbacher	O
-	O
like	O
disease	O
phenotype	O
.	O

PS322	O
Comparison	O
of	O
the	O
clinical	O
features	O
in	O
these	O
patients	O
and	O
in	O
a	O
previously	O
reported	O
patient	O
enables	O
refinement	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
strongly	O
suggests	O
that	O
increased	O
dosage	O
of	O
MECP2-30	BG
results	O
in	O
the	O
mental	BP
retardation-35	IP
phenotype	O
.	O

PS325	O
To	O
detect	O
gene	O
mutations	O
on	O
beta	BG
-	IG
myosin	IG
heavy	IG
chain	IG
gene	IG
MYH7-12	IG
in	O
3	O
Chinese	O
families	O
with	O
hypertrophic	BP
cardiomyopathy-19	IP
,	O
and	O
to	O
analyze	O
the	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
.	O

PS326	O
A	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
and	O
sequencing	O
mutation	O
screening	O
of	O
the	O
exons	O
(	O
exon3	O
-	O
23	O
)	O
coding	O
for	O
MYH7	BG
gene-23	IG
were	O
performed	O
in	O
3	O
Chinese	O
families	O
with	O
hypertrophic	BP
cardiomyopathy-32	IP
.	O

PS327	O
This	O
study	O
illustrated	O
the	O
high	O
frequency	O
of	O
mutation	O
in	O
MYH7	BG
gene-11	IG
in	O
Chinese	O
hypertrophic	BP
cardiomyopathy-15	IP
families	O
.	O

PS330	O
Herein	O
,	O
we	O
report	O
three	O
new	O
patients	O
from	O
a	O
single	O
family	O
who	O
present	O
with	O
phenotypes	O
that	O
associate	O
features	O
of	O
both	O
pigmented	O
hypertrichosis-22	BP
with	O
insulin-24	BG
dependent	O
diabetes	O
and	O
H	O
syndrome	O
.	O

PS331	O
One	O
sister	O
had	O
clinical	O
features	O
consistent	O
with	O
classical	O
pigmented	O
hypertrichosis-10	BP
with	O
insulin-12	BG
dependent	O
diabetes	O
phenotype	O
,	O
while	O
her	O
nephew	O
'	O
s	O
features	O
were	O
in	O
keeping	O
with	O
the	O
diagnosis	O
of	O
H	O
syndrome	O
.	O

PS332	O
Rett	O
syndrome	O
,	O
a	O
neurodevelopmental	O
disorder	O
that	O
is	O
a	O
leading	O
cause	O
of	O
mental	BP
retardation-14	IP
in	O
females	O
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
X	O
-	O
linked	O
gene	O
encoding	O
methyl	BG
-	IG
CpG	IG
-	IG
binding	IG
protein	IG
2-35	IG
.	O

PS335	O
Genetic	O
screening	O
of	O
HA	BG
-	IG
TTR-6	IG
could	O
be	O
worthwhile	O
in	O
any	O
idiopathic	O
progressive	O
axonal	O
peripheral	O
neuropathy-16	BP
,	O
as	O
well	O
as	O
in	O
drug	O
resistant	O
demyelinating	O
sensory	O
-	O
motor	O
neuropathy	O
or	O
in	O
pure	O
motor	O
neuropathy-33	BP
,	O
when	O
multi	O
-	O
organ	O
involvement	O
is	O
present	O
.	O

PS338	O
Patients	O
with	O
altered	O
albumin-4	BG
and	O
red	O
blood	O
cell	O
turnover	O
,	O
which	O
are	O
observed	O
in	O
those	O
with	O
chronic	BP
renal	IP
failure-19	IP
,	O
liver	O
cirrhosis-22	BP
,	O
and	O
anemia-25	BP
among	O
others	O
,	O
were	O
excluded	O
from	O
the	O
study	O
.	O

PS342	O
Haptoglobin-1	BG
phenotype	O
and	O
concentration	O
should	O
be	O
considered	O
in	O
interpreting	O
hemoglobinA	BG
(	IG
1c	IG
)-13	IG
and	O
glycated-15	BP
albumin-16	BG
levels	O
as	O
glycemic	O
control	O
indicators	O
in	O
diabetic	O
patients	O
.	O

PS343	O
We	O
suggest	O
that	O
in	O
type	O
2	O
diabetic	O
patients	O
with	O
Haptoglobin	BG
2	IG
-	IG
1-13	IG
and	O
high	O
Haptoglobin-16	BG
concentrations	O
,	O
hemoglobinA	BG
(	IG
1c	IG
)-22	IG
level	O
may	O
be	O
overestimated	O
relative	O
to	O
glycated-29	BP
albumin-30	BG
level	O
.	O

PS347	O
Cystic	BP
fibrosis-2	IP
is	O
the	O
most	O
common	O
autosomal	O
recessive	O
genetic	O
defect	O
of	O
one	O
gene	BG
CFTR-14	IG
,	O
where	O
a	O
variety	O
of	O
mutations	O
were	O
revealed	O
.	O

PS349	O
This	O
hypermutability	O
is	O
probably	O
due	O
to	O
a	O
slippage	O
in	O
DNA	BG
polymerase-11	IG
during	O
replication	O
,	O
resulting	O
in	O
gains	O
/	O
losses	O
of	O
repeat	O
units	O
,	O
causing	O
cancer	BP
predisposition-26	IP
.	O

PS350	O
Of	O
particular	O
interest	O
is	O
the	O
often	O
reported	O
genotype	O
/	O
phenotype	O
correlation	O
between	O
folliculin-13	BG
mutations	O
and	O
risk	O
of	O
colon	O
or	O
breast	BP
cancer-21	IP
.	O

PS353	O
Progression	O
of	O
hearing	BP
loss-4	IP
begins	O
in	O
the	O
first	O
decade	O
,	O
and	O
approximately	O
50	O
%	O
of	O
subjects	O
with	O
USH3-18	BG
become	O
profoundly	O
deaf	O
by	O
age	O
40	O
.	O

PS354	O
Depending	O
on	O
the	O
severity	O
of	O
hearing	BP
loss-7	IP
,	O
subjects	O
with	O
USH3-11	BG
might	O
be	O
misdiagnosed	O
as	O
either	O
Usher	O
type	O
IB	O
or	O
IIA	O
.	O

PS355	O
Our	O
findings	O
,	O
although	O
in	O
need	O
of	O
confirmation	O
,	O
suggest	O
that	O
variations	O
in	O
circadian	O
genes	O
are	O
associated	O
with	O
serum	BG
hormone-20	IG
levels	O
,	O
providing	O
biological	O
support	O
for	O
the	O
role	O
of	O
circadian	BG
genes-31	IG
in	O
hormone	O
-	O
related	O
cancers-36	BP
.	O

PS356	O
To	O
study	O
phenotype	O
-	O
genotype	O
correlation	O
in	O
patients	O
who	O
have	O
retinoma	O
,	O
which	O
is	O
a	O
benign	O
tumor	O
resembling	O
the	O
post	O
irradiation	O
regression	O
pattern	O
of	O
retinoblastoma-25	BG
.	O

PS360	O
The	O
association	O
of	O
an	O
individual	O
SNP	O
with	O
late	O
-	O
onset	O
Fuchs	O
corneal	BP
dystrophy-13	IP
was	O
evaluated	O
with	O
the	O
Fisher	O
exact	O
test	O
,	O
and	O
the	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
TCF4-32	BG
were	O
sequenced	O
in	O
96	O
affected	O
persons	O
.	O

PS362	O
We	O
investigated	O
MEFV-3	BG
and	O
serum	O
amyloid	O
A1	O
genotypes	O
(	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
isoforms	O
)	O
in	O
50	O
familial	O
Mediterranean	O
fever-22	BP
patients	O
and	O
50	O
healthy	O
children	O
.	O

PS365	O
Positive	O
family	O
history	O
for	O
amyloidosis	O
and	O
presence	O
of	O
serum	BG
amyloid	IG
A1	IG
alpha	IG
/	IG
alpha-14	IG
genotype	O
in	O
M694V	O
/	O
M694V	O
mutation	O
may	O
predispose	O
to	O
amyloidosis-24	BP
by	O
increasing	O
the	O
clinical	O
severity	O
.	O

PS366	O
Sixteen	O
patients	O
from	O
13	O
families	O
with	O
signs	O
of	O
Stargardt	O
macular	BP
dystrophy-11	IP
/	O
fundus	O
flavimaculatus	O
and	O
known	O
mutations	O
on	O
both	O
alleles	O
of	O
the	O
ABCA4	BG
gene-24	IG
(	O
15	O
compound	O
heterozygous	O
,	O
one	O
homozygous	O
)	O
were	O
characterized	O
by	O
clinical	O
examination	O
,	O
fundus	O
autofluorescence	O
,	O
psychophysics	O
(	O
color	O
vision	O
,	O
kinetic	O
and	O
two	O
-	O
color	O
dark	O
-	O
and	O
light	O
-	O
adapted	O
static	O
threshold	O
perimetry	O
)	O
,	O
and	O
electrophysiology	O
(	O
Ganzfeld	O
,	O
multifocal	O
ERG	O
,	O
EOG	O
)	O
.	O

PS370	O
Functional	O
studies	O
of	O
mutations	O
causing	O
Hypertrophic	O
cardiomyopathy-7	BP
have	O
shed	O
significant	O
light	O
into	O
the	O
pathogenesis	O
of	O
Hypertrophic	BP
cardiomyopathy-17	IP
and	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
mutant	BG
sarcomeric	IG
proteins-27	IG
function	O
as	O
'	O
poison	O
peptides	O
'	O
exerting	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
the	O
function	O
of	O
the	O
cardiac	O
myocytes	O
,	O
followed	O
by	O
structural	O
changes	O
and	O
a	O
compensatory	O
hypertrophy	O
.	O

PS371	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
is	O
a	O
recessive	O
,	O
X	O
-	O
linked	O
leukoencephalopathy-12	BP
attributed	O
to	O
impaired	BP
myelination	IP
during	IP
central	IP
nervous	IP
system-20	IP
development	O
,	O
caused	O
by	O
defects	O
in	O
the	O
proteolipid	BG
protein	IG
1-30	IG
gene	O
.	O

PS373	O
A	O
total	O
of	O
100	O
patients	O
with	O
cystic	BP
fibrosis-8	IP
were	O
screened	O
for	O
mutations	O
in	O
the	O
cystic	BG
fibrosisTR	IG
gene-17	IG
.	O

PS374	O
We	O
used	O
a	O
novel	O
RNase-5	BG
cleavage	O
assay	O
to	O
screen	O
for	O
neurofibromatosis-11	BP
2	O
mutations	O
in	O
neurofibromatosis	O
2	O
schwannomas	O
.	O

PS376	O
Of	O
19	O
isolates	O
that	O
expressed	O
the	O
ermTR	BG
gene-8	IG
,	O
16	O
displayed	O
the	O
inducible	O
macrolide	BP
resistance-15	IP
(	O
iMLS	O
(	O
B	O
)	O
)	O
phenotype	O
.	O

PS379	O
Susceptibility	O
to	O
inflammatory	BP
bowel	IP
disease-5	IP
is	O
partially	O
genetically	O
determined	O
and	O
the	O
human	BG
leukocyte	IG
antigen-14	IG
alloantigens	O
and	O
genes	O
located	O
in	O
the	O
human	BG
leukocyte	IG
antigen	IG
region-24	IG
have	O
been	O
studied	O
over	O
the	O
course	O
of	O
many	O
years	O
as	O
the	O
candidate	O
genes	O
responsible	O
for	O
ulcerative	O
colitis-41	BP
.	O

PS381	O
Compared	O
to	O
Europeans	O
,	O
we	O
found	O
a	O
low	O
frequency	O
of	O
the	O
protective	O
allele	O
at	O
R381Q-15	BG
in	O
interleukin	BG
-	IG
23	IG
receptor-20	IG
and	O
no	O
statistically	O
-	O
significant	O
association	O
with	O
inflammatory	BP
bowel	IP
disease-30	IP
.	O

PS382	O
Immunohistochemical	O
investigation	O
of	O
the	O
specimens	O
with	O
anti	BG
-	IG
p16	IG
antibody-10	IG
was	O
performed	O
in	O
order	O
to	O
elucidate	O
the	O
putative	O
role	O
of	O
p16-21	BG
as	O
a	O
surrogate	O
marker	O
of	O
human	O
papilloma-28	BP
virus	O
infection	O
.	O

PS384	O
A	O
simplified	O
test	O
for	O
human	O
papilloma-6	BP
virus	O
in	O
basaloid	O
squamous	BP
cell	IP
carcinoma-12	IP
of	O
the	O
oral	O
cavity	O
using	O
the	O
immunohistochemical	O
proof	O
of	O
p16-22	BG
expression	O
as	O
a	O
surrogate	O
marker	O
is	O
non	O
-	O
effective	O
.	O

PS385	O
Medium	O
-	O
chain	O
acyl	BG
-	IG
CoA	IG
dehydrogenase-7	IG
deficiency	O
is	O
the	O
most	O
common	O
inherited	O
disorder	O
of	O
fatty	O
acid	O
metabolism	O
presenting	O
with	O
hypoglycaemia-21	BP
,	O
hepatopathy	O
and	O
Reye	O
-	O
like	O
symptoms	O
during	O
catabolism	O
.	O

PS386	O
Mutations	O
in	O
the	O
acetylcholinesterase	BG
collagen	IG
-	IG
like	IG
tail	IG
subunit	IG
gene-10	IG
(	O
COlQ-12	BG
)	O
cause	O
recessive	O
forms	O
of	O
synaptic	O
Congenital	O
myasthenic	O
syndromes	O
with	O
end	O
plate	BG
acetylcholinesterase	IG
deficiency-26	IP
.	O

PS394	O
This	O
supports	O
the	O
need	O
to	O
characterize	O
the	O
spectrum	O
of	O
hematologic	O
abnormalities	O
in	O
individuals	O
with	O
Noonan	O
syndrome	O
and	O
to	O
better	O
define	O
the	O
impact	O
of	O
the	O
PTPN11-25	BG
lesion	O
on	O
the	O
disease	O
course	O
in	O
patients	O
with	O
Noonan	O
syndrome	O
/	O
MPD	O
and	O
juvenile	O
myelomonocytic	O
leukemia-41	BP
.	O

PS395	O
In	O
one	O
large	O
family	O
with	O
a	O
missense	O
mutation	O
(	O
V170D	O
)	O
of	O
the	O
Von	BG
Hippel	IG
-	IG
Lindau	IG
disease	IG
gene-19	IG
,	O
in	O
which	O
the	O
complete	O
spectrum	O
of	O
visceral	O
-	O
and	O
central	O
nervous	O
system	O
features	O
of	O
Von	O
Hippel	O
-	O
Lindau	O
disease	O
is	O
present	O
,	O
macular	O
,	O
parapapillary	O
,	O
optic	O
disc	O
and	O
ora	O
serrata	O
angiomas-52	BP
were	O
also	O
found	O
.	O

PS396	O
DLX1-1	BG
and	O
DLX2-3	BG
haploinsufficiency	O
was	O
suggested	O
as	O
the	O
most	O
plausible	O
explanation	O
for	O
the	O
observed	O
SHFM	O
-	O
like	O
limb	BP
anomalies-19	IP
in	O
these	O
cases	O
.	O

PS402	O
MECP2-1	BG
-	O
positive	O
females	O
had	O
more	O
problems	O
in	O
ambulation	O
,	O
muscle	O
tone	O
,	O
tremor	O
and	O
ataxia-16	BP
,	O
respiratory	BP
disturbances-19	IP
,	O
head	O
growth	O
,	O
hand	O
use	O
and	O
stereotypies	O
.	O

PS404	O
We	O
have	O
studied	O
five	O
Swedish	O
familial	BP
melanoma-7	IP
kindreds	O
characterized	O
by	O
germline	O
mutations	O
in	O
CDKN2A-14	BG
and	O
dysplastic	O
naevus-17	BP
syndrome	O
.	O

PS406	O
In	O
CDKN2A-2	BG
mutation	O
carriers	O
,	O
all	O
cases	O
of	O
early	O
-	O
onset	O
melanoma-12	BP
occurred	O
in	O
dysplastic	O
naevus-16	BP
syndrome	O
individuals	O
,	O
and	O
the	O
mean	O
age	O
at	O
melanoma	O
diagnosis	O
was	O
significantly	O
lower	O
in	O
individuals	O
with	O
dysplastic	O
naevus-34	BP
syndrome	O
than	O
in	O
those	O
without	O
a	O
confirmed	O
dysplastic	O
naevus-43	BP
syndrome	O
phenotype	O
.	O

PS407	O
In	O
one	O
family	O
where	O
the	O
proband	O
had	O
a	O
P48L-9	BG
mutation	O
in	O
CDKN2A	BG
exon	IG
1-14	IG
,	O
the	O
dysplastic	O
naevus-18	BP
syndrome	O
phenotype	O
was	O
studied	O
in	O
detail	O
.	O

PS409	O
Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
germline	BG
CDKN2A-10	IG
mutations	O
and	O
dysplastic	O
naevus-14	BP
syndrome	O
both	O
contribute	O
to	O
the	O
predisposition	O
to	O
melanoma-22	BP
and	O
may	O
lead	O
to	O
the	O
development	O
of	O
early	O
-	O
onset	O
melanoma-33	BP
when	O
present	O
in	O
the	O
same	O
individual	O
.	O

PS410	O
Evaluation	O
of	O
the	O
phenotypic	O
presentation	O
of	O
12	O
Hb-8	BG
Agrinio	O
homozygotes	O
or	O
compound	O
heterozygotes	O
,	O
diagnosed	O
in	O
a	O
single	O
center	O
in	O
Greece	O
during	O
a	O
15	O
-	O
year	O
period	O
,	O
found	O
a	O
wide	O
clinical	O
expression	O
,	O
ranging	O
from	O
thalassemia-37	BP
intermedia	O
(	O
with	O
or	O
without	O
transfusion	O
requirement	O
)	O
to	O
Hb	BG
H	IG
hydrops	IG
fetalis-50	IG
,	O
with	O
some	O
phenotype	O
-	O
to	O
-	O
genotype	O
correlation	O
.	O

PS412	O
Although	O
the	O
ability	O
to	O
discern	O
the	O
impact	O
of	O
a	O
mutation	O
is	O
imperfect	O
,	O
our	O
analyses	O
permit	O
substantial	O
discrimination	O
between	O
predicted	O
functional	O
classes	O
of	O
RET-24	BG
mutations	O
and	O
disease	O
severity	O
even	O
for	O
a	O
multigenic	O
disease	O
such	O
as	O
Hirschsprung	BP
disease-37	IP
.	O

PS413	O
To	O
screen	O
a	O
cohort	O
of	O
corneal	BP
dystrophy-7	IP
patients	O
from	O
North	O
India	O
for	O
mutations	O
in	O
the	O
transforming	BG
growth	IG
factor	IG
beta-19	IG
induced	O
gene	O
,	O
to	O
correlate	O
genotypes	O
to	O
phenotypes	O
,	O
to	O
describe	O
structural	O
implications	O
of	O
various	O
mutations	O
on	O
protein	O
function	O
,	O
and	O
to	O
discuss	O
the	O
implications	O
for	O
diagnosis	O
.	O

PS416	O
In	O
our	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
alterations	O
in	O
MEN1	BG
gene-13	IG
in	O
a	O
series	O
of	O
39	O
patients	O
who	O
had	O
undergone	O
surgery	O
for	O
sporadic	O
Primary	O
hyperparathyroidism-27	BP
(	O
35	O
with	O
parathyroid	BP
adenoma-32	IP
or	O
hyperplasia	O
,	O
4	O
with	O
a	O
carcinoma	O
)	O
.	O

PS418	O
The	O
International	O
RET	O
Mutation	O
Consortium	O
was	O
first	O
convened	O
as	O
part	O
of	O
the	O
Fifth	O
International	O
Workshop	O
on	O
Multiple	O
Endocrine	O
Neoplasia-19	BP
,	O
Stockholm	O
,	O
Sweden	O
,	O
in	O
an	O
attempt	O
to	O
analyse	O
the	O
relationship	O
of	O
RET-33	BG
mutation	O
and	O
disease	O
phenotype	O
in	O
the	O
autosomal	O
dominantly	O
inherited	O
multiple	O
endocrine	O
neoplasia-45	BP
type	O
2	O
syndromes	O
.	O

PS419	O
Over	O
93	O
%	O
of	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2B	IG
families-10	IG
had	O
the	O
RET	O
918	O
ATG	O
-	O
-	O
>	O
ACG	O
mutation	O
,	O
while	O
the	O
most	O
frequent	O
mutation	O
detected	O
in	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2A	IG
families-34	IG
was	O
cysteine	O
codon	O
634	O
(	O
87	O
%	O
of	O
all	O
mutations	O
)	O
.	O

PS422	O
To	O
gain	O
insight	O
into	O
these	O
genes	O
,	O
consecutive	O
Israeli	O
colorectal	BP
cancer-11	IP
patients	O
were	O
genotyped	O
using	O
SNPs	O
from	O
within	O
candidate	O
genes	O
:	O
APC-22	BG
,	O
beta	BG
-	IG
Catenin-26	IG
,	O
K	BG
-	IG
RAS-30	IG
,	O
DCC-32	BG
,	O
P16-34	BG
,	O
PTEN-36	BG
,	O
RB1-38	BG
,	O
P15-40	BG
,	O
APOE-42	BG
,	O
ERCC2-44	BG
,	O
P53-46	BG
,	O
MTHFR-48	BG
and	O
hMSH2-50	BG
.	O

PS425	O
To	O
evaluate	O
the	O
role	O
of	O
the	O
androgen	BG
receptor-8	IG
gene	O
CAG	O
repeat	O
in	O
women	O
with	O
polycystic	BP
ovary-16	IP
syndrome	O
.	O

PS427	O
A	O
subset	O
of	O
polycystic	BP
ovary-5	IP
syndrome	O
patients	O
with	O
relatively	O
longer	O
CAG	O
repeats	O
(	O
less	O
androgen	BG
receptor-16	IG
activity	O
)	O
tended	O
to	O
show	O
a	O
higher	O
serum	O
androgen	O
concentration	O
.	O

PS428	O
In	O
the	O
M1S1	BG
gene-4	IG
,	O
the	O
Q118X	O
mutation	O
was	O
the	O
most	O
common	O
alteration	O
,	O
and	O
a	O
founder	O
mutation	O
in	O
Japanese	O
Gelatinous	O
drop	O
-	O
like	O
corneal	BP
dystrophy-26	IP
patients	O
,	O
as	O
previously	O
reported	O
.	O

PS429	O
Over	O
100	O
mutations	O
have	O
been	O
described	O
in	O
patients	O
with	O
clinically	O
typical	O
Mowat	O
-	O
Wilson	O
syndrome	O
,	O
who	O
almost	O
always	O
have	O
whole	O
gene	O
deletions	O
or	O
truncating	O
mutations	O
(	O
nonsense	O
or	O
frameshift	O
)	O
of	O
ZFHX1B-33	BG
,	O
suggesting	BP
that	IP
haploinsufficiency-37	IP
is	O
the	O
basis	O
of	O
Mowat	O
-	O
Wilson	O
syndrome	O
pathology	O
.	O

PS432	O
From	O
our	O
linkage	O
study	O
of	O
Irish	O
families	O
with	O
a	O
high	O
density	O
of	O
schizophrenia-13	BP
,	O
we	O
have	O
previously	O
reported	O
evidence	O
for	O
susceptibility	O
genes	O
in	O
regions	O
5q21	O
-	O
31	O
,	O
6p24	O
-	O
21	O
,	O
8p22	O
-	O
21	O
,	O
and	O
10p15	BG
-	IG
p11-40	IG
.	O

PS435	O
Among	O
autosomal	O
dominant	O
types	O
,	O
spinocerebellar	O
ataxia-7	BP
2	O
genotype	O
has	O
been	O
found	O
in	O
31	O
%	O
of	O
our	O
autosomal	BG
dominant	IG
cerebellar	IG
ataxia	IG
families-22	IG
,	O
resulting	O
the	O
most	O
frequent	O
form	O
of	O
ataxia-30	BP
.	O

PS439	O
A	O
mutation	O
in	O
the	O
sarcomeric	O
gene	O
coding	O
for	O
the	O
myosin	BG
-	IG
binding	IG
protein	IG
C	IG
gene-15	IG
has	O
been	O
identified	O
in	O
a	O
colony	O
of	O
Maine	O
Coon	O
cats	O
with	O
hypertrophic	BP
cardiomyopathy-28	IP
(	O
MyBPC3	BG
-	IG
A31P	IG
mutation-33	IG
)	O
.	O

PS441	O
dystrophin	O
-	O
associated	O
proteins	O
were	O
highly	O
reduced	O
in	O
all	O
fibers	O
lacking	O
dystrophin	O
in	O
the	O
Duchenne	O
muscular	BP
dystrophy-17	IP
carriers	O
,	O
but	O
were	O
almost	O
normal	O
in	O
the	O
dystrophin-26	BG
-	O
deficient	O
fibers	O
of	O
the	O
2	O
Becker	O
muscular	BP
dystrophy-35	IP
carriers	O
with	O
highly	O
truncated	O
dystrophin-40	BG
.	O

PS442	O
In	O
the	O
11	O
Becker	O
muscular	BP
dystrophy-6	IP
carriers	O
with	O
nearly	O
normal	O
dystrophin	O
,	O
the	O
few	O
fibers	O
with	O
reduced	O
or	O
patchy	O
dystrophin	O
immunostaining	O
also	O
showed	O
reduced	O
DAP-25	BG
expression	O
in	O
correlation	O
with	O
dystrophin-30	BG
expression	O
.	O

PS445	O
WHAT	O
IS	O
KNOWN	O
ALREADY	O
:	O
The	O
absence	O
of	O
a	O
functional	O
aurora	BG
kinase	IG
C	IG
gene	IG
gene-15	IG
causes	O
primary	BP
infertility-18	IP
in	O
men	O
by	O
blocking	O
the	O
first	O
meiotic	O
division	O
and	O
leading	O
to	O
the	O
production	O
of	O
tetraploid	O
large	O
-	O
headed	O
spermatozoa	O
.	O

PS448	O
Aromatic	BG
L	IG
-	IG
amino	IG
acid	IG
decarboxylase	IG
deficiency-7	IP
is	O
a	O
rare	O
neurotransmitter	O
defect	O
leading	O
to	O
serotonin	O
,	O
dopamine	O
and	O
norepinephrine	O
deficiency	O
.	O

PS449	O
A	O
high	O
incidence	O
of	O
alpha	BG
1	IG
-	IG
antitrypsin-8	IG
deficiency	O
has	O
been	O
reported	O
in	O
patients	O
with	O
C	O
-	O
ANCA	O
systemic	O
vasculitis-20	BP
in	O
association	O
with	O
antibodies	O
against	O
proteinase	O
-	O
3	O
.	O

PS457	O
We	O
report	O
on	O
the	O
concurrence	O
of	O
Ablepharon	BG
macrostomia	IG
syndrome	IG
-	IG
like	IG
and	IG
Fraser	IG
phenotypes-14	IG
in	O
a	O
Brazilian	O
family	O
.	O

PS458	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
due	O
to	O
21	O
-	O
hydroxylase-8	BG
deficiency	O
results	O
in	O
deficiency	O
of	O
cortisol	O
and	O
aldosterone	O
and	O
overproduction	O
of	O
androgens	O
.	O

PS459	O
Accurate	O
and	O
rapid	O
diagnostic	O
evaluation	O
of	O
congenital	BP
adrenal	IP
hyperplasia-9	IP
due	O
to	O
21	O
-	O
hydroxylase-14	BG
deficiency	O
can	O
be	O
performed	O
by	O
typing	O
directly	O
for	O
disease	O
-	O
causing	O
mutations	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
.	O

PS461	O
However	O
,	O
the	O
lack	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
the	O
low	O
penetrance	O
and	O
the	O
sex	O
-	O
dependent	O
effect	O
of	O
RET-21	BG
mutations	O
supported	O
the	O
existence	O
of	O
one	O
or	O
more	O
modifier	O
gene	O
(	O
s	O
)	O
in	O
familial	O
Hirschsprung	BP
disease-38	IP
.	O

PS466	O
This	O
study	O
investigated	O
genetic	O
variability	O
in	O
the	O
angiotensin	BG
-	IG
II	IG
type	IG
-	IG
1	IG
receptor-14	IG
,	O
angiotensin	BG
-	IG
converting	IG
enzyme-19	IG
,	O
and	O
angiotensin	BG
-	IG
converting	IG
enzyme2	IG
genes-26	IG
as	O
cardiac	O
phenotype	O
modifying	O
factors	O
in	O
Friedreich	O
ataxia-34	BP
patients	O
.	O

PS467	O
This	O
study	O
supports	O
the	O
role	O
of	O
Renin-7	BG
-	O
Angiotensin-9	BG
-	O
Aldosterone	O
system	O
polymorphisms	O
as	O
modifiers	O
of	O
cardiac	O
phenotype	O
in	O
Friedreich	O
ataxia-21	BP
patients	O
.	O

PS471	O
In	O
our	O
patients	O
suspected	O
of	O
having	O
Sotos	O
syndrome	O
,	O
facial	O
features	O
and	O
overgrowth	O
were	O
highly	O
predictive	O
of	O
a	O
NSD1	BG
gene-20	IG
aberration	O
,	O
whereas	O
developmental	BP
delay-25	IP
and	O
advanced	O
bone	O
age	O
were	O
not	O
.	O

PS477	O
In	O
the	O
present	O
study	O
,	O
we	O
performed	O
a	O
quantitative	O
analysis	O
of	O
SMN2	O
in	O
22	O
patients	O
of	O
Spinal	BP
muscular	IP
atrophy-19	IP
to	O
further	O
clarify	O
the	O
correlation	O
between	O
clinical	O
severity	O
and	O
SMN2	BG
gene-30	IG
dosage	O
.	O

PS478	O
Here	O
,	O
we	O
report	O
the	O
mutational	O
analyses	O
of	O
CARD15-9	BG
in	O
453	O
patients	O
with	O
Crohn	O
disease	O
,	O
including	O
166	O
sporadic	O
and	O
287	O
familial	O
cases	O
,	O
159	O
patients	O
with	O
ulcerative	O
colitis-29	BP
,	O
and	O
103	O
healthy	O
control	O
subjects	O
.	O

PS480	O
The	O
most	O
distinctive	O
MEN2	BG
variants-5	IG
are	O
MEN2A-7	BG
(	O
medullary	O
thyroid	BP
carcinoma-11	IP
+	O
pheochromocytoma	O
+	O
hyperparathyroidism-15	BP
)	O
,	O
MEN2B-18	BG
(	O
medullary	O
thyroid	BP
carcinoma-22	IP
+	O
pheo	O
)	O
,	O
and	O
isolated	O
familial	O
medullary	O
thyroid	BP
carcinoma-32	IP
.	O

PS482	O
The	O
specific	O
RET	O
codon	O
mutation	O
correlates	O
with	O
the	O
MEN2-9	BG
syndromic	O
variant	O
and	O
with	O
the	O
age	O
of	O
onset	O
and	O
aggressiveness-19	BP
of	O
medullary	O
thyroid	BP
carcinoma-23	IP
.	O

PS484	O
In	O
this	O
report	O
we	O
present	O
a	O
large	O
family	O
with	O
malignant	BP
insulinoma-11	IP
and	O
hyperparathyroidism-13	BP
with	O
MEN	BG
-	IG
1	IG
gene-18	IG
mutation	O
analysis	O
.	O

PS487	O
The	O
coding	O
regions	O
of	O
PRSS1-5	BG
and	O
SPINK1	BG
genes-8	IG
were	O
sequenced	O
in	O
290	O
controls	O
and	O
198	O
patients	O
,	O
of	O
whom	O
120	O
were	O
diagnosed	O
as	O
idiopathic	O
(	O
ICP	O
)	O
,	O
41	O
as	O
alcoholic	O
(	O
ACP	O
)	O
,	O
and	O
37	O
as	O
hereditary	O
pancreatitis-40	BP
.	O

PS488	O
No	O
mutations	O
in	O
the	O
PRSS1	BG
gene-6	IG
were	O
detected	O
in	O
any	O
of	O
the	O
patients	O
,	O
including	O
hereditary	O
pancreatitis	BP
patients-18	IP
,	O
while	O
the	O
N34S	BG
mutation-23	IG
was	O
observed	O
in	O
the	O
SPINK1	BG
gene-29	IG
in	O
the	O
majority	O
of	O
hereditary	O
pancreatitis-35	BP
patients	O
(	O
73	O
%	O
)	O
.	O

PS490	O
Irrespective	O
of	O
the	O
aetiology	O
,	O
mutations	O
in	O
the	O
PRSS1	BG
gene-10	IG
are	O
not	O
associated	O
with	O
chronic	O
pancreatitis	O
,	O
including	O
hereditary	O
pancreatitis-20	BP
.	O

PS491	O
A	O
comparable	O
phenotype	O
in	O
terms	O
of	O
age	O
of	O
onset	O
,	O
diabetes	BP
mellitus-12	IP
,	O
and	O
other	O
phenotypic	O
features	O
in	O
patients	O
with	O
or	O
without	O
SPINK1-23	BG
mutations	O
and	O
N34S	BG
homozygotes-27	IG
and	O
heterozygotes	O
suggests	O
that	O
there	O
may	O
still	O
be	O
involvement	O
of	O
other	O
genetic	O
or	O
environmental	O
factors	O
.	O

PS492	O
The	O
most	O
common	O
cause	O
of	O
congenital	BP
adrenal	IP
hyperplasia-8	IP
is	O
steroid	BG
21	IG
-	IG
hydroxylase-13	IG
deficiency	O
.	O

PS493	O
Personality	O
traits	O
:	O
Patients	O
homozygous	O
for	O
the	O
Trp779Stop-8	BG
and	O
the	O
Thr977Met	O
mutations	O
had	O
high	O
scores	O
on	O
Psychopathy-17	BP
related	O
scales	O
whereas	O
patients	O
with	O
His1069Gln-23	BG
/	O
Arg1319Stop-25	BG
mutations	O
had	O
the	O
lowest	O
scores	O
on	O
these	O
scales	O
.	O

PS494	O
Familial	O
young	O
-	O
onset	O
primary	O
dystonia-6	BP
is	O
commonly	O
due	O
to	O
the	O
DYT1	BG
gene-13	IG
mutation	O
.	O

PS495	O
The	O
explanation	O
for	O
this	O
effect	O
differs	O
according	O
to	O
both	O
gene	O
and	O
dystonia	O
status	O
:	O
non	O
-	O
DYT1-17	BG
adult	O
-	O
onset	O
dystonia-21	BP
patients	O
and	O
asymptomatic	O
DYT1	O
carriers	O
have	O
significantly	O
larger	O
basal	O
ganglia	O
compared	O
to	O
healthy	O
subjects	O
and	O
symptomatic	O
DYT1	BG
mutation-39	IG
carriers	O
.	O

PS496	O
We	O
propose	O
that	O
differential	O
pathophysiological	O
and	O
compensatory	O
mechanisms	O
lead	O
to	O
brain	O
structure	O
changes	O
in	O
non	O
-	O
DYT1-17	BG
primary	O
adult	O
-	O
onset	O
dystonias-22	BP
and	O
DYT1	BG
gene-25	IG
carriers	O
.	O

PS499	O
Starting	O
in	O
early	BP
infancy-4	IP
,	O
identified	O
REarranged	O
during	O
Transfection	O
gene	O
carriers	O
should	O
be	O
scrutinized	O
until	O
stimulated	O
serum	O
calcitonin-18	BG
levels	O
become	O
positive	O
or	O
,	O
when	O
these	O
remain	O
normal	O
,	O
should	O
undergo	O
prophylactic	O
thyroidectomy	O
before	O
they	O
reach	O
5	O
years	O
of	O
age	O
.	O

PS500	O
Eleven	O
Acadian	O
families	O
with	O
Friedreich	O
ataxia-6	BP
who	O
were	O
from	O
southwest	O
Louisiana	O
were	O
studied	O
with	O
a	O
series	O
of	O
polymorphic	O
markers	O
spanning	O
310	O
kb	O
in	O
the	O
D9S5-25	BG
-	O
D9S15-27	BG
region	O
previously	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
the	O
disease	O
locus	O
.	O

PS501	O
BRCA1	BG
gene-2	IG
mutations	O
have	O
been	O
extensively	O
studied	O
in	O
relation	O
to	O
breast-11	BP
and	O
ovarian	BP
cancer-14	IP
susceptibility	O
.	O

PS504	O
Three	O
(	O
from	O
a	O
single	O
family	O
with	O
Facioscapulohumeral	O
muscular	BP
dystrophy-10	IP
)	O
had	O
additional	O
symptoms	O
of	O
chronic	O
progressive	O
external	O
ophthalmoplegia-19	BP
(	O
4q35	O
EcoRI-22	BG
/	O
BlnI-24	BG
fragment	O
size	O
,	O
20	O
kilobase	O
[	O
kb	O
]	O
)	O
,	O
and	O
3	O
patients	O
(	O
1	O
with	O
sporadic	O
disease	O
and	O
2	O
from	O
a	O
single	O
family	O
)	O
had	O
facial	O
-	O
sparing	O
scapulohumeral	BP
dystrophy-55	IP
(	O
4q35	O
EcoRI-58	BG
/	O
BlnI-60	BG
fragment	O
size	O
,	O
30	O
and	O
34	O
kb	O
,	O
respectively	O
)	O
.	O

PS505	O
In	O
order	O
to	O
investigate	O
the	O
molecular	O
basis	O
of	O
these	O
three	O
phenotypes	O
,	O
six	O
patients	O
with	O
Carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-19	IP
have	O
been	O
studied	O
.	O

PS506	O
All	O
six	O
unrelated	O
patients	O
in	O
this	O
study	O
experienced	O
the	O
clinical	O
symptoms	O
of	O
Carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-16	IP
.	O

PS512	O
We	O
report	O
the	O
mutational	O
spectrum	O
of	O
phenylalanine	BG
hydroxylase	IG
deficiency-9	IP
in	O
the	O
population	O
living	O
in	O
Catalonia-15	BP
and	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS513	O
CHARGE	O
(	O
coloboma-3	BP
,	O
heart	O
defects	O
,	O
atresia	O
choanae	O
,	O
retarded	O
growth	O
and	O
development	O
,	O
genital	BP
anomalies-17	IP
,	O
ear	O
anomalies	O
)	O
is	O
a	O
genetically	O
heterogeneous	O
syndrome	O
in	O
which	O
chromodomain	BG
helicase	IG
DNA	IG
-	IG
binding	IG
protein	IG
7-35	IG
mutations	O
account	O
for	O
about	O
60	O
%	O
of	O
the	O
cases	O
.	O

PS515	O
Three	O
distinct	O
clinical	O
forms	O
have	O
been	O
described	O
depending	O
on	O
the	O
phenotype	O
:	O
the	O
classical	BG
MEN	IG
2A-16	IG
,	O
MEN	BG
2B-19	IG
,	O
an	O
association	O
of	O
medullary	O
thyroid	BP
carcinoma-26	IP
,	O
pheochromocytoma	O
and	O
mucosal	O
neuroma	O
,	O
familial	O
medullary	O
thyroid	BP
carcinoma-36	IP
with	O
a	O
low	O
incidence	O
of	O
other	O
endocrinopathies	O
.	O

PS518	O
Tyrosinemia	BG
type	IG
1	IG
(	IG
HT1	IG
)-6	IG
is	O
a	O
rare	O
but	O
treatable	O
disease	O
.	O

PS519	O
Recently	O
,	O
the	O
MMP1	BG
promoter	IG
single	IG
nucleotide	IG
polymorphism	IG
rs1799750-9	IG
,	O
designated	O
as	O
1G	O
2G	O
,	O
was	O
shown	O
to	O
be	O
involved	O
in	O
modulation	O
of	O
disease	O
severity	O
in	O
patients	O
with	O
recessive	O
Dystrophic	O
epidermolysis	O
bullosa	O
,	O
and	O
was	O
proposed	O
as	O
a	O
genetic	O
modifier	O
.	O

PS521	O
However	O
,	O
we	O
observed	O
a	O
mature	O
T	O
cell	O
malignancy-9	BP
,	O
adult	O
T	O
-	O
cell	O
leukemia-15	BP
,	O
with	O
rearranged	O
beta	O
chain	O
gene	O
and	O
germ	BG
line	IG
gamma	IG
chain	IG
gene-27	IG
,	O
showing	O
the	O
possible	O
existence	O
of	O
another	O
pathway	O
of	O
T	O
cell	O
differentiation	O
.	O

PS525	O
however	O
,	O
during	O
hemolytic	BP
crisis-5	IP
,	O
which	O
frequently	O
develops	O
in	O
or	O
after	O
acute	O
infections	O
with	O
high	O
fever-17	BP
,	O
the	O
hemoglobin-20	BG
level	O
may	O
drop	O
significantly	O
and	O
patients	O
can	O
develop	O
shock	O
or	O
renal	O
shutdown	O
.	O

PS527	O
Alagille	O
syndrome	O
frequently	O
presents	O
with	O
neonatal	O
jaundice	O
and	O
can	O
mimic	O
other	O
causes	O
of	O
high	O
gamma	BG
-	IG
glutamyl	IG
transpeptidase-18	IG
cholestasis	O
,	O
most	O
notably	O
biliary	BP
atresia-24	IP
.	O

PS528	O
The	O
lack	O
of	O
arginine	O
or	O
histidine	O
in	O
Rel	BG
+-9	IG
strain	O
does	O
not	O
lead	O
to	O
derepression-15	BP
of	O
the	O
threonine	O
operon	O
.	O

PS529	O
Evidence	O
is	O
given	O
that	O
the	O
neurofibromatosis	BG
type	IG
1	IG
gene-9	IG
acts	O
as	O
a	O
true	O
tumor	O
suppressor	O
gene	O
and	O
that	O
oncogenesis	O
in	O
neurofibromatosis-21	BP
type	O
1	O
is	O
a	O
complex	O
multistep	O
phenomenon	O
with	O
the	O
second	O
hit	O
in	O
the	O
neurofibromatosis-35	BP
type	O
1	O
gene	O
as	O
the	O
initiating	O
event	O
.	O

PS530	O
The	O
haplotypes	O
of	O
50	O
patients	O
diagnosed	O
with	O
Sickle	O
cell	O
disease	O
were	O
determined	O
using	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
fragments	O
containing	O
nine	O
polymorphic	BP
restriction-23	IP
sites	O
around	O
and	O
within	O
the	O
epsilon	BG
-	IG
Ggamma	IG
-	IG
Agamma	IG
-	IG
psibeta	IG
-	IG
delta	IG
-	IG
beta	IG
-	IG
globin	IG
gene-42	IG
complex	O
.	O

PS531	O
Through	O
their	O
inhibition	O
of	O
chylomicron	O
secretion	O
,	O
mutations	O
of	O
the	O
Sar1B	BG
gene-12	IG
coding	O
for	O
Sar1	BG
GTPase-16	IG
are	O
associated	O
with	O
chylomicron	O
retention	O
disease	O
.	O

PS534	O
The	O
2	O
patients	O
of	O
this	O
pedigree	O
shared	O
an	O
early	O
clinical	O
phenotype	O
consisting	O
of	O
later	O
-	O
onset	O
,	O
progressive	O
aphasia-19	BP
,	O
but	O
preserved	O
visuospatial	O
ability	O
,	O
which	O
was	O
indistinguishable	O
from	O
those	O
of	O
other	O
presenilin	BG
1	IG
-	IG
associated	IG
Alzheimer	IG
disease	IG
cases-39	IG
.	O

PS535	O
Occurrence	O
,	O
distribution	O
,	O
and	O
phenotype	O
of	O
arylsulfatase	BG
A-9	IG
mutations	O
were	O
investigated	O
in	O
27	O
patients	O
with	O
metachromatic	O
leukodystrophy	O
from	O
Central	O
Europe	O
,	O
mainly	O
from	O
Austria-25	BP
(	O
n	O
=	O
15	O
)	O
and	O
Poland	O
(	O
n	O
=	O
9	O
)	O
.	O

PS537	O
Approximately	O
85	O
%	O
of	O
patients	O
with	O
defects	O
in	O
early	O
B	O
-	O
cell	O
development	O
have	O
X	O
-	O
linked	O
agammaglobulinemia-18	BP
,	O
a	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
cytoplasmic	BG
Bruton	IG
'	IG
s	IG
tyrosine	IG
kinase-32	IG
.	O

PS538	O
Although	O
there	O
is	O
no	O
strong	O
genotype	O
/	O
phenotype	O
correlation	O
in	O
X	O
-	O
linked	O
agammaglobulinemia-14	BP
,	O
the	O
specific	O
mutation	O
in	O
Bruton	O
'	O
s	O
tyrosine	BG
kinase-24	IG
is	O
one	O
of	O
the	O
factors	O
that	O
influences	O
the	O
severity	O
of	O
disease	O
.	O

PS539	O
Polymorphic	O
variants	O
in	O
the	O
components	O
of	O
the	O
pre	O
-	O
B	O
cell	O
and	O
B	BG
-	IG
cell	IG
receptor	IG
complex-17	IG
,	O
particularly	O
micro	O
heavy	O
chain	O
and	O
lambda5-24	BG
,	O
may	O
contribute	O
to	O
the	O
severity	O
of	O
X	O
-	O
linked	O
agammaglobulinemia-35	BP
.	O

PS540	O
To	O
characterize	O
the	O
MYOC	BG
genotype-5	IG
correlation	O
with	O
phenotypes	O
in	O
an	O
isolated	O
Greek	O
population	O
with	O
a	O
high	O
incidence	O
of	O
glaucoma-19	BP
.	O

PS541	O
We	O
have	O
now	O
found	O
homozygosity	O
for	O
the	O
epsilon1293insG	BG
mutation-9	IG
in	O
a	O
severely	O
affected	O
congenital	O
myasthenic	O
syndrome	O
patient	O
,	O
who	O
lost	O
the	O
ability	O
to	O
walk	O
in	O
midchildhood	O
and	O
shows	O
profound	O
weakness-30	BP
and	O
muscle	O
wasting	O
.	O

PS542	O
We	O
have	O
screened	O
31	O
families	O
fulfilling	O
the	O
Amsterdam	O
criteria	O
and	O
54	O
families	O
with	O
a	O
colorectal	O
cancer-16	BP
clustering	O
but	O
not	O
fulfilling	O
the	O
Amsterdam	O
criteria	O
for	O
mutations	O
in	O
MLH1-27	BG
and	O
MSH2-29	BG
by	O
direct	O
sequencing	O
,	O
and	O
detected	O
a	O
mutation	O
in	O
61	O
%	O
of	O
the	O
Amsterdam	O
positive	O
families	O
but	O
only	O
in	O
15	O
%	O
of	O
the	O
Amsterdam	O
negative	O
families	O
.	O

PS543	O
Problems	O
with	O
diagnosis	O
and	O
genetic	O
counseling	O
occur	O
for	O
patients	O
with	O
autosomal	O
recessive	O
proximal	O
spinal	BP
muscular	IP
atrophy-16	IP
who	O
do	O
not	O
show	O
the	O
most	O
common	O
mutation	O
:	O
homozygous	O
absence	O
of	O
at	O
least	O
exon	O
7	O
of	O
the	O
telomeric	O
survival	BG
motor	IG
neuron	IG
gene-39	IG
(	O
SMN1-41	BG
)	O
.	O

PS544	O
Genotype	O
-	O
phenotype	O
correlation	O
allowed	O
inference	O
of	O
the	O
effect	O
of	O
each	O
mutation	O
on	O
the	O
function	O
of	O
the	O
SMN1	BG
protein-19	IG
and	O
the	O
role	O
of	O
the	O
SMN2-25	BG
copy	O
number	O
in	O
modulating	O
the	O
spinal	BP
muscular	IP
atrophy-33	IP
phenotype	O
.	O

PS546	O
Adult	BG
-	IG
type	IG
hypolactasia-4	IG
(	O
lactase-6	BG
non	O
-	O
persistence	O
;	O
primary	O
lactose	O
malabsorption	O
)	O
is	O
characterized	O
by	O
the	O
down	O
-	O
regulation	O
of	O
the	O
lactase	BG
enzyme-25	IG
activity	O
in	O
the	O
intestinal	O
wall	O
after	O
weaning	O
.	O

PS547	O
Molecular	O
epidemiological	O
studies	O
on	O
the	O
prevalence	O
of	O
the	O
C	BG
/	IG
C	IG
-	IG
13910	IG
genotype-14	IG
associated	O
with	O
low	BG
lactase-18	IG
activity	O
are	O
in	O
agreement	O
with	O
the	O
prevalence	O
figures	O
for	O
adult	O
type	O
hypolactasia-30	BP
in	O
>	O
70	O
diverse	O
ethnic	O
groups	O
studied	O
.	O

PS548	O
Perhexiline	O
is	O
metabolized	O
by	O
CYP2D6-5	BG
and	O
has	O
concentration	O
-	O
related	O
hepatoxicity	O
and	O
peripheral	BP
neuropathy-14	IP
.	O

PS552	O
Constitutive	O
DNA	O
of	O
64	O
Multiple	O
endocrine	O
neoplasia-7	BP
type	O
2	O
patients	O
(	O
48	O
kindreds	O
)	O
were	O
searched	O
for	O
mutations	O
at	O
exons	O
10	O
,	O
11	O
,	O
13	O
,	O
14	O
and	O
16	O
of	O
the	O
RET	BG
proto	IG
-	IG
oncogene-35	IG
using	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
,	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O

PS555	O
However	O
,	O
clinical	O
studies	O
in	O
patients	O
with	O
colorectal	BP
cancer-9	IP
failed	O
to	O
find	O
a	O
consistent	O
relationship	O
between	O
thymidylate	BG
synthaseER-18	IG
polymorphisms	O
and	O
protein	O
levels	O
as	O
well	O
as	O
with	O
clinical	O
outcome	O
.	O

PS560	O
25	O
families	O
including	O
13	O
Brooke	O
-	O
Spiegler	O
syndrome	O
,	O
3	O
familial	BP
cylindromatosis-12	IP
,	O
and	O
9	O
multiple	O
familial	O
trichoepitheliomas	O
families	O
were	O
examined	O
and	O
evaluated	O
for	O
mutations	O
in	O
the	O
CYLD	BG
gene-29	IG
.	O

PS561	O
This	O
study	O
provides	O
further	O
evidence	O
on	O
the	O
role	O
of	O
CYLD-10	BG
in	O
the	O
pathogenesis	O
of	O
skin	O
appendage	O
tumours	O
characterised	O
by	O
cylindromas	O
,	O
trichoepitheliomas	O
and	O
/	O
or	O
spiradenomas-26	BP
,	O
but	O
the	O
molecular	O
mechanisms	O
of	O
CYLD	O
in	O
skin	O
tumorigenesis	O
and	O
the	O
reasons	O
for	O
phenotypic	O
variability	O
remain	O
to	O
be	O
explored	O
.	O

PS562	O
Despite	O
these	O
quantitative	O
and	O
qualitative	O
differences	O
in	O
high	BG
density	IG
lipoprotein-10	IG
,	O
neither	O
the	O
history	O
of	O
the	O
family	O
over	O
three	O
generations	O
nor	O
the	O
examination	O
of	O
the	O
patient	O
,	O
gave	O
any	O
indication	O
of	O
premature	O
occurrence	O
of	O
atherosclerosis-35	BP
or	O
coronary	O
heart	O
disease	O
.	O

PS564	O
One	O
patient	O
had	O
a	O
deletion	O
of	O
CYP21-7	BG
on	O
one	BG
allele-10	IG
consistent	O
with	O
carrier	O
status	O
for	O
the	O
classical	O
congenital	BP
adrenal	IP
hyperplasia-20	IP
.	O

PS565	O
Five	O
patients	O
,	O
one	O
of	O
whom	O
had	O
a	O
normal	O
17	O
-	O
OHP	O
response	O
to	O
Synacthen	O
,	O
were	O
heterozygous	O
for	O
the	O
val	BG
281	IG
leu	IG
mutation-24	IG
in	O
exon	O
7	O
of	O
the	O
CYP21-30	BG
and	O
were	O
therefore	O
carriers	O
for	O
a	O
mutation	O
associated	O
with	O
late	O
-	O
onset	O
congenital	BP
adrenal	IP
hyperplasia-45	IP
.	O

PS572	O
However	O
,	O
genes	O
such	O
as	O
c	BG
-	IG
myc-8	IG
might	O
represent	O
significant	O
exceptions	O
potentially	O
relevant	O
for	O
the	O
clinico	O
-	O
biological	O
behavior	O
of	O
the	O
neoplasms-23	BP
.	O

PS574	O
We	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
common	BG
apolipoprotein	IG
E	IG
variants-11	IG
on	O
plasma	BG
Lp-14	IG
(	O
a	O
)	O
levels	O
in	O
149	O
patients	O
with	O
heterozygous	O
familial	BP
hypercholesterolaemia-25	IP
.	O

PS575	O
To	O
clarify	O
the	O
bioenergetic	O
relevance	O
of	O
mtDNA	O
mutations	O
in	O
Leber	O
'	O
s	O
hereditary	O
optic	BP
neuropathy-15	IP
,	O
we	O
investigated	O
affected	O
individuals	O
and	O
healthy	O
carriers	O
from	O
six	O
Italian	O
Leber	O
'	O
s	O
hereditary	O
optic	BP
neuropathy-32	IP
families	O
harboring	O
the	O
11778	O
/	O
ND4	O
and	O
the	O
3460	O
/	O
ND1-43	BG
mtDNA	O
mutations	O
.	O

PS585	O
It	O
is	O
well	O
known	O
that	O
Multiple	O
endocrine	O
neoplasia-8	BP
type	O
2	O
syndrome	O
is	O
caused	O
by	O
mutations	O
of	O
different	O
codons	O
of	O
the	O
RET	BG
proto	IG
-	IG
oncogene-24	IG
.	O

PS586	O
To	O
detect	O
the	O
mutation	O
of	O
PORCN	BG
gene-7	IG
in	O
a	O
patient	O
with	O
focal	O
dermal	BP
hypoplasia-14	IP
and	O
study	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS588	O
CONCLUISONS	O
:	O
Thus	O
,	O
plasma	O
H	O
(	O
e	O
)	O
,	O
but	O
not	O
methylenetetrahydrofolate	BG
reductase	IG
genotype-15	IG
,	O
is	O
significantly	O
associated	O
with	O
carotid	O
atherosclerosis	O
,	O
suggesting	O
that	O
the	O
biochemical	O
test	O
may	O
be	O
sufficient	O
to	O
identify	O
patients	O
who	O
may	O
be	O
at	O
increased	O
risk	O
of	O
atherosclerosis-42	BP
through	O
this	O
mechanism	O
.	O

PS592	O
In	O
conclusion	O
,	O
the	O
greater	O
risk	O
of	O
coronary	BP
artery	IP
disease-10	IP
in	O
subjects	O
with	O
phenotype	O
B	O
may	O
result	O
,	O
in	O
part	O
,	O
from	O
increased	O
susceptibility	O
to	O
lipid	O
peroxidative	O
modification	O
of	O
low	O
-	O
density	O
lipoprotein	O
that	O
is	O
depleted	O
in	O
lipid	O
contents	O
,	O
especially	O
free	O
-	O
cholesterol	O
content	O
per	O
low	BG
-	IG
density	IG
lipoprotein	IG
particle-51	IG
.	O

PS594	O
Mutation	O
screening	O
of	O
the	O
major	O
autosomal	O
dominant	O
polycystic	BP
kidney-9	IP
disease	O
gene	O
(	O
PKD1-13	BG
)	O
has	O
been	O
complicated	O
by	O
the	O
large	O
transcript	O
size	O
(	O
>	O
14	O
kb	O
)	O
and	O
by	O
reiteration	O
of	O
the	O
genomic	O
area	O
encoding	O
75	O
%	O
of	O
the	O
protein	O
on	O
the	O
same	O
chromosome	O
(	O
the	O
HG	BG
loci-48	IG
)	O
.	O

PS595	O
The	O
second	O
patient	O
is	O
a	O
17	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
history	O
of	O
Pierre	O
Robin	BG
sequence-18	IG
,	O
cardiac	O
abnormalities	O
and	O
learning	BP
disabilities-24	IP
.	O

PS596	O
While	O
there	O
is	O
a	O
considerable	O
body	O
of	O
literature	O
correlating	O
the	O
role	O
of	O
dopaminergic	O
genes	O
and	O
obesity-16	BP
,	O
body	O
mass	O
index	O
,	O
body	O
type	O
,	O
overeating	O
,	O
carbohydrate	O
binging	O
,	O
energy	O
expenditure	O
and	O
low	O
dopamine	BG
D2	IG
receptor-36	IG
density	O
,	O
there	O
is	O
a	O
paucity	O
of	O
research	O
concerning	O
the	O
dopamine	BG
D2	IG
receptor	IG
gene-50	IG
(	O
DRD2-52	BG
)	O
variants	O
and	O
percent	O
body	O
fat	O
.	O

PS601	O
The	O
phenotypical	O
diversity	O
of	O
phenylalanine	BG
hydroxylase	IG
deficiency-7	IP
arises	O
from	O
multiple	O
mutant	O
alleles	O
.	O

PS606	O
To	O
determine	O
whether	O
germline	O
mutations	O
in	O
BRCA2-7	BG
are	O
associated	O
with	O
a	O
similar	O
variation	O
in	O
phenotypic	O
risk	O
,	O
we	O
have	O
analysed	O
the	O
distribution	O
of	O
mutations	O
in	O
25	O
families	O
with	O
multiple	O
cases	O
of	O
breast	O
and	O
/	O
or	O
ovarian	O
cancer-37	BP
ascertained	O
in	O
the	O
United	O
Kingdom	O
and	O
Eire	O
.	O

PS609	O
Putative	O
candidate	O
genes	O
are	O
paraoxonase	BG
-	IG
1	IG
gene-8	IG
and	O
the	O
IGF	BG
-	IG
2	IG
INS1-14	IG
/	O
VTR	BG
IGF	IG
cluster-18	IG
,	O
which	O
have	O
been	O
shown	O
to	O
be	O
genetically	O
linked	O
to	O
lipid	O
metabolism	O
o	O
insulin-32	BG
sensitivity	O
,	O
two	O
major	O
aspects	O
of	O
the	O
polycystic	BP
ovary-41	IP
syndrome	O
phenotype	O
.	O

PS614	O
Abnormalities	O
of	O
HDL	BG
cholesterol-4	IG
,	O
triglycerides	O
,	O
and	O
LDL-9	BG
particle	O
size	O
are	O
present	O
in	O
familial	O
dyslipidemic	BP
hypertension-17	IP
.	O

PS618	O
A	O
common	O
genetic	O
background	O
contributes	O
to	O
the	O
clustering	O
of	O
different	O
MSX	O
component	O
traits	O
and	O
central	O
obesity-16	BP
or	O
insulin	BG
resistance-19	IP
.	O

PS619	O
Prior	O
experience	O
in	O
kindreds	O
with	O
a	O
codon	BG
891	IG
RET	IG
protooncogene	IG
mutation-11	IG
indicates	O
that	O
carriers	O
of	O
this	O
mutation	O
develop	O
only	O
hereditary	O
medullary	BP
thyroid	IP
carcinoma-23	IP
without	O
evidence	O
of	O
other	O
manifestations	O
of	O
multiple	O
endocrine	O
neoplasia-32	BP
type	O
2	O
.	O

PS624	O
In	O
this	O
present	O
study	O
we	O
investigated	O
the	O
primary	O
site	O
of	O
Cited2-11	BG
function	O
and	O
mechanisms	O
of	O
haploinsufficiency-16	BP
.	O

PS625	O
To	O
investigate	O
the	O
molecular	O
lesions	O
underlying	O
Taiwanese	O
mucopolysaccharidosis-8	BP
type	O
II	O
,	O
probands	O
and	O
families	O
were	O
identified	O
and	O
screened	O
for	O
iduronate	BG
-	IG
2	IG
-	IG
sulfatase-24	IG
mutation	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
and	O
DNA	O
sequencing	O
.	O

PS626	O
In	O
this	O
study	O
,	O
we	O
characterized	O
five	O
Ullrich	O
scleroatonic	BP
muscular	IP
dystrophy-11	IP
patients	O
(	O
two	O
Italians	O
,	O
one	O
Belgian	O
,	O
and	O
two	O
Turks	O
)	O
with	O
a	O
clinical	O
phenotype	O
showing	O
different	O
degrees	O
of	O
severity	O
,	O
all	O
carrying	O
mutations	O
localized	O
in	O
COL6A1-39	BG
.	O

PS627	O
Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
report	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
demonstrating	O
that	O
heterozygous	O
glycine	O
substitutions	O
in	O
the	O
triple	O
-	O
helix	O
domain	O
of	O
COL6A1-27	BG
are	O
dominant	O
and	O
responsible	O
for	O
a	O
milder	O
Ullrich	O
scleroatonic	O
muscular	BP
dystrophy-38	IP
phenotype	O
,	O
and	O
that	O
recessive	O
mutations	O
in	O
COL6A1	O
correlate	O
with	O
more	O
severe	O
clinical	O
and	O
biochemical	O
Ullrich	O
scleroatonic	O
muscular	BP
dystrophy-57	IP
phenotypes	O
.	O

PS628	O
Noonan	O
syndrome	O
and	O
cardio	O
-	O
facio	O
-	O
cutaneous	O
syndrome	O
are	O
related	O
developmental	BP
disorders-13	IP
caused	O
by	O
mutations	O
in	O
genes	O
encoding	O
various	O
components	O
of	O
the	O
RAS-24	BG
-	O
MAPK-26	BG
signaling	O
cascade	O
.	O

PS630	O
We	O
have	O
reinvestigated	O
a	O
classification	O
of	O
clinical	O
heterogeneity	O
among	O
cystic	BP
fibrosis-11	IP
patients	O
that	O
we	O
previously	O
reported	O
and	O
investigated	O
the	O
possible	O
relationship	O
of	O
the	O
identified	O
cystic	O
fibrosis	O
subgroups	O
to	O
haplotypes	O
around	O
the	O
cystic	BG
fibrosis	IG
gene-34	IG
and	O
to	O
HLA	BG
-	IG
DR-39	IG
haplotypes	O
.	O

PS632	O
The	O
condition	O
appears	O
to	O
be	O
genetically	O
heterogeneous	O
and	O
recently	O
it	O
has	O
been	O
demonstrated	O
that	O
mutations	O
in	O
the	O
p63	BG
gene-19	IG
,	O
a	O
homologue	O
of	O
the	O
tumor	BG
suppressor	IG
gene	IG
p53-28	IG
,	O
are	O
the	O
cause	O
of	O
at	O
least	O
four	O
autosomal	O
dominant	O
genetic	O
syndromes	O
which	O
feature	O
ectrodactyly	O
:	O
ectrodactyly	O
,	O
ectodermal	BP
dysplasia-48	IP
,	O
and	O
facial	O
clefting	O
(	O
EEC	O
)	O
,	O
split	O
hand	O
/	O
split	O
foot	O
malformation	O
,	O
limb	O
-	O
mammary	O
syndrome	O
,	O
and	O
acro	O
-	O
dermato	O
-	O
ungual	O
-	O
lacrimal	O
-	O
tooth	O
syndrome	O
.	O

PS634	O
We	O
observed	O
a	O
strong	O
association	O
between	O
endometrial	O
cancer-8	BP
and	O
the	O
C	O
/	O
C	O
genotype	O
of	O
the	O
135G	O
>	O
C	O
polymorphism	O
of	O
the	O
RAD51	BG
gene-24	IG
.	O

PS638	O
Gitelman	O
syndrome	O
is	O
a	O
tubulopathy	O
caused	O
by	O
SLC12A3	BG
gene-9	IG
mutations	O
,	O
which	O
lead	O
to	O
hypokalaemic	BP
alkalosis-16	IP
,	O
secondary	O
hyperaldosteronism-19	BP
,	O
hypomagnesaemia-21	BP
and	O
hypocalciuria-23	BP
.	O

PS639	O
In	O
adult	O
patients	O
referred	O
for	O
renal	O
hypokalaemia-7	BP
,	O
we	O
confirmed	O
the	O
presence	O
of	O
mutations	O
of	O
the	O
SLC12A3	BG
gene-18	IG
in	O
80	O
%	O
of	O
cases	O
.	O

PS640	O
Bupropion	O
is	O
primarily	O
metabolized	O
in	O
human	O
liver	O
by	O
cytochrome	BG
P450-10	IG
2B6	O
,	O
an	O
isoform	O
that	O
shows	O
high	O
interindividual	O
variability	O
in	O
expression	O
and	O
catalysis-23	BP
.	O

PS643	O
Our	O
purpose	O
was	O
to	O
study	O
interactions	O
between	O
common	O
genotypes	O
in	O
ESR1-11	BG
,	O
breast	BP
cancer-14	IP
risk	O
and	O
tumor	O
phenotypes	O
.	O

PS645	O
Here	O
,	O
we	O
summarize	O
published	O
NKX2	BG
-	IG
5-8	IG
germline	O
mutations	O
and	O
explore	O
different	O
avenues	O
in	O
disease	O
pathogenesis	O
to	O
support	O
the	O
notion	O
of	O
a	O
multifactorial	O
cause	O
of	O
Congenital	BP
heart	IP
disease-29	IP
where	O
possibly	O
several	O
genes	O
and	O
associated	O
pathways	O
are	O
involved	O
.	O

PS646	O
The	O
resistance	O
genes	O
found	O
were	O
sul1-6	BG
and	O
/	O
or	O
sul2	O
(	O
sulfonamide	BP
resistance-13	IP
)	O
,	O
aadA2	O
(	O
streptomycin	O
/	O
spectinomycin	O
resistance	O
)	O
,	O
tet	O
(	O
A	O
)	O
(	O
tetracycline	BP
resistance-30	IP
)	O
,	O
tet	O
(	O
B	O
)	O
(	O
tetracycline	O
/	O
minocycline	O
resistance	O
)	O
,	O
bla	O
(	O
TEM	O
)	O
(	O
ampicillin	O
resistance	O
)	O
,	O
and	O
dfrA14	O
(	O
trimethoprim	O
resistance	O
)	O
.	O

PS649	O
We	O
characterized	O
phenylalanine	BG
hydroxylase-4	IG
genotypes	O
of	O
Japanese	O
patients	O
with	O
phenylketonuria	O
and	O
hyperphenylalaninemia-12	BP
.	O

PS651	O
Only	O
few	O
Rett	O
syndrome	O
families	O
with	O
a	O
segregating	O
MECP2-9	BG
mutation	O
,	O
which	O
affects	O
female	O
carriers	O
with	O
a	O
phenotype	O
of	O
mental	BP
retardation-21	IP
or	O
Rett	O
syndrome	O
,	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

PS653	O
Some	O
461	O
inpatients	O
affected	O
by	O
major	O
psychoses	O
were	O
assessed	O
by	O
the	O
Operational	O
Criteria	O
checklist	O
for	O
psychotic	BP
illness-17	IP
and	O
typed	O
for	O
dopamine	BG
receptor	IG
D4	IG
variants-24	IG
.	O

PS656	O
In	O
73	O
cancer-3	BP
patients	O
and	O
136	O
matched	O
healthy	O
controls	O
,	O
the	O
polymorphisms	O
of	O
glutathione	BG
S	IG
-	IG
transferase	IG
mu1	IG
and	IG
theta-20	IG
(	O
GSTM-22	BG
/	O
GSTT-24	BG
)	O
,	O
cytochrome	BG
p450	IG
1A1-29	IG
and	O
CYP2D6-31	BG
were	O
detected	O
.	O

PS659	O
We	O
examined	O
the	O
relationship	O
between	O
specific	O
Bruton	O
'	O
s	O
tyrosine	BG
kinase	IG
gene-12	IG
mutations	O
and	O
severity	O
of	O
clinical	O
presentation	O
in	O
62	O
patients	O
with	O
X	O
-	O
linked	O
agammagobulinemia-26	BP
.	O

PS660	O
We	O
also	O
tested	O
theEF	O
measures	O
'	O
associations	O
with	O
the	O
ADRA2A	BG
gene-11	IG
and	O
whether	O
they	O
mediated	O
or	O
moderated	O
the	O
associations	O
between	O
attention	BP
deficit	IP
hyperactivity	IP
disorder-24	IP
and	O
ADRA2A	O
.	O

PS661	O
Several	O
EF	O
measures	O
showed	O
association	O
with	O
ADRA2A-7	BG
,	O
as	O
well	O
as	O
moderation	O
,	O
but	O
not	O
mediation	O
,	O
of	O
its	O
association	O
with	O
attention	BP
deficit	IP
hyperactivity	IP
disorder-25	IP
.	O

PS663	O
A	O
total	O
of	O
253	O
unrelated	O
children	O
with	O
nonsyndromic	O
hearing	BP
loss-10	IP
were	O
screened	O
for	O
the	O
presence	O
of	O
variants	O
in	O
6	O
genes	O
of	O
the	O
connexin	BG
gene	IG
family-25	IG
.	O

PS664	O
Our	O
results	O
suggest	O
the	O
variants	O
of	O
GJC3-7	BG
,	O
GJB4-9	BG
,	O
and	O
GJB3-12	BG
may	O
be	O
the	O
common	O
genetic	O
risk	O
factor	O
,	O
after	O
variants	O
of	O
GJB2-24	BG
,	O
for	O
the	O
development	O
of	O
nonsyndromic	O
hearing	BP
loss-32	IP
in	O
Taiwan	O
.	O

PS665	O
The	O
existence	O
of	O
two	O
subgroups	O
of	O
BRCA1-7	BG
-	O
associated	O
breast	O
cancer	O
families	O
has	O
been	O
recently	O
posited	O
:	O
the	O
first	O
with	O
highly	O
proliferating	O
tumors	O
,	O
and	O
the	O
second	O
composed	O
of	O
cases	O
with	O
a	O
low	O
proliferation	O
rate	O
.	O

PS667	O
Our	O
laboratory	O
identified	O
disease	O
-	O
causing	O
mutations	O
in	O
157	O
families	O
with	O
Ornithine	BG
transcarbamylase	IG
deficiency-14	IP
,	O
100	O
of	O
which	O
came	O
to	O
medical	O
attention	O
through	O
a	O
hemizygous	O
propositus	O
and	O
in	O
57	O
the	O
index	O
case	O
was	O
a	O
heterozygous	O
female	O
.	O

PS668	O
Among	O
Tunisian	O
Xeroderma-3	BP
pigmentosum	O
patients	O
with	O
an	O
intermediate	O
skin	O
phenotype	O
,	O
92	O
%	O
presented	O
neurological	O
abnormalities	O
related	O
to	O
Xeroderma	BG
pigmentosumA	IG
gene-21	IG
deficiency	O
.	O

PS674	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
Receptor	BG
tyrosine	IG
kinase-11	IG
expression	O
genotype	O
-	O
phenotype	O
correlation	O
study	O
conducted	O
on	O
human	O
subjects	O
to	O
indicate	O
common	O
genetic	O
variants	O
in	O
the	O
regulatory	O
region	O
of	O
Receptor	BG
tyrosine	IG
kinase-34	IG
may	O
play	O
a	O
role	O
in	O
mediating	O
susceptibility	O
to	O
Hirschsprung	BP
'	IP
s	IP
disease-46	IP
,	O
by	O
conferring	O
a	O
significant	O
reduction	O
of	O
the	O
Receptor	BG
tyrosine	IG
kinase-57	IG
expression	O
.	O

PS675	O
Information	O
on	O
life	O
events	O
,	O
anxious	O
depression-7	BP
,	O
neuroticism-9	BP
and	O
extraversion	O
was	O
collected	O
in	O
5782	O
monozygotic	O
and	O
dizygotic	O
twins	O
who	O
participated	O
in	O
a	O
longitudinal	O
survey	O
study	O
of	O
the	O
Netherlands	O
Twin	BG
Register-31	IG
.	O

PS676	O
The	O
arbitrary	O
classification	O
of	O
Phenylalanine	BG
hydroxylase	IG
deficiency-7	IP
on	O
the	O
basis	O
of	O
clinical	O
parameters	O
has	O
been	O
complicated	O
by	O
the	O
lack	O
of	O
international	O
guidelines	O
,	O
leading	O
to	O
a	O
wide	O
confusion	O
in	O
both	O
methodology	O
and	O
terminology	O
.	O

PS679	O
Since	O
1993	O
,	O
when	O
the	O
first	O
missense	BG
RET	IG
proto	IG
-	IG
oncogene-11	IG
(	O
RET-13	BG
)	O
mutations	O
were	O
reported	O
in	O
Multiple	O
endocrine	O
neoplasia-21	BP
type	O
2	O
,	O
up	O
to	O
46	O
different	O
RET	O
-	O
causing	O
disease	O
mutations	O
have	O
been	O
described	O
.	O

PS682	O
They	O
were	O
first	O
diagnosed	O
as	O
having	O
atypical	O
spinal	BP
muscular	IP
atrophy-10	IP
and	O
,	O
subsequently	O
,	O
spinocerebellar	BP
ataxia-16	IP
,	O
but	O
,	O
recently	O
,	O
the	O
diagnosis	O
of	O
late	O
-	O
onset	O
Tay	O
-	O
Sachs	O
disease	O
was	O
confirmed	O
based	O
on	O
reduced	O
plasma	BG
hexosaminidase	IG
A-39	IG
activity	O
and	O
the	O
G269S-43	BG
/	O
InsTATC1278-45	BG
genotype	O
.	O

PS683	O
Our	O
review	O
of	O
previously	O
reported	O
cases	O
with	O
TCF4-8	BG
mutations	O
and	O
deletions	O
showed	O
that	O
all	O
patients	O
with	O
Pitt	O
-	O
Hopkins	O
syndrome	O
reported	O
to	O
date	O
have	O
severe	O
psychomotor	BP
retardation-27	IP
,	O
the	O
onsets	O
of	O
seizures-32	BP
and	O
hyperventilation	O
episodes	O
are	O
limited	O
to	O
the	O
first	O
decade	O
in	O
most	O
reported	O
patients	O
with	O
Pitt	O
-	O
Hopkins	O
syndrome	O
,	O
hyperventilation	O
episodes	O
are	O
more	O
common	O
than	O
seizures-58	BP
and	O
are	O
seen	O
in	O
the	O
oldest	O
patients	O
,	O
and	O
individuals	O
with	O
missense	O
TCF4-71	BG
mutations	O
are	O
more	O
likely	O
to	O
develop	O
seizures-78	BP
.	O

PS685	O
We	O
demonstrate	O
the	O
utility	O
of	O
these	O
methods	O
by	O
analyzing	O
intrafamilial	O
correlations	O
among	O
patients	O
with	O
neurofibromatosis-15	BP
2	O
,	O
an	O
autosomal	O
-	O
dominant	O
disease	O
caused	O
by	O
mutations	O
of	O
the	O
neurofibromatosis	BG
2	IG
tumor	IG
-	IG
suppressor	IG
gene-33	IG
.	O

PS690	O
Recent	O
identification	O
of	O
mutations	O
in	O
the	O
beta	BG
myosin	IG
heavy	IG
chain	IG
gene-11	IG
and	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Hypertrophic	BP
cardiomyopathy-19	IP
patients	O
have	O
shown	O
that	O
the	O
beta	BG
myosin	IG
heavy	IG
chain-28	IG
mutations	O
are	O
also	O
prognosticators	O
in	O
Hypertrophic	BP
cardiomyopathy-35	IP
families	O
.	O

PS695	O
Mutations	O
in	O
the	O
GLI3	BG
zinc	IG
-	IG
finger	IG
transcription	IG
factor	IG
gene-10	IG
cause	O
Greig	O
cephalopolysyndactyly	O
syndrome	O
and	O
Pallister	O
-	O
Hall	O
syndrome	O
,	O
which	O
are	O
variable	O
but	O
distinct	O
clinical	O
entities	O
.	O

PS696	O
To	O
test	O
these	O
hypotheses	O
,	O
we	O
screened	O
patients	O
with	O
Pallister	O
-	O
Hall	O
syndrome	O
and	O
Greig	BP
cephalopolysyndactyly-16	IP
syndrome	O
for	O
GLI3-19	BG
mutations	O
.	O

PS697	O
Odds	O
for	O
the	O
presence	O
of	O
eye	O
pigment	O
abnormality	O
,	O
white	O
forelock	O
,	O
and	O
skin	BP
hypopigmentation-15	IP
were	O
2	O
,	O
8	O
,	O
and	O
5	O
times	O
greater	O
,	O
respectively	O
,	O
for	O
individuals	O
with	O
deletions	O
of	O
the	O
homeodomain-34	BG
and	O
the	O
Pro	O
-	O
Ser	O
-	O
Thr	O
-	O
rich	O
region	O
compared	O
to	O
individuals	O
with	O
an	O
amino	O
acid	O
substitution	O
in	O
the	O
homeodomain	O
.	O

PS698	O
Alterations	O
in	O
the	O
expression	O
pattern	O
of	O
these	O
genes	O
are	O
associated	O
with	O
the	O
development	O
of	O
differentiated	O
neoplasms-16	BP
,	O
ranging	O
from	O
benign	O
toxic	O
adenomas	O
(	O
gsp	O
and	O
TSH	BG
receptor-27	IG
)	O
,	O
to	O
follicular	O
(	O
ras-33	BG
)	O
and	O
papillary	O
(	O
ret	O
/	O
PTC-40	BG
,	O
NTRK-42	BG
,	O
met	O
)	O
carcinomas	O
.	O

PS700	O
Interestingly	O
,	O
a	O
high	O
percentage	O
of	O
genetic	O
lesions	O
causing	O
thyroid	BP
cancer-11	IP
originate	O
from	O
gene	O
rearrangements	O
and	O
chromosomal	O
translocations	O
(	O
ret-20	BG
/	O
PTC-22	BG
,	O
NTRK-24	BG
,	O
Pax	BG
-	IG
8-28	IG
/	O
PPARgamma-30	BG
)	O
a	O
finding	O
which	O
,	O
being	O
a	O
rare	O
event	O
in	O
most	O
epithelial	O
tumours	O
,	O
makes	O
the	O
molecular	O
pathogenesis	O
of	O
thyroid	BP
cancer-51	IP
unique	O
.	O

PS702	O
Pulmonary	BP
stenosis-2	IP
is	O
the	O
only	O
anomaly	O
that	O
demonstrates	O
a	O
statistically	O
significant	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
being	O
more	O
common	O
in	O
individuals	O
with	O
a	O
BRAF-24	BG
mutation	O
.	O

PS703	O
The	O
gene	O
for	O
myotonic	BP
dystrophy-5	IP
(	O
DM	O
)	O
has	O
recently	O
been	O
isolated	O
and	O
amplification	O
of	O
an	O
unstable	O
CTG	O
trinucleotide	O
repeat	O
,	O
located	O
within	O
the	O
DM	BG
gene-26	IG
,	O
has	O
been	O
identified	O
in	O
virtually	O
all	O
patients	O
studied	O
to	O
date	O
.	O

PS705	O
This	O
is	O
the	O
first	O
report	O
of	O
the	O
clinical	O
and	O
genetic	O
investigation	O
of	O
complete	O
achromatopsia-14	BP
in	O
North	O
Africa	O
and	O
the	O
largest	O
family	O
with	O
recessive	O
achromatopsia	O
involving	O
GNAT2-26	BG
;	O

PS708	O
We	O
conclude	O
that	O
in	O
carriers	O
of	O
germline	O
TP53	O
mutations	O
transactivation	O
-	O
based	O
classification	O
of	O
TP53	BG
alleles-16	IG
appears	O
more	O
important	O
for	O
genotype	O
/	O
phenotype	O
correlations	O
than	O
dominant	O
-	O
negative	O
effects	O
and	O
that	O
haplo	O
-	O
insufficiency	O
of	O
the	O
TP53	BG
gene-38	IG
is	O
an	O
important	O
factor	O
in	O
cancer-44	BP
proneness	O
in	O
humans	O
.	O

PS710	O
The	O
breakpoints	O
in	O
patients	O
with	O
5p	O
terminal	O
deletions	O
were	O
characterized	O
with	O
respect	O
to	O
the	O
severity	O
of	O
mental	BP
retardation-18	IP
and	O
the	O
physical	O
location	O
of	O
the	O
delta	BG
-	IG
catenin	IG
gene-28	IG
.	O

PS711	O
A	O
strong	O
correlation	O
was	O
found	O
between	O
the	O
hemizygous	O
loss	O
of	O
delta	BG
-	IG
catenin-13	IG
and	O
severe	BP
mental	IP
retardation-17	IP
.	O

PS713	O
We	O
previously	O
described	O
cross	O
-	O
sectional	O
family	O
studies	O
of	O
two	O
hypertrophic	BP
cardiomyopathy-12	IP
-	O
causing	O
mutations	O
,	O
R92W-17	BG
(	O
TNNT2-19	BG
)	O
and	O
R403W-22	BG
(	O
MYH7-24	BG
)	O
,	O
both	O
associated	O
with	O
minimal	O
hypertrophy	O
,	O
but	O
with	O
widely	O
different	O
life	O
expectancies	O
.	O

PS714	O
Thus	O
,	O
these	O
findings	O
suggest	O
the	O
involvement	O
of	O
specific	O
single	O
-	O
nucleotide	O
polymorphisms	O
of	O
GATA4-15	BG
in	O
the	O
manifestation	O
of	O
Congenital	O
heart	BP
disease-22	IP
,	O
reported	O
for	O
the	O
first	O
time	O
in	O
an	O
Indian	O
scenario	O
.	O

PS718	O
Xeroderma	BG
pigmentosumD	IG
protein-3	IG
is	O
required	O
for	O
both	O
nucleotide	O
excision	O
repair	O
and	O
basal	O
transcription	O
.	O

PS720	O
Little	O
is	O
understood	O
of	O
the	O
genotype	O
/	O
phenotype	O
correlations	O
in	O
X	O
linked	O
glycerol	BG
kinase-14	IG
deficiency	O
where	O
most	O
cases	O
are	O
caused	O
by	O
extensive	O
deletions	O
of	O
Xp21-25	BG
,	O
which	O
often	O
include	O
genes	O
flanking	O
the	O
GK	BG
locus-34	IG
.	O

PS721	O
In	O
this	O
paper	O
,	O
we	O
present	O
the	O
mutation	O
data	O
from	O
four	O
confirmed	O
and	O
one	O
suspected	O
case	O
of	O
non	O
-	O
deletion	O
,	O
isolated	O
,	O
X-24	BG
linked	O
glycerol	BG
kinase	IG
deficiency-28	IP
and	O
therefore	O
extend	O
the	O
base	O
of	O
patients	O
that	O
can	O
allow	O
an	O
assessment	O
of	O
genotype	O
/	O
phenotype	O
correlations	O
for	O
this	O
disease	O
.	O

PS722	O
Mutations	O
in	O
the	O
gene	O
for	O
the	O
low	BG
density	IG
lipoprotein-9	IG
receptor	O
have	O
been	O
identified	O
in	O
15	O
patients	O
with	O
homozygous	O
familial	BP
hypercholesterolemia-20	IP
.	O

PS727	O
No	O
significant	O
correlation	O
could	O
be	O
found	O
between	O
M2	O
allele	O
and	O
lung	O
cancer-12	BP
or	O
between	O
M2	O
allele	O
and	O
CYP1A1	BG
inducibility-19	IG
;	O

PS729	O
Our	O
observations	O
do	O
not	O
support	O
the	O
view	O
that	O
the	O
presence	O
of	O
the	O
M2	BG
allele-14	IG
at	O
the	O
MspI	BG
site-18	IG
of	O
the	O
CYP1A1	BG
gene-22	IG
constitutes	O
a	O
significant	O
lung	O
cancer-27	BP
risk	O
in	O
Caucasians	O
.	O

PS730	O
Papillary	O
thyroid	BP
carcinoma-3	IP
represents	O
an	O
example	O
of	O
tumour	O
with	O
high	O
incidence	O
of	O
oncogenic	O
sequences	O
,	O
such	O
as	O
RET-18	BG
/	O
Papillary	O
thyroid	O
carcinoma	O
and	O
Trk	O
.	O

PS731	O
In	O
case	O
of	O
NTRK1	BG
oncogene-5	IG
,	O
several	O
rearrangement	O
types	O
are	O
observed	O
,	O
characteristic	O
for	O
Papillary	O
thyroid	O
carcinoma	O
:	O
Trk-19	BG
(	O
TMP3-21	BG
)	O
,	O
Trk	BG
-	IG
T1-26	IG
,	O
Trk	BG
-	IG
T2-30	IG
,	O
Trk	BG
-	IG
T3-34	IG
and	O
Trk	BG
-	IG
2h-38	IG
,	O
observed	O
in	O
human	O
breast	BP
cancer-44	IP
cell	O
line	O
.	O

PS737	O
Used	O
a	O
case	O
-	O
case	O
study	O
of	O
213	O
Chinese	O
angiographically	O
-	O
defined	O
coronary	BP
artery	IP
disease-15	IP
patients	O
who	O
were	O
screened	O
for	O
apolipoprotein	BG
E	IG
genotypes-23	IG
.	O

PS740	O
Mutations	O
described	O
here	O
cause	O
an	O
odd	O
number	O
of	O
cysteines	O
in	O
the	O
N	O
-	O
terminal	O
of	O
the	O
EGF-17	BG
domain	O
of	O
Notch3	BG
protein-21	IG
,	O
which	O
seems	O
to	O
have	O
an	O
important	O
functional	O
effect	O
in	O
the	O
pathophysiology	O
of	O
cerebral	O
autosomal	O
dominant	O
arteriopathy	O
with	O
subcortical	O
infarcts	O
and	O
leukoencephalopathy-43	BP
.	O

PS742	O
To	O
confirm	O
alkaptonuria-3	BP
and	O
ochronotic	O
arthropathy	O
diagnosis	O
by	O
mutation	O
screening	O
of	O
the	O
homogentisate	BG
1	IG
,	IG
2	IG
-	IG
dioxygenase-18	IG
gene	O
.	O

PS744	O
Taken	O
together	O
our	O
data	O
suggest	O
that	O
the	O
variant	O
allele	O
(	O
-	O
131C	O
-	O
-	O
>	O
G	O
)	O
of	O
CHI3L1	BG
promoter-20	IG
has	O
no	O
significant	O
impact	O
on	O
survival	O
and	O
is	O
not	O
a	O
prognostic	O
factor	O
for	O
glioblastoma-34	BP
.	O

PS746	O
These	O
findings	O
emphasize	O
the	O
importance	O
of	O
considering	O
Muscle	O
-	O
eye	O
-	O
brain	O
disease	O
and	O
searching	O
for	O
protein	O
O	O
-	O
linked	O
mannose	BG
beta1	IG
,	IG
2	IG
-	IG
N	IG
-	IG
acetylglucosaminyltransferase	IG
1-29	IG
mutations	O
in	O
Walker	O
-	O
Warburg	O
syndrome	O
or	O
other	O
congenital	BP
muscular	IP
dystrophy-40	IP
patients	O
worldwide	O
.	O

PS748	O
Collectively	O
,	O
the	O
results	O
provided	O
us	O
with	O
a	O
rationale	O
for	O
the	O
observed	BP
enzyme	IP
deficiency-14	IP
and	O
contribute	O
to	O
both	O
a	O
better	O
understanding	O
of	O
the	O
genotype	O
-	O
to	O
-	O
phenotype	O
correlation	O
in	O
Pyruvate	BG
kinase-32	IG
deficiency	O
as	O
well	O
as	O
the	O
enzyme	O
'	O
s	O
structure	O
and	O
function	O
.	O

PS749	O
We	O
tested	O
the	O
hypothesis	O
that	O
variants	O
in	O
2	O
genes	O
encoding	O
vascular	BG
endothelial	IG
growth	IG
factor-14	IG
and	O
vascular	BG
endothelial	IG
growth	IG
factor	IG
receptor	IG
-	IG
2-22	IG
are	O
associated	O
with	O
susceptibility	O
to	O
stroke-28	BP
and	O
its	O
recurrence	O
in	O
a	O
Chinese	O
case	O
-	O
control	O
study	O
comprising	O
1849	O
patients	O
with	O
stroke-43	BP
and	O
1798	O
control	O
subjects	O
and	O
replicated	O
the	O
investigation	O
in	O
an	O
independent	O
study	O
comprising	O
327	O
cases	O
and	O
327	O
control	O
subjects	O
.	O

PS750	O
Compared	O
with	O
their	O
corresponding	O
wild	O
-	O
type	O
genotypes	O
,	O
one	O
coding	O
variant	O
,	O
rs2305948	O
(	O
Val297Ile	O
)	O
,	O
in	O
the	O
vascular	BG
endothelial	IG
growth	IG
factor	IG
receptor	IG
-	IG
2	IG
gene-28	IG
was	O
associated	O
with	O
increased	O
susceptibility	O
to	O
intracerebral	O
hemorrhage	O
,	O
a	O
promoter	O
variant	O
rs2071559	O
(	O
-	O
604T	O
>	O
C	O
)	O
in	O
the	O
gene	O
was	O
associated	O
with	O
reduced	O
susceptibility	O
to	O
atherothrombotic	O
stroke-58	BP
and	O
was	O
reversely	O
correlated	O
with	O
carotid	BP
artery	IP
intima-66	IP
media	O
thickness	O
.	O

PS751	O
The	O
vascular	BG
endothelial	IG
growth	IG
factor	IG
receptor	IG
-	IG
2	IG
gene	IG
variants-10	IG
may	O
serve	O
as	O
novel	O
genetic	O
markers	O
for	O
the	O
risk	O
of	O
stroke-21	BP
and	O
its	O
recurrence	O
.	O

PS752	O
Adults	O
with	O
autosomal	O
dominant	O
polycystic	BP
kidney	IP
disease-7	IP
and	O
PKD1-9	BG
mutations	O
have	O
a	O
more	O
severe	O
disease	O
than	O
do	O
patients	O
with	O
PKD2-20	BG
mutations	O
.	O

PS753	O
Prenatal	O
renal	BP
cysts-3	IP
(	O
14	O
%	O
)	O
,	O
hypertension-9	BP
defined	O
by	O
ambulatory	O
blood	O
pressure	O
(	O
27	O
%	O
)	O
and	O
enlarged	BP
kidneys-21	IP
(	O
32	O
%	O
)	O
were	O
observed	O
only	O
in	O
the	O
PKD1-31	BG
children	O
.	O

PS754	O
PKD1-1	BG
children	O
have	O
more	O
and	O
larger	O
renal	BP
cysts-8	IP
,	O
larger	BP
kidneys-11	IP
and	O
higher	O
ambulatory	O
blood	O
pressure	O
than	O
do	O
PKD2-19	BG
children	O
.	O

PS755	O
Renal	BP
cysts-2	IP
and	O
enlarged	O
kidneys	O
detected	O
prenatally	O
are	O
highly	O
specific	O
for	O
children	O
with	O
PKD1-14	BG
.	O

PS756	O
Patients	O
with	O
Usher	O
syndrome	O
type	O
II	O
(	O
USH2-8	BG
)	O
show	O
moderate	O
-	O
to	O
-	O
severe	O
hearing	BP
loss-17	IP
,	O
retinitis	BP
pigmentosa-20	IP
and	O
normal	O
vestibular	O
function	O
.	O

PS759	O
Coincidentally	O
,	O
one	O
important	O
phenotype	O
of	O
Cleidocranial	BP
dysplasia-8	IP
,	O
the	O
short	BP
stature-12	IP
,	O
was	O
significantly	O
milder	O
in	O
the	O
patients	O
with	O
the	O
intact	O
Runt	BG
domain-24	IG
than	O
those	O
without	O
.	O

PS760	O
This	O
makes	O
an	O
interesting	O
contrast	O
to	O
the	O
case	O
of	O
familial	O
and	O
sporadic	O
leukemias	O
mediated	O
by	O
RUNX1	BG
mutations-17	IG
,	O
in	O
which	O
mutants	O
acting	O
in	O
a	O
dominant	O
negative	O
manner	O
have	O
been	O
suggested	O
to	O
confer	O
a	O
higher	O
propensity	O
to	O
develop	O
leukemia-38	BP
.	O

PS761	O
Additionally	O
,	O
based	O
on	O
the	O
clinical	O
data	O
collected	O
for	O
22	O
patients	O
from	O
the	O
16	O
families	O
,	O
we	O
observe	O
that	O
mutations	O
in	O
the	O
plant	O
homeodomain-24	BG
-	O
like	O
domain	O
produce	O
severe	O
and	O
permanent	BP
psychomotor	IP
deficiency-33	IP
,	O
usually	O
preventing	O
patients	O
from	O
walking	O
,	O
as	O
well	O
as	O
constant	O
urogenital	O
abnormalities	O
,	O
while	O
mutations	O
in	O
the	O
helicase	BG
domain-53	IG
lead	O
to	O
delayed	O
but	O
correct	O
psychomotor	O
acquisitions	O
together	O
with	O
mild	O
or	O
absent	O
urogenital	O
abnormalities	O
.	O

PS764	O
The	O
histopathological	O
characterization	O
of	O
the	O
liver	O
showed	O
no	O
signs	O
of	O
fibrinogen-11	BG
accumulation	O
,	O
a	O
difference	O
from	O
the	O
previously	O
reported	O
findings	O
in	O
two	O
hypofibrinogenemic	O
kindreds	O
with	O
endoplasmic	BP
reticulum	IP
storage	IP
disease-29	IP
.	O

PS765	O
The	O
results	O
confirm	O
that	O
Bbeta	BG
-	IG
Leu353Arg-7	IG
is	O
associated	O
with	O
impaired-11	BP
fibrinogen	BG
secretion-13	IP
,	O
but	O
not	O
with	O
hepatic	O
endoplasmic	O
reticulum	O
storage	O
disease	O
.	O

PS766	O
This	O
study	O
emphasises	O
the	O
principal	O
role	O
of	O
ATP	BG
binding	IG
cassette	IG
family	IG
C	IG
member	IG
6-14	IG
mutations	O
in	O
the	O
pathogenesis	O
of	O
Pseudoxanthoma-20	BP
elasticum	O
,	O
but	O
the	O
reasons	O
for	O
phenotypic	O
variability	O
remain	O
to	O
be	O
explored	O
.	O

PS768	O
The	O
GnRH	BG
gene-3	IG
was	O
excluded	O
as	O
a	O
candidate	O
gene	O
in	O
Idiopathic	BP
hypogonadotropic	IP
hypogonadism-13	IP
since	O
no	O
abnormality	O
was	O
found	O
in	O
several	O
patients	O
.	O

PS769	O
Recently	O
,	O
we	O
described	O
the	O
first	O
patient	O
with	O
partial	O
hypogonadotropic	BP
hypogonadism-11	IP
without	O
anosmia	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
of	O
the	O
GnRH	BG
receptor-23	IG
.	O

PS774	O
We	O
evaluated	O
the	O
relative	O
percentages	O
of	O
peripheral	O
blood	O
leukocyte	O
subtypes	O
(	O
lymphocytes	O
,	O
granulocytes	O
,	O
and	O
monocytes	O
)	O
and	O
lymphocyte	O
subpopulations	O
(	O
CD4	BG
+	IG
T-25	IG
,	O
CD8	BG
+-28	IG
T	O
,	O
B220	O
+	O
B	O
,	O
and	O
natural	BP
killer-37	IP
cells	O
)	O
of	O
mature	O
(	O
6	O
-	O
mo	O
-	O
old	O
)	O
mice	O
.	O

PS777	O
As	O
well	O
as	O
identifying	O
novel	O
variants	O
in	O
SPG4-8	BG
,	O
this	O
study	O
constitutes	O
the	O
molecular	O
characterization	O
of	O
the	O
largest	O
cohort	O
of	O
Italian	O
autosomal	O
dominant	O
hereditary	O
spastic	BP
paraplegia-26	IP
patients	O
studied	O
to	O
date	O
.	O

PS779	O
At	O
diagnosis	O
,	O
2	O
patients	O
manifested	O
signs	O
of	O
overt	O
neuromuscular	O
involvement	O
and	O
were	O
homozygous	O
for	O
the	O
6059delC	O
mutation	O
,	O
whereas	O
1	O
patient	O
had	O
only	O
hyporeflexia-25	BP
and	O
was	O
homozygous	O
for	O
the	O
EX23del	BG
mutation-32	IG
.	O

PS780	O
In	O
HXL	O
-	O
2	O
pedigree	O
,	O
I	O
:	O
1	O
and	O
I	O
:	O
2	O
carried	O
single	O
heterozygous	O
mutation	O
,	O
which	O
manifested	O
by	O
mild	O
-	O
moderate	O
deafness	O
while	O
II	O
:	O
2	O
,	O
II	O
:	O
3	O
,	O
II	O
:	O
5	O
and	O
III	O
:	O
2	O
presented	O
with	O
severe	O
or	O
profound	O
deafness-47	BP
in	O
phenotype	O
,	O
and	O
II	BG
-	IG
1	IG
genotype-55	IG
was	O
double	O
heterozygous	O
,	O
which	O
manifested	O
by	O
profound	O
deafness	O
.	O

PS781	O
In	O
particular	O
,	O
a	O
DNA	BG
-	IG
glycosylase-7	IG
assay	O
for	O
removal	O
of	O
8	O
-	O
oxoguanine	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
has	O
been	O
successfully	O
applied	O
to	O
identify	O
populations	O
with	O
increased	O
risk	O
for	O
lung	O
cancer-32	BP
and	O
squamous	O
cell	O
carcinomas	O
of	O
head	O
and	O
neck	O
.	O

PS783	O
Genotype	O
at	O
G972R	O
had	O
no	O
significant	O
effect	O
on	O
various	O
measures	O
of	O
insulin-12	BG
secretion	O
or	O
insulin	BG
resistance-16	IP
in	O
a	O
set	O
of	O
Scandinavian	O
samples	O
in	O
whom	O
we	O
had	O
detailed	O
phenotypic	O
data	O
.	O

PS784	O
DNA	O
samples	O
from	O
414	O
unrelated	O
Peruvian	O
subjects	O
,	O
including	O
205	O
open	O
-	O
angle	O
glaucoma-14	BP
cases	O
(	O
10	O
juvenile	O
glaucoma-19	BP
[	O
Jopen	O
-	O
angle	O
glaucoma-24	BP
]	O
,	O
19	O
normal	O
-	O
tension	O
glaucoma-31	BP
[	O
NTG	O
]	O
,	O
and	O
176	O
Popen	O
-	O
angle	O
glaucoma-41	BP
)	O
and	O
209	O
randomly	O
sampled	O
controls	O
,	O
were	O
screened	O
for	O
nucleotide	O
changes	O
in	O
myocilin	BG
gene	IG
exon	IG
3-58	IG
by	O
conformational	O
sensitive	O
gel	O
electrophoresis	O
and	O
mutation	O
screening	O
.	O

PS786	O
We	O
also	O
found	O
the	O
known	O
causative	O
myocilin	BG
gene	IG
mutation	IG
Trp286Arg-10	IG
in	O
one	O
Jopen	O
-	O
angle	O
glaucoma-16	BP
case	O
and	O
one	O
Popen	O
-	O
angle	O
glaucoma-23	BP
case	O
.	O

PS787	O
A	O
known	O
causative	O
single	O
base	O
myocilin	BG
gene-7	IG
deletion	O
,	O
T1357	O
,	O
was	O
found	O
in	O
one	O
Popen	O
-	O
angle	O
glaucoma-19	BP
case	O
.	O

PS788	O
The	O
screening	O
of	O
exon	O
3	O
of	O
myocilin	BG
gene-8	IG
in	O
a	O
representative	O
sample	O
of	O
205	O
independent	O
Popen	O
-	O
angle	O
glaucoma-19	BP
patients	O
from	O
Peru	O
and	O
209	O
matched	O
controls	O
identified	O
novel	O
and	O
previously	O
reported	O
mutations	O
(	O
both	O
pathogenic	O
and	O
nonpathogenic	O
)	O
from	O
other	O
global	O
regions	O
.	O

PS789	O
It	O
will	O
be	O
important	O
to	O
gather	O
information	O
about	O
the	O
ancestral	O
origin	O
of	O
myocilin	BG
gene-14	IG
and	O
other	O
Popen	O
-	O
angle	O
glaucoma-20	BP
gene	O
mutations	O
to	O
develop	O
screening	O
panels	O
and	O
risk	O
assessment	O
for	O
Popen	O
-	O
angle	O
glaucoma-34	BP
in	O
Peru	O
.	O

PS792	O
Since	O
mutations	O
in	O
the	O
four	O
major	O
genes	O
(	O
SHH-9	BG
,	O
ZIC2-11	BG
,	O
SIX3-13	BG
,	O
and	O
TGIF	O
)	O
have	O
been	O
identified	O
in	O
Holoprosencephaly-22	BP
patients	O
,	O
molecular	O
study	O
is	O
performed	O
routinely	O
in	O
nonsyndromic	O
Holoprosencephaly	O
.	O

PS794	O
Frequency	O
of	O
mutations	O
of	O
this	O
gene	O
in	O
normal	O
population	O
of	O
breast	BP
cancer-12	IP
is	O
low	O
suggesting	O
that	O
the	O
effort	O
of	O
primary	O
screening	O
for	O
BRCA1	BG
gene-24	IG
should	O
be	O
restricted	O
to	O
only	O
familial	O
cases	O
with	O
a	O
strong	O
history	O
of	O
breast	O
and	O
ovarian	O
cancer-40	BP
.	O

PS796	O
The	O
nature	O
of	O
the	O
tumorigenic	O
mutation	O
was	O
analyzed	O
in	O
30	O
retinoblastoma	BG
tumors-12	IG
(	O
16	O
non	O
-	O
hereditary	O
and	O
14	O
hereditary	O
)	O
and	O
categorized	O
into	O
loss	O
of	O
heterozygosity	O
or	O
retention	O
of	O
heterozygosity	O
(	O
non	O
-	O
loss	O
of	O
heterozygosity	O
)	O
at	O
the	O
RB1	BG
locus-42	IG
.	O

PS799	O
This	O
study	O
analysed	O
the	O
effect	O
of	O
human	BG
leucocyte	IG
antigen	IG
-	IG
A-11	IG
on	O
clinical	O
variables	O
in	O
a	O
large	O
Scandinavian	O
sample	O
set	O
,	O
but	O
could	O
not	O
identify	O
any	O
significant	O
contribution	O
from	O
human	BG
leucocyte	IG
antigen	IG
-	IG
A-34	IG
on	O
the	O
clinical	O
phenotype	O
in	O
multiple	O
sclerosis-41	BP
.	O

PS800	O
However	O
,	O
associations	O
between	O
human	BG
leucocyte	IG
antigen	IG
-	IG
DRB1-9	IG
*	O
15	O
and	O
age	O
at	O
onset	O
of	O
multiple	BP
sclerosis-18	IP
were	O
reproduced	O
in	O
this	O
extended	O
Scandinavian	O
multiple	O
sclerosis	O
cohort	O
.	O

PS802	O
Our	O
analyses	O
identified	O
haplotypes	O
carrying	O
quantitative	O
trait	BG
loci	IG
alleles-9	IG
associated	O
with	O
high	O
protein	O
yield	O
and	O
simultaneously	O
fewer	O
incidences	O
of	O
clinical	O
mastitis-21	BP
.	O

PS805	O
In	O
this	O
study	O
,	O
human	O
immunodeficiency-6	BP
virus	O
-	O
infected	O
patients	O
under	O
highly	O
active	O
anti	O
-	O
retroviral	O
therapy	O
at	O
Hacettepe	O
University	O
Faculty	O
of	O
Medicine	O
,	O
Department	O
of	O
Internal	O
Medicine	O
,	O
Division	O
of	O
Infectious	O
Diseases	O
,	O
were	O
evaluated	O
for	O
the	O
presence	O
of	O
anti	BG
-	IG
R7V	IG
antibodies-44	IG
.	O

PS806	O
For	O
human	O
immunodeficiency-3	BP
virus	O
-	O
infected	O
patients	O
,	O
determination	O
of	O
viral	O
load	O
and	O
CD4	BG
+-15	IG
T	O
lymphocyte	O
counts	O
were	O
performed	O
by	O
a	O
commercial	O
real	O
-	O
time	O
PCR	O
assay	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

PS810	O
We	O
present	O
a	O
family	O
from	O
Northeast	O
China	O
affected	O
by	O
epidermolytic	BP
palmoplantar	IP
keratoderma-12	IP
in	O
which	O
we	O
confirmed	O
the	O
presence	O
of	O
the	O
N161S	O
mutation	O
as	O
the	O
result	O
of	O
a	O
548A	O
>	O
G	O
transition	O
in	O
exon1	O
of	O
the	O
keratin	BG
9	IG
gene-38	IG
.	O

PS812	O
No	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
is	O
established	O
,	O
except	O
for	O
patients	O
with	O
deletion	O
of	O
the	O
entire	BG
neurofibromatosis	IG
type	IG
1	IG
gene-21	IG
.	O

PS813	O
From	O
53	O
index	O
patients	O
diagnosed	O
with	O
either	O
Familial	O
adenomatous	O
polyposis	O
or	O
attenuated	BP
Familial	IP
adenomatous	IP
polyposis-15	IP
,	O
27	O
harboured	O
changes	O
in	O
the	O
APC	BG
gene-23	IG
.	O

PS815	O
Mutations	O
in	O
the	O
gene	O
for	O
the	O
thrombopoietin	BG
receptor	IG
MPL-9	IG
were	O
defined	O
as	O
the	O
molecular	O
cause	O
in	O
Congenital	BP
amegakaryocytic	IP
thrombocytopenia-19	IP
patients	O
.	O

PS816	O
Seven	O
different	O
mutations	O
predicted	O
to	O
lead	O
to	O
a	O
complete	O
loss	O
of	O
function	O
of	O
the	O
thrombopoietin	BG
receptor-16	IG
were	O
found	O
in	O
13	O
patients	O
belonging	O
to	O
group	O
Congenital	O
amegakaryocytic	O
thrombocytopenia	O
I	O
with	O
persistently	O
low	O
platelet	O
counts	O
and	O
a	O
fast	O
progression	O
into	O
pancytopenia-39	BP
.	O

PS817	O
Using	O
in	O
vitro	O
assays	O
with	O
hematopoietic	O
progenitors	O
from	O
patients	O
of	O
both	O
patient	O
groups	O
we	O
could	O
provide	O
experimental	O
evidence	O
for	O
a	O
residual	O
activity	O
of	O
the	O
thrombopoietin	BG
receptor-26	IG
in	O
Congenital	O
amegakaryocytic	O
thrombocytopenia-30	BP
II	O
patients	O
.	O

PS818	O
Recently	O
,	O
a	O
homozygous	O
mutation	O
in	O
the	O
gene	O
HPGD	O
,	O
which	O
encodes	O
15	BG
-	IG
hydroxyprostaglandin	IG
dehydrogenase-16	IG
,	O
was	O
found	O
to	O
be	O
associated	O
with	O
Pachydermoperiostosis-24	BP
.	O

PS822	O
This	O
genetically	O
and	O
phenotypically	O
heterogeneous	O
group	O
includes	O
infantile	O
onset	O
spinocerebellar	O
ataxia-11	BP
(	O
OMIM	O
#	O
271245	O
)	O
a	O
neurodegenerative	O
disease	O
caused	O
by	O
mutations	O
in	O
the	O
mtDNA	BG
helicase	IG
gene-27	IG
,	O
c10orf2	O
,	O
with	O
an	O
increased	O
frequency	O
in	O
the	O
Finnish	O
population	O
due	O
to	O
a	O
founder	O
mutation	O
.	O

PS825	O
The	O
mice	O
do	O
not	O
appear	O
to	O
show	O
increased	O
anxiety-9	BP
,	O
supporting	O
a	O
specific	O
effect	O
of	O
Gtf2i-16	BG
on	O
defined	O
domains	O
of	O
the	O
Williams	O
-	O
Beuren	O
syndrome	O
phenotype	O
.	O

PS826	O
Patient	O
gender	O
,	O
age	O
at	O
tuberous	O
sclerosis	O
complex	O
diagnosis	O
,	O
presence	O
of	O
tuberous	O
sclerosis	BG
complex1-15	IG
or	O
tuberous	BG
sclerosis	IG
complex2	IG
mutations-20	IG
,	O
detailed	O
ophthalmic	O
examination	O
findings	O
,	O
systemic	O
manifestations	O
,	O
and	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
diagnosis	O
of	O
epilepsy	O
or	O
cognitive	BP
impairment-43	IP
were	O
analyzed	O
.	O

PS833	O
Variations	O
in	O
the	O
mdr1	BG
gene	IG
product-64	IG
may	O
directly	O
affect	O
the	O
therapeutic	O
effectiveness	O
,	O
and	O
single	O
nucleotide	O
polymorphisms	O
for	O
the	O
mdr1	BG
gene-79	IG
may	O
be	O
associated	O
with	O
altered	O
oral	O
bioavailability	O
of	O
multidrug	O
resistance1	O
substrates	O
,	O
drug	O
resistance	O
,	O
and	O
a	O
susceptibility	O
to	O
some	O
human	O
diseases	O
.	O

PS834	O
Integration	O
and	O
correlation	O
of	O
functional	O
single	O
photon	O
emission	O
tomography	O
or	O
positron	O
emission	O
tomography	O
imaging	O
findings	O
with	O
mdr1	BG
genotype-18	IG
and	O
clinical	O
data	O
may	O
contribute	O
to	O
efficient	O
management	O
by	O
selecting	O
cancer-29	BP
patients	O
with	O
the	O
appropriate	O
molecular	O
phenotype	O
for	O
maximal	O
individual	O
therapeutic	O
benefit	O
,	O
as	O
well	O
as	O
those	O
who	O
are	O
non	O
-	O
responders	O
.	O

PS836	O
Data	O
about	O
the	O
clinical	O
manifestations	O
of	O
congenital	BP
adrenal	IP
hyperplasia-9	IP
caused	O
by	O
21	O
-	O
hydroxylase-14	BG
deficiency	O
(	O
21	O
-	O
OHD	O
)	O
are	O
lacking	O
in	O
Taiwan	O
.	O

PS837	O
Measurement	O
of	O
platelet	BG
factor	IG
V-5	IG
levels	O
in	O
7	O
F5F8D	O
patients	O
(	O
4	O
with	O
LMAN1	BG
and	IG
3-16	IG
with	O
MCFD2	BG
mutations-19	IG
)	O
demonstrated	O
similar	O
reductions	O
to	O
those	O
observed	O
for	O
plasma	BG
factor	IG
V-30	IG
.	O

PS839	O
We	O
analysed	O
the	O
presence	O
of	O
a	O
correlation	O
among	O
both	O
the	O
clinical	O
features	O
associated	O
with	O
glycogen	BG
storage	IG
disease	IG
type1b-18	IG
(	O
neutropenia-20	BP
,	O
frequency	O
of	O
admission	O
to	O
the	O
hospital	O
for	O
severe	O
infections	O
)	O
and	O
the	O
presence	O
of	O
systemic	O
complications	O
(	O
liver	O
adenomas	O
,	O
nephropathy-42	BP
,	O
bone	O
mineral	O
density	O
defect	O
,	O
polycystic	BP
ovaries-50	IP
,	O
short	BP
stature-53	IP
,	O
inflammatory	BP
bowel	IP
disease-57	IP
)	O
and	O
the	O
mutations	O
detected	O
in	O
each	O
patient	O
.	O

PS840	O
one	O
of	O
these	O
patients	O
did	O
not	O
show	O
neutropenia-8	BP
,	O
whereas	O
the	O
other	O
one	O
had	O
severe	O
neutropenia-16	BP
needing	O
frequent	O
hospital	O
admission	O
and	O
was	O
under	O
granulocyte	BG
-	IG
colony	IG
stimulating	IG
factor-28	IG
treatment	O
.	O

PS841	O
Our	O
results	O
showed	O
that	O
patients	O
with	O
Congenital	O
bilateral	O
absence	O
of	O
the	O
vas	O
deferens	O
and	O
renal	BP
agenesis-16	IP
have	O
the	O
same	O
reproductive	O
tract	O
abnormalities	O
as	O
those	O
with	O
congenital	O
unilateral	O
absence	O
of	O
the	O
vas	O
deferens	O
,	O
and	O
reproductive	O
tract	O
abnormalities	O
were	O
independent	O
of	O
the	O
subtypes	O
of	O
CFTR	BG
genotype-45	IG
in	O
patients	O
with	O
absence	O
of	O
the	O
vas	O
deferens	O
and	O
CFTR	BG
gene-56	IG
mutations	O
.	O

PS847	O
A	O
Val606Met	O
missen	O
mutation	O
was	O
identified	O
in	O
the	O
exon	O
16	O
of	O
MYH7	BG
gene-13	IG
in	O
a	O
Chinese	O
family	O
and	O
this	O
mutation	O
was	O
identified	O
in	O
all	O
hypertrophic	BP
cardiomyopathy-26	IP
patients	O
(	O
n	O
=	O
4	O
)	O
and	O
there	O
was	O
also	O
a	O
15	O
-	O
years	O
-	O
old	O
young	O
mutation	O
carrier	O
who	O
was	O
not	O
hypertrophic	BP
cardiomyopathy-50	IP
patient	O
now	O
(	O
penetrance	O
of	O
80	O
%	O
)	O
.	O

PS852	O
After	O
exclusion	O
of	O
four	O
persons	O
with	O
apolipoproteinlipoprotein	BG
E	IG
2	IG
-	IG
2-11	IG
phenotype	O
,	O
there	O
were	O
89	O
familial	O
hypercholesterolemia-18	BP
patients	O
and	O
110	O
non	O
-	O
familial	O
hypercholesterolemia	O
subjects	O
.	O

PS855	O
There	O
was	O
a	O
statistically	O
significant	O
interaction	O
between	O
familial	O
hypercholesterolemia-9	BP
and	O
the	O
presence	O
of	O
a	O
single	O
E2	BG
allele-17	IG
for	O
the	O
ratio	O
of	O
VLDL	BG
cholesterol-23	IG
to	O
plasma	O
triglycerides	O
and	O
for	O
a	O
newly	O
derived	O
estimate	O
of	O
beta	O
-	O
VLDL	O
cholesterol	O
concentration	O
.	O

PS856	O
Estimated	O
beta	O
-	O
VLDL	O
cholesterol	O
level	O
was	O
strongly	O
correlated	O
with	O
age	O
in	O
the	O
subgroup	O
with	O
familial	BP
hypercholesterolemia-17	IP
and	O
an	O
E2	BG
allele-21	IG
but	O
not	O
in	O
other	O
subgroups	O
.	O

PS857	O
if	O
so	O
,	O
then	O
a	O
sizable	O
subset	O
of	O
familial	BP
hypercholesterolemia-10	IP
patients	O
having	O
at	O
least	O
one	O
apolipoproteinlipoprotein	BG
E2	IG
allele	IG
and	IG
DLPIII-20	IG
may	O
be	O
at	O
increased	O
risk	O
for	O
premature	O
coronary	O
heart	O
disease	O
.	O

PS859	O
The	O
expected-2	BP
COL3A1	BG
haploinsufficiency-4	IP
in	O
her	O
healthy	O
ascendants	O
did	O
not	O
lead	O
to	O
the	O
manifestations	O
of	O
vascular	O
Ehlers	O
-	O
Danlos	O
syndrome	O
.	O

PS861	O
It	O
can	O
be	O
concluded	O
that	O
fibrillin	BG
-	IG
1-8	IG
mutations	O
involving	O
cysteine	O
substitutions	O
are	O
usually	O
associated	O
with	O
Marfan	O
syndrome	O
and	O
ectopia-20	BP
lentis	O
with	O
some	O
Marfan	O
syndrome	O
features	O
.	O

PS863	O
We	O
studied	O
the	O
glucose	BG
-	IG
6	IG
-	IG
phosphatase-8	IG
gene	O
of	O
30	O
unrelated	O
glycogen	O
storage	O
disease	O
type	O
Ia	O
patients	O
using	O
single	O
strand	O
conformational	O
polymorphism	O
prior	O
to	O
automated	O
sequencing	O
of	O
exons	O
revealing	O
an	O
aberrant	O
single	O
strand	O
conformational	O
polymorphism	O
pattern	O
.	O

PS864	O
We	O
studied	O
the	O
glucose	BG
-	IG
6	IG
-	IG
phosphatase-8	IG
gene	O
of	O
30	O
unrelated	O
glycogen	O
storage	O
disease	O
type	O
Ia	O
patients	O
using	O
single	O
strand	O
conformational	O
polymorphism	O
prior	O
to	O
automated	O
sequencing	O
of	O
exons	O
revealing	O
an	O
aberrant	O
single	O
strand	O
conformational	O
polymorphism	O
pattern	O
.	O

PS865	O
Muscle	O
-	O
eye	O
-	O
brain	O
disease	O
is	O
a	O
congenital	BP
muscular	IP
dystrophy-11	IP
with	O
eye	O
and	O
brain	O
involvement	O
due	O
to	O
POMGnT1-19	BG
mutations	O
.	O

PS866	O
Myotonic	BG
dystrophy	IG
type	IG
1-4	IG
is	O
a	O
multisystem	O
disorder	O
that	O
affects	O
skeletal	O
and	O
smooth	O
muscle	O
as	O
well	O
as	O
the	O
eye	O
,	O
heart	O
,	O
endocrine	O
system	O
,	O
and	O
central	O
nervous	O
system	O
.	O

PS867	O
The	O
WTX	BG
gene-3	IG
is	O
mutated	O
in	O
different	O
types	O
of	O
cancer-10	BP
,	O
and	O
it	O
remains	O
to	O
be	O
explained	O
why	O
osteopathia-19	BP
striata	O
patients	O
appear	O
not	O
to	O
have	O
an	O
increased	O
risk	O
of	O
cancer-30	BP
.	O

PS873	O
The	O
present	O
study	O
suggests	O
an	O
allele	O
dose	O
-	O
dependent	O
effect	O
of	O
JAK2-12	BG
(	O
V617F-14	BG
)	O
on	O
granulocyte	O
polycythaemia-18	BP
rubra	O
vera	O
-	O
1	O
expression	O
.	O

PS874	O
However	O
,	O
compared	O
with	O
the	O
polycythaemia	O
rubra	O
vera	O
-	O
1	O
assay	O
,	O
mutation	O
screening	O
for	O
JAK2-16	BG
(	O
V617F-18	BG
)	O
displayed	O
greater	O
accuracy	O
in	O
distinguishing	O
Polycythaemia-25	BP
vera	O
from	O
secondary	O
polycythaemia-29	BP
.	O

PS876	O
To	O
explore	O
whether	O
predisposition	O
to	O
bone	BP
marrow	IP
failure-8	IP
syndromes	O
,	O
such	O
aplastic	BP
anemia-13	IP
,	O
paroxysmal	BP
nocturnal	IP
hemoglobinuria-17	IP
and	O
myelosysplastic	O
syndromes	O
,	O
is	O
found	O
in	O
killer	BG
cell	IG
immunoglobulin	IG
-	IG
like	IG
receptor-30	IG
and	O
human	BG
leukocyte	IG
antigen-34	IG
ligand	O
gene	O
variations	O
or	O
cytokine	O
polymorphisms	O
.	O

PS877	O
We	O
studied	O
a	O
cohort	O
of	O
77	O
patients	O
with	O
anemia-9	BP
,	O
129	O
with	O
myelosysplastic	O
syndromes	O
and	O
285	O
healthy	O
controls	O
for	O
the	O
frequencies	O
of	O
killer	BG
cell	IG
immunoglobulin	IG
-	IG
like	IG
receptor	IG
-	IG
L-30	IG
and	O
killer	BG
cell	IG
immunoglobulin	IG
-	IG
like	IG
receptor-37	IG
genotypes	O
and	O
22	O
selected	O
single	O
nucleotide	O
polymorphisms	O
located	O
within	O
10	O
cytokine	O
and	O
3	O
cytokine	O
receptor	O
.	O

PS879	O
insulin	BG
-	IG
like	IG
growth	IG
factor	IG
1	IG
receptor-7	IG
haploinsufficiency	O
is	O
a	O
rare	O
event	O
causing	O
difficulties	O
in	O
defining	O
clear	O
genotype	O
-	O
phenotype	O
correlations	O
,	O
although	O
short	BP
stature-25	IP
is	O
its	O
well	O
established	O
hallmark	O
.	O

PS883	O
We	O
describe	O
the	O
first	O
case	O
of	O
prenatal	O
diagnosis	O
for	O
pyruvate	BG
kinase-11	IG
deficiency	O
in	O
Chinese	O
and	O
emphasize	O
that	O
this	O
disease	O
is	O
an	O
important	O
differential	O
diagnosis	O
in	O
pediatric	O
patients	O
with	O
non	O
-	O
spherocytic	O
hemolytic	BP
anemia-33	IP
.	O

PS884	O
A	O
Han	O
Chinese	O
child	O
with	O
a	O
history	O
of	O
severe	O
transfusion	O
-	O
dependent	O
hemolytic	BP
anemia-14	IP
was	O
diagnosed	O
to	O
have	O
pyruvate	BG
kinase-20	IG
deficiency	O
.	O

PS885	O
Severe	O
pyruvate	BG
kinase	IG
deficiency-4	IP
warranting	O
prenatal	O
diagnosis	O
is	O
seen	O
in	O
Han	O
Chinese	O
.	O

PS887	O
Deletion	O
-	O
mapping	O
analysis	O
showed	O
the	O
retention	O
of	O
the	O
distal	O
locus	O
,	O
D3S18-13	BG
,	O
in	O
one	O
of	O
the	O
renal	BP
cell	IP
carcinoma-21	IP
cell	O
lines	O
,	O
which	O
further	O
localized	O
the	O
position	O
of	O
the	O
putative	O
tumor	O
suppressor	O
gene	O
to	O
the	O
region	O
proximal	O
to	O
D3S18-41	BG
.	O

PS888	O
ARG1-1	BG
deficiency	O
usually	O
presents	O
later	O
in	O
life	O
with	O
spasticity	O
,	O
seizures-11	BP
,	O
failure	O
to	O
thrive	O
and	O
developmental	O
regression	O
.	O

PS892	O
In	O
addition	O
,	O
the	O
clinical	O
spectrum	O
of	O
seven	O
previously	O
unpublished	O
patients	O
with	O
later	O
onset	O
ARG1-15	BG
deficiency	O
,	O
who	O
also	O
experienced	O
recurrent	O
hyperammonemia-22	BP
,	O
is	O
presented	O
.	O

PS897	O
The	O
results	O
of	O
our	O
study	O
indicate	O
that	O
genetic	O
diagnosis	O
of	O
subjects	O
with	O
auditory	BP
neuropathy-14	IP
and	O
profound	O
hearing	BP
impairment-18	IP
should	O
be	O
directed	O
to	O
the	O
otoferlin	BG
gene-25	IG
.	O

PS898	O
The	O
congenital	BG
FVII	IG
deficiency-4	IP
is	O
a	O
rare	O
haemorrhagic	O
disorder	O
with	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
.	O

PS899	O
In	O
Crohn	BP
'	IP
s	IP
disease-5	IP
,	O
patients	O
with	O
haptoglobin	BG
2	IG
-	IG
1-12	IG
type	O
carried	O
a	O
higher	O
probability	O
for	O
inflammatory	O
form	O
compared	O
to	O
the	O
other	O
two	O
phenotypes	O
,	O
while	O
the	O
stricturing	O
form	O
developed	O
less	O
frequently	O
.	O

PS902	O
Two	O
affected	O
girls	O
with	O
moderate	O
and	O
severe	O
forms	O
of	O
Mucopolysaccharidosis-10	BP
type	O
II	O
with	O
normal	O
karyotypes	O
and	O
increased	O
urinary	O
dermatan	O
sulphate	O
and	O
heparin	O
sulphate	O
excretion	O
and	O
marked	O
deficiencies	O
of	O
iduronate	BG
-	IG
2	IG
-	IG
sulfatase-33	IG
activity	O
are	O
reported	O
.	O

PS905	O
To	O
determine	O
the	O
pattern	O
of	O
deletions	O
of	O
the	O
dystrophin	BG
gene-10	IG
,	O
the	O
major	O
class	O
of	O
mutations	O
among	O
the	O
Duchenne	O
and	O
Becker	O
muscular	BP
dystrophy-23	IP
patients	O
of	O
eastern	O
India	O
and	O
to	O
analyze	O
the	O
carrier	O
frequency	O
of	O
the	O
female	O
members	O
of	O
the	O
proband	O
'	O
s	O
family	O
.	O

PS911	O
Retrospective	O
analysis	O
of	O
patients	O
with	O
Carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-9	IP
has	O
made	O
it	O
possible	O
to	O
correlate	O
the	O
presence	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
the	O
CPT2	BG
gene-26	IG
with	O
residual	O
CPT-29	BG
activity	O
in	O
muscle	O
.	O

PS912	O
We	O
present	O
evidence	O
that	O
the	O
ratio	O
of	O
Carnitine	BG
palmitoyltransferase	IG
II-10	IG
activity	O
to	O
citrate	BG
synthase-14	IG
activity	O
in	O
the	O
skeletal	O
muscle	O
of	O
patients	O
presumed	O
to	O
have	O
Carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-28	IP
is	O
important	O
for	O
predicting	O
whether	O
the	O
patient	O
has	O
one	O
,	O
two	O
,	O
or	O
no	O
mutations	O
in	O
the	O
CPT2	BG
gene-47	IG
.	O

PS914	O
One	O
hundred	O
and	O
one	O
subjects	O
(	O
82	O
normal	O
histology	O
/	O
chronic	O
gastritis	O
,	O
17	O
atrophic	O
gastritis	O
,	O
two	O
gastric	BP
cancer-20	IP
)	O
showed	O
a	O
pepsinogen	BG
phenotype-25	IG
with	O
presence	O
of	O
pepsinogen	BG
A3-30	IG
and	O
a	O
corresponding	O
pepsinogen	BG
genotype-35	IG
with	O
presence	O
of	O
pepsinogen	BG
A3	IG
encoding	IG
genes-42	IG
.	O

PS915	O
In	O
39	O
of	O
them	O
(	O
23	O
normal	O
histology	O
/	O
chronic	O
gastritis	O
,	O
11	O
atrophic	O
gastritis	O
,	O
five	O
gastric	BP
cancer-19	IP
)	O
,	O
a	O
corresponding	O
genotype	O
without	O
pepsinogen	BG
A3	IG
encoding	IG
genes-29	IG
was	O
found	O
.	O

PS920	O
These	O
findings	O
suggest	O
that	O
,	O
besides	O
the	O
L	BG
-	IG
ferritin	IG
iron	IG
regulatory	IG
element	IG
genotype-14	IG
,	O
additional	O
factors	O
are	O
likely	O
to	O
modulate	O
the	O
lens	O
involvement	O
and	O
the	O
rate	O
of	O
progression	O
to	O
severe	O
cataract-32	BP
in	O
Hereditary	O
hyperferritinemia	BP
-	IP
cataract	IP
syndrome-38	IP
patients	O
.	O

PS923	O
However	O
,	O
the	O
phenotypic	O
frequency	O
of	O
tumor	BG
necrosis	IG
factorb6-9	IG
was	O
significantly	O
higher	O
in	O
rheumatoid	BP
arthritis-15	IP
patients	O
than	O
in	O
controls	O
in	O
the	O
presence	O
of	O
HLA	BG
-	IG
DR4-26	IG
.	O

PS926	O
The	O
associations	O
of	O
tumor	BG
necrosis	IG
factor-6	IG
microsatellites	O
with	O
the	O
susceptibility	O
to	O
rheumatoid	BP
arthritis-13	IP
in	O
Taiwan	O
are	O
not	O
completely	O
independent	O
of	O
the	O
HLA	BG
-	IG
DR-24	IG
associations	O
.	O

PS930	O
The	O
tumor	BG
necrosis	IG
factor	IG
microsatellite	IG
alleles-6	IG
are	O
not	O
related	O
to	O
the	O
clinical	O
manifestations	O
and	O
severity	O
of	O
rheumatoid	BP
arthritis-18	IP
patients	O
in	O
Taiwan	O
.	O

PS931	O
The	O
exons	O
3	O
to	O
26	O
of	O
MYH7-7	BG
were	O
amplified	O
by	O
PCR	O
,	O
and	O
the	O
PCR	O
products	O
were	O
sequenced	O
in	O
five	O
non	O
-	O
kin	O
Hypertrophic	BP
cardiomyopathy-25	IP
patients	O
.	O

PS932	O
To	O
analyse	O
the	O
mutational	O
spectrum	O
,	O
the	O
associated	O
haplotypes	O
and	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
and	O
to	O
design	O
a	O
reliable	O
and	O
rational	O
approach	O
for	O
CYP21	BG
mutation-27	IG
detection	O
in	O
Slovenian	O
congenital	BP
adrenal	IP
hyperplasia-33	IP
patients	O
.	O

PS933	O
Molecular	O
analysis	O
of	O
the	O
CYP21	BG
gene-6	IG
was	O
performed	O
in	O
36	O
congenital	BP
adrenal	IP
hyperplasia-13	IP
patients	O
and	O
79	O
family	O
members	O
.	O

PS934	O
In	O
two	O
siblings	O
with	O
a	O
salt	O
wasting	O
form	O
of	O
congenital	BP
adrenal	IP
hyperplasia-12	IP
,	O
a	O
novel	O
mutation	O
Ala15Thr	O
was	O
found	O
on	O
the	O
allele	O
characterised	O
by	O
Pro30Leu-25	BG
mutation	O
and	O
gene	O
conversion	O
involving	O
the	O
promoter	O
region	O
.	O

PS935	O
In	O
order	O
to	O
examine	O
the	O
phenotypic	O
variability	O
in	O
nevoid	O
basal	BP
cell	IP
carcinoma-12	IP
syndrome	O
and	O
to	O
highlight	O
functionally	O
important	O
domains	O
of	O
the	O
PTCH	BG
protein-23	IG
,	O
we	O
have	O
now	O
screened	O
71	O
unrelated	O
nevoid	O
basal	BP
cell	IP
carcinoma-34	IP
syndrome	O
individuals	O
for	O
mutations	O
in	O
the	O
PTCH	O
exons	O
.	O

PS938	O
We	O
reviewed	O
250	O
cases	O
of	O
patients	O
with	O
phenylalanine	BG
hydroxylase	IG
deficiency-10	IP
,	O
using	O
published	O
data	O
from	O
198	O
cases	O
and	O
unpublished	O
data	O
from	O
52	O
cases	O
of	O
patients	O
attending	O
our	O
own	O
clinic	O
.	O

PS940	O
Our	O
objective	O
was	O
to	O
study	O
the	O
gene	O
mutation	O
,	O
expression	O
of	O
HRPT2-12	BG
and	O
the	O
clinical	O
outcome	O
after	O
32	O
years	O
of	O
follow	O
-	O
up	O
in	O
one	O
Brazilian	O
kindred	O
with	O
familial	O
isolated	O
hyperparathyroidism-31	BP
.	O

PS941	O
We	O
concluded	O
that	O
it	O
is	O
necessary	O
to	O
individualize	O
the	O
surgical	O
approach	O
for	O
HRPT2-13	BG
-	O
related	O
hyperparathyroidism-16	BP
until	O
we	O
can	O
gather	O
a	O
better	O
phenotype	O
-	O
genotype	O
correlation	O
in	O
larger	O
series	O
,	O
to	O
best	O
define	O
their	O
treatment	O
.	O

PS942	O
Heterozygotes	O
for	O
the	O
mutant	BG
Fbn1	IG
allele-6	IG
mgdeltaloxPneo	O
,	O
carrying	O
the	O
same	O
internal	O
deletion	O
of	O
exons	O
19	O
-	O
24	O
as	O
the	O
mgdelta	O
mouse	O
model	O
,	O
present	O
defective	O
microfibrillar	O
deposition	O
,	O
emphysema-30	BP
,	O
deterioration	O
of	O
aortic	O
wall	O
and	O
kyphosis-37	BP
.	O

PS943	O
Investigation	O
of	O
autoimmune	O
manifestations	O
associated	O
with	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
has	O
shown	O
that	O
autoimmune	O
hemolytic	BP
anemia-16	IP
and	O
elevated	O
serum	O
IgM-20	BG
associate	O
with	O
a	O
more	O
severe	O
clinical	O
course	O
.	O

PS945	O
Using	O
current	O
-	O
clamp	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
Q10R-12	BG
induces	O
hyperexcitability	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
,	O
but	O
produces	O
an	O
increase	O
in	O
excitability	O
that	O
is	O
smaller	O
than	O
the	O
change	O
produced	O
by	O
I848T	O
,	O
an	O
early	O
-	O
onset	O
erythromelalgia-41	BP
mutation	O
.	O

PS946	O
In	O
this	O
study	O
the	O
relationship	O
among	O
genotype	O
,	O
glycolipid	BP
substrates-10	IP
,	O
lysosomal	BG
proteins-13	IG
,	O
and	O
the	O
clinical	O
manifestations	O
of	O
Gaucher	O
disease	O
has	O
been	O
evaluated	O
.	O

PS950	O
The	O
highest	O
sensitivity	O
to	O
correctly	O
predict	O
the	O
true	O
spinocerebellar	BP
ataxia-10	IP
type	O
was	O
found	O
for	O
spinocerebellar	BG
ataxia5-16	IG
,	O
spinocerebellar	BG
ataxia7-19	IG
,	O
and	O
spinocerebellar	O
ataxia8	O
.	O

PS951	O
PRPF31-1	BG
is	O
one	O
of	O
four	O
pre	O
-	O
mRNA	O
splicing	O
factors	O
identified	O
as	O
causing	O
autosomal	O
dominant	O
retinitis	O
pigmentosa-17	BP
,	O
with	O
incomplete	O
penetrance	O
being	O
the	O
unique	O
feature	O
associated	O
with	O
mutations	O
in	O
this	O
gene	O
.	O

PS952	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
PRPF31-9	BG
mutations	O
in	O
a	O
cohort	O
of	O
118	O
cases	O
of	O
autosomal	O
dominant	O
retinitis	O
pigmentosa-21	BP
and	O
determine	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
emerging	O
from	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
.	O

PS960	O
We	O
genotyped	O
12	O
tagging	O
and	O
potentially	O
functional	O
single	O
nucleotide	O
polymorphisms	O
of	O
Xeroderma	BG
pigmentosum	IG
group	IG
G-15	IG
/	O
ERCC5-17	BG
in	O
a	O
case	O
-	O
control	O
study	O
of	O
1059	O
non	O
-	O
Hispanic	O
white	O
patients	O
with	O
squamous	BP
cell	IP
carcinoma-34	IP
of	O
the	O
head	O
and	O
neck	O
and	O
1066	O
cancer	O
-	O
free	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
,	O
and	O
evaluated	O
their	O
associations	O
with	O
the	O
risk	O
of	O
squamous	BP
cell	IP
carcinoma-63	IP
of	O
the	O
head	O
and	O
neck	O
.	O

PS962	O
In	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
analysis	O
using	O
peripheral	O
lymphocytes	O
from	O
44	O
patients	O
with	O
squamous	BP
cell	IP
carcinoma-17	IP
of	O
the	O
head	O
and	O
neck	O
,	O
we	O
found	O
that	O
rs4150351	BG
AC	IG
/	IG
CC-30	IG
was	O
associated	O
with	O
a	O
statistically	O
significant	O
increase	O
in	O
the	O
Xeroderma	BG
pigmentosum	IG
group	IG
G	IG
/	IG
ERCC5	IG
mRNA-46	IG
expression	O
.	O

PS967	O
One	O
criterion	O
of	O
Cleidocranial	O
dysplasia	O
,	O
short	BP
stature-8	IP
,	O
was	O
much	O
milder	O
in	O
the	O
patients	O
with	O
the	O
intact	O
Runt	BG
domain-20	IG
than	O
in	O
those	O
without	O
.	O

PS968	O
Obesity-1	BP
and	O
insulin	BG
resistance-4	IP
,	O
the	O
cardinal	O
features	O
of	O
metabolic	O
syndrome	O
,	O
are	O
closely	O
associated	O
with	O
a	O
state	O
of	O
low	O
-	O
grade	O
inflammation	O
.	O

PS969	O
In	O
adipose	O
tissue	O
chronic	O
overnutrition	O
leads	O
to	O
macrophage	O
infiltration	O
,	O
resulting	O
in	O
local	O
inflammation	O
that	O
potentiates	O
insulin	BG
resistance-18	IP
.	O

PS970	O
For	O
instance	O
,	O
transgenic	O
expression	O
of	O
Mcp1-7	BG
(	O
also	O
known	O
as	O
chemokine	BG
ligand	IG
2-14	IG
,	O
Ccl2-16	BG
)	O
in	O
adipose	O
tissue	O
increases	O
macrophage	O
infiltration	O
,	O
inflammation	O
and	O
insulin	BG
resistance-28	IP
.	O

PS971	O
These	O
findings	O
together	O
suggest	O
a	O
correlation	O
between	O
macrophage	O
content	O
in	O
adipose	O
tissue	O
and	O
insulin	BG
resistance-15	IP
.	O

PS972	O
Despite	O
their	O
higher	O
capacity	O
to	O
repair	O
tissue	O
,	O
the	O
precise	O
role	O
of	O
alternatively	O
activated	O
macrophages	O
in	O
obesity	O
-	O
induced	O
insulin	BG
resistance-21	IP
remains	O
unknown	O
.	O

PS976	O
We	O
also	O
found	O
that	O
vervet	O
monkeys	O
had	O
the	O
transthyretin	BG
Ile122	IG
allele-11	IG
,	O
which	O
is	O
well	O
known	O
as	O
a	O
frequent	O
mutation	O
-	O
causing	O
human	BG
transthyretin	IG
amyloidosis-25	IG
.	O

PS977	O
The	O
nearly	O
normal	O
height	O
of	O
this	O
patient	O
could	O
be	O
explained	O
by	O
a	O
combination	O
of	O
trisomy	O
of	O
the	O
Xp	BG
-	IG
located	IG
SHOX	IG
gene-22	IG
and	O
mosaicism-24	BP
with	O
a	O
45	O
,	O
X	O
cell	O
line	O
.	O

PS978	O
Molecular	O
studies	O
of	O
cystic	BP
fibrosis-5	IP
have	O
allowed	O
the	O
genetic	O
analysis	O
of	O
patients	O
by	O
means	O
of	O
DNA	O
markers	O
and	O
the	O
direct	O
analysis	O
of	O
the	O
cystic	BG
fibrosis	IG
gene-26	IG
.	O

PS980	O
The	O
beta	BG
-	IG
myosin	IG
heavy	IG
chain	IG
,	IG
cardiac	IG
troponin	IG
T-10	IG
and	O
myosin	BG
binding	IG
protein	IG
-	IG
C-16	IG
are	O
the	O
most	O
common	O
genes	O
accounting	O
for	O
approximately	O
2	O
/	O
3	O
of	O
all	O
Hypertrophic	BP
cardiomyopathy-31	IP
cases	O
.	O

PS984	O
In	O
addition	O
,	O
crumbs	BG
homologue	IG
1	IG
mutations-7	IG
were	O
detected	O
in	O
five	O
of	O
nine	O
patients	O
who	O
had	O
retinitis	BP
pigmentosa-18	IP
with	O
Coats	O
-	O
like	O
exudative	O
vasculopathy-24	BP
,	O
a	O
relatively	O
rare	O
complication	O
of	O
retinitis	BP
pigmentosa-32	IP
that	O
may	O
progress	O
to	O
partial	O
or	O
total	O
retinal	BP
detachment-41	IP
.	O

PS985	O
Given	O
that	O
four	O
of	O
five	O
patients	O
had	O
developed	O
the	O
complication	O
in	O
one	O
eye	O
and	O
that	O
not	O
all	O
siblings	O
with	O
retinitis	BP
pigmentosa-21	IP
have	O
the	O
complication	O
,	O
crumbs	BG
homologue	IG
1	IG
mutations-29	IG
should	O
be	O
considered	O
an	O
important	O
risk	O
factor	O
for	O
the	O
Coats	O
-	O
like	O
reaction	O
,	O
although	O
its	O
development	O
may	O
require	O
additional	O
genetic	O
or	O
environmental	O
factors	O
.	O

PS988	O
In	O
addition	O
,	O
crumbs	BG
homologue	IG
1	IG
mutations-7	IG
were	O
detected	O
in	O
five	O
of	O
nine	O
patients	O
who	O
had	O
retinitis	BP
pigmentosa-18	IP
with	O
Coats	O
-	O
like	O
exudative	O
vasculopathy-24	BP
,	O
a	O
relatively	O
rare	O
complication	O
of	O
retinitis	BP
pigmentosa-32	IP
that	O
may	O
progress	O
to	O
partial	O
or	O
total	O
retinal	BP
detachment-41	IP
.	O

PS989	O
Given	O
that	O
four	O
of	O
five	O
patients	O
had	O
developed	O
the	O
complication	O
in	O
one	O
eye	O
and	O
that	O
not	O
all	O
siblings	O
with	O
retinitis	BP
pigmentosa-21	IP
have	O
the	O
complication	O
,	O
crumbs	BG
homologue	IG
1	IG
mutations-29	IG
should	O
be	O
considered	O
an	O
important	O
risk	O
factor	O
for	O
the	O
Coats	O
-	O
like	O
reaction	O
,	O
although	O
its	O
development	O
may	O
require	O
additional	O
genetic	O
or	O
environmental	O
factors	O
.	O

PS991	O
Pain	O
characteristics	O
were	O
examined	O
in	O
24	O
patients	O
with	O
myophosphorylase	BG
deficiency-10	IP
(	O
McArdle	O
'	O
s	O
disease	O
)	O
.	O

PS993	O
Although	O
perforin	BG
gene-3	IG
mutations	O
have	O
been	O
described	O
in	O
a	O
proportion	O
of	O
patients	O
with	O
Familial	O
hemophagocytic	O
lymphohistiocytosis-16	BP
,	O
the	O
genotype	O
/	O
phenotype	O
correlation	O
is	O
still	O
limited	O
.	O

PS994	O
We	O
report	O
on	O
a	O
family	O
in	O
which	O
2	O
fraternal	O
twins	O
both	O
homozygous	O
for	O
a	O
perforin-15	BG
mutation	O
previously	O
described	O
as	O
causative	O
of	O
the	O
disease	O
,	O
markedly	O
differed	O
in	O
phenotypic	O
expression	O
of	O
Familial	O
hemophagocytic	O
lymphohistiocytosis-33	BP
.	O

PS995	O
Sixteen	O
patients	O
from	O
nine	O
Chinese	O
families	O
with	O
spinocerebellar	BP
ataxia-9	IP
type	O
2	O
were	O
heterozygous	O
for	O
a	O
CAG	O
repeat	O
expansion	O
in	O
the	O
spinocerebellar	BG
ataxia	IG
type	IG
2	IG
gene-25	IG
containing	O
37	O
to	O
56	O
repeats	O
,	O
whereas	O
the	O
normal	O
alleles	O
carried	O
14	O
to	O
28	O
repeats	O
.	O

PS996	O
L	O
-	O
thyroxine	O
(	O
T4	O
)	O
,	O
the	O
most	O
widely	O
used	O
drug	O
for	O
hypothyroidism-14	BP
,	O
undergoes	O
glucuronidation	O
by	O
UDP	BG
-	IG
glucuronosyltransferases-21	IG
.	O

PS998	O
A	O
further	O
study	O
with	O
larger	O
sample	O
size	O
including	O
assessment	O
of	O
vitamin	O
status	O
is	O
needed	O
to	O
better	O
clarify	O
the	O
relationship	O
between	O
methylene	BG
tetrahydrofolate	IG
reductase-23	IG
genotypes	O
and	O
coronary	BP
artery	IP
disease-28	IP
.	O

PS1001	O
PATIENTS	O
AND	O
METHODS	O
We	O
first	O
resequenced	O
the	O
full	O
-	O
length	O
HSPB1	BG
gene-12	IG
and	O
then	O
genotyped	O
three	O
selected	O
tag	O
single	O
nucleotide	O
polymorphisms	O
in	O
1	O
,	O
152	O
paired	O
Chinese	O
lung	BP
cancer-29	IP
patient	O
cases	O
and	O
controls	O
.	O

PS1003	O
Besides	O
being	O
a	O
major	O
target	O
of	O
anti	BG
-	IG
neutrophil	IG
cytoplasm	IG
antibodies-11	IG
,	O
previous	O
findings	O
have	O
shown	O
increased	O
circulating	O
levels	O
of	O
proteinase	O
3	O
in	O
vasculitis-24	BP
patients	O
,	O
increased	O
levels	O
of	O
neutrophil	O
membrane	O
-	O
proteinase	O
3	O
expression	O
and	O
a	O
skewed	O
distribution	O
of	O
the	O
-	O
564	O
A	O
/	O
G	O
polymorphism	O
in	O
the	O
promotor	O
region	O
of	O
the	O
proteinase	BG
3	IG
gene-56	IG
.	O

PS1006	O
METHODS	O
:	O
The	O
cytochrome	BG
P450	IG
2D6	IG
genotype-7	IG
was	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
previously	O
untreated	O
patients	O
with	O
hormone	O
receptor	O
-	O
positive	O
invasive	O
breast	BP
cancer-25	IP
considered	O
to	O
receive	O
antihormonal	O
therapy	O
.	O

PS1007	O
To	O
determine	O
if	O
genetic	O
variation	O
influences	O
bone	O
mineral	O
density	O
and	O
thus	O
can	O
be	O
a	O
determinanucleotides	O
of	O
susceptibility	O
to	O
osteoporosis-19	BP
in	O
older	O
women	O
,	O
we	O
examined	O
the	O
association	O
of	O
bone	O
mineral	O
density	O
with	O
the	O
osteocalcin	BG
genotypes-35	IG
found	O
in	O
the	O
presenucleotides	O
study	O
.	O

PS1011	O
Considering	O
the	O
different	O
diagnostic	O
circumstances	O
,	O
therapeutic	O
strategies	O
and	O
the	O
limitations	O
of	O
a	O
systematic	O
analysis	O
of	O
case	O
reports	O
due	O
to	O
the	O
restricted	O
number	O
of	O
case	O
reports	O
and	O
limited	O
follow	O
-	O
up	O
we	O
found	O
no	O
consistent	O
relation	O
of	O
the	O
TSH	BG
receptor-40	IG
mutation	O
'	O
s	O
in	O
vitro	O
activity	O
determined	O
by	O
linear	O
regression	O
analysis	O
with	O
the	O
clinical	O
course	O
of	O
patients	O
with	O
sporadic	O
non	O
-	O
autoimmune	BP
hyperthyroidism-63	IP
.	O

PS1013	O
The	O
novel	O
mutation	O
,	O
R124S	O
,	O
is	O
at	O
the	O
identical	O
position	O
to	O
the	O
mutation	O
causing	O
lattice	BG
corneal	IG
dystrophy	IG
type	IG
I-20	IG
(	O
CDL1-22	BG
)	O
.	O

PS1016	O
In	O
an	O
attempt	O
to	O
clarify	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Achondroplasia-11	BP
and	O
hypochondroplasia-13	BP
,	O
we	O
investigated	O
the	O
presence	O
of	O
the	O
previously	O
identified	O
mutations	O
of	O
FGFR3-25	BG
in	O
26	O
patients	O
with	O
Achondroplasia	O
-	O
or	O
hypochondroplasia	O
-	O
mimicking	O
features	O
and	O
compared	O
clinical	O
and	O
radiographic	O
findings	O
between	O
the	O
two	O
groups	O
.	O

PS1017	O
This	O
report	O
describes	O
the	O
relationships	O
between	O
tau	O
markers	O
in	O
the	O
cerebrospinal	O
fluid	O
,	O
the	O
degree	O
of	O
cognitive	BP
impairment-18	IP
and	O
the	O
predictive	O
value	O
of	O
genetic	O
markers	O
such	O
the	O
alleles	O
of	O
apolipoprotein	BG
E-31	IG
,	O
namely	O
,	O
the	O
presence	O
of	O
Apo	BG
-	IG
epsilon4-40	IG
,	O
as	O
part	O
of	O
a	O
longitudinal	O
study	O
.	O

PS1020	O
Studies	O
indicate	O
that	O
hyperphosphorylated	O
tau	O
is	O
a	O
good	O
indicator	O
of	O
the	O
degree	O
of	O
cognitive	BP
disorders-15	IP
in	O
early	O
stages	O
of	O
Alzheimer	O
'	O
s	O
disease	O
patients	O
and	O
that	O
no	O
clear	O
correlation	O
exists	O
with	O
the	O
epsilon4-33	BG
/	O
epsilon4-35	BG
and	O
epsilon3-37	BG
/	O
epsilon4-39	BG
genotypes	O
,	O
even	O
though	O
a	O
higher	O
proportion	O
of	O
epsilon4	BG
allele-49	IG
in	O
the	O
mild	O
cognitive	BP
impairment-54	IP
group	O
with	O
a	O
more	O
significant	O
level	O
of	O
impairment	O
and	O
in	O
Alzheimer	O
'	O
s	O
disease	O
patients	O
patients	O
was	O
evidenced	O
.	O

PS1022	O
Mucopolysaccharidosis-1	BP
IVA	O
,	O
a	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
N	BG
-	IG
acetylgalactosamine	IG
-	IG
6	IG
-	IG
sulfate	IG
sulfatase-20	IG
(	O
GALNS-22	BG
)	O
,	O
has	O
variable	O
clinical	O
phenotypes	O
.	O

PS1024	O
Blepharophimosis-1	BP
syndrome	O
,	O
an	O
autosomal	O
dominant	O
syndrome	O
in	O
which	O
an	O
eyelid	O
malformation	O
is	O
associated	O
(	O
type	O
I	O
)	O
or	O
not	O
(	O
type	O
II	O
)	O
with	O
premature	BP
ovarian	IP
failure-28	IP
,	O
has	O
recently	O
been	O
ascribed	O
to	O
mutations	O
in	O
FOXL2-37	BG
,	O
a	O
putative	O
forkhead	BG
transcription	IG
factor	IG
gene-44	IG
.	O

PS1025	O
Blepharophimosis-1	BP
syndrome	O
,	O
an	O
autosomal	O
dominant	O
syndrome	O
in	O
which	O
an	O
eyelid	O
malformation	O
is	O
associated	O
(	O
type	O
I	O
)	O
or	O
not	O
(	O
type	O
II	O
)	O
with	O
premature	BP
ovarian	IP
failure-28	IP
,	O
has	O
recently	O
been	O
ascribed	O
to	O
mutations	O
in	O
FOXL2-37	BG
,	O
a	O
putative	O
forkhead	BG
transcription	IG
factor	IG
gene-44	IG
.	O

PS1026	O
The	O
four	O
patients	O
with	O
congenital	BP
cataracts-6	IP
all	O
had	O
mutations	O
in	O
the	O
C	O
-	O
terminal	O
proline	O
-	O
serine	O
-	O
threonine	O
-	O
rich	O
domain	O
of	O
the	O
PAX6	BG
protein-26	IG
.	O

PS1032	O
Our	O
study	O
presents	O
the	O
first	O
epidemiologic	O
evidence	O
that	O
ATM	BG
genetic	IG
variants-11	IG
may	O
affect	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer-20	BP
predisposition	O
,	O
and	O
that	O
the	O
risk	O
-	O
conferring	O
variants	O
might	O
act	O
through	O
down	O
-	O
regulating	O
the	O
functions	O
of	O
ATM	O
in	O
DNA	O
repair	O
activity	O
upon	O
genetic	O
insults	O
such	O
as	O
ionizing	O
radiation	O
.	O

PS1035	O
Germline	O
mutations	O
in	O
the	O
MADH4-5	BG
or	O
BMPR1A	BG
genes-8	IG
have	O
been	O
found	O
to	O
be	O
causative	O
of	O
the	O
disease	O
in	O
a	O
subset	O
of	O
Juvenile	BP
polyposis-23	IP
syndrome	O
patients	O
.	O

PS1036	O
The	O
T	BG
locus-3	IG
on	O
mouse	O
chromosome	O
17	O
is	O
haploid	O
-	O
insufficient	O
:	O
deletion	O
/	O
+	O
heterozygous	O
mice	O
have	O
a	O
short	BP
tail-21	IP
.	O

PS1037	O
By	O
immunohistochemical	O
analysis	O
,	O
the	O
liver	O
lymphoid	O
nodules	O
contained	O
predominantly	O
B	O
cells	O
with	O
a	O
CD5	BG
+-16	IG
/	O
bcl2-18	BG
+	O
/	O
Ki67-21	BG
-	O
phenotype	O
,	O
which	O
were	O
always	O
polyclonal	O
in	O
type	O
III	O
mixed	BP
cryoglobulinemia-33	IP
and	O
chronic	O
hepatitis	O
C	O
,	O
and	O
monoclonal	O
in	O
type	O
II	O
mixed	O
cryoglobulinemia-45	BP
.	O

PS1040	O
We	O
reviewed	O
the	O
pertinent	O
literature	O
on	O
hereditary	O
paragangliomas-8	BP
,	O
which	O
showed	O
the	O
established	O
classification	O
of	O
types	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
4	O
paraganglioma-25	BP
syndrome	O
(	O
PGL1-28	BG
,	O
PGL2-30	BG
,	O
PGL3-32	BG
,	O
and	O
PGL4-35	BG
,	O
respectively	O
)	O
.	O

PS1044	O
The	O
genotype	O
-	O
phenotype	O
relationship	O
of	O
compound	O
heterozygous	O
factor	BG
X-10	IG
deficiency	O
in	O
a	O
young	O
girl	O
with	O
severe	O
factor	BG
X	IG
deficiency-20	IP
and	O
bleeding	O
symptoms	O
is	O
characterized	O
.	O

PS1045	O
Therapeutic	O
options	O
for	O
patients	O
with	O
symptomatic	O
factor	BG
X	IG
deficiency-9	IP
are	O
demonstrated	O
.	O

PS1046	O
Males	O
with	O
MECP2-3	BG
mutations	O
present	O
with	O
a	O
broad	O
spectrum	O
of	O
phenotypes	O
ranging	O
from	O
neonatal	BP
encephalopathy-15	IP
to	O
nonsyndromic	O
mental	BP
retardation-19	IP
.	O

PS1048	O
Identifying	O
and	O
characterizing	O
the	O
RET	BG
proto	IG
-	IG
oncogene-8	IG
as	O
the	O
disease	O
-	O
causing	O
gene	O
for	O
hereditary	O
medullary	O
thyroid	BP
carcinoma-19	IP
and	O
then	O
establishing	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
served	O
as	O
the	O
prerequisite	O
for	O
the	O
risk	O
-	O
adapted	O
prophylactic	O
surgical	O
approach	O
practised	O
today	O
.	O

PS1053	O
We	O
have	O
evaluated	O
its	O
role	O
in	O
both	O
initiation	O
and	O
/	O
or	O
progression	O
of	O
primary	O
immunoglobulin	BG
A-16	IG
nephropathy-17	BP
(	O
IGAN	O
)	O
in	O
a	O
case	O
-	O
control	O
study	O
involving	O
a	O
probeta	O
/	O
standard	O
errortive	O
cohort	O
of	O
318	O
IGAN	O
patients	O
and	O
a	O
matched	O
group	O
of	O
294	O
controls	O
.	O

PS1054	O
The	O
d32	BG
-	IG
CCR5-4	IG
polymorphism	O
played	O
a	O
significant	O
role	O
in	O
the	O
progression	O
of	O
primary	O
IGAN	O
,	O
with	O
the	O
normal	O
allele	O
/	O
normal	O
allele	O
genotype	O
being	O
an	O
independent	O
protective	O
factor	O
for	O
late	O
progression	O
towardbeta	O
/	O
standard	O
errord	O
-	O
stage	O
renal	BP
failure-40	IP
/	O
dialysis	O
.	O

PS1055	O
have	O
been	O
shown	O
to	O
be	O
genetically	O
linked	O
to	O
lipid	O
metabolism	O
or	O
insulin	BG
sensitivity-13	IP
.	O

PS1056	O
A	O
26	O
-	O
year	O
-	O
old	O
woman	O
with	O
mild	O
DM	O
-	O
epidermolysis	O
bullosa	O
simplex	O
with	O
prominent	O
palmoplantar	BP
hyperkeratosis-18	IP
and	O
without	O
active	O
blister	O
formation	O
had	O
a	O
novel	O
R125G	BG
mutation-28	IG
in	O
keratin	O
14	O
.	O

PS1057	O
The	O
patients	O
with	O
PTPN11	BG
mutations-5	IG
showed	O
higher	O
prevalences	O
of	O
patent	O
ductus	O
arteriosus	O
and	O
thrombocytopenia-14	BP
.	O

PS1058	O
The	O
patients	O
with	O
SOS1-4	BG
mutations	O
had	O
a	O
lower	O
prevalence	O
of	O
delayed	BP
psychomotor	IP
development-13	IP
.	O

PS1059	O
All	O
patients	O
with	O
RAF1-4	BG
mutations	O
had	O
hypertrophic	BP
cardiomyopathy-8	IP
.	O

PS1066	O
This	O
first	O
report	O
on	O
transporters	O
associated	O
with	O
antigen	O
processing	O
and	O
HPA	BG
gene-12	IG
polymorphism	O
in	O
dengue	O
suggested	O
that	O
the	O
heterozygous	O
pattern	O
at	O
the	O
transporters	O
associated	O
with	O
antigen	BG
processing1	IG
333	IG
locus-29	IG
and	O
HPA1a	BG
/	IG
1a-33	IG
and	O
HPA2a	BG
/	IG
2b-37	IG
genotypes	O
confer	O
susceptibility	O
to	O
dengue	O
hemorrhagic	O
fever-44	BP
and	O
the	O
HPA1a	BG
/	IG
1b	IG
genotype-50	IG
was	O
determined	O
to	O
be	O
a	O
genetic	O
risk	O
factor	O
for	O
dengue	O
shock	O
syndrome	O
.	O

PS1068	O
The	O
results	O
also	O
indicated	O
that	O
Sotos	O
syndrome	O
due	O
to	O
a	O
deletion	O
falls-12	BP
into	O
a	O
contiguous	O
gene	O
syndrome	O
,	O
while	O
Sotos	O
syndrome	O
due	O
to	O
an	O
NSD1-25	BG
point	O
mutation	O
is	O
a	O
single	O
gene	O
defect	O
,	O
occasionally	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
.	O

PS1071	O
Several	O
rare	O
disorders	O
,	O
such	O
as	O
LCAT-7	BG
and	O
LPL	BG
deficiency-10	IP
,	O
as	O
well	O
as	O
liver	O
diseases	O
and	O
abetalipoproteinemia	O
are	O
associated	O
with	O
low	O
plasma	O
levels	O
or	O
lack	O
of	O
Lp	BG
(	IG
a	IG
)-31	IG
.	O

PS1073	O
Isolated	O
methylmalonic	BP
acidemia-3	IP
is	O
a	O
genetically	O
heterogeneous	O
organic	O
acid	O
disorder	O
caused	O
by	O
either	O
deficiency	O
of	O
the	O
enzyme	O
methylmalonyl	O
-	O
CoA	O
mutase	O
,	O
or	O
a	O
defect	O
in	O
the	O
biosynthesis	O
of	O
its	O
cofactor	O
,	O
adenosyl	BG
-	IG
cobalamin-35	IG
.	O

PS1074	O
We	O
confirm	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
isolated	O
methylmalonic	BP
acidemia-11	IP
in	O
the	O
study	O
population	O
,	O
and	O
identified	O
a	O
new	O
molecular	O
basis	O
of	O
the	O
cblB	BG
disorder-26	IG
.	O

PS1079	O
The	O
family	O
with	O
the	O
Pro370Leu	BG
myocilin-6	IG
mutation	O
presents	O
with	O
juvenile	O
-	O
onset	O
glaucoma-13	BP
.	O

PS1082	O
PAX6	BG
haploinsufficiency-2	IP
,	O
the	O
major	O
cause	O
of	O
classic	O
hereditary	O
aniridia	O
worldwide	O
,	O
is	O
also	O
associated	O
with	O
the	O
phenotype	O
in	O
two	O
different	O
families	O
from	O
the	O
Arabian	O
Peninsula	O
.	O

PS1085	O
The	O
frequency	O
of	O
lipoprotein	BG
lipase	IG
gene-6	IG
mutation	O
rates	O
in	O
hyperlipidemic	O
pancreatitis-11	BP
patients	O
was	O
significantly	O
higher	O
than	O
that	O
without	O
hyperlipidemic	BP
pancreatitis-20	IP
attack	O
.	O

PS1087	O
Multivariate	O
analysis	O
in	O
hyperlipidemic	BP
pancreatitis-5	IP
patients	O
indicated	O
that	O
the	O
presence	O
of	O
lipoprotein	BG
lipase-13	IG
mutation	O
and	O
episode	O
of	O
acute	O
attack	O
were	O
independent	O
risks	O
for	O
pancreatic	BP
calcification-25	IP
and	O
steatorrhea	O
.	O

PS1090	O
In	O
addition	O
,	O
mutations	O
in	O
gene	O
coding	O
for	O
the	O
gamma	O
subunit	O
of	O
AMP	BG
-	IG
activated	IG
protein	IG
kinase-17	IG
and	O
triplet	O
-	O
repeat	O
syndromes	O
,	O
as	O
well	O
as	O
in	O
mitochondrial	O
DNA	O
have	O
been	O
identified	O
in	O
patients	O
with	O
hypertrophic	BP
cardiomyopathy-37	IP
.	O

PS1091	O
Mutations	O
in	O
genes	O
coding	O
for	O
the	O
beta	BG
-	IG
myosin	IG
heavy	IG
chain-11	IG
,	O
myosin	BG
binding	IG
protein	IG
-	IG
C	IG
,	IG
and	IG
cardiac	IG
troponin	IG
T-22	IG
account	O
for	O
approximately	O
2	O
/	O
3	O
of	O
all	O
hypertrophic	BP
cardiomyopathy-32	IP
cases	O
.	O

PS1092	O
The	O
patient	O
carrying	O
a	O
truncating	O
mutation	O
of	O
Cx43-8	BG
did	O
not	O
have	O
palmoplantar	O
keratoderma-13	BP
,	O
in	O
contradiction	O
with	O
the	O
previously	O
suggested	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
truncating	O
mutation	O
and	O
skin	O
involvement	O
.	O

PS1096	O
Mutations	O
in	O
C	O
-	O
terminal	O
titin-6	BG
cause	O
autosomal	O
dominant	O
tibial	O
muscular	BP
dystrophy-12	IP
as	O
reported	O
previously	O
.	O

PS1098	O
Resistance	O
to	O
saquinavir	O
(	O
Ro	O
31	O
-	O
8959	O
)	O
,	O
an	O
inhibitor	O
of	O
human	BG
immunodeficiency	IG
virus	IG
type	IG
I	IG
proteinase-19	IG
,	O
was	O
studied	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
-	O
derived	O
proviral	O
DNA	O
from	O
patients	O
undergoing	O
prolonged	O
treatment	O
.	O

PS1099	O
Previously	O
we	O
have	O
found	O
that	O
early	O
-	O
onset	O
gastric	O
cancer-10	BP
has	O
a	O
unique	O
COX	BG
-	IG
2-16	IG
low	O
-	O
expressing	O
phenotype	O
that	O
differs	O
significantly	O
from	O
that	O
of	O
the	O
frequent	O
overexpression	O
seen	O
in	O
conventional	O
gastric	O
cancers-34	BP
.	O

PS1100	O
To	O
investigate	O
whether	O
the	O
COX	BG
-	IG
2	IG
-	IG
765	IG
G-10	IG
>	O
C	O
promoter	O
polymorphism	O
(	O
known	O
to	O
lead	O
to	O
a	O
reduction	O
of	O
COX	BG
-	IG
2	IG
promoter-26	IG
activity	O
in	O
the	O
colon	O
)	O
may	O
explain	O
this	O
difference	O
in	O
expression	O
,	O
we	O
carried	O
out	O
single	O
-	O
nucleotide	O
polymorphism	O
analysis	O
of	O
241	O
gastric	BP
cancers-50	IP
,	O
including	O
early	O
-	O
onset	O
gastric	BP
cancer-57	IP
,	O
conventional	O
gastric	O
cancers-61	BP
and	O
gastric	O
stump	O
cancers	O
,	O
as	O
well	O
as	O
in	O
100	O
control	O
patients	O
,	O
using	O
real	O
-	O
time	O
PCR	O
and	O
sequence	O
analysis	O
,	O
and	O
correlated	O
these	O
findings	O
with	O
COX	BG
-	IG
2-91	IG
expression	O
using	O
immunohistochemistry	O
.	O

PS1101	O
We	O
found	O
that	O
the	O
C	BG
allele-6	IG
was	O
present	O
in	O
30	O
%	O
of	O
early	O
-	O
onset	O
gastric	O
cancers-17	BP
,	O
24	O
%	O
of	O
conventional	O
gastric	O
cancer-24	BP
,	O
23	O
%	O
of	O
stump	O
cancers-30	BP
,	O
in	O
contrast	O
to	O
41	O
%	O
in	O
the	O
control	O
group	O
.	O

PS1106	O
Most	O
interestingly	O
,	O
mutations	O
at	O
the	O
RET	BG
locus-8	IG
accounted	O
for	O
at	O
least	O
1	O
/	O
3	O
of	O
sporadic	O
Hirschsprung	BP
disease-19	IP
in	O
our	O
series	O
.	O

PS1107	O
Finally	O
,	O
among	O
the	O
mutations	O
identified	O
in	O
sporadic	O
cases	O
(	O
16	O
/	O
45	O
)	O
,	O
seven	O
proved	O
to	O
be	O
de	O
novo	O
mutations	O
suggesting	O
that	O
new	O
mutations	O
at	O
the	O
RET	BG
locus-30	IG
significantly	O
contribute	O
to	O
sporadic	O
Hirschsprung	BP
disease-36	IP
.	O

PS1109	O
In	O
a	O
population	O
-	O
based	O
cohort	O
of	O
57	O
,	O
053	O
Danes	O
,	O
we	O
examined	O
associations	O
between	O
mRNA	O
levels	O
of	O
OGG1-20	BG
,	O
NEIL1-22	BG
,	O
MUTYH-24	BG
and	O
NUDT-26	BG
in	O
buffy	O
coat	O
material	O
and	O
subsequent	O
lung	O
cancer-34	BP
risk	O
.	O

PS1110	O
We	O
found	O
that	O
OGG1	BG
mRNA-5	IG
levels	O
in	O
healthy	O
individuals	O
were	O
not	O
associated	O
with	O
risk	O
of	O
subsequent	O
getting	O
lung	O
cancer-19	BP
.	O

PS1111	O
We	O
identified	O
a	O
novel	O
mutation	O
(	O
867delA	O
)	O
in	O
the	O
glucose	BG
-	IG
6	IG
-	IG
phosphatase	IG
gene-16	IG
of	O
two	O
siblings	O
with	O
glycogen	BP
storage	IP
disease-23	IP
type	O
Ia	O
.	O

PS1116	O
The	O
high	O
rate	O
of	O
cpb2-5	BG
-	O
positivity	O
among	O
strains	O
from	O
neonatal	O
pigs	O
with	O
enteritis-14	BP
and	O
the	O
high	O
correlation	O
of	O
genotype	O
with	O
phenotype	O
,	O
supports	O
the	O
contention	O
that	O
beta2	BG
toxin-29	IG
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
these	O
infections	O
.	O

PS1117	O
Myotonic	BG
dystrophy	IG
type	IG
1-4	IG
is	O
associated	O
with	O
an	O
expansion	O
of	O
CTG	O
repeats	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
DMPK	BG
gene-21	IG
.	O

PS1118	O
Analysis	O
of	O
mutations	O
within	O
the	O
receptor	O
resulting	O
in	O
relative	O
glucocorticoid	BP
resistance-11	IP
has	O
identified	O
two	O
regions	O
of	O
clustered	O
mutations	O
in	O
the	O
proximity	O
of	O
previously	O
identified	O
affinity	O
-	O
labeled	O
residues	O
,	O
the	O
putative	O
steroid	BG
-	IG
binding	IG
site-35	IG
.	O

PS1119	O
From	O
a	O
clinical	O
point	O
of	O
view	O
,	O
in	O
addition	O
to	O
preexisting	O
genetic	BP
resistance-13	IP
to	O
glucocorticoids	O
,	O
it	O
is	O
important	O
to	O
consider	O
acquired	O
changes	O
in	O
glucocorticoid	BG
receptor-26	IG
gene	O
structure	O
and	O
organization	O
,	O
including	O
alterations	O
of	O
noncoding	O
sequences	O
,	O
and	O
the	O
importance	O
of	O
the	O
resultant	O
mutations	O
,	O
deletions	O
,	O
and	O
other	O
changes	O
affecting	O
receptor	O
function	O
.	O

PS1120	O
Finally	O
,	O
studies	O
of	O
New	O
World	O
primates	O
and	O
cell	O
lines	O
derived	O
from	O
hematologic	O
malignancies	O
constitute	O
animal	O
and	O
human	O
models	O
for	O
the	O
molecular	O
basis	O
of	O
glucocorticoid	BP
resistance-26	IP
where	O
a	O
number	O
of	O
inherited	O
and	O
acquired	O
mutations	O
in	O
the	O
glucocorticoid	BG
receptor	IG
gene-39	IG
have	O
been	O
demonstrated	O
.	O

PS1122	O
We	O
have	O
therefore	O
genotyped	O
166	O
unrelated	O
cases	O
of	O
spinal	BP
muscular	IP
atrophy-11	IP
to	O
determine	O
whether	O
the	O
presence	O
of	O
specific	O
apolipoprotein	BG
E	IG
genotypes-21	IG
correlates	O
with	O
severity	O
of	O
disease	O
.	O

PS1125	O
Factors	O
other	O
than	O
apolipoprotein	BG
E	IG
genotype-6	IG
must	O
therefore	O
be	O
responsible	O
for	O
determining	O
spinal	BP
muscular	IP
atrophy-15	IP
disease	O
severity	O
.	O

PS1126	O
To	O
explore	O
the	O
association	O
of	O
its	O
polymorphism	O
of	O
TFRC	O
with	O
the	O
susceptibility	O
,	O
clinical	O
and	O
pathologic	O
phenotypes	O
of	O
IgA-19	BG
nephropathy-20	BP
.	O

PS1127	O
A	O
total	O
of	O
380	O
patients	O
with	O
IgA-7	BG
nephropathy-8	BP
and	O
250	O
normal	O
controls	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

PS1128	O
There	O
were	O
no	O
differences	O
between	O
genotypes	O
in	O
age	O
,	O
blood	O
pressure	O
,	O
24	O
h	O
urine	O
protein	O
excretion	O
,	O
serum	O
creatinine	O
,	O
creatinine	BP
clearance-23	IP
and	O
serum	BG
IgA-26	IG
.	O

PS1131	O
In	O
the	O
Sardinian	O
population	O
,	O
haemoglobin	BG
H	IG
disease-8	IP
needs	O
regular	O
monitoring	O
for	O
early	O
detection	O
and	O
treatment	O
of	O
possible	O
complications	O
,	O
such	O
as	O
worsening	O
of	O
anaemia-25	BP
that	O
may	O
require	O
red	O
cell	O
transfusion	O
,	O
cholelithiasis	O
and	O
iron	O
overload	O
.	O

PS1132	O
However	O
,	O
the	O
rare	O
,	O
further	O
progression	O
to	O
undifferentiated	O
(	O
anaplastic	O
)	O
cancer-13	BP
provides	O
a	O
particularly	O
clear	O
-	O
cut	O
illustration	O
of	O
the	O
role	O
of	O
the	O
tumour	BG
-	IG
suppressor	IG
gene	IG
p53-30	IG
in	O
human	O
cancer-33	BP
.	O

PS1133	O
Genetic	O
testing	O
can	O
be	O
performed	O
on	O
patients	O
and	O
the	O
potential	O
carriers	O
of	O
the	O
menin	BG
gene-15	IG
mutation	O
,	O
but	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
multiple	O
endocrine	O
neoplasia-27	BP
type	O
1	O
is	O
less	O
straightforward	O
than	O
multiple	O
endocrine	O
neoplasia-36	BP
type	O
2	O
.	O

PS1135	O
Inactivating	O
mutations	O
of	O
the	O
gene	BG
RS1-6	IG
lead	O
to	O
X	O
-	O
linked	O
retinoschisis-12	BP
,	O
a	O
progressive	O
retinal	BP
dystrophy-17	IP
characterised	O
by	O
schisis	O
within	O
the	O
inner	O
layers	O
of	O
the	O
neuroretina	O
.	O

PS1136	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
due	O
to	O
21	O
-	O
hydroxylase-8	BG
deficiency	O
is	O
one	O
of	O
the	O
most	O
common	O
autosomal	O
recessive	O
disorders	O
.	O

PS1143	O
Our	O
results	O
suggest	O
that	O
these	O
polymorphisms	O
of	O
the	O
Interleukin4	BG
gene-10	IG
may	O
be	O
genetic	O
risk	O
factors	O
for	O
susceptibility	O
towards	O
vitiligo-19	BP
and	O
the	O
upregulation	O
of	O
the	O
Interleukin4	BG
transcript-26	IG
,	O
protein	O
and	O
IgE-30	BG
levels	O
in	O
individuals	O
with	O
susceptible	O
haplotypes	O
reveal	O
the	O
crucial	O
role	O
of	O
Interleukin	BG
-	IG
4-44	IG
in	O
the	O
pathogenesis	O
of	O
vitiligo	O
.	O

PS1144	O
Of	O
the	O
Tuberous	BG
sclerosis	IG
complex2	IG
mutation	IG
loci-7	IG
,	O
the	O
correlation	O
with	O
cardiac	BP
rhabdomyoma-13	IP
was	O
more	O
significant	O
when	O
the	O
mutation	O
was	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
tuberin-28	BG
than	O
the	O
N	O
-	O
terminal	O
part	O
.	O

PS1147	O
By	O
analyzing	O
a	O
large	O
number	O
of	O
patients	O
with	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
/	O
X	O
-	O
linked	O
thrombocytopenia-17	BP
at	O
the	O
molecular	O
level	O
we	O
identified	O
5	O
mutational	O
hotspots	O
in	O
the	O
Wiskott	BG
-	IG
Aldrich	IG
syndromeP	IG
gene-33	IG
and	O
have	O
been	O
able	O
to	O
establish	O
a	O
strong	O
association	O
between	O
genotype	O
and	O
phenotype	O
.	O

PS1149	O
Moreover	O
,	O
we	O
tried	O
to	O
correlate	O
differences	O
in	O
epithelial	O
Cl	O
-	O
and	O
Na	O
+	O
conductance	O
with	O
the	O
level	O
of	O
Cystic	BG
fibrosisTR-21	IG
messenger	O
ribonucleic	O
acid	O
expression	O
and	O
studied	O
whether	O
these	O
properties	O
correlate	O
to	O
the	O
clinical	O
phenotype	O
of	O
Cystic	BP
fibrosis-38	IP
patients	O
.	O

PS1151	O
A	O
serum	O
ferritin-3	BG
less	O
than	O
1000	O
g	O
/	O
l	O
in	O
C282Y	O
homozygotes	O
was	O
found	O
to	O
be	O
associated	O
with	O
milder	O
symptoms	O
of	O
hemochromatosis-22	BP
.	O

PS1152	O
Goltz	O
-	O
Gorlin-3	BG
syndrome	O
or	O
focal	O
dermal	BP
hypoplasia-8	IP
is	O
a	O
highly	O
variable	O
,	O
X	O
-	O
linked	O
dominant	O
syndrome	O
with	O
abnormalities	O
of	O
ectodermal	O
and	O
mesodermal	O
origin	O
.	O

PS1157	O
In	O
order	O
to	O
assess	O
the	O
Neurofibromatosis	O
type	O
1	O
mutational	O
spectrum	O
in	O
Korean	O
Neurofibromatosis	O
type	O
1	O
patients	O
,	O
we	O
screened	O
23	O
unrelated	O
Korean	O
Neurofibromatosis	O
type	O
1	O
patients	O
for	O
mutations	O
in	O
the	O
coding	O
region	O
and	O
splice	O
sites	O
of	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-41	IG
.	O

PS1158	O
The	O
mutations	O
are	O
evenly	O
distributed	O
across	O
exon	O
3	O
through	O
intron	O
47	O
of	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-17	IG
and	O
no	O
mutational	O
hot	O
spots	O
were	O
found	O
.	O

PS1159	O
Possible	O
:	O
IgE-3	BG
>	O
1000IU	O
/	O
mL	O
plus	O
a	O
weighted	O
score	O
of	O
clinical	O
features	O
>	O
30	O
based	O
on	O
recurrent	O
pneumonia-20	BP
,	O
newborn	O
rash	O
,	O
pathologic	O
bone	O
fractures	O
,	O
characteristic	O
face	O
,	O
and	O
high	BP
palate-34	IP
.	O

PS1161	O
transient	O
neonatal	BP
hyperkalaemia-3	IP
was	O
present	O
in	O
two	O
-	O
thirds	O
of	O
the	O
children	O
with	O
KCNJ1-14	BG
mutations	O
.	O

PS1162	O
Three	O
patients	O
developed	O
chronic	O
renal	BP
failure-6	IP
:	O
one	O
with	O
KCNJ1-10	BG
mutations	O
during	O
the	O
second	O
decade	O
of	O
age	O
and	O
two	O
with	O
CLCNKB	O
and	O
Bartter	O
syndromeND	O
mutations	O
and	O
without	O
nephrocalcinosis	O
during	O
the	O
first	O
year	O
of	O
life	O
.	O

PS1165	O
Here	O
,	O
we	O
studied	O
the	O
muscular	O
phenotype	O
of	O
Nemaline	O
myopathy-10	BP
patients	O
with	O
a	O
well	O
-	O
defined	O
nebulin-17	BG
mutation	O
(	O
Nemaline	O
myopathy	O
-	O
NEB	O
)	O
,	O
using	O
a	O
multidisciplinary	O
approach	O
to	O
study	O
thin	O
filament	O
length	O
regulation	O
and	O
muscle	O
contractile	O
performance	O
.	O

PS1168	O
The	O
mouse	O
cpk-3	BG
mutation	O
is	O
the	O
most	O
extensively	O
characterized	O
murine	O
model	O
of	O
polycystic	BP
kidney-14	IP
disease	O
and	O
closely	O
resembles	O
human	O
autosomal	O
recessive	O
polycystic	BP
kidney-23	IP
disease	O
,	O
with	O
the	O
exception	O
that	O
B6	BG
-	IG
cpk-32	IG
/	O
cpk	BG
homozygotes-35	IG
do	O
not	O
express	O
the	O
biliary	O
ductal	O
plate	O
malformation	O
lesion	O
.	O

PS1170	O
In	O
the	O
absence	O
of	O
interleukin	BG
-	IG
10-7	IG
,	O
B10-9	BG
mice	O
are	O
resistant	O
to	O
lethal	BP
infection-15	IP
.	O

PS1172	O
Two	O
familial	O
and	O
seven	O
sporadic	O
patients	O
with	O
neurofibromatosis	O
1	O
-	O
who	O
showed	O
dysmorphism	O
,	O
learning	BP
disabilities-16	IP
/	O
mental	BP
retardation-19	IP
,	O
and	O
additional	O
signs	O
and	O
carried	O
deletions	O
of	O
the	O
NF1	BG
gene-30	IG
-	O
were	O
investigated	O
by	O
use	O
of	O
a	O
two	O
-	O
step	O
FISH	O
approach	O
to	O
characterize	O
the	O
deletions	O
.	O

PS1175	O
Achondroplasia	O
is	O
a	O
skeletal	BP
dysplasia-5	IP
caused	O
by	O
substitution	O
of	O
arginine	O
for	O
glycine	O
at	O
codon	O
380	O
(	O
G380R	O
)	O
mutation	O
of	O
the	O
fibroblast	BG
growth	IG
factor	IG
receptor	IG
3-26	IG
.	O

PS1176	O
Impaired	O
ability	O
to	O
signal	O
and	O
activate	O
specific	O
gene	O
transcription	O
through	O
nuclear	BG
factor	IG
kappaB-13	IG
has	O
been	O
directly	O
linked	O
to	O
immunodeficiency-19	BP
.	O

PS1179	O
To	O
evaluate	O
the	O
relationship	O
between	O
pituitary	O
size	O
,	O
partial	O
isolatedT1-10	BG
and	O
PROP1	BG
genotype-13	IG
,	O
and	O
the	O
severity	O
of	O
childhood	BG
onset	IG
growth	IG
hormone-22	IG
deficiency	O
.	O

PS1182	O
Genetic	O
analyses	O
have	O
shown	O
a	O
linkage	O
between	O
loci	O
on	O
several	O
chromosomes	O
and	O
inflammatory	O
bowel	O
disease	O
(	O
inflammatory	O
bowel	BG
disease1	IG
gene-20	IG
on	O
chromosome	O
16	O
for	O
Crohn	O
'	O
s	O
disease	O
and	O
on	O
chromosome	O
12	O
for	O
ulcerative	BP
colitis-35	IP
)	O
.	O

PS1184	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
GUCY2D-8	BG
mutation	O
causing	O
central	O
areolar	O
choroidal	BP
dystrophy-14	IP
and	O
adds	O
to	O
our	O
understanding	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
this	O
heterogeneous	O
group	O
of	O
choroidoretinal	BP
dystrophies-31	IP
.	O

PS1185	O
Mutations	O
in	O
the	O
progressive	BP
external	IP
ophthalmoplegia-6	IP
1	O
,	O
adenine	BG
nucleotide	IG
translocator	IG
1-12	IG
and	O
DNA	O
polymerase	O
gamma	O
genes	O
were	O
reported	O
in	O
patients	O
with	O
progressive	BP
external	IP
ophthalmoplegia-25	IP
and	O
parkinsonism	O
.	O

PS1186	O
In	O
order	O
to	O
define	O
the	O
molecular	O
basis	O
of	O
progressive	BP
external	IP
ophthalmoplegia-11	IP
and	O
parkinsonism-13	BP
,	O
we	O
screened	O
for	O
mutations	O
in	O
progressive	O
external	BG
ophthalmoplegia	IG
1-23	IG
,	O
adenine	BG
nucleotide	IG
translocator	IG
1-28	IG
,	O
polymerase	BG
gamma	IG
genes-32	IG
and	O
the	O
whole	O
mitochondrial	O
genome	O
in	O
two	O
families	O
.	O

PS1189	O
We	O
report	O
two	O
previously	O
undescribed	O
homozygous	O
ITGB4	BG
mutations-8	IG
in	O
two	O
unrelated	O
families	O
,	O
which	O
resulted	O
in	O
severe	O
skin	O
blistering	O
,	O
pyloric	BP
atresia-22	IP
and	O
lethality	O
in	O
infancy	O
.	O

PS1190	O
RET	O
genotypes	O
(	O
exons	O
10	O
,	O
11	O
,	O
13	O
,	O
and	O
14	O
)	O
of	O
63	O
patients	O
with	O
hereditary	O
medullary	O
thyroid	BP
carcinoma-21	IP
(	O
from	O
November	O
1994	O
to	O
October	O
1999	O
)	O
were	O
correlated	O
with	O
age	O
at	O
diagnosis	O
,	O
sex	O
,	O
the	O
TNM	O
system	O
,	O
and	O
basal	O
calcitonin-45	BG
levels	O
.	O

PS1191	O
The	O
distributions	O
of	O
the	O
bi	O
-	O
allelic	O
interleukin	BG
-	IG
1beta	IG
+	IG
3953-12	IG
and	O
tumor	BG
necrosis	IG
factor	IG
-	IG
alpha	IG
-	IG
308	IG
genotypes-21	IG
were	O
determined	O
in	O
20	O
patients	O
with	O
advanced	O
adult	O
periodontitis-30	BP
,	O
20	O
patients	O
with	O
plaque	O
associated	O
gingivitis-37	BP
,	O
and	O
45	O
referent	O
population	O
subjects	O
.	O

PS1201	O
To	O
determine	O
the	O
frequency	O
of	O
mutations	O
in	O
the	O
beta	BG
-	IG
myosin	IG
heavy	IG
-	IG
chain	IG
gene-15	IG
(	O
MYH7-17	BG
)	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
hypertrophic	BP
cardiomyopathy-26	IP
and	O
their	O
families	O
,	O
and	O
to	O
investigate	O
correlations	O
between	O
genotype	O
and	O
phenotype	O
.	O

PS1202	O
Single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
sequencing	O
of	O
fragments	O
with	O
abnormal	O
MYH7	BG
gene-14	IG
mobility	O
were	O
carried	O
out	O
in	O
128	O
consecutive	O
index	O
patients	O
with	O
hypertrophic	BP
cardiomyopathy-26	IP
.	O

PS1208	O
Case-1	BG
Report	O
:	O
We	O
present	O
the	O
rare	O
case	O
of	O
a	O
4	O
-	O
year	O
-	O
old	O
boy	O
who	O
was	O
referred	O
to	O
the	O
pediatric	O
endocrinology	O
unit	O
for	O
evaluation	O
of	O
slight	BP
growth	IP
delay-30	IP
.	O

PS1209	O
Wild	O
-	O
type	O
plants	O
exhibited	O
relatively	O
high	O
levels	O
of	O
free	O
threonine	O
,	O
suggesting	O
that	O
in	O
Arabidopsis-16	BP
aspartate	BG
kinase-18	IG
regulation	O
may	O
be	O
more	O
relaxed	O
than	O
in	O
other	O
plants	O
.	O

PS1210	O
Yet	O
,	O
the	O
relaxed	O
regulation	O
of	O
threonine	O
synthesis	O
in	O
Arabidopsis-10	BP
was	O
not	O
simply	O
due	O
to	O
a	O
reduced	O
sensitivity	O
of	O
the	O
endogenous	BG
aspartate	IG
kinase-23	IG
to	O
feedback-25	BG
inhibition	O
by	O
lysine	O
and	O
threonine	O
because	O
growth	O
of	O
wild	BG
-	IG
type	IG
plants-37	IG
,	O
but	O
not	O
of	O
transgenic	O
plants	O
expressing	O
the	O
bacterial	BG
aspartate	IG
kinase-48	IG
,	O
was	O
arrested	O
in	O
media	O
containing	O
these	O
two	O
amino	O
acids	O
.	O

PS1211	O
Patients	O
2	O
and	O
3	O
,	O
but	O
not	O
patient	O
1	O
,	O
were	O
demonstrated	O
to	O
have	O
detectable	O
p22-16	BG
-	O
phox-18	BG
expression	O
and	O
significant	O
granulocyte	O
respiratory	O
burst	O
activity	O
.	O

PS1215	O
However	O
,	O
in	O
Naxos	O
disease	O
,	O
a	O
recessive	O
form	O
of	O
arrhythmogenic	BP
right	IP
ventricular	IP
cardiomyopathy-14	IP
with	O
coexpression	O
of	O
palmoplantar	BP
keratoderma-19	IP
and	O
woolly	BP
hair-22	IP
,	O
a	O
mutation	O
in	O
the	O
plakoglobin	BG
gene-29	IG
has	O
recently	O
been	O
discovered	O
,	O
thus	O
underscoring	O
the	O
potential	O
role	O
of	O
genetic	O
alterations	O
in	O
cytoskeletal	O
proteins	O
in	O
arrhythmogenic	O
right	O
ventricular	BP
cardiomyopathy-50	IP
.	O

PS1218	O
Our	O
data	O
confirm	O
the	O
phenotypic	O
similarities	O
at	O
the	O
genetic	O
level	O
between	O
colorectal	BP
cancer-13	IP
and	O
Intestinal	O
-	O
type	O
adenocarcinomas	O
showing	O
deregulation	O
of	O
K	BG
-	IG
Ras-24	IG
/	O
BRAF-26	BG
and	O
loss	O
of	O
heterozygosity	O
of	O
chromosome	O
18q	O
.	O

PS1219	O
By	O
contrast	O
,	O
both	O
frequency	O
rate	O
and	O
type	O
of	O
inactivation	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
-	O
beta	BG
-	IG
catenin-19	IG
pathway	O
differ	O
in	O
the	O
2	O
tumors	O
,	O
suggesting	O
different	O
gatekeeper	O
events	O
in	O
the	O
early	O
development	O
of	O
Intestinal	O
-	O
type	O
adenocarcinoma	O
(	O
p16-41	BG
(	O
INK4a-43	BG
)	O
and	O
TP53-46	BG
)	O
and	O
colorectal	BP
cancer-50	IP
(	O
adenomatous	O
polyposis	O
coli	O
)	O
.	O

PS1221	O
In	O
the	O
1990s	O
the	O
genetic	O
mechanism	O
of	O
inheritance	O
of	O
a	O
proportion	O
of	O
these	O
familial	O
cancers-15	BP
was	O
found	O
to	O
be	O
attributable	O
to	O
germline	O
mutation	O
in	O
either	O
of	O
two	O
newly	O
discovered	O
genes	O
,	O
namely	O
BRCA1-33	BG
and	O
BRCA2-35	BG
.	O

PS1224	O
A	O
less	O
distinct	O
phenotype	O
has	O
been	O
described	O
for	O
BRCA2	BG
cancers-10	IG
.	O

PS1225	O
Succinic	BG
semialdehyde	IG
dehydrogenase	IG
deficiency-4	IP
is	O
one	O
of	O
the	O
disorders	O
of	O
GABA	O
metabolism	O
,	O
so	O
it	O
is	O
not	O
surprising	O
that	O
seizures-20	BP
occur	O
as	O
one	O
of	O
the	O
symptoms	O
in	O
affected	O
patients	O
.	O

PS1226	O
Children	O
with	O
symptoms	O
of	O
profound	O
biotinidase-6	BG
deficiency	O
with	O
null	O
mutations	O
are	O
more	O
likely	O
to	O
have	O
hearing	BP
loss-17	IP
develop	O
than	O
those	O
with	O
missense	O
mutations	O
,	O
even	O
if	O
not	O
treated	O
for	O
a	O
period	O
of	O
time	O
.	O

PS1228	O
The	O
risk	O
of	O
attention	BP
deficit	IP
hyperactivity	IP
disorder-7	IP
appears	O
to	O
be	O
higher	O
in	O
patients	O
carrying	O
mutations	O
predicted	O
to	O
affect	O
dystrophin-19	BG
isoforms	O
expressed	O
in	O
the	O
brain	O
and	O
are	O
known	O
to	O
be	O
associated	O
with	O
higher	O
risk	O
of	O
cognitive	BP
impairment-36	IP
.	O

PS1232	O
Constitutional	O
RB1	BG
gene-3	IG
mutations	O
were	O
studied	O
in	O
a	O
series	O
of	O
21	O
families	O
with	O
unilateral	O
and	O
bilateral	O
retinoblastoma-17	BP
patients	O
.	O

PS1233	O
mutations	O
in	O
the	O
gene	O
defective	O
in	O
Fanconi	BG
anemia	IG
complementation	IG
group	IG
C	IG
,	IG
Fanconi	IG
anemiaC-14	IG
,	O
are	O
responsible	O
for	O
the	O
syndrome	O
in	O
a	O
subset	O
of	O
patients	O
.	O

PS1234	O
To	O
determine	O
whether	O
there	O
is	O
a	O
correlation	O
among	O
mutations	O
in	O
the	O
cytochrome	BG
P450	IG
1B1-14	IG
gene	O
,	O
the	O
degree	O
of	O
angle	O
dysgenesis	O
observed	O
histologically	O
,	O
and	O
disease	O
severity	O
in	O
congenital	O
glaucoma-30	BP
.	O

PS1235	O
Direct	O
DNA	O
sequencing	O
was	O
utilized	O
to	O
screen	O
six	O
unrelated	O
children	O
with	O
congenital	O
glaucoma-13	BP
,	O
each	O
set	O
of	O
parents	O
,	O
and	O
all	O
siblings	O
for	O
cytochrome	BG
P450	IG
1B1	IG
gene-27	IG
mutations	O
.	O

PS1240	O
This	O
study	O
shows	O
how	O
an	O
exonic	O
mutation	O
that	O
weakens	O
the	O
5	O
'	O
splice	O
site	O
enhances	O
a	O
minor	O
alternative	O
splicing	O
without	O
abolishing	O
a	O
complete	O
exclusion	O
of	O
the	O
exon	O
and	O
therefore	O
causes	O
a	O
less	O
severe	O
retinitis-34	BP
pigmentosa	O
than	O
the	O
USH1B	BG
-	IG
associated	IG
alleles-41	IG
.	O

PS1241	O
We	O
screened	O
for	O
HLA-4	BG
type	O
,	O
24	O
patients	O
with	O
advanced	O
ovarian	O
cancer-12	BP
and	O
26	O
patients	O
with	O
hormone	O
-	O
refractory	O
prostate	BP
cancer-21	IP
,	O
in	O
order	O
to	O
be	O
recruited	O
to	O
vaccine	O
protocols	O
.	O

PS1242	O
The	O
results	O
were	O
then	O
extended	O
to	O
a	O
population	O
level	O
,	O
comparing	O
the	O
HLA	BG
genotype-14	IG
frequencies	O
in	O
Europe	O
with	O
ovarian	O
and	O
prostate	BP
cancer-22	IP
mortality	O
rates	O
.	O

PS1243	O
Ovarian	O
and	O
prostate	BP
cancer-4	IP
mortality	O
rates	O
decrease	O
as	O
well	O
as	O
the	O
demographic	O
changes	O
in	O
HLA	BG
-	IG
A2-17	IG
.	O

PS1245	O
WT1-1	BG
is	O
not	O
the	O
major	O
gene	O
mutated	O
in	O
Wilms	O
tumour	O
,	O
but	O
has	O
given	O
important	O
insights	O
into	O
the	O
molecular	O
genetics	O
of	O
this	O
childhood	O
embryonal	O
kidney	O
cancer-26	BP
.	O

PS1246	O
Inherited	O
mutations	O
in	O
the	O
BRCA2	BG
gene-6	IG
predispose	O
women	O
to	O
breast	O
and	O
ovarian	O
cancer-13	BP
.	O

PS1247	O
The	O
complete	O
fumarylacetoacetate	BG
hydrolase-4	IG
genotype	O
of	O
probands	O
of	O
thirteen	O
unrelated	O
families	O
with	O
hereditary	BP
tyrosinemia-14	IP
type	O
1	O
was	O
established	O
.	O

PS1248	O
Medullary	O
thyroid	BP
cancer-3	IP
is	O
a	O
rare	O
endocrine	O
tumor	O
that	O
may	O
be	O
sporadic	O
or	O
inherited	O
in	O
settings	O
of	O
MEN2A-18	BG
,	O
MEN2B-20	BG
and	O
FMedullary	O
thyroid	BP
cancer-24	IP
.	O

PS1250	O
The	O
results	O
of	O
our	O
study	O
support	O
the	O
role	O
of	O
MDR1-10	BG
as	O
a	O
candidate	O
gene	O
for	O
ulcerative	BP
colitis-17	IP
.	O

PS1251	O
This	O
is	O
predicted	O
to	O
result	O
in	O
precipitation	O
of	O
the	O
unstable	O
alpha	O
chains	O
or	O
Hb	BG
variant-15	IG
,	O
a	O
concomitant	O
decrease	O
in	O
the	O
overall	O
quantity	O
of	O
normal	O
alpha	BG
-	IG
globin-28	IG
in	O
the	O
red	O
cells	O
and	O
a	O
potential	O
degree	O
of	O
anemia-38	BP
and	O
possibly	O
,	O
hemolysis	O
.	O

PS1252	O
Mutations	O
in	O
the	O
cyclin	BG
-	IG
dependent	IG
kinase	IG
-	IG
like	IG
5	IG
gene-11	IG
have	O
been	O
described	O
in	O
girls	O
with	O
Rett	O
-	O
like	O
features	O
and	O
early	O
-	O
onset	O
epileptic	O
encephalopathy-27	BP
including	O
infantile	O
spasms-30	BP
.	O

PS1253	O
To	O
date	O
,	O
with	O
more	O
than	O
80	O
reported	O
cases	O
,	O
the	O
phenotype	O
of	O
cyclin	BG
-	IG
dependent	IG
kinase	IG
-	IG
like	IG
5	IG
gene-21	IG
-	O
related	O
encephalopathy-24	BP
is	O
better	O
defined	O
.	O

PS1258	O
We	O
performed	O
p63	BG
mutation-4	IG
analysis	O
in	O
a	O
sample	O
of	O
43	O
individuals	O
and	O
families	O
affected	O
with	O
EEC	O
syndrome	O
,	O
in	O
35	O
individuals	O
affected	O
with	O
SHFM	O
,	O
and	O
in	O
three	O
families	O
with	O
the	O
EEC	O
-	O
like	O
condition	O
limb	O
-	O
mammary	O
syndrome	O
(	O
LMS	O
)	O
,	O
which	O
is	O
characterized	O
by	O
ectrodactyly	O
,	O
cleft	BP
palate-51	IP
,	O
and	O
mammary	O
-	O
gland	O
abnormalities	O
.	O

PS1259	O
We	O
have	O
previously	O
shown	O
that	O
two	O
distinct	O
stromal	O
signatures	O
derived	O
from	O
a	O
macrophage	O
(	O
CSF1-15	BG
)	O
response	O
and	O
a	O
fibroblastic	O
(	O
DTF	O
-	O
like	O
)	O
response	O
are	O
present	O
in	O
subsets	O
of	O
invasive	O
breast	BP
cancers-34	IP
and	O
show	O
a	O
correlation	O
with	O
clinical	O
outcome	O
.	O

PS1260	O
We	O
also	O
find	O
that	O
the	O
macrophage	O
response	O
signature	O
is	O
associated	O
with	O
higher	O
grade	O
ductal	O
carcinoma	O
in	O
situ	O
and	O
cases	O
which	O
are	O
ER-22	BG
and	O
PR-24	BG
negative	O
,	O
whereas	O
the	O
fibroblast	O
signature	O
was	O
not	O
associated	O
with	O
any	O
clinicopathologic	O
features	O
in	O
ductal	BP
carcinoma-40	IP
in	O
situ	O
.	O

PS1265	O
Non	O
-	O
induced	O
aryl	BG
hydrocarbon	IG
hydroxylase	IG
activity-7	IP
was	O
also	O
correlated	O
with	O
these	O
polymorphisms	O
.	O

PS1267	O
Thus	O
,	O
the	O
positive	O
relationship	O
between	O
aryl	BG
hydrocarbon	IG
hydroxylase	IG
inducibility-10	IP
and	O
lung	O
cancer-13	BP
is	O
supported	O
by	O
our	O
study	O
.	O

PS1268	O
To	O
identify	O
possible	O
correlations	O
between	O
the	O
putative	O
mutations	O
and	O
the	O
clinical	O
characteristics	O
in	O
X	O
-	O
linked	O
retinitis-17	BP
pigmentosa	O
,	O
RP2-20	BG
.	O

PS1269	O
To	O
identify	O
the	O
mutation	O
spectrum	O
and	O
the	O
distribution	O
of	O
minihaplotypes	O
(	O
short	O
tandem	O
repeat	O
/	O
variable	O
number	O
tandem	O
repeat	O
)	O
of	O
phenylalanine	BG
hydroxylase-23	IG
gene	O
and	O
explore	O
the	O
correlations	O
between	O
genotype	O
and	O
phenotype	O
of	O
patients	O
with	O
phenylketonuria-36	BP
in	O
Beijing	O
area	O
of	O
China	O
.	O

PS1270	O
Human	O
beta	O
-	O
mannosidosis	O
,	O
a	O
rare	O
disorder	O
of	O
oligosaccharide	O
catabolism-11	BP
,	O
results	O
from	O
a	O
deficiency	O
of	O
beta	BG
-	IG
mannosidase-20	IG
activity	O
.	O

PS1279	O
Although	O
the	O
underlying	O
mechanisms	O
are	O
still	O
unclear	O
,	O
our	O
findings	O
are	O
consistent	O
with	O
a	O
complex	O
relationship	O
between	O
height	O
,	O
hypertension-20	BP
,	O
growth	BG
hormone1	IG
promoter	IG
haplotype-25	IG
,	O
growth	BG
hormoneR-28	IG
polymorphism	O
and	O
the	O
risk	O
of	O
stroke-34	BP
.	O

PS1280	O
Inverse	O
correlations	O
have	O
been	O
reported	O
between	O
birth	O
weight	O
and	O
the	O
Metabolic	O
Syndrome	O
(	O
abdominal	O
obesity-15	BP
,	O
insulin	BG
resistance-18	IP
,	O
hyperinsulinemia-20	BP
,	O
glucose	BP
intolerance-23	IP
,	O
dyslipidemia-25	BP
,	O
and	O
hypertension-28	BP
)	O
.	O

PS1281	O
Mutations	O
in	O
the	O
four	O
main	O
genes	O
involved	O
in	O
Holoprosencephaly-9	BP
(	O
SHH-11	BG
,	O
ZIC2-13	BG
,	O
SIX3-15	BG
,	O
TGIF-17	BG
)	O
were	O
identified	O
in	O
25	O
%	O
of	O
cases	O
.	O

PS1283	O
To	O
investigate	O
whether	O
CCND1-4	BG
genetic	O
variations	O
associated	O
with	O
a	O
constitutive	O
nuclear	O
protein	O
may	O
influence	O
either	O
the	O
pathologic	O
response	O
to	O
preoperative	O
RT	O
or	O
the	O
prognosis	O
in	O
a	O
series	O
of	O
rectal	BP
cancer-30	IP
patients	O
.	O

PS1288	O
Only	O
in	O
disorders	O
of	O
the	O
mitochondrial	BG
trifunctional	IG
protein-8	IG
complex	O
,	O
including	O
long	O
-	O
chain	O
3	O
-	O
hydroxyacyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
LCHAD-23	BG
)	O
deficiency	O
,	O
neuropathy-27	BP
and	O
retinopathy-29	BP
develop	O
that	O
are	O
progressive	O
and	O
irreversible	O
despite	O
current	O
treatment	O
measures	O
.	O

PS1289	O
The	O
frequency	O
of	O
well	O
-	O
known	O
mutations	O
(	O
R702W	O
,	O
G908W	O
and	O
1007fs	O
in	O
the	O
NOD2	BG
gene-17	IG
;	O
K469E	O
in	O
the	O
ICAM	BG
-	IG
1	IG
gene-25	IG
,	O
and	O
Delta32	O
in	O
the	O
CCR5	BG
gene-32	IG
)	O
involved	O
in	O
inflammatory	BP
bowel	IP
disease-38	IP
was	O
tested	O
in	O
45	O
patients	O
with	O
CD	O
and	O
22	O
patients	O
with	O
UC	O
.	O

PS1291	O
Dominantly	O
acting	O
,	O
allelic	O
mutations	O
of	O
the	O
fibroblast	BG
growth	IG
factor	IG
receptor	IG
2-12	IG
gene	O
have	O
been	O
described	O
in	O
five	O
craniosynostosis-19	BP
syndromes	O
.	O

PS1292	O
In	O
Apert	O
syndrome	O
,	O
characterised	O
by	O
syndactyly-7	BP
of	O
the	O
hands	O
and	O
feet	O
,	O
recurrent	O
mutations	O
of	O
a	O
serine	O
-	O
proline	O
dipeptide	O
(	O
either	O
Ser252Trp	O
or	O
Pro253Arg	O
)	O
in	O
the	O
linker	O
between	O
the	O
IgII-33	BG
and	O
IgIII	BG
extracellular	IG
immunoglobulin-37	IG
-	O
like	O
domains	O
,	O
have	O
been	O
documented	O
in	O
more	O
than	O
160	O
unrelated	O
individuals	O
.	O

PS1294	O
Van	O
der	O
Woude	O
syndrome	O
and	O
popliteal	BP
pterygium-7	IP
syndrome	O
are	O
autosomal	O
dominant	O
disorders	O
characterized	O
by	O
combinations	O
of	O
cleft	BP
lip-18	IP
,	O
cleft	BP
palate-21	IP
,	O
lip	O
pits	O
,	O
skin	O
-	O
folds	O
,	O
syndactyly	O
and	O
oral	O
adhesions	O
which	O
arise	O
as	O
the	O
result	O
of	O
mutations	O
in	O
interferon	BG
regulatory	IG
factor	IG
6-45	IG
.	O

PS1295	O
In	O
order	O
to	O
identify	O
the	O
molecular	O
basis	O
of	O
phenylketonuria-9	BP
in	O
Italy	O
,	O
we	O
screened	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
phenylalanine	BG
hydroxylase	IG
gene-23	IG
in	O
20	O
Italian	O
phenylketonuria-27	BP
patients	O
,	O
whose	O
origins	O
are	O
scattered	O
throughout	O
Italy	O
.	O

PS1297	O
Mutation	O
of	O
NEFL	O
or	O
KIF1B	O
cause	O
dominantly	O
inherited	O
axonal	BP
neuropathies-10	IP
,	O
whereas	O
mutation	O
of	O
GJB1-15	BG
or	O
MPZ-17	BG
can	O
present	O
as	O
genocopies	O
of	O
dominant	O
axonal	O
neuropathies	O
.	O

PS1302	O
These	O
results	O
indicate	O
that	O
insulin	BP
resistance-6	IP
and	O
endothelial	O
activation	O
were	O
found	O
in	O
normotensive	O
adolescents	O
with	O
an	O
family	O
history	O
of	O
hypertension-20	BP
.	O

PS1303	O
We	O
should	O
make	O
great	O
efforts	O
to	O
alleviate	O
the	O
insulin	BP
resistance-10	IP
and	O
endothelial	O
activation	O
by	O
diet	O
and	O
exercise	O
,	O
and	O
it	O
would	O
reduce	O
the	O
incidence	O
of	O
hypertension-26	BP
in	O
adolescents	O
with	O
an	O
family	O
history	O
of	O
hypertension-34	BP
.	O

PS1305	O
Phenotypes	O
of	O
MICA	BG
A6	IG
allele-5	IG
in	O
Japanese	O
are	O
closely	O
related	O
to	O
the	O
disease	O
susceptibility	O
and	O
behavior	O
in	O
ulcerative	BP
colitis-19	IP
.	O

PS1309	O
This	O
review	O
will	O
consider	O
the	O
evidence	O
supporting	O
the	O
view	O
that	O
a	O
specific	O
substrain	O
of	O
Fawn	O
-	O
Hooded	O
rat	O
(	O
FH-20	BG
/	O
Wjd-22	BG
)	O
exhibits	O
co	O
-	O
occurring	O
depressive	BP
-	IP
like	IP
behavior-31	IP
and	O
high	O
alcohol	O
intake	O
independently	O
.	O

PS1310	O
Other	O
literature	O
in	O
addition	O
to	O
the	O
high	O
swim	O
test	O
immobility	O
suggests	O
that	O
the	O
FH-14	BG
/	O
Wjd-16	BG
rat	O
may	O
also	O
be	O
an	O
animal	O
model	O
of	O
depression-25	BP
(	O
high	O
basal	O
corticosterone	O
levels	O
,	O
blunted	O
hormonal	O
responses	O
to	O
serotonergic	O
agonists	O
)	O
.	O

PS1311	O
The	O
main	O
childhood	O
asthma-4	BP
phenotypes	O
are	O
:	O
transient	O
infant	O
wheezing	O
,	O
non	O
atopic	O
wheezing	O
of	O
the	O
toddler	O
and	O
early	O
school	O
years	O
,	O
persistent	O
IgE-24	BG
-	O
mediated	O
wheezing	O
/	O
asthma-29	BP
,	O
late	O
-	O
onset	O
childhood	O
asthma-35	BP
.	O

PS1313	O
We	O
sought	O
to	O
identify	O
mutations	O
in	O
the	O
MLC1	BG
gene-9	IG
,	O
to	O
evaluate	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
and	O
to	O
develop	O
a	O
strategy	O
for	O
diagnosing	O
Indian	O
patients	O
with	O
megalencephalic	O
leukoencephalopathy-30	BP
.	O

PS1314	O
Genotyping	O
of	O
the	O
signal	O
sequence	O
region	O
of	O
the	O
vacA	BG
gene-10	IG
identified	O
68	O
%	O
(	O
70	O
out	O
of	O
103	O
)	O
of	O
patients	O
with	O
non	O
ulcer	O
dyspepsia	O
and	O
79	O
%	O
(	O
23	O
out	O
of	O
29	O
)	O
of	O
the	O
patients	O
with	O
peptic	O
ulcer	O
disease	O
possessing	O
the	O
s1	BG
genotype-45	IG
.	O

PS1316	O
A	O
rapid	O
and	O
convenient	O
approach	O
for	O
the	O
detection	O
of	O
the	O
most	O
common	O
CYP21	BG
gene-14	IG
mutations	O
in	O
patients	O
with	O
congenital	BP
adrenal	IP
hyperplasia-21	IP
with	O
classical	O
forms	O
of	O
21	O
-	O
hydroxylase-28	BG
deficiency	O
was	O
used	O
.	O

PS1317	O
Design	O
:	O
Molecular	O
analysis	O
of	O
the	O
CYP21	BG
gene-8	IG
for	O
the	O
detection	O
of	O
the	O
9	O
most	O
common	O
mutations	O
(	O
CYP21gene	BG
deletion-20	IG
,	O
P30L-22	BG
,	O
i2g-24	BG
,	O
del	BG
-	IG
8bp-28	IG
,	O
I172N-30	BG
,	O
E6	BG
cluster-33	IG
,	O
V281L	O
,	O
Q318X	O
and	O
R356W	O
)	O
was	O
performed	O
on	O
30	O
congenital	BP
adrenal	IP
hyperplasia-47	IP
patients	O
and	O
for	O
prenatal	O
diagnosis	O
in	O
2	O
cases	O
.	O

PS1318	O
This	O
case	O
further	O
broadens	O
the	O
clinical	O
spectrum	O
,	O
including	O
now	O
an	O
example	O
of	O
a	O
cognitively	O
normal	O
adult	O
with	O
Pyruvate	BG
dehydrogenase	IG
deficiency-21	IP
.	O

PS1320	O
In	O
the	O
acute	O
phase	O
,	O
acylcarnitine	O
analysis	O
of	O
blood	O
suggested	O
a	O
defect	O
of	O
long	O
chain	O
fatty	O
acid	O
oxidation	O
,	O
and	O
carnitine	BG
palmitoyltransferase	IG
2	IG
deficiency-24	IP
was	O
genetically	O
confirmed	O
.	O

PS1322	O
Our	O
case	O
may	O
contribute	O
to	O
the	O
elucidation	O
of	O
the	O
genetic	O
factor	O
involved	O
in	O
acute	O
encephalopathy-15	BP
in	O
carnitine	BG
palmitoyltransferase	IG
2-19	IG
deficiency	O
.	O

PS1323	O
The	O
results	O
of	O
this	O
study	O
give	O
basis	O
for	O
large	O
-	O
scale	O
C3435T	BG
MDR1-13	IG
genotype	O
-	O
phenotype	O
correlation	O
investigations	O
in	O
Polish	O
population	O
that	O
may	O
be	O
useful	O
to	O
individualize	O
therapy	O
of	O
cancer-30	BP
,	O
HIV	O
-	O
1	O
infection	O
and	O
some	O
other	O
diseases	O
.	O

PS1324	O
Forty	O
-	O
one	O
patients	O
were	O
homozygous	O
for	O
C282Y-8	BG
,	O
the	O
genotype	O
considered	O
to	O
be	O
characteristic	O
of	O
hereditary	O
hemochromatosis-18	BP
.	O

PS1326	O
Brachydactyly-1	BP
type	O
C	O
and	O
angel	O
-	O
shaped	O
phalango	O
-	O
epiphyseal	O
dysplasia	O
result	O
from	O
mutations	O
in	O
the	O
CDMP1	BG
gene-18	IG
.	O

PS1327	O
We	O
report	O
here	O
a	O
Mexican	O
patient	O
with	O
Brachydactyly-8	BP
type	O
C	O
and	O
clinical	O
features	O
of	O
angel	O
-	O
shaped	O
phalango	O
-	O
epiphyseal	O
dysplasia	O
who	O
carries	O
a	O
novel	O
mutation	O
in	O
CDMP1-28	BG
,	O
confirming	O
that	O
Brachydactyly-32	BP
type	O
C	O
and	O
angel	O
-	O
shaped	O
phalango	O
-	O
epiphyseal	O
dysplasia	O
are	O
part	O
of	O
the	O
CDMP1	BG
mutational	IG
spectrum-49	IG
.	O

PS1328	O
Screening	O
for	O
SOD1-3	BG
,	O
TARDBP-5	BG
,	O
FUS-7	BG
,	O
ANG-9	BG
,	O
ATXN2-11	BG
,	O
OPTN-13	BG
,	O
and	O
C9ORF72	O
was	O
carried	O
out	O
in	O
480	O
consecutive	O
patients	O
with	O
sporadic	O
amyotrophic	BP
lateral	IP
sclerosis-28	IP
and	O
in	O
48	O
familial	O
amyotrophic	BP
lateral	IP
sclerosis-35	IP
index	O
patients	O
admitted	O
to	O
a	O
single	O
Italian	O
referral	O
center	O
.	O

PS1332	O
In	O
order	O
to	O
understand	O
the	O
genetic	O
and	O
phenotypic	O
basis	O
for	O
Dihydropyrimidine	BG
dehydrogenase	IG
deficiency-13	IP
,	O
we	O
have	O
reviewed	O
17	O
families	O
presenting	O
22	O
patients	O
with	O
complete	O
deficiency	O
of	O
Dihydropyrimidine	BG
dehydrogenase-28	IG
.	O

PS1333	O
An	O
altered	O
beta	O
-	O
alanine	O
,	O
uracil	O
and	O
thymine	O
homeostasis	O
might	O
underlie	O
the	O
various	O
clinical	O
abnormalities	O
encountered	O
in	O
patients	O
with	O
Dihydropyrimidine	BG
dehydrogenase	IG
deficiency-23	IP
.	O

PS1334	O
Although	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
cystic	BP
fibrosis-8	IP
patients	O
has	O
been	O
defined	O
,	O
a	O
clear	O
relationship	O
between	O
the	O
defect	O
in	O
the	O
cystic	BG
fibrosis	IG
transmembrane	IG
regulator-25	IG
gene	O
and	O
pulmonary	O
inflammation	O
has	O
not	O
been	O
established	O
.	O

PS1335	O
Group	O
A	O
included	O
25	O
patients	O
who	O
carried	O
two	O
mutations	O
associated	O
with	O
a	O
pathological	O
sweat	O
test	O
and	O
pancreatic	BP
insufficiency-18	IP
(	O
deltaF508-20	BG
,	O
W1282X-22	BG
,	O
G542X-24	BG
,	O
N1303K-26	BG
,	O
S549R-28	BG
)	O
.	O

PS1336	O
The	O
disease	O
caused	O
by	O
mutation	O
in	O
GLRA1-7	BG
and	O
beta	BG
subunit	IG
of	IG
inhibitory	IG
glycine	IG
receptor-14	IG
in	O
mice	O
supports	O
the	O
notion	O
that	O
human	O
hyperekplexia-22	BP
with	O
no	O
detectable	O
mutations	O
in	O
GLRA1-28	BG
may	O
harbor	O
mutations	O
in	O
GLRA1-33	BG
and	O
beta	BG
subunit	IG
of	IG
inhibitory	IG
glycine	IG
receptor-40	IG
.	O

PS1337	O
The	O
disease	O
caused	O
by	O
mutation	O
in	O
GLRA1-7	BG
and	O
beta	BG
subunit	IG
of	IG
inhibitory	IG
glycine	IG
receptor-14	IG
in	O
mice	O
supports	O
the	O
notion	O
that	O
human	O
hyperekplexia-22	BP
with	O
no	O
detectable	O
mutations	O
in	O
GLRA1-28	BG
may	O
harbor	O
mutations	O
in	O
GLRA1-33	BG
and	O
beta	BG
subunit	IG
of	IG
inhibitory	IG
glycine	IG
receptor-40	IG
.	O

PS1340	O
We	O
report	O
a	O
novel	O
BRCA1	BG
germline	IG
4156delAA-7	IG
mutation	O
detected	O
in	O
a	O
41	O
-	O
year	O
-	O
old	O
woman	O
with	O
breast	O
and	O
ovarian	O
cancer-22	BP
.	O

PS1341	O
The	O
classification	O
of	O
thalassemia	O
intermedia	O
will	O
be	O
useful	O
for	O
genotype	O
phenotype	O
correlation	O
,	O
to	O
develop	O
management	O
guidelines	O
for	O
the	O
subgroups	O
and	O
to	O
try	O
new	O
treatment	O
modalities	O
like	O
hydroxyurea-28	BP
,	O
erythropoetin-30	BG
etc	O
.	O

PS1342	O
The	O
correlation	O
and	O
regression	O
analysis	O
of	O
all	O
possible	O
clinical	O
and	O
laboratory	O
predictors	O
of	O
intraplaque	O
iron	O
deposition	O
showed	O
that	O
four	O
factors	O
were	O
independently	O
associated	O
with	O
intraplaque	O
iron	O
deposition	O
:	O
male	O
gender	O
,	O
serum	O
homocysteine	O
,	O
Hp	BG
2	IG
-	IG
2	IG
genotype-39	IG
and	O
diabetes	BP
mellitus-42	IP
treatment	O
.	O

PS1346	O
At	O
present	O
,	O
of	O
the	O
six	O
proteins	O
involved	O
on	O
alpha	O
-	O
dystroglycanopathies-12	BP
,	O
the	O
function	O
of	O
the	O
gene	O
products	O
is	O
only	O
known	O
for	O
POMT1-24	BG
,	O
POMT2-26	BG
,	O
and	O
POMGnT1-29	BG
,	O
all	O
responsible	O
for	O
the	O
O	O
-	O
mannosylglycan	O
biosynthesis	O
.	O

PS1347	O
This	O
chapter	O
describes	O
the	O
assay	O
protocols	O
to	O
diagnose	O
patients	O
with	O
alpha	O
-	O
dystroglycanopathy-13	BP
by	O
measuring	O
glycosyltransferase-16	BG
activity	O
.	O

PS1349	O
Familial	O
isolated	O
medullary	O
thyroid	BP
carcinoma-5	IP
is	O
characterised	O
by	O
medullary	O
thyroid	BP
carcinoma-11	IP
only	O
,	O
and	O
the	O
three	O
variants	O
of	O
Multiple	O
Endocrine	O
Neoplasia2	O
are	O
related	O
to	O
germline	O
missense	O
mutations	O
of	O
the	O
RET	BG
proto	IG
-	IG
oncogene-33	IG
,	O
which	O
encodes	O
a	O
tyrosine	BG
-	IG
kinase	IG
receptor-41	IG
.	O

PS1350	O
Germline	O
RET	O
mutations	O
in	O
Multiple	O
Endocrine	O
Neoplasia2	O
patients	O
are	O
related	O
to	O
the	O
two	O
main	O
functionnal	O
domains	O
in	O
the	O
RET	BG
protein-20	IG
,	O
the	O
extracellular	O
ligand	O
binding	O
domain	O
(	O
Multiple	O
Endocrine	O
Neoplasia2A	O
and	O
Fmedullary	O
thyroid	BP
carcinoma-34	IP
)	O
and	O
the	O
intracellular	O
catalytic	O
domain	O
(	O
Multiple	O
Endocrine	O
Neoplasia2A	O
,	O
Multiple	O
Endocrine	O
Neoplasia2B	O
and	O
Fmedullary	O
thyroid	BP
carcinoma-52	IP
)	O
.	O

PS1351	O
Mechanisms	O
of	O
tumourigenesis	O
induced	O
by	O
Multiple	O
Endocrine	O
Neoplasia2	O
-	O
related	O
RET	BG
germline	IG
mutations-13	IG
have	O
been	O
analysed	O
by	O
in	O
vitro	O
studies	O
and	O
the	O
generation	O
of	O
transgenic	O
mice	O
which	O
develop	O
true	O
bilateral	O
medullary	O
thyroid	BP
carcinoma-33	IP
.	O

PS1352	O
In	O
this	O
study	O
,	O
we	O
performed	O
allelic	O
association	O
studies	O
in	O
154	O
German	O
spinal	BP
muscular	IP
atrophy-15	IP
families	O
with	O
the	O
multicopy	O
markers	O
Ag1	BG
-	IG
CA-23	IG
(	O
D5S1556-25	BG
)	O
;	O

PS1353	O
Deletions	O
were	O
detected	O
for	O
all	O
copies	O
of	O
the	O
markers	O
Ag1	BG
-	IG
CA-12	IG
(	O
C272-14	BG
)	O
and	O
C212	O
in	O
13	O
of	O
88	O
(	O
15	O
%	O
)	O
type	O
I	O
spinal	BP
muscular	IP
atrophy-30	IP
patients	O
and	O
three	O
of	O
48	O
(	O
6	O
%	O
)	O
type	O
II	O
patients	O
.	O

PS1354	O
In	O
two	O
further	O
cases	O
(	O
one	O
type	O
I	O
and	O
one	O
type	O
III	O
spinal	BP
muscular	IP
atrophy-15	IP
)	O
,	O
de	O
novo	O
deletions	O
of	O
only	O
one	O
copy	O
of	O
Ag1	BG
-	IG
CA-28	IG
and	O
C212-30	BG
were	O
found	O
.	O

PS1355	O
In	O
both	O
cases	O
the	O
patients	O
were	O
homozygously	O
deleted	O
for	O
the	O
survival	O
motor	O
neuron	O
gene	O
(	O
exons	O
7	O
and	O
8	O
)	O
but	O
only	O
the	O
type	O
I	O
spinal	BP
muscular	IP
atrophy-28	IP
patient	O
was	O
deleted	O
for	O
the	O
neuronal	BG
apoptosis	IG
inhibitory	IG
protein	IG
gene-38	IG
(	O
exons	O
5	O
and	O
6	O
)	O
.	O

PS1356	O
A	O
third	O
case	O
(	O
type	O
II	O
spinal	BP
muscular	IP
atrophy-9	IP
)	O
showed	O
de	O
novo	O
deletion	O
of	O
survival	O
motor	O
neuron	O
,	O
but	O
not	O
of	O
Ag1	BG
-	IG
CA-25	IG
,	O
C212-27	BG
and	O
neuronal	O
apoptosis	O
inhibitory	O
protein	O
.	O

PS1362	O
Expression	O
of	O
cyclooxygenase	BG
-	IG
2-5	IG
and	O
MDR1-7	BG
/	O
Pgp170-9	BG
was	O
investigated	O
in	O
tumor	O
specimens	O
along	O
with	O
normal	O
epithelium	O
in	O
breast	BP
cancer-21	IP
patients	O
using	O
immunohistochemisrty	O
.	O

PS1363	O
Expression	O
of	O
cyclooxygenase	BG
-	IG
2-5	IG
,	O
MDR1-7	BG
/	O
Pgp170-9	BG
,	O
Protein	BG
Kinase	IG
C-13	IG
,	O
and	O
Activator	BG
Protein	IG
1-18	IG
were	O
investigated	O
in	O
a	O
series	O
of	O
increasingly	O
resistant	O
human	O
MCF	O
-	O
7	O
breast	BP
cancer-32	IP
cells	O
compared	O
to	O
wild	O
type	O
using	O
immunohistochemistry	O
,	O
Western	O
blots	O
,	O
Northern	O
blots	O
,	O
RT	O
-	O
PCR	O
,	O
and	O
Southern	O
blots	O
.	O

PS1364	O
We	O
propose	O
that	O
pretreatment	O
with	O
selective	O
cyclooxygenase	BG
-	IG
2-9	IG
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
prevention	O
of	O
multidrug	O
resistance	O
in	O
response	O
to	O
cancer-23	BP
chemotherapy	O
and	O
should	O
be	O
further	O
evaluated	O
.	O

PS1365	O
Three	O
types	O
of	O
muscle	BP
glycogenosis-5	IP
are	O
briefly	O
reviewed	O
for	O
recent	O
progress	O
in	O
molecular	O
pathology	O
and	O
gene	O
diagnosis	O
,	O
type	O
II	O
glycogenosis	O
(	O
Pompe	O
disease	O
)	O
,	O
type	O
V	O
glycogenosis	O
(	O
McArdle	O
disease	O
)	O
and	O
type	BG
VII	IG
glycogenosis	IG
(	IG
Tarui	IG
disease	IG
)-41	IG
.	O

PS1367	O
Current	O
research	O
efforts	O
are	O
directed	O
towards	O
the	O
elucidation	O
of	O
various	O
features	O
of	O
the	O
disorder	O
including	O
investigations	O
on	O
Cerebral	O
autosomal	O
dominant	O
arteriopathy	O
with	O
subcortical	O
infarcts	O
and	O
leukoencephalopathy	BP
-	IP
like	IP
disorders-29	IP
,	O
early	O
cognitive	O
changes	O
,	O
specificity	O
of	O
neuroimaging	O
for	O
diagnosis	O
,	O
discovery	O
of	O
de	O
novo	O
mutations	O
,	O
the	O
development	O
of	O
Notch3-50	BG
transgenic	O
mouse	O
models	O
and	O
molecular	O
cellular	O
studies	O
in	O
Notch3-59	BG
signaling	O
.	O

PS1369	O
Glycerol	BG
kinase	IG
deficiency-3	IP
is	O
a	O
complex	O
,	O
single	O
-	O
gene	O
,	O
inborn	O
error	O
of	O
metabolism	O
wherein	O
no	O
genotype	O
-	O
phenotype	O
correlation	O
has	O
been	O
established	O
.	O

PS1370	O
Three	O
siblings	O
born	O
to	O
second	O
-	O
degree	O
cousins	O
of	O
Jewish	O
-	O
Iraqi	O
origin	O
exhibited	O
rhabdomyolysis-15	BP
and	O
myoglobinuria	O
as	O
the	O
presenting	O
signs	O
of	O
the	O
mild	O
late	O
-	O
onset	O
form	O
of	O
very	O
-	O
long	O
-	O
chain	O
acyl	BG
-	IG
CoA	IG
dehydrogenase-38	IG
deficiency	O
.	O

PS1374	O
We	O
hypothesized	O
that	O
children	O
with	O
Congenital	BP
Central	IP
Hypoventilation-8	IP
Syndrome	O
would	O
have	O
a	O
relationship	O
between	O
PHOX2B	BG
genotype-16	IG
and	O
two	O
clinically	O
applicable	O
cardiovascular	O
measures	O
of	O
autonomic	O
nervous	O
system	O
dysregulation	O
/	O
dysfunction	O
:	O
duration	O
of	O
longest	O
r	O
-	O
r	O
interval	O
and	O
longest	O
corrected	O
QT	O
interval	O
(	O
QTc	O
)	O
.	O

PS1375	O
These	O
results	O
confirm	O
a	O
disturbance	O
of	O
cardiac	O
autonomic	O
regulation	O
in	O
Congenital	BP
Central	IP
Hypoventilation-13	IP
Syndrome	O
,	O
indicate	O
that	O
PHOX2B	BG
genotype-19	IG
is	O
related	O
to	O
the	O
severity	O
of	O
dysregulation	O
,	O
predict	O
the	O
need	O
for	O
cardiac	O
pacemaker	O
,	O
and	O
offer	O
the	O
clinician	O
the	O
potential	O
to	O
avert	O
sudden	O
death	O
.	O

PS1378	O
The	O
Prolyl	BG
hydroxylase	IG
1-4	IG
(	O
EGLN2-6	BG
)	O
is	O
known	O
to	O
affect	O
tumorigenesis	O
by	O
regulating	O
the	O
degradation	O
of	O
hypoxia	BG
-	IG
inducible	IG
factor-21	IG
.	O

PS1381	O
Taken	O
together	O
,	O
our	O
findings	O
provided	O
strong	O
evidence	O
for	O
the	O
hypothesis	O
that	O
rs10680577	O
contributes	O
to	O
hepatocarcinogenesis	O
,	O
possibly	O
by	O
affecting	O
RERT	BG
-	IG
lncRNA-23	IG
structure	O
and	O
subsequently	O
EGLN2-27	BG
expression	O
,	O
making	O
it	O
a	O
promising	O
biomarker	O
for	O
early	O
diagnosis	O
of	O
hepatocelluar	BP
carcinoma-40	IP
.	O

PS1383	O
We	O
conducted	O
a	O
case	O
-	O
control	O
association	O
study	O
in	O
which	O
we	O
examined	O
the	O
correlation	O
between	O
a	O
dinucleotide	O
(	O
cytosine	O
-	O
adenine	O
,	O
CA	O
)	O
repeat	O
polymorphism	O
at	O
the	O
Calcitonin	BG
locus-30	IG
and	O
Osteoarthritis-32	BP
of	O
the	O
knee	O
in	O
88	O
patients	O
with	O
Osteoarthritis-40	BP
and	O
in	O
111	O
control	O
subjects	O
from	O
the	O
Mexican	O
mestizo	O
population	O
.	O

PS1388	O
Slow	O
saccades	O
and	O
peripheral	O
neuropathy-5	BP
were	O
not	O
seen	O
consistently	O
in	O
our	O
ethnic	O
Bengalee	O
subjects	O
with	O
SCA2	BG
genotype-17	IG
.	O

PS1389	O
Similarly	O
,	O
extrapyramidal	O
features	O
,	O
ophthalmoplegias-6	BP
and	O
distal	BP
amyotrophy-9	IP
were	O
seen	O
in	O
some	O
but	O
not	O
all	O
families	O
with	O
the	O
SCA3	BG
genotype-21	IG
.	O

PS1390	O
Of	O
the	O
20	O
sporadic	O
cases	O
with	O
cerebellar	O
ataxia-8	BP
,	O
genotype	O
analysis	O
revealed	O
2	O
cases	O
with	O
SCA1	BG
and	IG
1-18	IG
with	O
SCA2-20	BG
.	O

PS1391	O
Slow	O
saccades	O
and	O
peripheral	O
neuropathy-5	BP
were	O
not	O
seen	O
consistently	O
in	O
our	O
ethnic	O
Bengalee	O
subjects	O
with	O
SCA2	BG
genotype-17	IG
.	O

PS1392	O
Similarly	O
,	O
extrapyramidal	O
features	O
,	O
ophthalmoplegias-6	BP
and	O
distal	BP
amyotrophy-9	IP
were	O
seen	O
in	O
some	O
but	O
not	O
all	O
families	O
with	O
the	O
SCA3	BG
genotype-21	IG
.	O

PS1393	O
Of	O
the	O
20	O
sporadic	O
cases	O
with	O
cerebellar	O
ataxia-8	BP
,	O
genotype	O
analysis	O
revealed	O
2	O
cases	O
with	O
SCA1	BG
and	IG
1-18	IG
with	O
SCA2-20	BG
.	O

PS1407	O
Expansion	O
of	O
the	O
spectrum	O
of	O
disease	O
associated	O
with	O
the	O
Cystic	BG
fibrosisTR	IG
mutant	IG
genes-13	IG
creates	O
a	O
need	O
for	O
revision	O
of	O
the	O
diagnostic	O
criteria	O
for	O
Cystic	O
fibrosis	O
and	O
a	O
dilemma	O
for	O
setting	O
nosologic	O
boundaries	O
between	O
Cystic	BP
fibrosis-35	IP
and	O
other	O
diseases	O
with	O
Cystic	BG
fibrosisTR	IG
etiology-42	IG
.	O

PS1409	O
Hybrids	O
between	O
Syrian	O
hamster	O
melanoma-5	BP
cells	O
and	O
mouse	O
fibroblasts	O
,	O
containing	O
one	O
genome	O
(	O
1s	O
)	O
of	O
each	O
parent	O
,	O
produce	O
neither	O
melanin	O
nor	O
DOPA	BG
-	IG
oxidase-27	IG
(	O
"	O
extinction	O
"	O
)	O
.	O

PS1413	O
Individuals	O
affected	O
by	O
the	O
most	O
common	O
mutations	O
,	O
SZ	O
and	O
ZZ	O
,	O
have	O
serum	O
Alpha	BG
-	IG
1	IG
antitrypsin-18	IG
concentrations	O
of	O
25	O
%	O
and	O
15	O
%	O
of	O
normal	O
levels	O
,	O
and	O
present	O
a	O
higher	O
risk	O
of	O
emphysema-36	BP
.	O

PS1417	O
Disease	O
severity	O
varies	O
among	O
cystic	BP
fibrosis-6	IP
patients	O
carrying	O
the	O
same	O
cystic	BG
fibrosisTR	IG
genotype-13	IG
.	O

PS1418	O
Only	O
aberrantly	O
spliced	O
cystic	BG
fibrosisTR	IG
RNA-6	IG
was	O
detected	O
in	O
the	O
lung	O
of	O
a	O
patient	O
with	O
severe	BP
lung	IP
disease-18	IP
who	O
underwent	O
lung	O
transplantation	O
.	O

PS1419	O
Merosin-1	BG
deficient	O
congenital	O
muscular	BG
dystrophy	IG
1A-6	IG
results	O
from	O
mutations	O
in	O
the	O
LAMA2	BG
gene-13	IG
.	O

PS1422	O
Diagnosis	O
can	O
be	O
confirmed	O
either	O
by	O
biochemical	O
assays	O
showing	O
qualitative	O
or	O
quantitative	BP
abnormalities-13	IP
in	O
type	BG
III	IG
collagen-17	IG
secretion	O
or	O
by	O
molecular	O
biology	O
studies	O
demonstrating	O
mutation	O
of	O
the	O
COL3A1	BG
gene-29	IG
.	O

PS1423	O
mRNA	O
and	O
protein	O
expression	O
of	O
BAG	BG
-	IG
1-8	IG
in	O
lung	O
tissue	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer-18	BP
postoperative	O
patients	O
(	O
I	O
-	O
IIIA	O
stage	O
)	O
or	O
healthy	O
subjects	O
were	O
detected	O
using	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O

PS1426	O
Merosin-1	BG
-	O
deficient	O
congenital	O
muscular	BP
dystrophy-6	IP
type	O
1A	O
is	O
one	O
of	O
the	O
most	O
frequent	O
forms	O
of	O
Cmuscular	BP
dystrophy-18	IP
in	O
Western	O
countries	O
.	O

PS1427	O
To	O
explore	O
the	O
relationship	O
between	O
electrophysiological	O
changes	O
,	O
clinical	O
phenotype	O
and	O
genotype	O
in	O
Duchenne	O
and	O
Becker	O
muscular	BP
dystrophy-18	IP
(	O
DMD	O
/	O
BMD	O
)	O
,	O
to	O
address	O
the	O
expression	O
and	O
roles	O
of	O
dystrophin-32	BG
and	O
its	O
isoforms	O
on	O
the	O
retina	O
,	O
and	O
to	O
inquire	O
into	O
the	O
molecular	O
mechanism	O
of	O
the	O
abnormal	O
electroretinogram	O
(	O
ERG	O
)	O
on	O
DMD	O
/	O
BMD	O
patients	O
with	O
different	O
genotype	O
.	O

PS1430	O
The	O
risk	O
of	O
amyloidosis	O
is	O
increased	O
in	O
male	O
Familial	O
Mediterranean	O
fever-11	BP
patients	O
and	O
in	O
patients	O
bearing	O
polymorphism	O
a	O
/	O
a	O
in	O
the	O
SAA1	BG
gene-24	IG
.	O

PS1432	O
Over	O
30	O
mutations	O
have	O
been	O
described	O
in	O
the	O
Diastrophic	BG
dysplasia	IG
sulfate	IG
transporter	IG
gene-13	IG
,	O
which	O
result	O
in	O
a	O
continuous	O
clinical	O
spectrum	O
of	O
recessively	O
inherited	O
chondrodysplasias	O
,	O
including	O
,	O
in	O
order	O
of	O
increasing	O
severity	O
,	O
a	O
recessive	O
form	O
of	O
multiple	O
epiphyseal	O
dysplasia	O
,	O
diastrophic	O
dysplasia	O
,	O
atelosteogenesis	BP
type	IP
II-48	IP
and	O
achondrogenesis	O
1B	O
.	O

PS1435	O
The	O
four	O
polymorphisms	O
of	O
the	O
feoB	BG
gene-7	IG
observed	O
appear	O
to	O
be	O
related	O
to	O
the	O
clinical	O
phenotype	O
of	O
iron	O
-	O
deficiency	O
anemia-21	BP
,	O
but	O
the	O
relation	O
is	O
unclear	O
because	O
of	O
the	O
small	O
number	O
of	O
strains	O
studied	O
.	O

PS1438	O
To	O
date	O
,	O
associated	O
with	O
episodic	BP
ataxia-7	IP
type	O
2	O
,	O
in	O
the	O
CACNA1A	BG
gene-14	IG
thirty	O
different	O
mutations	O
have	O
been	O
described	O
,	O
resulting	O
in	O
altered	O
or	O
truncated	O
protein	O
products	O
and	O
,	O
as	O
a	O
consequence	O
,	O
in	O
nonfunctional	O
calcium	O
channels	O
.	O

PS1442	O
FEV1	O
values	O
were	O
significantly	O
lowered	O
and	O
a	O
significantly	O
earlier	O
age	O
at	O
onset	O
of	O
Pseudomonas	BP
aeruginosa	IP
colonisation-16	IP
was	O
found	O
in	O
CF	O
patients	O
with	O
at	O
least	O
one	O
MBL2	BG
variant-27	IG
.	O

PS1443	O
Mutations	O
in	O
the	O
RMRP	BG
gene-5	IG
lead	O
to	O
a	O
wide	O
spectrum	O
of	O
autosomal	O
recessive	O
skeletal	O
dysplasias	O
,	O
ranging	O
from	O
the	O
milder	O
phenotypes	O
metaphyseal	O
dysplasia	O
without	O
hypotrichosis-25	BP
and	O
cartilage	BP
hair	IP
hypoplasia-29	IP
to	O
the	O
severe	O
anauxetic	BP
dysplasia-34	IP
.	O

PS1444	O
In	O
vitro	O
testing	O
of	O
RNase	BG
MRP-6	IG
multiprotein	O
-	O
specific	O
messenger	O
RNA	O
and	O
ribosomal	O
RNA	O
cleavage	O
of	O
different	O
mutations	O
revealed	O
a	O
strong	O
correlation	O
between	O
the	O
decrease	O
in	O
ribosomal	O
RNA	O
cleavage	O
in	O
ribosomal	O
assembly	O
and	O
the	O
degree	O
of	O
bone	BP
dysplasia-38	IP
,	O
whereas	O
reduced	O
messenger	O
RNA	O
cleavage	O
,	O
and	O
thus	O
cell	O
-	O
cycle	O
impairment	O
,	O
predicts	O
the	O
presence	O
of	O
hair	BP
hypoplasia-58	IP
,	O
immunodeficiency	O
,	O
and	O
hematological	O
abnormalities	O
and	O
thus	O
increased	BP
cancer	IP
risk-69	IP
.	O

PS1447	O
Recently	O
,	O
six	O
different	O
mutations	O
on	O
the	O
UBIAD1	BG
gene-9	IG
on	O
chromosome	O
1p36	O
were	O
found	O
to	O
result	O
in	O
Schnyder	O
crystalline	O
corneal	BP
dystrophy-21	IP
.	O

PS1448	O
The	O
purpose	O
of	O
this	O
article	O
is	O
to	O
further	O
characterize	O
the	O
mutation	O
spectrum	O
of	O
Schnyder	O
crystalline	O
corneal	BP
dystrophy-17	IP
and	O
identify	O
structural	O
and	O
functional	O
consequences	O
for	O
UBIAD1	BG
protein-26	IG
activity	O
.	O

PS1449	O
Protein	O
analysis	O
revealed	O
structural	O
and	O
functional	O
implications	O
of	O
Schnyder	O
crystalline	O
corneal	BP
dystrophy-12	IP
mutations	O
which	O
may	O
affect	O
UBIAD1-17	BG
function	O
,	O
ligand	O
binding	O
and	O
interaction	O
with	O
binding	O
partners	O
,	O
like	O
apo	BG
E-30	IG
.	O

PS1455	O
Late	O
-	O
onset	O
STGD1-4	BG
is	O
at	O
the	O
mild	O
end	O
of	O
the	O
spectrum	O
of	O
retinal	BP
dystrophies-15	IP
caused	O
by	O
ABCA4	O
mutations	O
.	O

PS1456	O
A	O
total	O
of	O
54	O
Finnish	O
Osteogenesis	O
imperfecta	O
patients	O
with	O
previously	O
diagnosed	O
hearing	BP
loss-13	IP
or	O
age	O
35	O
or	O
more	O
years	O
were	O
analyzed	O
here	O
for	O
mutations	O
in	O
COL1A1-26	BG
or	O
COL1A2-28	BG
.	O

PS1457	O
Records	O
from	O
nine	O
purebred	O
and	O
three	O
composite	O
breeds	O
and	O
a	O
variety	O
of	O
F1-13	BG
and	O
three	O
-	O
way	O
crosses	O
,	O
including	O
the	O
progeny	O
of	O
12	O
additional	O
different	O
sire	O
breeds	O
produced	O
over	O
a	O
20	O
-	O
yr	O
period	O
(	O
1983	O
to	O
2002	O
)	O
,	O
were	O
evaluated	O
for	O
breed	O
and	O
heterozygosity	O
effects	O
on	O
the	O
observed	O
incidence	O
of	O
bovine	O
respiratory	BP
disease-56	IP
.	O

PS1458	O
Analysis	O
of	O
hereditary	O
pheochromocytoma-4	BP
two	O
gene	O
tests	O
are	O
established	O
:	O
detection	O
of	O
multiple	O
endocrine	O
neoplasia-15	BP
type	O
2	O
using	O
mutational	O
analysis	O
of	O
RET	BG
gene-23	IG
and	O
detection	O
of	O
von	O
Hippel	O
-	O
Lindau	O
syndrome	O
using	O
mutational	O
analysis	O
of	O
VHL	BG
gene-37	IG
.	O

PS1459	O
In	O
extensive	O
epidemiology	O
the	O
following	O
facts	O
are	O
established	O
:	O
hereditary	O
mutations	O
in	O
the	O
RET	BG
gene-15	IG
in	O
>	O
92	O
%	O
of	O
cases	O
with	O
multiple	O
endocrine	O
neoplasia-25	BP
type	O
2	O
syndrome	O
while	O
in	O
patients	O
with	O
von	O
Hippel	O
-	O
Lindau	O
syndrome	O
hereditary	O
mutations	O
were	O
detected	O
in	O
VHL	O
gene	O
in	O
>	O
95	O
%	O
of	O
cases	O
.	O

PS1460	O
If	O
a	O
patient	O
with	O
pheochromocytoma-5	BP
presents	O
with	O
hereditary	O
mutation	O
in	O
the	O
RET-12	BG
or	O
VHL	BG
gene-15	IG
,	O
family	O
gene	O
testing	O
is	O
recommended	O
.	O

PS1466	O
A	O
significant	O
negative	O
correlation	O
was	O
found	O
between	O
residuals	O
of	O
log	O
spleen	O
mass	O
(	O
controlled	O
for	O
body	O
mass	O
)	O
and	O
phytohaemagglutinin-20	BG
response	O
,	O
suggesting	O
that	O
these	O
two	O
components	O
of	O
immune	O
function	O
are	O
not	O
independent	O
measures	O
of	O
defence	O
against	O
parasitism-38	BP
.	O

PS1467	O
Lactase-1	BG
non	O
-	O
persistence	O
(	O
adult	O
-	O
type	O
hypolactasia-9	BP
)	O
is	O
present	O
in	O
more	O
than	O
half	O
of	O
the	O
human	O
population	O
and	O
is	O
caused	O
by	O
the	O
down	O
-	O
regulation	O
of	O
lactase	BG
enzyme-31	IG
activity	O
during	O
childhood	O
.	O

PS1468	O
Congenital	BG
lactase	IG
deficiency-3	IP
is	O
a	O
rare	O
severe	O
gastrointestinal	O
disorder	O
of	O
new	O
-	O
borns	O
enriched	O
in	O
the	O
Finnish	O
population	O
.	O

PS1471	O
This	O
study	O
reveals	O
that	O
germline	O
Von	O
Hippel	O
-	O
Lindau	O
disease	O
deletions	O
provide	O
a	O
particularly	O
rich	O
source	O
for	O
the	O
study	O
of	O
Alu-21	BG
-	O
mediated	O
unequal	O
crossover	O
events	O
,	O
and	O
provides	O
evidence	O
for	O
a	O
protective	O
role	O
of	O
the	O
loss	O
of	O
the	O
actin	BG
-	IG
regulator	IG
gene-43	IG
HSPC300	O
for	O
the	O
development	O
of	O
both	O
renal	BP
cell	IP
carcinomas-52	IP
and	O
AR	O
.	O

PS1473	O
The	O
GNAS1	BG
gene-3	IG
exhibits	O
imprinting	O
and	O
maternally	O
inherited	O
mutations	O
have	O
previously	O
been	O
shown	O
to	O
result	O
in	O
Albright	O
'	O
s	O
hereditary	O
osteodystrophy-21	BP
(	O
OMIM	O
103580	O
)	O
with	O
pseudohypothyroidism-27	BP
type	O
1a	O
,	O
whereas	O
paternally	O
inherited	O
mutations	O
result	O
in	O
progressive	O
osseous	O
heteroplasia-39	BP
or	O
the	O
Albright	O
'	O
s	O
hereditary	BP
osteodystrophy-46	IP
phenotype	O
with	O
pseudopseudohypothyroidism-49	BP
(	O
OMIM	O
300800	O
)	O
.	O

PS1474	O
With	O
only	O
nine	O
mutations	O
of	O
the	O
GNAS1	BG
gene-8	IG
reported	O
so	O
far	O
in	O
progressive	O
osseous	O
heteroplasia-15	BP
,	O
this	O
new	O
mutation	O
helps	O
to	O
extend	O
further	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS1475	O
WDR36-1	BG
,	O
at	O
locus	O
GLC1G	O
,	O
was	O
initially	O
identified	O
as	O
a	O
gene	O
with	O
a	O
low	O
frequency	O
of	O
non	O
-	O
synonymous	O
sequence	O
variations	O
that	O
were	O
exclusive	O
to	O
adult	O
-	O
onset	O
Primary	O
open	O
-	O
angle	O
glaucoma-34	BP
patients	O
.	O

PS1477	O
The	O
19q	O
segment	O
contained	O
the	O
genes	O
AKT2-7	BG
,	O
CEACAM1-9	BG
,	O
CEBPA-11	BG
,	O
LIPE	O
,	O
and	O
TGFB1-16	BG
which	O
are	O
involved	O
in	O
adipose	O
tissue	O
homeostasis	O
and	O
insulin	BP
resistance-26	IP
,	O
and	O
could	O
potentially	O
contribute	O
to	O
the	O
obese	O
phenotype	O
observed	O
.	O

PS1478	O
Deficiency	O
of	O
21	O
hydroxylase	BG
enzyme	IG
deficiency-6	IP
(	O
21OH	O
)	O
activity	O
accounts	O
for	O
90	O
%	O
cases	O
of	O
congenital	BP
adrenal	IP
hyperplasia-19	IP
.	O

PS1481	O
Optineurin	BG
gene-2	IG
mutations	O
are	O
reported	O
in	O
primary	O
open	O
angle	O
glaucoma-10	BP
patients	O
from	O
different	O
populations	O
.	O

PS1482	O
The	O
coding	O
and	O
noncoding	O
regions	O
of	O
Optineurin	BG
gene-8	IG
were	O
screened	O
for	O
mutations	O
in	O
100	O
Indian	O
high	O
tension	O
glaucoma-18	BP
patients	O
.	O

PS1483	O
The	O
frequency	O
of	O
the	O
Optineurin	BG
gene	IG
M98K	IG
mutation-8	IG
in	O
an	O
additional	O
120	O
patients	O
(	O
70	O
high	O
tension	O
glaucoma-18	BP
patients	O
and	O
50	O
normal	O
tension	O
glaucoma-24	BP
[	O
NTG	O
]	O
)	O
was	O
analyzed	O
by	O
restriction	O
enzyme	O
digestion	O
.	O

PS1485	O
The	O
current	O
study	O
suggests	O
a	O
possible	O
role	O
of	O
SNPs	O
rather	O
than	O
mutations	O
in	O
Optineurin	BG
gene-15	IG
in	O
primary	O
open	O
angle	O
glaucoma-20	BP
patients	O
pathology	O
in	O
the	O
Indian	O
population	O
.	O

PS1488	O
Our	O
findings	O
provide	O
support	O
for	O
diverse	O
roles	O
of	O
ESR1-9	BG
polymorphism	O
in	O
determining	O
susceptibility	O
in	O
different	O
stages	O
of	O
breast	BP
cancer-19	IP
.	O

PS1489	O
The	O
differences	O
between	O
the	O
important	O
ESR1	O
single	O
-	O
nucleotide	O
polymorphismss	O
identified	O
in	O
Chinese	O
women	O
in	O
this	O
study	O
and	O
those	O
identified	O
in	O
studies	O
on	O
Western	O
women	O
with	O
breast	BP
cancer-28	IP
suggest	O
different	O
roles	O
of	O
estrogen	BG
receptor	IG
alpha-35	IG
in	O
these	O
two	O
populations	O
.	O

PS1490	O
We	O
previously	O
reported	O
a	O
family	O
,	O
in	O
which	O
three	O
individuals	O
had	O
partial	O
complement	O
regulator	O
factor	BG
H	IG
deficiency-17	IP
but	O
only	O
one	O
was	O
affected	O
by	O
Atypical	O
hemolytic	O
uremic	O
syndrome	O
.	O

PS1493	O
In	O
this	O
paper	O
we	O
present	O
the	O
phenotype	O
-	O
genotype	O
correlation	O
of	O
20	O
unrelated	O
Chinese	O
families	O
with	O
15	O
cases	O
of	O
multiple	O
endocrine	O
neoplasia-22	BP
type	O
2A	O
and	O
five	O
cases	O
of	O
MEN2B-29	BG
.	O

PS1494	O
Among	O
them	O
,	O
119	O
family	O
members	O
were	O
from	O
multiple	O
endocrine	O
neoplasia-11	BP
type	O
2A	O
pedigrees	O
(	O
including	O
15	O
multiple	O
endocrine	O
neoplasia-20	BP
type	O
2A	O
probands	O
)	O
and	O
28	O
members	O
from	O
MEN2B-29	BG
pedigrees	O
(	O
including	O
five	O
MEN2B	O
probands	O
)	O
.	O

PS1495	O
Five	O
germline	O
mutations	O
,	O
all	O
located	O
at	O
codon	O
634	O
of	O
exon11	O
in	O
the	O
RET	BG
proto	IG
-	IG
oncogene-17	IG
,	O
were	O
detected	O
in	O
all	O
of	O
the	O
37	O
multiple	O
endocrine	O
neoplasia-28	BP
type	O
2A	O
patients	O
.	O

PS1496	O
RET	BG
proto	IG
-	IG
oncogene-4	IG
mutations	O
were	O
restricted	O
to	O
codon	O
634	O
and	O
918	O
in	O
Chinese	O
families	O
with	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2A-21	IG
and	O
MEN2B-23	BG
.	O

PS1497	O
In	O
general	O
the	O
genetic	O
characteristics	O
of	O
these	O
patients	O
with	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2A-14	IG
and	O
MEN2B-16	BG
reflect	O
the	O
general	O
pattern	O
around	O
the	O
world	O
and	O
it	O
remains	O
to	O
be	O
determined	O
with	O
larger	O
studies	O
in	O
China	O
whether	O
Chinese	O
patients	O
have	O
a	O
different	O
genetic	O
pattern	O
of	O
mutations	O
.	O

PS1499	O
some	O
may	O
require	O
regular	O
blood	O
transfusions	O
and	O
even	O
be	O
as	O
severely	O
affected	O
as	O
Hb	BG
H	IG
hydrops	IG
fetalis-17	IG
.	O

PS1500	O
Humans	O
carrying	O
HCN4-3	BG
mutations	O
indeed	O
display	O
significant	O
bradycardia-8	BP
.	O

PS1501	O
Thirty	O
four	O
symptomatic	O
and	O
17	O
presymptomatic	O
patients	O
from	O
21	O
autosomal	O
dominant	O
facioscapuloperoneal	O
muscular	BP
dystrophy-14	IP
families	O
were	O
found	O
by	O
the	O
probe	O
p13E	O
-	O
11	O
and	O
enzymes	O
EcoRI-26	BG
/	O
BlnI-28	BG
to	O
have	O
DNA	O
fragments	O
size	O
between	O
13	O
-	O
35	O
kb	O
(	O
double	O
digestion	O
)	O
and	O
in	O
other	O
8	O
presymptomatic	O
patients	O
-	O
37	O
-	O
39	O
kb	O
,	O
in	O
one	O
presymptomatic	O
woman	O
-	O
45	O
kb	O
caused	O
by	O
deletion	O
related	O
to	O
the	O
disease	O
and	O
linked	O
with	O
chromosome	O
4q35	O
.	O

PS1502	O
We	O
report	O
here	O
the	O
ability	O
to	O
resist	O
to	O
5	O
-	O
fluorouracil	O
-	O
induced	O
apoptosis	O
of	O
8	O
colon	BP
cancer-18	IP
cell	O
lines	O
differing	O
in	O
p53-23	BG
and	O
bax-25	BG
status	O
:	O
p53	O
(	O
-	O
/	O
0	O
)	O
bax	O
(	O
+	O
/	O
+	O
)	O
for	O
TC7-41	BG
,	O
SW480-43	BG
,	O
HT	BG
-	IG
29-47	IG
;	O

PS1505	O
The	O
frequency	O
of	O
the	O
apolipoproteinlipoprotein	BG
B3500	IG
mutation-7	IG
was	O
8	O
%	O
in	O
Belgians	O
with	O
type	O
IIa	O
hyperlipidemia-16	BP
,	O
indicating	O
that	O
the	O
prevalence	O
of	O
familial	O
defective	O
apolipoprotein	BG
B	IG
-	IG
100-28	IG
may	O
be	O
as	O
high	O
as	O
1	O
in	O
250	O
in	O
the	O
general	O
Belgian	O
population	O
.	O

PS1507	O
In	O
the	O
present	O
study	O
,	O
mutation	O
analysis	O
of	O
the	O
TECTA	BG
gene-11	IG
was	O
performed	O
in	O
62	O
Korean	O
patients	O
with	O
hereditary	O
hearing	BP
loss-21	IP
.	O

PS1509	O
Ten	O
years	O
after	O
the	O
first	O
description	O
of	O
activating	O
mutations	O
in	O
the	O
thyroid	BG
stimulating	IG
hormone	IG
receptor-15	IG
gene	O
in	O
sporadic	O
autonomous	O
hyperfunctioning	O
thyroid	BP
adenomas-22	IP
,	O
there	O
is	O
general	O
agreement	O
in	O
assigning	O
a	O
major	O
pathogenic	O
role	O
of	O
this	O
genetic	O
abnormality	O
,	O
acting	O
via	O
the	O
constitutive	O
activation	O
of	O
the	O
cAMP	O
pathway	O
,	O
in	O
both	O
the	O
growth	O
and	O
functional	O
characteristic	O
of	O
these	O
tumours	O
.	O

PS1516	O
We	O
report	O
a	O
family	O
and	O
a	O
single	O
patient	O
in	O
China	O
involved	O
with	O
merosin-13	BG
-	O
deficient	O
congenital	O
muscular	BP
dystrophy-18	IP
(	O
MDC1A	O
)	O
with	O
typical	O
clinical	O
symptoms	O
.	O

PS1518	O
Such	O
an	O
effect	O
may	O
be	O
synergistic	O
with	O
other	O
genetic	O
variables	O
,	O
such	O
as	O
fetal-14	BP
hemoglobin-15	BG
levels	O
,	O
F	O
-	O
cell	O
numbers	O
,	O
and	O
the	O
number	O
of	O
alpha	BG
-	IG
globin	IG
genes-30	IG
,	O
in	O
determining	O
intracellular	O
polymerization	O
and	O
,	O
thus	O
,	O
the	O
severity	O
of	O
the	O
sickle	O
cell	O
syndromes	O
.	O

PS1519	O
Mice	BG
lacking	IG
peroxisome	IG
proliferator	IG
activated	IG
receptor	IG
alpha-7	IG
fail	O
to	O
respond	O
to	O
the	O
inductive	O
effects	O
of	O
peroxisome	O
proliferators	O
,	O
whereas	O
those	O
lacking	O
fatty	O
acyl	BG
-	IG
CoA	IG
oxidase-26	IG
,	O
the	O
first	O
enzyme	O
of	O
the	O
peroxisomal	O
beta	O
-	O
oxidation	O
system	O
,	O
exhibit	O
extensive	O
microvesicular	BP
steatohepatitis-42	IP
,	O
leading	O
to	O
hepatocellular	BP
regeneration-47	IP
and	O
massive	O
peroxisome	O
proliferation	O
,	O
implying	O
sustained	O
activation	O
of	O
peroxisome	BG
proliferator	IG
activated	IG
receptor	IG
alpha-61	IG
by	O
natural	O
ligands	O
.	O

PS1520	O
In	O
acyl	BG
-	IG
CoA	IG
oxidase-5	IG
mice	O
,	O
the	O
hyperactivity	O
of	O
peroxisome	BG
proliferator-12	IG
activated	O
receptor	BG
alpha-15	IG
enhances	O
the	O
severity	O
of	O
steatosis	O
by	O
inducing	O
CYP4A	BG
family	IG
proteins-25	IG
that	O
generate	O
dicarboxylic	O
acids	O
and	O
since	O
they	O
are	O
not	O
metabolized	O
in	O
the	O
absence	O
of	O
peroxisomal	O
beta	O
-	O
oxidation	O
,	O
they	O
damage	O
mitochondria	O
leading	O
to	O
steatosis-50	BP
.	O

PS1522	O
These	O
data	O
define	O
a	O
critical	O
role	O
for	O
both	O
peroxisome	BG
proliferator	IG
activated	IG
receptor	IG
alpha-13	IG
and	O
AOX-15	BG
in	O
hepatic	O
lipid	O
metabolism	O
and	O
in	O
the	O
pathogenesis	O
of	O
specific	O
fatty	BP
liver-27	IP
phenotype	O
.	O

PS1523	O
We	O
have	O
identified	O
a	O
germline	O
2631	O
bp	O
duplication	O
that	O
includes	O
exon	O
6	O
of	O
SMARCB1-14	BG
in	O
a	O
unique	O
family	O
with	O
a	O
four	O
generation	O
history	O
of	O
malignant	O
rhabdoid	O
tumour	O
predisposition	O
and	O
schwannomatosis-30	BP
.	O

PS1524	O
A	O
molecular	O
study	O
of	O
the	O
variability	O
of	O
the	O
RD2	BG
region-10	IG
was	O
carried	O
out	O
with	O
77	O
independent	O
Italian	O
group	O
A	O
streptococci	O
,	O
66	O
erythromycin	O
resistant	O
and	O
11	O
erythromycin	O
susceptible	O
,	O
which	O
had	O
previously	O
been	O
investigated	O
for	O
the	O
association	O
between	O
erythromycin	BP
resistance-40	IP
and	O
ability	O
to	O
enter	O
human	O
respiratory	O
cells	O
.	O

PS1525	O
Comparison	O
and	O
correlation	O
of	O
RD2	O
typing	O
data	O
with	O
the	O
genotype	O
and	O
phenotype	O
of	O
macrolide	BP
resistance-15	IP
and	O
with	O
data	O
from	O
PCR	O
M	O
typing	O
and	O
SmaI-24	BG
macrorestriction	O
analysis	O
allowed	O
us	O
to	O
identify	O
41	O
different	O
clones	O
(	O
31	O
among	O
the	O
66	O
erythromycin	O
resistant	O
isolates	O
and	O
10	O
among	O
the	O
11	O
erythromycin	O
susceptible	O
isolates	O
)	O
.	O

PS1526	O
In	O
this	O
retrospective	O
study	O
,	O
we	O
analyze	O
the	O
drug	BG
susceptibility-10	IG
phenotype	O
and	O
the	O
replication	O
capacity	O
of	O
virus	O
isolates	O
obtained	O
at	O
the	O
peaks	O
of	O
viremia	O
during	O
five	O
consecutive	O
structured	O
treatment	O
interruptions	O
in	O
12	O
chronically	O
human	O
immunodeficiency-35	BP
virus	O
type	O
1	O
-	O
infected	O
patients	O
.	O

PS1527	O
X	O
-	O
linked	O
alpha	O
-	O
thalassemia	O
/	O
mental	O
retardation	O
syndrome	O
(	O
ATR	BG
-	IG
X-14	IG
)	O
is	O
one	O
of	O
the	O
many	O
known	O
X	O
-	O
linked	O
mental	BP
retardation-26	IP
syndromes	O
.	O

PS1529	O
The	O
known	O
tumor	BG
necrosis	IG
factor	IG
(	IG
ligand	IG
)	IG
superfamily	IG
,	IG
member	IG
4	IG
gene-13	IG
(	O
TNFSF4-15	BG
)	O
systemic	BP
lupus	IP
erythematosus-19	IP
risk	O
locus	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
systemic	O
sclerosis	O
in	O
2	O
studies	O
,	O
but	O
with	O
discrepancies	O
between	O
them	O
for	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS1530	O
Known	O
systemic	BP
lupus	IP
erythematosus-4	IP
and	O
systemic	O
sclerosis	O
TNFSF4	BG
susceptibility	IG
variants-10	IG
(	O
rs2205960-12	BG
,	O
rs1234317-14	BG
,	O
rs12039904-16	BG
,	O
rs10912580-18	BG
,	O
and	O
rs844648	O
)	O
were	O
genotyped	O
in	O
1031	O
patients	O
with	O
systemic	O
sclerosis-30	BP
and	O
1014	O
controls	O
of	O
French	O
white	O
ancestry	O
.	O

PS1531	O
The	O
newly	O
identified	O
patient	O
is	O
consanguineous	O
with	O
the	O
first	O
patients	O
reported	O
with	O
alpha	O
-	O
NAGA	O
deficiency	O
and	O
neuroaxonal	BP
dystrophy-19	IP
and	O
they	O
all	O
had	O
the	O
alpha	BG
-	IG
NAGA-27	IG
genotype	O
E325K-29	BG
/	O
E325K-31	BG
.	O

PS1532	O
Two	O
affected	O
sibs	O
,	O
homozygotes	O
for	O
E325K-7	BG
,	O
are	O
severely	O
affected	O
and	O
have	O
the	O
signs	O
and	O
symptoms	O
of	O
infantile	O
neuroaxonal	BP
dystrophy-21	IP
,	O
but	O
prominent	O
vacuolisation	O
is	O
lacking	O
.	O

PS1533	O
Studies	O
of	O
distal	O
myopathy-4	BP
with	O
rimmed	O
vacuoles	O
revealed	O
that	O
most	O
patients	O
had	O
mutations	O
in	O
the	O
UDP	BG
-	IG
N	IG
-	IG
acetylglucosamine	IG
2	IG
-	IG
epimerase	IG
/	IG
N	IG
-	IG
acetylmannosamine	IG
kinase-28	IG
(	O
GNE-30	BG
)	O
gene	O
.	O

PS1534	O
The	O
compound	O
heterozygous	O
mutations	O
in	O
the	O
epimerase	BG
domain-8	IG
of	O
the	O
GNE	BG
gene-12	IG
are	O
important	O
in	O
the	O
severe	O
phenotype	O
of	O
distal	O
myopathy-21	BP
with	O
rimmed	O
vacuoles	O
.	O

PS1536	O
In	O
contrast	O
to	O
mice	O
transgenic	O
for	O
the	O
same	O
gene	O
construct	O
,	O
tyrosinase-12	BG
-	O
transgenic	O
rabbits	O
showed	O
a	O
greater	O
variety	O
in	O
hue	O
,	O
intensity	O
and	O
extent	O
of	O
coat	O
pigmentation-28	BP
,	O
which	O
is	O
caused	O
by	O
the	O
diversity	O
in	O
the	O
loci	O
affecting	O
the	O
melanization	O
.	O

PS1537	O
Organic	O
cation	O
transporter	O
gene	O
cluster	O
variants	O
may	O
confer	O
susceptibility	O
to	O
both	O
Crohn	BP
'	IP
s	IP
disease-15	IP
and	O
ulcerative	BP
colitis-18	IP
,	O
and	O
the	O
TC	O
haplotype	O
may	O
influence	O
some	O
clinical	O
features	O
of	O
IBD	O
,	O
but	O
does	O
not	O
interact	O
with	O
CARD15	BG
variants-38	IG
.	O

PS1538	O
Once	O
introduced	O
to	O
Arabidopsis-4	BP
(	O
Arabidopsis	O
thaliana	O
)	O
,	O
GhVacuolar	BG
invertase1-11	IG
complemented	O
the	O
short	O
-	O
root	O
phenotype	O
of	O
a	O
Vacuolar	BG
invertase	IG
T	IG
-	IG
DNA	IG
mutant-25	IG
and	O
enhanced	O
the	O
elongation	O
of	O
root	O
cells	O
in	O
the	O
wild	O
type	O
.	O

PS1540	O
Individuals	O
from	O
13	O
families	O
with	O
phenotypes	O
suggestive	O
of	O
MYH9-9	BG
-	O
related	O
hereditary	O
macrothrombocytopenia-13	BP
were	O
screened	O
for	O
mutations	O
by	O
Denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
followed	O
by	O
direct	O
sequencing	O
of	O
samples	O
with	O
aberrant	O
column	O
retention	O
time	O
.	O

PS1542	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
due	O
to	O
21	O
-	O
hydroxylase-8	BG
deficiency	O
is	O
one	O
of	O
the	O
most	O
common	O
autosomal	O
recessive	O
hereditary	O
diseases	O
.	O

PS1543	O
In	O
patients	O
with	O
classic	O
Congenital	O
adrenal	O
hyperplasia	O
obesity-8	BP
,	O
hyperinsulinaemia-10	BP
,	O
insulin	BP
resistance-13	IP
,	O
and	O
hyperleptinaemia-16	BP
are	O
more	O
often	O
seen	O
than	O
in	O
the	O
general	O
population	O
.	O

PS1545	O
Three	O
asymptomatic	O
parents	O
of	O
children	O
affected	O
with	O
Congenital	BP
Central	IP
Hypoventilation-10	IP
Syndrome	O
,	O
and	O
found	O
to	O
carry	O
the	O
same	O
PHOX2B-19	BG
expansion	O
mutations	O
as	O
their	O
siblings	O
,	O
were	O
studied	O
by	O
overnight	O
polysomnography	O
and	O
somatic	O
mosaicism	O
analysis	O
.	O

PS1547	O
However	O
,	O
dy	O
(	O
W	O
)	O
/	O
dy	O
(	O
W	O
)	O
mice	O
,	O
expressing	O
the	O
human	BG
laminin	IG
alpha2-18	IG
under	O
the	O
control	O
of	O
the	O
striated	O
muscle	O
-	O
specific	O
portion	O
of	O
the	O
desmin	BG
promoter-32	IG
,	O
still	O
developed	O
muscular	BP
dystrophy-37	IP
.	O

PS1551	O
The	O
findings	O
suggest	O
that	O
mu	BG
-	IG
opioid	IG
receptor-8	IG
haplotypes	O
in	O
monkeys	O
can	O
contribute	O
to	O
individual	O
variability	O
in	O
stress	O
response	O
and	O
related	O
aggression-22	BP
.	O

PS1552	O
Both	O
angiomyolipoma-2	BP
and	O
cysts	O
were	O
significantly	O
more	O
common	O
and	O
more	O
numerous	O
in	O
TSC2-13	BG
than	O
in	O
TSC1-16	BG
.	O

PS1553	O
Deficient	O
activity	O
in	O
the	O
glucose	O
-	O
6	O
-	O
phosphatase	O
-	O
a	O
(	O
glucose	O
-	O
6	O
-	O
phosphatase	O
-	O
a	O
)	O
catalytic	O
unit	O
characterizes	O
Glycogen	BP
storage	IP
disease-26	IP
type	O
IA	O
and	O
defects	O
in	O
the	O
glucose	BG
-	IG
6	IG
-	IG
phosphate	IG
transporter	IG
protein-39	IG
(	O
G6PC-41	BG
)	O
characterize	O
Glycogen	O
storage	O
disease	O
type	O
IB	O
.	O

PS1555	O
Deletion	O
junctions	O
of	O
the	O
azoospermia	BG
factor	IG
region	IG
c	IG
region-9	IG
were	O
determined	O
by	O
analysis	O
of	O
sequence	O
-	O
tagged	O
sites	O
and	O
gene	O
-	O
specific	O
markers	O
.	O

PS1557	O
We	O
identified	O
a	O
group	O
of	O
infertile	O
men	O
with	O
uniform	O
deletion	O
junctions	O
of	O
azoospermia	BG
factor	IG
region	IG
c-16	IG
in	O
the	O
Taiwan	O
population	O
.	O

PS1558	O
Despite	O
this	O
homogeneous	O
genetic	O
defect	O
in	O
the	O
azoospermia	BG
factor	IG
region	IG
c	IG
region-12	IG
,	O
no	O
clear	O
genotype	O
/	O
phenotype	O
correlation	O
could	O
be	O
demonstrated	O
.	O

PS1560	O
The	O
characterization	O
of	O
pathological	O
lesions	O
in	O
several	O
other	O
pituitary	O
-	O
expressed	O
genes	O
that	O
are	O
epistatic	O
to	O
growth	O
hormone1-18	BG
(	O
POU1F1-20	BG
,	O
PROP1-22	BG
and	O
growth	BG
hormoneRHR-25	IG
)	O
has	O
identified	O
additional	O
causes	O
of	O
growth	BG
hormone	IG
deficiency-34	IP
,	O
the	O
molecular	O
genetics	O
of	O
which	O
are	O
also	O
explored	O
.	O

PS1561	O
Clinical	O
and	O
biochemical	O
evaluation	O
,	O
right	O
ventricular	O
endomyocardial	O
biopsy	O
,	O
light	O
and	O
electron	O
microscopic	O
and	O
immunohistochemical	O
studies	O
of	O
biopsy	O
samples	O
,	O
six	O
multiplex	O
and	O
two	O
single	O
polymerase	O
chain	O
reactions	O
for	O
38	O
exons	O
and	O
automated	O
sequencing	O
of	O
exon	O
9	O
and	O
muscle	O
promoter	O
-	O
exon	O
1	O
were	O
undertaken	O
in	O
201	O
consecutive	O
male	O
patients	O
presenting	O
with	O
dilated	BP
cardiomyopathy-55	IP
,	O
with	O
(	O
n	O
=	O
14	O
)	O
and	O
without	O
(	O
n	O
=	O
187	O
)	O
increased	O
serum	BG
creatine	IG
phosphokinase-73	IG
.	O

PS1562	O
Patients	O
with	O
the	O
KCNQ4-4	BG
missense	O
mutations	O
had	O
younger	O
-	O
onset	O
and	O
more	O
profound	O
hearing	BP
loss-15	IP
than	O
patients	O
with	O
the	O
211	O
_	O
223del	O
mutation	O
.	O

PS1563	O
Our	O
results	O
support	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
that	O
the	O
KCNQ4-11	BG
deletions	O
are	O
associated	O
with	O
later	O
-	O
onset	O
and	O
milder	BP
hearing-21	IP
impairment	O
than	O
the	O
missense	O
mutations	O
.	O

PS1568	O
One	O
had	O
a	O
deletion	O
confined	O
to	O
the	O
azoospermia	BG
factor	IG
b-10	IG
region	O
(	O
encompassing	O
the	O
RBM	BG
gene-16	IG
)	O
.	O

PS1569	O
Two	O
were	O
found	O
to	O
have	O
deletions	O
of	O
both	O
the	O
azoospermia	BG
factor	IG
b-12	IG
and	O
AZFc-14	BG
regions	O
.	O

PS1573	O
The	O
authors	O
performed	O
a	O
clinical	O
,	O
biochemical	O
,	O
and	O
genetic	O
study	O
on	O
21	O
unrelated	O
patients	O
with	O
juvenile	O
and	O
adult	O
-	O
onset	O
acid	BG
maltase	IG
deficiency-24	IP
.	O

PS1574	O
This	O
study	O
shows	O
a	O
high	O
genetic	O
heterogeneity	O
of	O
juvenile	O
and	O
adult	BG
acid	IG
maltase	IG
deficiency-14	IP
in	O
the	O
French	O
population	O
.	O

PS1576	O
The	O
authors	O
performed	O
a	O
clinical	O
,	O
biochemical	O
,	O
and	O
genetic	O
study	O
on	O
21	O
unrelated	O
patients	O
with	O
juvenile	O
and	O
adult	O
-	O
onset	O
acid	BG
maltase	IG
deficiency-24	IP
.	O

PS1577	O
This	O
study	O
shows	O
a	O
high	O
genetic	O
heterogeneity	O
of	O
juvenile	O
and	O
adult	BG
acid	IG
maltase	IG
deficiency-14	IP
in	O
the	O
French	O
population	O
.	O

PS1579	O
Recently	O
,	O
reduced	O
activity	O
of	O
the	O
serine	BG
/	IG
threonine	IG
protein	IG
phosphatase-11	IG
in	O
keratinocytes	O
was	O
suggested	O
to	O
be	O
the	O
cause	O
of	O
harlequin	O
ichthyosis-22	BP
.	O

PS1583	O
Three	O
type	O
IV	O
Spinal	BP
muscular	IP
atrophy-6	IP
patients	O
had	O
four	O
and	O
one	O
had	O
six	O
SMN2	BG
copies-15	IG
.	O

PS1586	O
Pedigrees	O
analysis	O
and	O
the	O
observed	O
association	O
between	O
these	O
glial	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
alterations	O
and	O
RET	BG
variants-20	IG
in	O
the	O
same	O
patients	O
raised	O
the	O
question	O
of	O
whether	O
the	O
glial	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	BG
factor	IG
gene-39	IG
plays	O
any	O
causative	O
/	O
predisposing	O
role	O
in	O
Hirschsprung	BP
disease-48	IP
pathogenesis	O
.	O

PS1587	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
the	O
ability	O
of	O
glial	O
cell	O
-	O
line	O
-	O
derived	O
neurotrophic	BG
factor	IG
proteins-20	IG
,	O
each	O
bearing	O
one	O
of	O
the	O
reported	O
mutations	O
,	O
to	O
activate	O
RET-32	BG
by	O
performing	O
a	O
functional	O
test	O
in	O
cultured	O
neuroblastoma-40	BP
cells	O
.	O

PS1588	O
The	O
association	O
of	O
genetic	O
polymorphisms	O
of	O
CYP1A2-7	BG
and	O
NAT2-9	BG
,	O
two	O
major	O
enzymes	O
responsible	O
for	O
the	O
metabolism	O
of	O
heterocyclic	O
amines	O
,	O
with	O
lung	O
cancer-24	BP
has	O
been	O
investigated	O
with	O
inconclusive	O
results	O
.	O

PS1590	O
Factor	BG
XI	IG
deficiency-3	IP
is	O
particularly	O
common	O
in	O
Ashkenazi	O
Jews	O
.	O

PS1591	O
The	O
factor	BG
XI	IG
gene-4	IG
is	O
23	O
kb	O
long	O
,	O
and	O
two	O
mutations	O
are	O
responsible	O
for	O
most	O
factor	BG
XI	IG
deficiency-19	IP
in	O
the	O
Ashkenazi	O
population	O
.	O

PS1592	O
Although	O
a	O
factor	BG
XI-4	IG
concentrate	O
is	O
available	O
there	O
have	O
been	O
recent	O
reports	O
of	O
coagulation	O
activation	O
and	O
thrombosis-17	BP
indicating	O
that	O
it	O
should	O
be	O
used	O
cautiously	O
.	O

PS1595	O
The	O
myocilin	BG
Gln368stop	IG
mutation-4	IG
shows	O
a	O
good	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
should	O
be	O
investigated	O
in	O
all	O
familiar	O
cases	O
of	O
chronic	O
primary	O
open	O
-	O
angle	O
glaucoma-26	BP
.	O

PS1596	O
Haploinsufficiency	O
of	O
a	O
region	O
located	O
distal	O
to	O
10p14	O
designated	O
HDR1-10	BG
,	O
is	O
responsible	O
for	O
hypoparathyroidism-15	BP
,	O
sensorineural	O
deafness-18	BP
,	O
and	O
renal	BP
anomalies-22	IP
(	O
HDR	O
syndrome	O
)	O
.	O

PS1598	O
Our	O
patient	O
,	O
carrying	O
a	O
partial	O
deletion	O
of	O
the	O
DGCR2	BG
region-11	IG
and	O
of	O
the	O
HDR1	BG
region-16	IG
,	O
including	O
the	O
GATA3	BG
gene-21	IG
,	O
showed	O
,	O
unexpectedly	O
,	O
only	O
few	O
of	O
the	O
clinical	O
features	O
of	O
DiGeorge	O
2	O
syndrome	O
(	O
psychomotor	BP
retardation-39	IP
,	O
palpebral	BP
ptosis-42	IP
,	O
epicanthic	O
folds	O
,	O
anteverted	BP
nares-48	IP
,	O
cryptorchidism-50	BP
,	O
hand	O
/	O
foot	O
abnormalities	O
)	O
and	O
did	O
not	O
show	O
other	O
typical	O
signs	O
,	O
such	O
as	O
cardiac	O
defect	O
,	O
cleft	BP
palate-71	IP
,	O
and	O
abnormal	O
T	O
cell	O
levels	O
.	O

PS1599	O
Of	O
the	O
three	O
characteristic	O
features	O
of	O
the	O
HDR	BG
syndrome-9	IG
,	O
our	O
patient	O
had	O
only	O
sensorineural	O
deafness-16	BP
.	O

PS1600	O
To	O
determine	O
whether	O
there	O
is	O
a	O
correlation	O
among	O
mutations	O
in	O
the	O
cytochrome	BG
P4501B1	IG
gene-14	IG
,	O
the	O
degree	O
of	O
angle	O
dysgenesis	O
observed	O
histologically	O
,	O
and	O
disease	O
severity	O
in	O
congenital	O
glaucoma-29	BP
.	O

PS1601	O
Direct	O
DNA	O
sequencing	O
was	O
used	O
to	O
screen	O
six	O
unrelated	O
children	O
with	O
congenital	O
glaucoma-13	BP
,	O
each	O
set	O
of	O
parents	O
,	O
and	O
all	O
siblings	O
for	O
cytochrome	BG
P4501B1	IG
gene-26	IG
mutations	O
.	O

PS1603	O
Fifty	O
-	O
six	O
unrelated	O
Japanese	O
patients	O
with	O
insulin-8	BG
-	O
dependent	O
diabetes	O
mellitus	O
were	O
HLA	O
-	O
typed	O
,	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
was	O
performed	O
after	O
enzyme	O
digestion	O
with	O
Bam	BG
HI-31	IG
and	O
Taq	BG
I-34	IG
by	O
using	O
both	O
DR	O
and	O
DQ	O
probes	O
.	O

PS1604	O
The	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
also	O
showed	O
the	O
strongest	O
correlation	O
to	O
insulin	BP
-	IP
dependent	IP
diabetes	IP
mellitus-17	IP
when	O
the	O
DQ	O
probe	O
was	O
applied	O
.	O

PS1605	O
The	O
correlation	O
of	O
DQ	BG
beta	IG
amino	IG
acid	IG
sequences-8	IG
strongly	O
associated	O
with	O
insulin-12	BP
-	O
dependent	O
diabetes	BP
mellitus-16	IP
in	O
Japanese	O
are	O
discussed	O
in	O
this	O
study	O
,	O
and	O
contrasting	O
results	O
were	O
found	O
when	O
such	O
sequences	O
were	O
compared	O
with	O
those	O
of	O
Caucasians	O
.	O

PS1607	O
To	O
evaluate	O
the	O
limits	O
between	O
normal	O
and	O
disease	O
size	O
ranges	O
we	O
analysed	O
the	O
repeat	O
length	O
and	O
composition	O
of	O
the	O
spinocerebellar	BG
ataxia	IG
type	IG
1	IG
gene-24	IG
in	O
15	O
individuals	O
with	O
alleles	O
ranging	O
from	O
36	O
and	O
41	O
triplets	O
for	O
genotype	O
-	O
phenotype	O
correlation	O
studies	O
.	O

PS1608	O
The	O
clinical	O
features	O
of	O
individuals	O
carrying	O
39	O
uninterrupted	O
CAG	O
repeats	O
did	O
not	O
differ	O
from	O
the	O
spinocerebellar	O
ataxia-17	BP
type	O
1	O
phenotype	O
in	O
general	O
with	O
dysphagia-24	BP
,	O
pale	O
discs	O
,	O
pyramidal	O
signs	O
and	O
cerebellar	O
tremor	O
being	O
more	O
frequent	O
as	O
compared	O
to	O
other	O
SCA	BG
genotypes-42	IG
.	O

PS1609	O
Phenotypes	O
were	O
determined	O
by	O
validated	O
recombinant	O
assays	O
that	O
incorporate	O
either	O
an	O
approximately	O
2	O
,	O
500	O
-	O
bp	O
(	O
"	O
Trofile	O
"	O
assay	O
)	O
or	O
an	O
approximately	O
900	O
-	O
bp	O
(	O
TRT-31	BG
assay	O
)	O
fragment	O
of	O
the	O
human	BG
immunodeficiency	IG
virus	IG
envelope	IG
gp120-41	IG
.	O

PS1611	O
The	O
Val	O
/	O
Val	O
phenotype	O
was	O
demonstrated	O
to	O
occur	O
in	O
Chronic	BP
obstructive	IP
pulmonary	IP
disease-14	IP
patients	O
more	O
frequently	O
than	O
in	O
the	O
control	O
group	O
,	O
as	O
well	O
as	O
being	O
associated	O
with	O
a	O
lower	O
expression	O
level	O
of	O
manganese	BG
superoxide	IG
dismutase	IG
mRNA-38	IG
.	O

PS1613	O
The	O
presence	O
of	O
valine	O
at	O
position	O
9	O
of	O
the	O
manganese	BG
superoxide	IG
dismutase-12	IG
signal	O
peptide	O
encoded	O
by	O
exon	O
2	O
is	O
a	O
risk	O
factor	O
for	O
the	O
occurrence	O
of	O
respiratory	BP
failure-28	IP
in	O
the	O
course	O
of	O
Chronic	BP
obstructive	IP
pulmonary	IP
disease-36	IP
in	O
the	O
Polish	O
population	O
.	O

PS1621	O
Our	O
data	O
indicated	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
genetic	O
polymorphisms	O
in	O
the	O
precursor	O
microRNA	O
flanking	O
region	O
may	O
be	O
prognostic	O
biomarkers	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer-29	BP
,	O
and	O
rs928508-32	BG
is	O
such	O
a	O
potential	O
candidate	O
.	O

PS1623	O
We	O
report	O
on	O
a	O
novel	O
RET	BG
mutation-7	IG
at	O
codon	O
611	O
in	O
a	O
family	O
with	O
Medullary	O
thyroid	BP
carcinoma-17	IP
without	O
other	O
clinical	O
manifestations	O
and	O
of	O
rather	O
benign	O
course	O
.	O

PS1624	O
Familial	O
adenomatous	O
polyposis	O
(	O
FAP-5	BG
)	O
is	O
inherited	O
disease	O
as	O
an	O
autosomal	O
dominant	O
trait	O
in	O
which	O
the	O
large	O
intestine	O
is	O
diffusely	O
carpeted	O
by	O
numerous	O
adenomas	O
with	O
a	O
high	O
incidence	O
of	O
colorectal	BP
cancer-32	IP
.	O

PS1625	O
Initial	O
reports	O
of	O
patients	O
with	O
laminin	BG
alpha2	IG
chain-8	IG
(	O
merosin-10	BG
)	O
deficiency	O
had	O
a	O
relatively	O
homogeneous	O
phenotype	O
,	O
with	O
classical	O
congenital	BP
muscular	IP
dystrophy-23	IP
characterised	O
by	O
severe	O
muscle	BP
weakness-28	IP
,	O
inability	O
to	O
achieve	O
independent	O
ambulation	O
,	O
markedly	O
raised	O
creatine	BG
kinase-39	IG
,	O
and	O
characteristic	O
white	O
matter	O
hypodensity-45	BP
on	O
cerebral	O
magnetic	O
resonance	O
imaging	O
.	O

PS1626	O
We	O
report	O
a	O
series	O
of	O
five	O
patients	O
with	O
laminin	BG
alpha2-10	IG
deficiency	O
,	O
only	O
one	O
of	O
whom	O
has	O
this	O
severe	O
classical	O
congenital	O
muscular	BP
dystrophy-23	IP
phenotype	O
,	O
and	O
review	O
published	O
reports	O
to	O
characterise	O
the	O
expanded	O
phenotype	O
of	O
laminin	BG
alpha2-37	IG
deficiency	O
,	O
as	O
illustrated	O
by	O
this	O
case	O
series	O
.	O

PS1633	O
Coexpression	O
of	O
Cystic	BG
fibrosisTR-4	IG
and	O
h	BG
-	IG
SGK1-8	IG
in	O
Xenopus	O
oocytes	O
increased	O
ENaC-13	BG
currents	O
as	O
previously	O
described	O
.	O

PS1634	O
Coexpression	O
of	O
Cystic	BG
fibrosisTR-4	IG
and	O
h	BG
-	IG
SGK1-8	IG
in	O
Xenopus	O
oocytes	O
increased	O
ENaC-13	BG
currents	O
as	O
previously	O
described	O
.	O

PS1637	O
The	O
current	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
prevalence	O
of	O
BRCA1-11	BG
and	O
BRCA2	BG
germline-14	IG
mutations	O
in	O
Greek	O
moderate	O
-	O
and	O
low	O
-	O
risk	O
individuals	O
with	O
respect	O
to	O
clinicopathological	O
phenotype	O
and	O
clinical	O
outcome	O
of	O
breast	BP
cancer-35	IP
.	O

PS1640	O
Breast	BP
cancer-2	IP
due	O
to	O
mutations	O
in	O
BRCA1-7	BG
and	O
BRCA2	BG
genes-10	IG
appears	O
to	O
be	O
a	O
heterogeneous	O
syndrome	O
in	O
the	O
Greek	O
population	O
.	O

PS1643	O
Additional	O
radiological	O
and	O
clinical	O
findings	O
are	O
11	O
pairs	O
of	O
ribs	O
and	O
a	O
bell	O
-	O
shaped	O
thorax	O
,	O
hypoplastic	BP
scapulae-19	IP
,	O
narrow	O
iliac	O
wings	O
,	O
non	O
-	O
mineralized	O
thoracic	O
pedicles	O
,	O
clubbed	O
feet	O
,	O
Robin-34	BG
sequence	O
,	O
typical	O
facial	O
anomalies	O
and	O
tracheomalacia-41	BP
.	O

PS1644	O
Ventricular	O
tachycardia-2	BP
/	O
torsades	O
de	O
pointes	O
and	O
atrioventricular	O
block	O
were	O
almost	O
exclusively	O
observed	O
in	O
patients	O
with	O
LQT2-17	BG
,	O
LQT3-19	BG
,	O
and	O
LQT8-22	BG
,	O
as	O
well	O
as	O
in	O
those	O
with	O
no	O
known	O
mutation	O
.	O

PS1645	O
Patients	O
with	O
long	O
-	O
QT	O
syndrome	O
who	O
showed	O
life	O
-	O
threatening	O
arrhythmias-12	BP
at	O
perinatal	O
periods	O
were	O
mostly	O
those	O
with	O
LQT2-20	BG
,	O
LQT3-22	BG
,	O
or	O
no	O
known	O
mutations	O
.	O

PS1647	O
Mutations	O
in	O
lamin	BG
A	IG
/	IG
C	IG
gene-7	IG
have	O
been	O
found	O
in	O
patients	O
with	O
dilated	BP
cardiomyopathy-15	IP
with	O
familial	O
conduction	O
defects	O
and	O
muscular	BP
dystrophy-22	IP
,	O
but	O
the	O
clinical	O
spectrum	O
,	O
prognosis	O
,	O
and	O
clinical	O
relevance	O
of	O
laminopathies	O
in	O
dilated	O
cardiomyopathy-38	BP
are	O
unknown	O
.	O

PS1648	O
A	O
cohort	O
of	O
49	O
nuclear	O
families	O
,	O
40	O
with	O
familial	O
dilated	BP
cardiomyopathy-12	IP
and	O
9	O
with	O
sporadic	O
dilated	BP
cardiomyopathy-18	IP
(	O
269	O
subjects	O
,	O
105	O
affected	O
)	O
,	O
was	O
screened	O
for	O
mutations	O
in	O
lamin	BG
A	IG
/	IG
C	IG
gene-36	IG
using	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
and	O
sequence	O
analysis	O
.	O

PS1649	O
Mutations	O
in	O
lamin	BG
A	IG
/	IG
C	IG
gene-7	IG
were	O
detected	O
in	O
four	O
families	O
(	O
8	O
%	O
)	O
,	O
three	O
with	O
familial	O
(	O
R89L	O
,	O
959delT	O
,	O
R377H	O
)	O
and	O
one	O
with	O
sporadic	O
dilated	BP
cardiomyopathy-33	IP
(	O
S573L	O
)	O
.	O

PS1651	O
The	O
lamin	BG
A	IG
/	IG
C	IG
gene	IG
mutation	IG
carriers-8	IG
had	O
a	O
significantly	O
poorer	O
cumulative	O
survival	O
compared	O
with	O
non	O
-	O
carrier	O
dilated	BP
cardiomyopathy-21	IP
patients	O
:	O
event	O
-	O
free	O
survival	O
at	O
the	O
age	O
of	O
45	O
years	O
was	O
31	O
%	O
versus	O
75	O
%	O
in	O
non	O
-	O
carriers	O
.	O

PS1653	O
Mutation	O
screening	O
should	O
be	O
considered	O
in	O
patients	O
with	O
dilated	BP
cardiomyopathy-10	IP
,	O
in	O
particular	O
when	O
clinical	O
predictors	O
of	O
lamin	BG
A	IG
/	IG
C	IG
gene-22	IG
mutation	O
are	O
present	O
,	O
regardless	O
of	O
family	O
history	O
.	O

PS1655	O
In	O
this	O
study	O
,	O
SURF1	BG
gene-6	IG
was	O
sequenced	O
in	O
590	O
patients	O
with	O
clinical	O
suspicion	O
of	O
Leigh	O
syndrome	O
,	O
complex	BP
IV	IP
deficiency-21	IP
,	O
or	O
clinical	O
features	O
of	O
mitochondrial	O
disorders	O
.	O

PS1656	O
The	O
positions	O
of	O
the	O
Epidermolysis	O
bullosa	O
simplex	O
-	O
EBS	O
-	O
Dowling	O
-	O
Meara	O
mutations	O
were	O
consistent	O
with	O
previous	O
studies	O
,	O
whereas	O
the	O
Epidermolysis	O
bullosa	O
simplex	O
-	O
EBS	O
-	O
Weber	O
-	O
Cockayne	O
and	O
Epidermolysis-33	BP
bullosa	O
simplex	O
-	O
K	O
mutations	O
were	O
found	O
in	O
regions	O
of	O
the	O
keratin	BG
genes-46	IG
not	O
typically	O
associated	O
with	O
this	O
type	O
of	O
Epidermolysis	O
bullosa	O
simplex	O
mutations	O
.	O

PS1659	O
Detailed	O
analyses	O
of	O
this	O
locus	O
have	O
demonstrated	O
the	O
existence	O
of	O
one	O
SNP	BP
haplotype	IP
block-14	IP
,	O
carrying	O
the	O
complement	BG
factor	IG
H	IG
402His	IG
allele-22	IG
,	O
which	O
confers	O
increased	O
risk	O
for	O
Age	O
-	O
related	O
macular	O
degeneration	O
,	O
and	O
two	O
protective	O
SNP	O
haplotypes	O
,	O
one	O
of	O
them	O
carrying	O
a	O
deletion	O
of	O
the	O
complement	BG
factor	IG
HR1-51	IG
and	O
complement	BG
factor	IG
HR3	IG
genes-56	IG
.	O

PS1660	O
In	O
the	O
meningitis-3	BP
patients	O
,	O
no	O
increased	O
incidence	O
of	O
hetero	O
-	O
or	O
homozygous	O
deficiency	O
of	O
either	O
C4A-17	BG
or	O
C4B-19	BG
was	O
found	O
.	O

PS1661	O
Insulin	BG
-	IG
like	IG
growth	IG
factor-5	IG
-	O
axis	O
mediated	O
signaling	O
pathways	O
play	O
an	O
important	O
role	O
in	O
pancreatic	BP
cancer-17	IP
development	O
and	O
progression	O
.	O

PS1663	O
We	O
retrospectively	O
genotyped	O
41	O
single	O
-	O
nucleotide	O
polymorphisms	O
from	O
10	O
Insulin	BG
-	IG
like	IG
growth	IG
factor	IG
-	IG
axis	IG
genes-18	IG
in	O
333	O
patients	O
with	O
localized	O
pancreatic	BP
adenocarcinoma-25	IP
and	O
validated	O
the	O
findings	O
in	O
373	O
patients	O
with	O
advanced	O
disease	O
.	O

PS1664	O
These	O
data	O
suggest	O
that	O
individual	O
genetic	O
variations	O
in	O
the	O
Insulin	BG
-	IG
like	IG
growth	IG
factor-14	IG
axis	O
pathway	O
may	O
predict	O
worse	O
survival	O
in	O
patients	O
with	O
pancreatic	BP
cancer-25	IP
.	O

PS1674	O
These	O
results	O
suggest	O
that	O
at	O
least	O
a	O
subset	O
of	O
schizophrenia	BG
susceptibility	IG
genes-12	IG
also	O
affects	O
schizotypy	O
in	O
non	O
-	O
psychotic	O
relatives	O
.	O

PS1675	O
Mutations	O
in	O
the	O
BTK	BG
gene-5	IG
cause	O
X	O
-	O
linked	O
agammaglobulinemia-10	BP
;	O

PS1676	O
To	O
determine	O
how	O
differently	O
mutations	O
in	O
BTK-7	BG
affect	O
the	O
severity	O
of	O
the	O
disease	O
and	O
if	O
BTK	BG
promoter	IG
polymorphic	IG
variant	IG
or	IG
intron	IG
1	IG
polymorphic	IG
variant-24	IG
in	O
Tec-26	BG
,	O
a	O
cytoplasmic	BG
tyrosine	IG
kinase-31	IG
that	O
might	O
substitute	O
for	O
Bruton	O
'	O
s	O
tyrosine	BG
kinase-40	IG
,	O
could	O
contribute	O
to	O
the	O
clinical	O
phenotype	O
,	O
we	O
analyzed	O
the	O
clinical	O
and	O
molecular	O
findings	O
in	O
a	O
cohort	O
of	O
X	O
-	O
linked	O
agammaglobulinemia-63	BP
patients	O
.	O

PS1678	O
Spinocerebellar	BG
ataxias	IG
type	IG
1	IG
and	IG
type	IG
2-7	IG
(	O
SCA2-9	BG
)	O
belong	O
to	O
neurodegenerative	O
disorders	O
of	O
autosomal	O
dominant	O
inheritance	O
,	O
genetically	O
and	O
clinically	O
heterogeneous	O
,	O
caused	O
by	O
the	O
expansion	O
of	O
CAG	O
trinucleotides	O
.	O

PS1679	O
44	O
patients	O
with	O
Spinocerebellar	O
ataxias-5	BP
type	O
1	O
and	O
24	O
cases	O
with	O
SCA2-12	BG
confirmed	O
molecularly	O
were	O
examined	O
neurologically	O
and	O
using	O
the	O
International	O
Cooperative	O
Ataxia	O
Rating	O
Scale	O
.	O

PS1681	O
Exposed	O
boys	O
with	O
the	O
low	O
-	O
activity	O
monoamine	BG
oxidase	IG
A	IG
5	IG
'	IG
untranslated	IG
region	IG
variable	IG
number	IG
of	IG
tandem	IG
repeats-19	IG
genotype	O
were	O
at	O
increased	O
risk	O
for	O
conduct	BP
disorder-27	IP
symptoms	O
.	O

PS1683	O
In	O
this	O
study	O
,	O
RPGRIP1-5	BG
,	O
RANBP2-7	BG
,	O
NPM1-9	BG
,	O
PDE6D-11	BG
,	O
NPHP5-13	BG
,	O
and	O
ABCA4	BG
genes-17	IG
were	O
selected	O
on	O
the	O
basis	O
of	O
interaction	O
with	O
RPGR-26	BG
or	O
RPGRIP1-28	BG
or	O
their	O
implication	O
in	O
related	O
retinal	O
diseases	O
,	O
and	O
were	O
investigated	O
as	O
candidate	O
genetic	O
modifiers	O
of	O
X	O
-	O
linked	O
progressive	O
retinal	BP
atrophy1-50	IP
.	O

PS1685	O
To	O
clarify	O
the	O
relationship	O
between	O
SMN2-6	BG
and	O
the	O
disease	O
severity	O
of	O
Spinal	BP
muscular	IP
atrophy-14	IP
,	O
we	O
performed	O
fluorescence	O
-	O
based	O
quantitative	O
polymerase	O
chain	O
reaction	O
assay	O
of	O
the	O
copy	O
number	O
of	O
SMN2	O
in	O
27	O
patients	O
(	O
11	O
type	O
I	O
and	O
16	O
type	O
intermediate	O
-	O
intermediateI-44	BG
)	O
homozygous	O
for	O
SMN1-48	BG
deletion	O
.	O

PS1687	O
Genetic	O
background	O
influencing	O
splicing	O
mechanisms	O
of	O
the	O
SMN2	BG
gene-9	IG
may	O
be	O
more	O
critical	O
in	O
some	O
Spinal	BP
muscular	IP
atrophy-18	IP
patients	O
.	O

PS1699	O
The	O
carbonic	BG
anhydrase	IG
II-4	IG
deficiency	O
syndrome	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
that	O
produces	O
osteopetrosis-14	BP
,	O
renal	O
tubular	O
acidosis-18	BP
,	O
and	O
cerebral	BP
calcification-22	IP
.	O

PS1700	O
With	O
one	O
exception	O
,	O
all	O
patients	O
with	O
osteopetrosis-8	BP
and	O
renal	O
tubular	O
acidosis-12	BP
examined	O
have	O
proven	O
to	O
have	O
carbonic	O
anhydrase	BG
II	IG
deficiency-21	IP
.	O

PS1701	O
Application	O
of	O
this	O
method	O
allowed	O
identification	O
of	O
eleven	O
new	O
mutations	O
in	O
21	O
patients	O
referred	O
for	O
confirmation	O
of	O
the	O
diagnosis	O
of	O
carbonic	O
anhydrase	BG
II	IG
deficiency-24	IP
.	O

PS1702	O
These	O
studies	O
expand	O
our	O
knowledge	O
of	O
the	O
heterogeneity	O
in	O
mutations	O
underlying	O
the	O
carbonic	BG
anhydrase	IG
II	IG
deficiency-16	IP
syndrome	O
.	O

PS1705	O
Genetic	O
variation	O
in	O
the	O
ABCA4	BG
(	IG
ABCR	IG
)	IG
gene-9	IG
has	O
been	O
associated	O
with	O
several	O
distinct	O
retinal	O
phenotypes	O
,	O
including	O
Stargardt	O
disease	O
/	O
fundus	O
flavimaculatus	O
,	O
cone	O
-	O
rod	O
dystrophy	O
,	O
retinitis	BP
pigmentosa-32	IP
and	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

PS1706	O
The	O
current	O
model	O
of	O
genotype	O
/	O
phenotype	O
association	O
suggests	O
that	O
patients	O
harboring	O
deleterious	O
mutations	O
in	O
both	O
ABCR	BG
alleles-18	IG
would	O
develop	O
retinitis	O
pigmentosa	BP
-	IP
like	IP
retinal	IP
pathology-26	IP
.	O

PS1708	O
No	O
significant	O
differences	O
in	O
demographic	O
or	O
clinical	O
features	O
were	O
observed	O
between	O
rheumatoid	BP
arthritis-13	IP
patients	O
carrying	O
the	O
migration	BG
inhibitory	IG
factor	IG
-	IG
173C	IG
allele-22	IG
or	O
the	O
migration	BG
inhibitory	IG
factor	IG
CATT7	IG
allele-29	IG
or	O
both	O
and	O
non	O
-	O
carrier	O
rheumatoid	BP
arthritis-37	IP
patients	O
.	O

PS1711	O
Multivariate	O
and	O
conditioning	O
analyses	O
showed	O
a	O
primary	O
association	O
between	O
NOD2-10	BG
allelic	O
variants	O
and	O
fibrostenosing	O
disease	O
,	O
but	O
not	O
with	O
small	BP
-	IP
bowel	IP
disease-23	IP
.	O

PS1712	O
The	O
genetic	O
heterogeneity	O
at	O
the	O
phenylalanine	BG
hydroxylase-7	IG
locus	O
was	O
studied	O
in	O
88	O
families	O
including	O
93	O
of	O
the	O
105	O
children	O
with	O
phenylketonuria-21	BP
or	O
hyperphenylalaninemia-23	BP
detected	O
through	O
the	O
Swedish	O
neonatal	O
screening	O
program	O
from	O
1966	O
to	O
the	O
end	O
of	O
1986	O
.	O

PS1716	O
Comparison	O
of	O
allele	O
frequencies	O
between	O
Gastric	BP
cancer-7	IP
patients	O
and	O
healthy	O
controls	O
showed	O
no	O
significant	O
difference	O
at	O
the	O
human	BG
leukocyte	IG
antigen-20	IG
-	O
DRB1-22	BG
locus	O
.	O

PS1725	O
In	O
a	O
murine	O
pneumonia-4	BP
model	O
,	O
infection	O
with	O
a	O
zmpC	BG
-	IG
mutant-12	IG
reduced	O
mortality	O
at	O
3	O
-	O
4	O
days	O
post	O
-	O
infection	O
by	O
75	O
%	O
,	O
when	O
compared	O
with	O
infection	O
with	O
wild	O
-	O
type	O
strains	O
.	O

PS1726	O
Identification	O
of	O
dystrophic	O
characteristics	O
of	O
intact	O
and	O
regenerating	O
muscle	BP
fibers-10	IP
was	O
made	O
by	O
cytochemical	O
analysis	O
of	O
mitochondrial	BG
succinic	IG
dehydrogenase-19	IG
and	O
by	O
fiber	O
size	O
.	O

PS1735	O
FOXC2-1	BG
,	O
EphrinB2-3	BG
,	O
VEGFR	BG
-	IG
3-7	IG
,	O
VEGF	BG
-	IG
C-11	IG
,	O
angiopoietin	BG
-	IG
2-15	IG
,	O
Prox	BG
-	IG
1-19	IG
and	O
podoplanin-21	BG
have	O
proved	O
to	O
be	O
important	O
factors	O
of	O
the	O
genetic	O
cascade	O
linking	O
to	O
hereditary	O
lymphedema-35	BP
,	O
and	O
embryonic	O
and	O
postnatal	O
lymphatic	O
development	O
.	O

PS1737	O
Screening	O
of	O
FRMD7-3	BG
was	O
undertaken	O
in	O
pedigree	O
1	O
and	O
in	O
37	O
other	O
congenital	BP
idiopathic	IP
nystagmus-15	IP
probands	O
and	O
controls	O
.	O

PS1743	O
It	O
is	O
more	O
likely	O
that	O
the	O
MYH-7	BG
associated	O
polyposis-9	BP
syndrome	O
is	O
the	O
real	O
AFamilial	O
adenomatous	O
polyposis	O
.	O

PS1744	O
The	O
detailed	O
analysis	O
of	O
the	O
Y	O
chromosome	O
in	O
men	O
with	O
azoospermia-11	BP
or	O
severe	O
oligozoospermia-14	BP
has	O
resulted	O
in	O
the	O
identification	O
of	O
three	O
regions	O
of	O
the	O
long	O
arm	O
of	O
the	O
human	O
Y	O
chromosome	O
,	O
termed	O
AZFa-34	BG
,	O
AZFb-36	BG
and	O
AZFc-38	BG
,	O
(	O
AZF	O
:	O
AZoospermia	O
Factor	O
)	O
that	O
are	O
currently	O
deleted	O
in	O
men	O
with	O
otherwise	O
unexplained	O
spermatogenic	O
failure	O
.	O

PS1745	O
P426L	BG
homozygotes-2	IG
principally	O
presented	O
with	O
progressive	O
gait	BP
disturbance-8	IP
caused	O
by	O
spastic	BP
paraparesis-12	IP
or	O
cerebellar	BP
ataxia-15	IP
;	O

PS1746	O
The	O
characteristic	O
clinical	O
differences	O
between	O
homozygous	O
P426L-7	BG
and	O
compound	O
heterozygous	O
I179S	O
patients	O
establish	O
a	O
distinct	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
late	O
-	O
onset	O
metachromatic	O
leukodystrophy-25	BP
.	O

PS1747	O
We	O
report	O
here	O
the	O
molecular	O
study	O
of	O
two	O
isoforms	O
,	O
MECP2-11	BG
_	O
e1-13	BG
and	O
MECP2-15	BG
_	O
e2-17	BG
,	O
in	O
45	O
Lebanese	O
girls	O
presenting	O
developmental	O
delay	O
and	O
at	O
least	O
one	O
of	O
the	O
following	O
features	O
:	O
microcephaly-35	BP
,	O
neurodegeneration-37	BP
,	O
abnormal	O
behaviour	O
,	O
stereotypical	O
hand	O
movements	O
,	O
teeth	O
grinding	O
and	O
difficulty	O
in	O
walking	O
.	O

PS1749	O
Twenty	O
-	O
six	O
patients	O
suffering	O
from	O
autosomal	O
dominant	O
cerebellar	BP
ataxia-10	IP
type	O
I	O
were	O
subjected	O
to	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
analysis	O
using	O
molecular	O
genetic	O
assignment	O
to	O
the	O
genetic	O
loci	O
for	O
spinocerebellar	BG
ataxia	IG
type	IG
1	IG
,	IG
2	IG
or	IG
3-38	IG
(	O
SCA1-40	BG
,	O
SCA2-42	BG
,	O
SCA3-44	BG
)	O
and	O
MRI	O
-	O
based	O
volumetry	O
of	O
posterior	O
fossa	O
structures	O
and	O
basal	O
ganglia	O
nuclei	O
.	O

PS1752	O
A	O
large	O
proportion	O
of	O
sterile	O
healthy	O
men	O
with	O
congenital	BP
bilateral	IP
absence-11	IP
of	O
the	O
vas	O
deferens	O
carry	O
a	O
mutation	O
in	O
at	O
least	O
one	O
of	O
their	O
Cystic	BG
fibrosisTR	IG
genes-27	IG
.	O

PS1753	O
Rapp	O
-	O
Hodgkin	O
syndrome	O
and	O
Hay	O
-	O
Wells	O
[	O
also	O
known	O
as	O
ankyloblepharon	O
-	O
ectodermal	O
defects	O
-	O
cleft	O
lip	O
/	O
palate	O
]	O
syndrome	O
have	O
been	O
designated	O
as	O
distinct	O
ectodermal	BP
dysplasia-30	IP
syndromes	O
despite	O
both	O
disorders	O
having	O
overlapping	O
clinical	O
features	O
and	O
the	O
same	O
mutated	O
gene	O
,	O
TP63-45	BG
.	O

PS1757	O
The	O
Aspartate	O
-	O
90	O
-	O
Alanine	O
(	O
D90A	O
)	O
mutation	O
on	O
SOD	BG
-	IG
1	IG
gene-15	IG
,	O
the	O
only	O
known	O
change	O
causing	O
recessive	O
familial	O
amyotrophic	BP
lateral	IP
sclerosis-26	IP
,	O
is	O
associated	O
with	O
a	O
uniform	O
phenotype	O
characterized	O
by	O
slowly	O
ascending	O
paresis	O
and	O
long	O
survival	O
.	O

PS1758	O
This	O
supports	O
the	O
hypothesis	O
of	O
hepatic	BP
insulin	IP
resistance-8	IP
and	O
increased	O
peripheral	O
glucose	O
uptake	O
as	O
compensatory	O
events	O
secondary	O
to	O
the	O
decrease	O
in	O
fatty	O
acid	O
oxidation	O
characteristic	O
of	O
the	O
peroxisomal	BG
proliferator	IG
-	IG
activated	IG
receptor	IG
alpha-33	IG
knockout	O
.	O

PS1759	O
a	O
large	O
proportion	O
of	O
autosomal	O
dominant	O
Hereditary	O
spastic	O
paraparesis	O
belongs	O
to	O
Hereditary	O
spastic	BP
paraparesis-14	IP
type	O
4	O
,	O
which	O
has	O
been	O
linked	O
to	O
the	O
SPG4	BG
locus-25	IG
on	O
chromosome	O
2	O
.	O

PS1760	O
In	O
addition	O
,	O
the	O
incidence	O
of	O
recovery	O
from	O
splenomegaly-9	BP
induced	O
by	O
a	O
given	O
level	O
of	O
virus	O
dosage	O
is	O
significantly	O
greater	O
in	O
H	O
-	O
2	O
(	O
b	O
)	O
homozygotes	O
than	O
in	O
segregants	O
of	O
other	O
H	BG
-	IG
2-36	IG
types	O
among	O
their	O
littermates	O
.	O

PS1765	O
Previous	O
research	O
found	O
an	O
association	O
between	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4-15	BG
and	O
statistically	O
derived	O
phenotypes	O
generated	O
from	O
attention	O
-	O
deficit	O
/	O
hyperactivity-26	BP
disorder	O
symptoms	O
.	O

PS1766	O
This	O
study	O
partially	O
replicated	O
a	O
previous	O
finding	O
by	O
identifying	O
an	O
association	O
between	O
rs7124601-13	BG
and	O
a	O
quantitative	O
trait	O
generated	O
from	O
attention	O
-	O
deficit	O
/	O
hyperactivity-24	BP
disorder	O
symptoms	O
.	O

PS1768	O
A	O
range	O
of	O
phenotypes	O
including	O
Greig	O
cephalopolysyndactyly-7	BP
and	O
Pallister	O
-	O
Hall	O
syndromes	O
(	O
Greig	O
cephalopolysyndactyly	O
and	O
Pallister	O
-	O
Hall	O
syndromes	O
,	O
PHS	O
)	O
are	O
caused	O
by	O
pathogenic	O
mutation	O
of	O
the	O
GLI3	BG
gene-32	IG
.	O

PS1770	O
This	O
study	O
identifies	O
a	O
link	O
between	O
Hormone	O
-	O
sensitive	O
lipase-10	BG
and	O
polyamine	O
metabolism	O
,	O
which	O
deserves	O
further	O
attention	O
in	O
view	O
of	O
the	O
emerging	O
data	O
suggesting	O
that	O
disturbances	O
in	O
polyamine	O
metabolism	O
may	O
affect	O
insulin	BP
sensitivity-34	IP
.	O

PS1772	O
Mutations	O
in	O
the	O
WFS1	BG
gene-5	IG
have	O
been	O
reported	O
in	O
Wolfram	O
syndrome	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
defined	O
by	O
early	BP
onset-20	IP
of	O
diabetes	BP
mellitus-23	IP
and	O
progressive	O
optic	BP
atrophy-27	IP
.	O

PS1775	O
The	O
frequency	O
and	O
prognostic	O
relevance	O
of	O
RET	BG
proto	IG
-	IG
oncogene-10	IG
somatic	O
mutations	O
in	O
sporadic	O
medullary	O
thyroid	BP
carcinoma-17	IP
remain	O
controversial	O
.	O

PS1776	O
In	O
44	O
neuroblastoma-3	BP
primary	O
samples	O
,	O
we	O
determined	O
the	O
gene	O
dosages	O
of	O
MYCN-13	BG
and	O
Survivin-15	BG
(	O
as	O
the	O
target	O
of	O
17q	O
gain	O
)	O
and	O
the	O
expression	O
levels	O
of	O
MYCN-29	BG
,	O
Survivin-31	BG
,	O
and	O
BIN1	O
using	O
highly	O
sensitive	O
analysis	O
(	O
the	O
quantitative	O
polymerase	O
chain	O
reaction	O
method	O
)	O
;	O

PS1782	O
Screening	O
all	O
17	O
exons	O
of	O
TGFB1-6	BG
in	O
the	O
proband	O
identified	O
a	O
single	O
missense	O
mutation	O
(	O
C1710T	O
)	O
in	O
exon	O
12	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
granular	O
corneal	BP
dystrophy-29	IP
.	O

PS1785	O
Our	O
results	O
emphasize	O
the	O
role	O
of	O
lamin	BG
A	IG
/	IG
C	IG
gene-11	IG
mutations	O
at	O
position	O
R541	O
in	O
dilated	BP
cardiomyopathy-18	IP
cases	O
with	O
segmental	O
LV	O
wall	O
motion	O
akinesis	O
/	O
dyskinesis	O
.	O

PS1787	O
Although	O
correlation	O
of	O
the	O
genotype	O
and	O
biochemistry	O
with	O
the	O
clinical	O
phenotype	O
of	O
Glucose	BG
-	IG
6	IG
-	IG
phosphate	IG
dehydrogenase-18	IG
deficient	O
individuals	O
remains	O
somewhat	O
variable	O
,	O
there	O
is	O
better	O
correlation	O
among	O
individuals	O
presenting	O
with	O
chronic	O
non	O
-	O
spherocytic	O
haemolytic	BP
anaemia-38	IP
,	O
which	O
is	O
related	O
to	O
the	O
NADP	O
structure	O
of	O
the	O
enzyme	O
.	O

PS1788	O
We	O
provide	O
the	O
first	O
evidence	O
that	O
partial-7	BP
CYP11A1	BG
deficiency-9	IP
has	O
to	O
be	O
considered	O
as	O
a	O
differential	O
diagnosis	O
in	O
clinically	O
isolated	O
adrenal	O
insufficiency	O
.	O

PS1792	O
Consistent	O
with	O
the	O
role	O
of	O
Cdc25-6	BG
(	O
String	O
)	O
in	O
promoting	O
mitosis	O
and	O
with	O
our	O
genetic	O
interaction	O
data	O
,	O
we	O
find	O
a	O
strong	O
correlation	O
between	O
progression	O
through	O
mitosis-28	BP
and	O
a	O
reduction	O
in	O
Armadillo	O
levels	O
.	O

PS1793	O
In	O
a	O
fifth	O
strain	O
,	O
xeroderma-6	BP
pigmentosum82TO	O
,	O
p48-9	BG
was	O
detectable	O
and	O
both	O
damage	O
-	O
specific	O
DNA	O
binding	O
protein2	O
mRNA	O
and	O
p48-22	BG
levels	O
were	O
more	O
up	O
-	O
regulated	O
after	O
UV	O
-	O
irradiation	O
than	O
in	O
normal	O
primary	O
cells	O
.	O

PS1794	O
These	O
results	O
,	O
coupled	O
with	O
our	O
findings	O
that	O
most	O
,	O
if	O
not	O
all	O
damage	O
-	O
specific	O
DNA	O
binding	O
protein	O
(	O
+	O
)	O
cells	O
classified	O
as	O
xeroderma	BG
pigmentosum	IG
-	IG
E-29	IG
were	O
misclassified	O
,	O
suggests	O
a	O
direct	O
correlation	O
between	O
damage	O
-	O
specific	O
DNA	O
binding	O
protein2	O
levels	O
and	O
the	O
xeroderma	O
pigmentosum	O
-	O
E	O
phenotype	O
.	O

PS1798	O
A	O
correlation	O
with	O
NKX2	BG
-	IG
3-6	IG
and	O
need	O
for	O
surgery	O
,	O
and	O
with	O
HLA-14	BG
and	O
steroid	O
-	O
responsiveness	O
in	O
ulcerative	BP
colitis-21	IP
patients	O
was	O
observed	O
.	O

PS1800	O
The	O
objective	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
relationship	O
between	O
HLA-12	BG
genotypes	O
and	O
disease	O
severity	O
as	O
measured	O
by	O
brain	O
MRI	O
quantitative	O
markers	O
of	O
demyelinating	O
and	O
destructive	O
pathology	O
in	O
patients	O
with	O
multiple	BP
sclerosis-33	IP
.	O

PS1802	O
We	O
describe	O
a	O
new	O
human	O
immunodeficiency-6	BP
virus	O
type	O
1	O
mutational	O
pattern	O
associated	O
with	O
phenotypic	O
resistance	O
to	O
lamivudine	O
(	O
3TC	O
)	O
in	O
the	O
absence	O
of	O
the	O
characteristic	O
replacement	O
of	O
methionine	O
by	O
valine	O
at	O
position	O
184	O
(	O
M184V	O
)	O
of	O
reverse	BG
transcriptase-40	IG
.	O

PS1807	O
The	O
investigated	O
polymorphisms	O
of	O
the	O
multidrug	BG
resistance	IG
1	IG
gene-9	IG
have	O
no	O
significant	O
role	O
in	O
disease	O
susceptibility	O
and	O
response	O
to	O
medical	O
therapy	O
in	O
our	O
Italian	O
population	O
of	O
inflammatory	BP
bowel	IP
disease-29	IP
patients	O
.	O

PS1808	O
Congenital	O
disorders	O
of	O
glycosylation-4	BP
type	O
Ia	O
,	O
(	O
previous	O
name	O
carbohydrate	O
-	O
deficient	O
glycoprotein	O
syndrome	O
type	O
Ia	O
;	O
CDG	BG
-	IG
Ia-21	IG
)	O
is	O
an	O
inherited	O
disorder	O
of	O
the	O
glycosylation	O
of	O
certain	O
glycoproteins	O
.	O

PS1809	O
To	O
evaluate	O
the	O
usefulness	O
and	O
the	O
pitfalls	O
inherent	O
to	O
the	O
assessment	O
of	O
the	O
epidermal	BG
growth	IG
factor	IG
receptor-17	IG
gene	O
copy	O
number	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
for	O
outcome	O
prediction	O
to	O
cetuximab	O
in	O
metastatic	O
colorectal	BP
cancer-34	IP
.	O

PS1811	O
Among	O
them	O
,	O
Xeroderma	BG
pigmentosum	IG
group	IG
A-7	IG
is	O
characterized	O
by	O
the	O
presence	O
of	O
neurological	O
abnormalities	O
in	O
addition	O
to	O
cutaneous	O
symptoms	O
.	O

PS1812	O
Molecular	O
investigation	O
allowed	O
identification	O
of	O
a	O
novel	O
Xeroderma	BG
pigmentosumA	IG
mutation-10	IP
and	O
complete	O
phenotype	O
-	O
genotype	O
correlation	O
for	O
this	O
new	O
phenotypic	O
expression	O
of	O
Xeroderma	BG
pigmentosum	IG
-	IG
A-26	IG
.	O

PS1813	O
To	O
investigate	O
the	O
possible	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
of	O
epilepsy-11	BP
,	O
we	O
analyzed	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
alpha1	O
-	O
subunit	O
(	O
SCN1A-25	BG
)	O
gene	O
,	O
beta1	BG
-	IG
subunit-31	IG
(	O
SCN1B-33	BG
)	O
gene	O
,	O
and	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
A	O
)	O
receptor	O
gamma2	O
-	O
subunit	O
(	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
A	O
)	O
receptor	O
gamma2	O
-	O
subunit	O
)	O
gene	O
in	O
DNAs	O
from	O
peripheral	O
blood	O
cells	O
of	O
29	O
patients	O
with	O
severe	O
myoclonic	O
epilepsy	O
in	O
infancy	O
and	O
11	O
patients	O
with	O
other	O
types	O
of	O
epilepsy	O
.	O

PS1814	O
Mutation	O
screening	O
of	O
the	O
Sequestosome	BG
1	IG
gene-7	IG
was	O
conducted	O
in	O
70	O
kindreds	O
with	O
familial	BP
Paget-15	IP
'	O
s	O
disease	O
of	O
bone	O
.	O

PS1815	O
Cardinal	O
features	O
of	O
Arthrogryposis	O
-	O
renal	O
dysfunction	O
-	O
cholestasis	O
include	O
congenital	O
joint	BP
contractures-13	IP
,	O
renal	BP
tubular	IP
dysfunction-17	IP
,	O
cholestasis-19	BP
,	O
severe	BP
failure-22	IP
to	O
thrive	O
,	O
ichthyosis-26	BP
,	O
and	O
a	O
defect	O
in	O
platelet	BG
alpha	IG
-	IG
granule-35	IG
biogenesis	O
.	O

PS1816	O
Hypofunction	O
of	O
the	O
N	BG
-	IG
methyl	IG
-	IG
D	IG
-	IG
aspartate-10	IG
receptor	O
has	O
been	O
hypothesized	O
to	O
underlie	O
the	O
pathophysiology	O
of	O
schizophrenia-20	BP
,	O
based	O
on	O
the	O
observation	O
that	O
non	O
-	O
competitive	O
antagonists	O
of	O
the	O
N	BG
-	IG
methyl	IG
-	IG
D	IG
-	IG
aspartate	IG
receptor-40	IG
,	O
such	O
as	O
phencyclidine	O
,	O
induce	O
schizophrenia	BP
-	IP
like	IP
symptoms-50	IP
.	O

PS1817	O
The	O
expression	O
of	O
NR2A-4	BG
starts	O
at	O
puberty	O
,	O
a	O
period	O
corresponding	O
to	O
the	O
clinical	O
onset	O
of	O
schizophrenia-17	BP
.	O

PS1819	O
These	O
results	O
illustrate	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
schizophrenia-10	BP
and	O
suggest	O
that	O
the	O
longer	O
(	O
GT	O
)	O
(	O
n	O
)	O
stretch	O
may	O
act	O
as	O
a	O
risk	O
-	O
conferring	O
factor	O
that	O
worsens	O
chronic	O
outcome	O
by	O
reducing	O
GRIN2A-37	BG
levels	O
in	O
the	O
brain	O
.	O

PS1822	O
Crigler	O
-	O
Najjar2	O
presents	O
intermediate	O
levels	O
of	O
hyperbilirubinaemia-8	BP
as	O
a	O
result	O
of	O
an	O
incomplete	O
deficiency	O
of	O
hepatic	O
UGT1A1-18	BG
activity	O
.	O

PS1824	O
The	O
initial	O
germline	O
mutation	O
,	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
,	O
and	O
modifying	O
genetic	O
and	O
possibly	O
epigenetic	O
and	O
environmental	O
events	O
eventually	O
result	O
in	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
tumors-31	IG
.	O

PS1825	O
Our	O
understanding	O
of	O
the	O
function	O
of	O
the	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene	IG
product-14	IG
,	O
menin	O
,	O
has	O
increased	O
significantly	O
over	O
the	O
years	O
.	O

PS1827	O
We	O
evaluated	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
Fanconi	BP
Anemia-9	IP
/	O
BRCA-11	BG
pathway	O
in	O
relation	O
to	O
grade	O
3	O
/	O
4	O
neurotoxicities	O
in	O
patients	O
(	O
n	O
=	O
888	O
)	O
from	O
SWOG0221-29	BG
,	O
a	O
phase	O
III	O
adjuvant	O
trial	O
for	O
breast	BP
cancer-38	IP
of	O
4	O
dose	O
/	O
schedules	O
of	O
cyclophosphamide	O
(	O
C	O
)	O
,	O
doxorubicin	O
(	O
A	O
)	O
,	O
and	O
paclitaxel	O
(	O
T	O
)	O
.	O

PS1828	O
In	O
this	O
trial	O
of	O
CA	O
+	O
T	O
for	O
breast	BP
cancer-10	IP
,	O
single	O
nucleotide	O
polymorphisms	O
in	O
Fanconi	O
AnemiaNCD2	O
,	O
but	O
not	O
in	O
BRCA1-22	BG
,	O
were	O
associated	O
with	O
a	O
70	O
-	O
80	O
%	O
increase	O
in	O
the	O
odds	O
of	O
grade	O
3	O
/	O
4	O
neurological	O
toxicities	O
and	O
increased	O
expression	O
of	O
the	O
gene	O
.	O

PS1829	O
However	O
,	O
a	O
discordance	O
between	O
CYP2C19	BG
genotype-7	IG
and	O
phenotype	O
has	O
been	O
reported	O
previously	O
in	O
a	O
small	O
study	O
of	O
cancer-19	BP
patients	O
.	O

PS1831	O
The	O
disease	O
is	O
caused	O
by	O
mutations	O
within	O
the	O
factor	BG
VIII	IG
gene-11	IG
leading	O
to	O
decreased	O
or	O
absent	O
factor	BG
VIII-18	IG
activities	O
with	O
a	O
bleeding	O
tendency	O
depending	O
on	O
the	O
degree	O
of	O
factor	BG
VIII	IG
deficiency-31	IP
.	O

PS1832	O
Type	O
III	O
hyperlipoproteinaemia-3	BP
is	O
common	O
in	O
this	O
group	O
of	O
patients	O
and	O
need	O
not	O
be	O
associated	O
with	O
the	O
apolipoprotein	BG
-	IG
E2-20	IG
/	O
E2-22	BG
isoform	O
.	O

PS1833	O
Type	O
III	O
hyperlipoproteinaemia-3	BP
is	O
common	O
in	O
this	O
group	O
of	O
patients	O
and	O
need	O
not	O
be	O
associated	O
with	O
the	O
apolipoprotein	BG
-	IG
E2-20	IG
/	O
E2-22	BG
isoform	O
.	O

PS1836	O
cSNP-1	BG
in	O
WNK4	BG
gene-4	IG
in	O
a	O
small	O
samples	O
was	O
detected	O
by	O
sequencing	O
,	O
then	O
PCR	O
-	O
RFLP	O
was	O
performed	O
in	O
98	O
patients	O
with	O
essential	O
hypertension-25	BP
and	O
95	O
control	O
subjects	O
.	O

PS1837	O
A	O
cSNP	O
was	O
detected	O
in	O
WNK4	BG
gene	IG
exon7	IG
G1662A-9	IG
,	O
and	O
there	O
were	O
significant	O
differences	O
in	O
the	O
distribution	O
of	O
allele	O
frequency	O
of	O
G1662A	O
between	O
essential	O
hypertension-26	BP
group	O
and	O
control	O
group	O
.	O

PS1842	O
We	O
studied	O
44	O
consecutive	O
patients	O
with	O
Friedreich	O
'	O
s	O
ataxia-10	BP
,	O
determined	O
the	O
size	O
of	O
GAA	O
expansions	O
in	O
the	O
frataxin	BG
gene-21	IG
,	O
and	O
examined	O
the	O
relation	O
between	O
the	O
genotype	O
and	O
cardiac	O
phenotype	O
assessed	O
by	O
M	O
-	O
mode	O
and	O
two	O
-	O
dimensional	O
echocardiography	O
.	O

PS1843	O
These	O
results	O
suggest	O
that	O
abnormalities	O
of	O
the	O
gene	BG
encoding	IG
frataxin-10	IG
,	O
a	O
protein	O
of	O
unknown	O
function	O
highly	O
expressed	O
in	O
the	O
normal	O
heart	O
,	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
modulation	O
of	O
cardiac	BP
hypertrophy-34	IP
.	O

PS1846	O
In	O
cystic	BP
fibrosis-3	IP
,	O
the	O
cloning	O
and	O
identification	O
of	O
several	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
chloride	BG
channel	IG
transmembrane	IG
regulator-20	IG
(	O
CFTR-22	BG
)	O
have	O
resolved	O
several	O
important	O
issues	O
in	O
clinical	O
practice	O
:	O
cystic	O
fibrosis	O
constitutes	O
a	O
molecular	O
defect	O
of	O
a	O
single	O
gene	O
.	O

PS1849	O
The	O
objective	O
was	O
to	O
evaluate	O
the	O
prevalence	O
and	O
association	O
of	O
several	O
markers	O
(	O
islet	O
cell	O
antibodies	O
:	O
ICA	O
,	O
insulin-20	BG
autoantibodies	O
:	O
IAA	O
,	O
glutamic	BG
acid	IG
decarboxylase	IG
antibodies-28	IG
:	O
GADA-30	BG
and	O
ICA512	BG
antibodies-33	IG
:	O
ICA512A	O
)	O
along	O
with	O
HLA	BG
DQB1-40	IG
genotype	O
in	O
type	O
1	O
diabetes	BP
mellitus-46	IP
of	O
recent	O
onset	O
,	O
including	O
siblings	O
and	O
individuals	O
without	O
any	O
history	O
of	O
this	O
disease	O
,	O
in	O
an	O
Argentine	O
population	O
.	O

PS1851	O
Molecular	O
analysis	O
of	O
the	O
CYP21	BG
gene-6	IG
was	O
performed	O
in	O
432	O
congenital	BP
adrenal	IP
hyperplasia-13	IP
patients	O
and	O
298	O
family	O
members	O
.	O

PS1852	O
The	O
presence	O
of	O
elevated	O
basal	O
and	O
ACTH-7	BG
-	O
stimulated	O
17	O
-	O
hydroxyprogesterone	O
,	O
premature	O
pubarche	O
,	O
advanced	O
bone	BP
age-19	IP
and	O
clitoral	BP
hypertrophy-22	IP
directly	O
implicated	O
Asn493Ser	O
polymorphism	O
in	O
the	O
manifestation	O
of	O
nonclassical	O
-	O
and	O
even	O
SV	O
-	O
congenital	BP
adrenal	IP
hyperplasia-39	IP
.	O

PS1853	O
The	O
role	O
of	O
mutant	BG
TARDBP-5	IG
and	O
ANG	BG
genes-8	IG
on	O
blood	O
-	O
brain	O
barrier	O
integrity	O
of	O
amyotrophic	BP
lateral	IP
sclerosis-18	IP
patients	O
warrants	O
further	O
investigation	O
.	O

PS1854	O
By	O
sequence	O
analysis	O
,	O
we	O
identified	O
a	O
recurrent	O
mutation	O
2272C	O
>	O
T	O
(	O
R758X	O
)	O
of	O
the	O
CYLD	BG
gene-19	IG
in	O
the	O
affected	O
individuals	O
of	O
this	O
family	O
,	O
which	O
was	O
previously	O
identified	O
in	O
other	O
ethnic	O
families	O
with	O
familial	O
cylindromatosis-38	BP
.	O

PS1855	O
The	O
C8orf13	BG
-	IG
BLK	IG
rs13277113	IG
genotype-6	IG
was	O
determined	O
in	O
1	O
,	O
031	O
patients	O
with	O
systemic	O
sclerosis-16	BP
and	O
1	O
,	O
014	O
control	O
subjects	O
for	O
whom	O
BANK1	BG
genotypes-26	IG
were	O
available	O
.	O

PS1861	O
We	O
did	O
not	O
detect	O
22q11	O
interstitial	O
deletions	O
associated	O
with	O
the	O
DiGeorge	O
syndrome	O
among	O
the	O
320	O
patients	O
of	O
our	O
sample	O
and	O
we	O
found	O
no	O
association	O
between	O
common	BG
proline	IG
dehydrogenase-28	IG
polymorphisms	O
and	O
any	O
of	O
the	O
psychotic	BP
disorders-35	IP
.	O

PS1862	O
Here	O
,	O
we	O
describe	O
a	O
previously	O
unreported	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
family-13	IG
in	O
which	O
two	O
siblings	O
presented	O
with	O
malignant	O
thymic	O
carcinoids	O
.	O

PS1863	O
All	O
six	O
siblings	O
share	O
a	O
novel	O
nonsense	O
mutation	O
Q395X	O
on	O
exon	O
8	O
of	O
the	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene-20	IG
.	O

PS1864	O
In	O
the	O
22	O
separate	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
families-10	IG
with	O
thymic	O
carcinoids	O
,	O
all	O
but	O
two	O
(	O
91	O
%	O
)	O
have	O
mutations	O
coding	O
for	O
a	O
truncated	O
protein	O
.	O

PS1865	O
The	O
combination	O
of	O
pulmonary	BP
emphysema-5	IP
and	O
liver	O
cirrhosis	O
in	O
early	O
childhood	O
is	O
documented	O
for	O
the	O
first	O
time	O
in	O
a	O
31	O
/	O
2	O
year	O
old	O
girl	O
with	O
homozygous	O
(	O
ZZ-29	BG
)	O
deficiency	O
of	O
a1	BG
-	IG
antitrypsin-35	IG
.	O

PS1867	O
Mutation	O
scans	O
identified	O
a	O
missense	O
mutation	O
(	O
D1275N-8	BG
)	O
that	O
cosegregated	O
with	O
an	O
age	O
-	O
dependent	O
,	O
variably	O
expressed	O
phenotype	O
of	O
Dilated	BP
cardiomyopathy-23	IP
,	O
atrial	BP
fibrillation-26	IP
,	O
impaired	O
automaticity	O
,	O
and	O
conduction	O
delay	O
.	O

PS1868	O
A	O
clear	O
heterogeneity	O
in	O
serum	BG
ferritin-6	IG
and	O
transferrin-8	BG
saturation	O
values	O
,	O
and	O
in	O
iron	O
removed	O
by	O
phlebotomy	O
was	O
observed	O
among	O
haemochromatosis-21	BP
patients	O
that	O
is	O
correlated	O
with	O
the	O
presence	O
of	O
two	O
subgroups	O
of	O
individuals	O
homozygous	O
and	O
non	O
-	O
homozygous	O
for	O
the	O
mutant	O
allele	O
C282Y	O
,	O
the	O
latter	O
being	O
characterized	O
by	O
lower	O
phenotypic	O
values	O
.	O

PS1873	O
Although	O
the	O
phenotype	O
of	O
CDKL5-5	BG
mutation	O
is	O
similar	O
to	O
Rett	O
syndrome	O
caused	O
by	O
MECP2-14	BG
mutation	O
,	O
the	O
former	O
is	O
characterized	O
by	O
early	O
-	O
onset	O
seizures-25	BP
and	O
association	O
with	O
West	O
syndrome	O
.	O

PS1875	O
The	O
disease	O
is	O
caused	O
by	O
mutations	O
of	O
the	O
PKD1-9	BG
(	O
affecting	O
roughly	O
85	O
%	O
of	O
Autosomal	O
dominant	O
polycystic	BP
kidney-19	IP
disease	O
patients	O
)	O
and	O
PKD2-24	BG
(	O
affecting	O
roughly	O
14	O
%	O
of	O
Autosomal	O
dominant	O
polycystic	BP
kidney-34	IP
disease	O
patients	O
)	O
genes	O
,	O
although	O
in	O
several	O
Autosomal	O
dominant	O
polycystic	BP
kidney-46	IP
disease	O
families	O
,	O
the	O
PKD1-51	BG
and	O
/	O
or	O
PKD2-55	BG
linkage	O
was	O
not	O
found	O
.	O

PS1876	O
The	O
direct	O
detection	O
of	O
mutations	O
in	O
the	O
non	O
-	O
duplicated	O
region	O
of	O
the	O
PKD1	BG
gene-15	IG
was	O
performed	O
in	O
90	O
unrelated	O
individuals	O
,	O
consisting	O
of	O
58	O
patients	O
with	O
end	O
-	O
stage	O
renal	BP
failure-32	IP
(	O
manifesting	O
before	O
their	O
50th	O
year	O
of	O
life	O
)	O
and	O
32	O
individuals	O
from	O
families	O
where	O
the	O
disease	O
was	O
clearly	O
linked	O
to	O
the	O
PKD1	BG
gene-56	IG
.	O

PS1877	O
Patients	O
with	O
an	O
interstitial	O
13q	O
deletion	O
that	O
contains	O
the	O
RB1	BG
gene-11	IG
show	O
retinoblastoma-13	BP
and	O
variable	O
clinical	O
features	O
.	O

PS1878	O
Milder	O
phenotypic	O
expression	O
of	O
retinoblastoma-5	BP
was	O
observed	O
in	O
patients	O
with	O
deletions	O
larger	O
than	O
1	O
Mb	O
,	O
which	O
contained	O
the	O
MED4	BG
gene-21	IG
.	O

PS1882	O
Multiple	O
endocrine	O
neoplasia-3	BP
type	O
2	O
is	O
divided	O
into	O
three	O
varieties	O
depending	O
on	O
its	O
clinical	O
features	O
:	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
2A-21	IG
,	O
multiple	O
endocrine	O
neoplasia-25	BP
type	O
2B	O
,	O
and	O
familial	O
medullary	O
thyroid	BP
carcinoma-33	IP
.	O

PS1883	O
Mutations	O
in	O
the	O
cationic	O
trypsinogen	BG
gene-6	IG
(	O
PRSS1-8	BG
)	O
have	O
been	O
detected	O
in	O
patients	O
with	O
hereditary	O
pancreatitis-17	BP
.	O

PS1886	O
The	O
patient	O
'	O
s	O
clinical	O
values	O
(	O
C3-8	BG
,	O
C4-10	BG
,	O
CA19	BG
-	IG
9-14	IG
and	O
HbA1c-16	BG
)	O
were	O
higher	O
than	O
those	O
of	O
the	O
other	O
patients	O
with	O
chronic	O
pancreatitis-28	BP
.	O

PS1889	O
Genetic	O
mapping	O
studies	O
have	O
identified	O
two	O
major	O
loci	O
for	O
X	O
-	O
linked	O
form	O
of	O
retinitis	BP
pigmentosa-16	IP
:	O
RP3	O
(	O
70	O
%	O
-	O
75	O
%	O
of	O
X	O
-	O
linked	O
form	O
of	O
retinitis	BP
pigmentosa-32	IP
)	O
and	O
RP2-35	BG
(	O
20	O
%	O
-	O
25	O
%	O
of	O
X	O
-	O
linked	O
form	O
of	O
retinitis	BP
pigmentosa-49	IP
)	O
.	O

PS1890	O
The	O
retinitis	BG
pigmentosa	IG
GTPase	IG
regulator	IG
gene-6	IG
has	O
been	O
cloned	O
within	O
the	O
RP3-12	BG
genomic	O
interval	O
and	O
it	O
has	O
been	O
shown	O
that	O
10	O
%	O
-	O
20	O
%	O
of	O
X	O
-	O
linked	O
form	O
of	O
retinitis	BP
pigmentosa-33	IP
families	O
have	O
mutations	O
in	O
this	O
gene	O
.	O

PS1891	O
Here	O
,	O
we	O
describe	O
a	O
single	O
-	O
strand	O
conformational	O
polymorphism	O
-	O
based	O
mutation	O
screening	O
of	O
retinitis	BG
pigmentosa	IG
GTPase	IG
regulator-19	IG
in	O
a	O
pool	O
of	O
29	O
X	O
-	O
linked	O
form	O
of	O
retinitis	O
pigmentosa	O
families	O
for	O
which	O
the	O
disease	O
segregates	O
with	O
the	O
RP3	BG
locus-41	IG
,	O
in	O
order	O
to	O
investigate	O
the	O
proportion	O
of	O
RP3	BG
families-51	IG
with	O
retinitis	BG
pigmentosa	IG
GTPase	IG
regulator	IG
mutations-57	IG
and	O
to	O
relate	O
the	O
results	O
to	O
previous	O
reports	O
.	O

PS1893	O
This	O
figure	O
is	O
comparable	O
to	O
the	O
percentage	O
of	O
RP2	BG
gene-10	IG
mutations	O
that	O
we	O
have	O
detected	O
in	O
our	O
entire	O
X	O
-	O
linked	O
form	O
of	O
retinitis	BP
pigmentosa-25	IP
patient	O
pool	O
(	O
10	O
%	O
-	O
15	O
%	O
)	O
.	O

PS1894	O
A	O
correlation	O
of	O
retinitis	BG
pigmentosa	IG
GTPase	IG
regulator	IG
mutations-8	IG
with	O
phenotype	O
in	O
the	O
families	O
described	O
in	O
this	O
study	O
and	O
the	O
biochemical	O
characterisation	O
of	O
reported	O
mutations	O
may	O
provide	O
insights	O
into	O
the	O
function	O
of	O
the	O
protein	O
.	O

PS1895	O
The	O
complex	O
gene	O
product	O
of	O
Wiskott	O
-	O
Aldrich	O
syndromeP	O
has	O
multiple	O
functional	O
domains	O
that	O
contribute	O
to	O
actin-17	BG
polymerization	O
,	O
cell	O
motility	O
,	O
intracellular	O
signaling	O
,	O
and	O
apoptosis-27	BP
.	O

PS1896	O
A	O
broad	O
spectrum	O
of	O
pathogenetic	O
mutations	O
(	O
missense	O
,	O
splice	O
site	O
,	O
insertion	O
,	O
and	O
deletions	O
)	O
were	O
identified	O
in	O
the	O
megalencephalic	O
leukoencephalopathy-23	BP
and	O
subcortical	O
cysts1	BG
gene-27	IG
,	O
enlarging	O
the	O
spectrum	O
of	O
allelic	O
variants	O
without	O
a	O
straightforward	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS1899	O
This	O
meta	O
-	O
analysis	O
suggests	O
a	O
lack	O
of	O
statistical	O
evidence	O
for	O
the	O
association	O
between	O
the	O
four	O
XPF	BG
SNPs-18	IG
and	O
overall	O
risk	O
of	O
cancers-23	BP
.	O

PS1901	O
To	O
address	O
whether	O
the	O
molecular	O
basis	O
of	O
the	O
phenotype	O
-	O
genotype	O
correlation	O
could	O
be	O
related	O
to	O
altered	O
MEFV	O
messenger	O
RNA	O
expression	O
,	O
we	O
quantified	O
the	O
relative	O
abundance	O
of	O
MEFV	BG
transcripts-30	IG
in	O
peripheral	O
blood	O
leukocytes	O
from	O
patients	O
with	O
Familial	O
Mediterranean	O
fever-40	BP
,	O
healthy	O
carriers	O
of	O
a	O
single	O
MEFV	O
mutation	O
,	O
and	O
healthy	O
control	O
subjects	O
.	O

PS1903	O
The	O
identification	O
of	O
the	O
spinocerebellar	BP
ataxia-6	IP
type	O
2	O
mutation	O
in	O
31	O
out	O
of	O
38	O
families	O
with	O
the	O
autosomal	O
dominant	O
cerebellar	O
ataxia-21	BP
I	O
phenotype	O
,	O
but	O
in	O
none	O
of	O
those	O
with	O
autosomal	BG
dominant	IG
cerebellar	IG
ataxia	IG
II-35	IG
,	O
autosomal	BG
dominant	IG
cerebellar	IG
ataxia	IG
III-41	IG
or	O
idiopathic	O
late	O
onset	O
cerebellar	O
ataxia-47	BP
confirms	O
the	O
specificity	O
of	O
this	O
mutation	O
.	O

PS1904	O
However	O
,	O
these	O
neurological	O
signs	O
were	O
also	O
seen	O
in	O
an	O
autosomal	BG
dominant	IG
cerebellar	IG
ataxia	IG
I	IG
family-16	IG
in	O
which	O
the	O
spinocerebellar	BP
ataxia-21	IP
type	O
2	O
mutation	O
was	O
not	O
identified	O
,	O
illustrating	O
the	O
importance	O
of	O
a	O
direct	O
genetic	O
test	O
.	O

PS1905	O
The	O
spinocerebellar	BP
ataxia-3	IP
type	O
2	O
mutation	O
is	O
the	O
most	O
frequent	O
amongst	O
autosomal	O
dominant	O
cerebellar	O
ataxia	O
I	O
patients	O
,	O
accounting	O
for	O
40	O
%	O
,	O
compared	O
with	O
SCA1-26	BG
and	O
SCA3-28	BG
which	O
account	O
for	O
35	O
%	O
and	O
15	O
%	O
,	O
respectively	O
.	O

PS1909	O
In	O
inflamed	O
sigmoidal	O
tissue	O
from	O
ulcerative	O
colitis-7	BP
patients	O
,	O
11	O
genes	O
(	O
NAT1-13	BG
,	O
NR2B1-15	BG
,	O
CEBPB-17	BG
,	O
IFG-19	BG
,	O
IL8-21	BG
,	O
IL10-23	BG
,	O
S100A12-25	BG
,	O
SPP1-27	BG
,	O
DEFA5-29	BG
,	O
DEFA6-31	BG
and	O
HAMP-33	BG
)	O
were	O
overexpressed	O
.	O

PS1912	O
We	O
performed	O
a	O
retrospective	O
review	O
to	O
describe	O
clinical	O
outcomes	O
in	O
patients	O
with	O
medullary	O
thyroid	BP
carcinoma-15	IP
,	O
screening	O
a	O
subset	O
of	O
patients	O
for	O
somatic	O
mutations	O
in	O
the	O
RET-27	BG
and	O
p18	BG
genes-30	IG
and	O
performing	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
a	O
tertiary	O
-	O
care	O
referral	O
hospital	O
from	O
1967	O
to	O
2009	O
.	O

PS1915	O
Mutations	O
in	O
the	O
p18	BG
gene-5	IG
were	O
not	O
a	O
major	O
factor	O
in	O
medullary	O
thyroid	BP
carcinoma	IP
tumorigenesis-15	IP
.	O

PS1918	O
These	O
correlations	O
,	O
found	O
between	O
different	O
mutation	O
types	O
and	O
clinical	O
manifestations	O
,	O
might	O
be	O
explained	O
by	O
different	O
underlying	O
genetic	O
mechanisms	O
(	O
dominant	BP
negative	IP
versus	IP
haploinsufficiency-25	IP
)	O
and	O
by	O
consideration	O
of	O
the	O
two	O
main	O
physiological	O
functions	O
of	O
fibrillin	BG
-	IG
1-39	IG
(	O
structural	O
versus	O
mediator	O
of	O
TGF	BG
beta-46	IG
signalling	O
)	O
.	O

PS1920	O
These	O
constructs	O
were	O
used	O
to	O
generate	O
a	O
series	O
of	O
chimeric	O
clones	O
to	O
test	O
the	O
individual	O
contributions	O
of	O
LTR	O
,	O
surface	O
,	O
and	O
transmembrane	O
/	O
Rev-25	BG
regions	O
to	O
the	O
disease	O
potential	O
of	O
the	O
highly	O
virulent	O
equine	O
infectious	O
anemia-37	BP
virus	O
(	O
17	O
)	O
.	O

PS1922	O
Maturity	O
onset	O
diabetes	O
of	O
the	O
young	O
type	O
2	O
(	O
or	O
glucokinase	BG
gene	IG
MODY-13	IG
)	O
is	O
a	O
genetic	O
form	O
of	O
diabetes	BP
mellitus-21	IP
provoked	O
by	O
mutations	O
in	O
the	O
glucokinase	O
gene	O
.	O

PS1925	O
However	O
,	O
we	O
found	O
a	O
small	O
but	O
distinct	O
elevation	O
in	O
the	O
serum	BG
carbohydrate	IG
antigen	IG
19	IG
-	IG
9-17	IG
level	O
in	O
three	O
cancer-21	BP
patients	O
with	O
the	O
Lewis	O
-	O
negative	O
phenotype	O
.	O

PS1926	O
Six	O
cancer-2	BP
patients	O
with	O
a	O
Lewis	O
-	O
negative	O
phenotype	O
were	O
selected	O
by	O
very	O
low	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
concentrations	O
:	O
three	O
showed	O
a	O
small	O
elevation	O
(	O
Group	O
A	O
)	O
and	O
the	O
other	O
three	O
showed	O
no	O
elevation	O
(	O
Group	O
B	O
)	O
in	O
the	O
serum	BG
carbohydrate	IG
antigen	IG
19	IG
-	IG
9-49	IG
.	O

PS1927	O
Even	O
genuinely	O
Le	O
-	O
negative	O
patients	O
,	O
who	O
genetically	O
lack	O
the	O
Le	O
enzyme	O
and	O
theoretically	O
never	O
produce	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
,	O
occasionally	O
show	O
a	O
slight	O
increase	O
in	O
serum	BG
carbohydrate	IG
antigen	IG
19	IG
-	IG
9-35	IG
level	O
when	O
they	O
are	O
homozygous	O
for	O
Se	O
-	O
negative	O
genotypes	O
and	O
suffer	O
from	O
advanced	BP
cancer-50	IP
with	O
overproduction	O
of	O
glycans	O
as	O
precursors	O
of	O
carbohydrate	O
antigen	O
19	O
-	O
9	O
.	O

PS1932	O
Moreover	O
,	O
14	O
subjects	O
with	O
sporadic	O
non	O
-	O
autoimmune	BP
hyperthyroidism-10	IP
and	O
10	O
different	O
TSH	BG
receptor-15	IG
germline	O
mutations	O
have	O
been	O
reported	O
.	O

PS1937	O
By	O
genotyping	O
six	O
microsatellite	O
markers	O
(	O
D17S921-7	BG
,	O
D17S955-9	BG
,	O
D17S1358-11	BG
,	O
D17S839-13	BG
,	O
D17S122-15	BG
and	O
D17S261-17	BG
)	O
,	O
Hereditary	BP
neuropathy-21	IP
with	O
liability	O
to	O
pressure	O
palsies	O
with	O
the	O
deletion	O
was	O
observed	O
in	O
79	O
%	O
(	O
19	O
of	O
24	O
)	O
of	O
Hereditary	O
neuropathy-42	BP
with	O
liability	O
to	O
pressure	O
palsies	O
families	O
.	O

PS1946	O
We	O
report	O
the	O
iduronate	BG
-	IG
2	IG
-	IG
sulfatase-8	IG
mutation	O
and	O
polymorphisms	O
causing	O
the	O
Hunter	O
syndrome	O
in	O
patients	O
from	O
one	O
family	O
in	O
Tunisia	O
A	O
preliminary	O
diagnosis	O
was	O
made	O
by	O
qualitative	O
detection	O
of	O
urinary	O
glycosaminoglycans	O
of	O
the	O
suspected	O
Mucopolysaccharidosis-37	BP
type	O
II	O
probands	O
.	O

PS1951	O
Molecular	O
diagnosis	O
was	O
performed	O
in	O
a	O
small	O
number	O
of	O
Congenital	BP
adrenal	IP
hyperplasia-12	IP
patients	O
proved	O
not	O
to	O
suffer	O
from	O
21	O
-	O
hydroxylase-21	BG
deficiency	O
but	O
from	O
11beta	BG
-	IG
hydroxylase	IG
deficiency-28	IP
,	O
and	O
a	O
new	O
mutation	O
was	O
identified	O
.	O

PS1956	O
Neurofibromatosis	BG
type	IG
1-3	IG
shows	O
a	O
broad	O
clinic	O
variability	O
even	O
within	O
a	O
single	O
family	O
.	O

PS1957	O
For	O
an	O
appropriate	O
management	O
of	O
patients	O
and	O
family	O
counseling	O
,	O
molecular	O
study	O
of	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-18	IG
should	O
be	O
considered	O
in	O
patients	O
not	O
fulfilling	O
NIH	O
criteria	O
when	O
other	O
features	O
suggestive	O
of	O
Neurofibromatosis-33	BP
type	O
1	O
are	O
present	O
.	O

PS1958	O
We	O
determined	O
ARIX	O
and	O
PHOX2B-5	BG
polymorphisms	O
as	O
genotypes	O
,	O
and	O
analyzed	O
phenotype	O
-	O
phenotype	O
and	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
37	O
patients	O
with	O
idiopathic	O
superior	O
oblique	O
muscle	BP
palsy-28	IP
.	O

PS1965	O
The	O
correlation	O
of	O
thromboelastometry	O
assay	O
and	O
severe	O
Factor	BG
X	IG
deficiency-10	IP
is	O
less	O
striking	O
.	O

PS1966	O
An	O
isogenic	O
derivative	O
strain	O
of	O
RN6390	O
containing	O
the	O
wild	BG
-	IG
type	IG
rsbU	IG
gene-13	IG
had	O
significantly	O
increased	BP
acetate	IP
catabolism-18	IP
,	O
demonstrating	O
that	O
sigma	BG
(	IG
B	IG
)-25	IG
is	O
required	O
for	O
acetate	O
catabolism	O
.	O

PS1970	O
There	O
was	O
a	O
significant	O
association	O
between	O
colorectal	BP
cancer-8	IP
and	O
T	O
allele	O
-	O
bearing	O
genotype	O
distribution	O
of	O
HIF1A-17	BG
1772C	O
/	O
T	O
polymorphism	O
.	O

PS1972	O
There	O
is	O
a	O
significant	O
association	O
between	O
the	O
HIF1A	BG
1772C	IG
/	IG
T-11	IG
single	O
nucleotide	O
polymorphisms	O
and	O
the	O
risk	O
of	O
developing	O
colorectal	O
cancer-21	BP
,	O
especially	O
in	O
individuals	O
older	O
than	O
60	O
years	O
.	O

PS1973	O
To	O
identify	O
any	O
mutation	O
of	O
the	O
UbiA	BG
prenyltransferase	IG
domain	IG
-	IG
containing	IG
protein	IG
1-13	IG
gene	O
in	O
Japanese	O
patients	O
with	O
Schnyder	O
'	O
s	O
crystalline	O
corneal	BP
dystrophy-24	IP
and	O
to	O
investigate	O
in	O
vivo	O
microstructural	O
phenotype	O
and	O
genotype	O
correlations	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
(	O
Heidelberg	O
Retina	O
Tomograph	O
2	O
Rostock	O
Cornea	O
Module	O
;	O
Heidelberg	O
Engineering	O
GmbH	O
,	O
Dossenheim	O
,	O
Germany	O
)	O
.	O

PS1974	O
Additionally	O
,	O
cosegregation	O
of	O
the	O
mutation	O
(	O
Y174C	O
)	O
and	O
Schnyder	O
'	O
s	O
crystalline	O
corneal	BP
dystrophy-16	IP
was	O
confirmed	O
in	O
1	O
pedigree	O
,	O
indicating	O
that	O
the	O
mutation	O
of	O
the	O
UbiA	BG
prenyltransferase	IG
domain	IG
-	IG
containing	IG
protein	IG
1	IG
gene-36	IG
is	O
causative	O
for	O
Schnyder	O
'	O
s	O
crystalline	O
corneal	BP
dystrophy-45	IP
.	O

PS1976	O
Nonsynonymous	O
novel	O
mutations	O
in	O
the	O
UbiA	BG
prenyltransferase	IG
domain	IG
-	IG
containing	IG
protein	IG
1	IG
gene-13	IG
were	O
detected	O
in	O
3	O
unrelated	O
Japanese	O
pedigrees	O
with	O
Schnyder	O
'	O
s	O
crystalline	O
corneal	BP
dystrophy-27	IP
,	O
confirming	O
the	O
genetic	O
heterogeneity	O
of	O
this	O
disorder	O
.	O

PS1978	O
The	O
angiotensinogen	BG
gene-3	IG
TT	O
,	O
MT	O
and	O
MM	O
genotypic	O
frequencies	O
were	O
neither	O
statistically	O
different	O
between	O
coronary	BP
artery	IP
disease-18	IP
patients	O
and	O
controls	O
nor	O
between	O
the	O
acute	O
myocardial	O
infarction	O
subgroup	O
.	O

PS1979	O
No	O
association	O
was	O
found	O
between	O
the	O
angiotensinogen	BG
gene-8	IG
M235T	O
polymorphism	O
and	O
coronary	BP
artery	IP
disease-14	IP
,	O
neither	O
with	O
its	O
severity	O
nor	O
with	O
acute	O
myocardial	BP
infarction-24	IP
.	O

PS1981	O
Sequence	O
analysis	O
in	O
a	O
patient	O
with	O
complete-7	BP
Dihydropyrimidine	BG
dehydrogenase	IG
deficiency-10	IP
,	O
previously	O
shown	O
to	O
be	O
heterozygous	O
for	O
the	O
delta	O
C1897	O
frame	O
-	O
shift	O
mutation	O
,	O
revealed	O
the	O
presence	O
of	O
a	O
novel	O
missense	O
mutation	O
,	O
R235W-35	BG
.	O

PS1992	O
A	O
total	O
of	O
119	O
unrelated	O
children	O
(	O
107	O
sporadic	O
and	O
12	O
familial	O
cases	O
)	O
with	O
prelingual	O
nonsyndromic	O
hearing	BP
loss-19	IP
underwent	O
mutational	O
screening	O
for	O
DFNB1-24	BG
in	O
the	O
noncoding	O
and	O
coding	O
exons	O
of	O
GJB2-32	BG
,	O
in	O
addition	O
to	O
the	O
del	O
(	O
GJB6	BG
-	IG
D13S1830-42	IG
)	O
mutation	O
of	O
GJB6-46	BG
.	O

PS1993	O
The	O
prevalence	O
of	O
DFNB1-4	BG
in	O
cases	O
of	O
prelingual	O
nonsyndromic	O
hearing	BP
loss-11	IP
was	O
26	O
%	O
(	O
25	O
%	O
in	O
sporadic	O
and	O
50	O
%	O
in	O
familial	O
cases	O
)	O
.	O

PS1994	O
Most	O
probands	O
have	O
a	O
congenital	BP
hearing	IP
loss-7	IP
that	O
is	O
stable	O
,	O
symmetrical	O
and	O
without	O
associated	O
manifestations	O
,	O
but	O
the	O
audiometric	O
profile	O
should	O
not	O
be	O
the	O
only	O
criteria	O
for	O
offering	O
mutational	O
screening	O
of	O
DFNB1-33	BG
because	O
of	O
the	O
observed	O
variability	O
.	O

PS1996	O
In	O
11	O
patients	O
with	O
heterozygous	O
alpha1	BG
-	IG
antitrypsin-8	IG
deficiency	BP
liver-10	IP
disease	O
was	O
apparent	O
despite	O
normal	O
serum	O
Alpha	BG
-	IG
1	IG
-	IG
antitrypsin-21	IG
levels	O
.	O

PS1997	O
Concentrations	O
of	O
all	O
HDL	BG
fractions-5	IG
and	O
ApoA	BG
-	IG
I-9	IG
were	O
higher	O
in	O
the	O
CETPd	O
group	O
and	O
clearance	O
was	O
delayed	O
,	O
as	O
demonstrated	O
by	O
modified	O
lipemia-25	BP
parameters	O
(	O
AUC	O
,	O
AUIC	O
,	O
RR	O
,	O
AR	O
and	O
late	O
peaks	O
and	O
meal	O
response	O
patterns	O
)	O
.	O

PS1998	O
To	O
date	O
,	O
the	O
human	O
angiotensinogen	BG
gene-7	IG
and	O
some	O
of	O
its	O
variants	O
represent	O
the	O
best	O
examples	O
of	O
genetic	O
influences	O
that	O
are	O
involved	O
in	O
the	O
determination	O
of	O
essential	O
hypertension-28	BP
and	O
associated	O
cardiovascular	BP
diseases-32	IP
.	O

PS1999	O
To	O
assess	O
the	O
value	O
of	O
genotyping	O
angiotensinogen-7	BG
in	O
a	O
genetically	O
homogeneous	O
population	O
,	O
we	O
carried	O
out	O
a	O
retrospective	O
,	O
case	O
control	O
study	O
of	O
variants	O
M235T	O
and	O
T174M	O
for	O
putative	O
correlations	O
with	O
cardiovascular	BP
diseases-33	IP
among	O
nationals	O
from	O
the	O
United	O
Arab	O
Emirates	O
(	O
Emirati	O
)	O
-	O
-	O
an	O
ethnic	O
group	O
characterized	O
by	O
no	O
alcohol	O
intake	O
and	O
no	O
cigarette	O
smoking	O
.	O

PS2003	O
By	O
analogy	O
with	O
apparent	O
mineralocorticoid	O
excess	O
,	O
low	O
placental	O
11	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	BG
K-15	IG
activity	O
in	O
humans	O
might	O
be	O
a	O
risk	O
factor	O
for	O
low	O
birth	O
weight	O
and	O
subsequent	O
hypertension-30	BP
.	O

PS2004	O
Twelve	O
such	O
haplotypes	O
associated	O
with	O
normal	O
and	O
mutant	O
phenylalanine	BG
hydroxylase	IG
alleles-11	IG
have	O
been	O
identified	O
in	O
33	O
Danish	O
families	O
with	O
children	O
with	O
phenylketonuria-22	BP
.	O

PS2005	O
Forty	O
-	O
one	O
patients	O
suffering	O
from	O
autosomal	O
dominant	O
cerebellar	O
ataxia	O
type	O
I	O
were	O
subjected	O
to	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
analysis	O
using	O
molecular	O
genetic	O
assignment	O
to	O
the	O
spinocerebellar	BG
ataxia	IG
type	IG
1	IG
,	IG
2	IG
or	IG
3-35	IG
(	O
SCA1-37	BG
,	O
-	O
2	O
or	O
-	O
3	O
)	O
genetic	O
locus	O
,	O
clinical	O
examination	O
and	O
nerve	O
conduction	O
as	O
well	O
as	O
evoked	O
potential	O
studies	O
.	O

PS2006	O
Pyramidal	O
tract	O
signs	O
,	O
pale	O
discs	O
,	O
and	O
dysphagia-9	BP
were	O
more	O
frequent	O
in	O
SCA1-14	BG
compared	O
with	O
SCA2-17	BG
and	O
SCA3-19	BG
patients	O
,	O
while	O
double	O
vision	O
occurred	O
less	O
frequently	O
.	O

PS2007	O
PCR	O
-	O
SSCP	O
and	O
clone	O
sequencing	O
were	O
performed	O
to	O
identify	O
the	O
mutations	O
and	O
polymorphism	O
in	O
PCR	O
products	O
of	O
KCNQ4	BG
coding	IG
sequence-21	IG
in	O
the	O
six	O
-	O
generations	O
pedigree	O
of	O
autosomal	O
dominant	O
hereditary	O
hearing	BP
loss-33	IP
.	O

PS2009	O
Thus	O
,	O
the	O
present	O
data	O
show	O
that	O
the	O
certain	O
NAT2	BG
genotypes-11	IG
and	O
some	O
styles	O
of	O
life	O
can	O
be	O
considered	O
as	O
risk	O
factors	O
of	O
psoriasis-24	BP
development	O
in	O
this	O
muscovite	O
population	O
.	O

PS2011	O
This	O
study	O
identified	O
novel	O
mutations	O
in	O
the	O
CYP4V2	BG
gene-9	IG
as	O
a	O
cause	O
of	O
Bietti	O
crystalline	BP
dystrophy-16	IP
.	O

PS2016	O
A	O
substantial	O
arylsulphatase	BG
A	IG
deficiency-5	IP
can	O
also	O
be	O
found	O
in	O
healthy	O
individuals	O
at	O
high	O
frequency	O
.	O

PS2017	O
The	O
absence	O
of	O
M2A-4	BG
and	O
[	O
anti	O
-	O
Mullerian	O
hormone	O
immunoreactivity	O
in	O
adult	O
gonads	O
was	O
observed	O
without	O
any	O
correlation	O
to	O
spermatogenetic	BP
impairment-22	IP
or	O
molecular	O
deficit	O
in	O
the	O
AZF	O
region	O
.	O

PS2018	O
Deletions	O
in	O
these	O
regions	O
remove	O
one	O
or	O
more	O
of	O
the	O
candidate	O
genes	O
(	O
DAZ-14	BG
,	O
RBMY-16	BG
,	O
USP9Y-18	BG
,	O
and	O
DBY	O
)	O
and	O
cause	O
severe	O
testiculopathy	O
leading	O
to	O
male	BP
infertility-30	IP
.	O

PS2019	O
Such	O
deletions	O
determine	O
azoospermia-4	BP
more	O
frequently	O
than	O
severe	O
oligozoospermia-9	BP
and	O
involve	O
especially	O
the	O
AZFc	BG
region-15	IG
including	O
the	O
DAZ	BG
gene	IG
family-20	IG
.	O

PS2020	O
The	O
relevant	O
single	O
nucleotide	O
polymorphism	O
component	O
was	O
contributed	O
to	O
significantly	O
by	O
10	O
single	O
nucleotide	O
polymorphisms	O
located	O
in	O
genes	O
,	O
including	O
those	O
coding	O
for	O
the	O
nicotinic	BG
alpha	IG
-	IG
7	IG
cholinergic	IG
receptor-30	IG
,	O
aromatic	BG
amino	IG
acid	IG
decarboxylase-35	IG
,	O
disrupted	O
in	O
schizophrenia-39	BP
1	O
,	O
among	O
others	O
.	O

PS2022	O
A	O
review	O
of	O
medical	O
records	O
and	O
mutational	O
analyses	O
of	O
the	O
PHEX	O
and	O
FGF23	BG
genes-14	IG
were	O
performed	O
on	O
17	O
unrelated	O
Korean	O
children	O
with	O
hypophosphatemic	BP
rickets-24	IP
.	O

PS2024	O
Mutations	O
in	O
MyBPC3-3	BG
are	O
present	O
in	O
15	O
%	O
of	O
our	O
hypertrophic	BP
cardiomyopathy-12	IP
families	O
.	O

PS2025	O
Mutations	O
in	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-7	IG
gene	O
have	O
been	O
reported	O
in	O
patients	O
with	O
chronic	O
pancreatitis-16	BP
.	O

PS2030	O
Upon	O
systematic	O
review	O
,	O
we	O
describe	O
different	O
phenotypes	O
of	O
immune	BP
dysregulation-11	IP
polyendocrinopathy	O
autoimmune	O
enteropathy	O
X	O
-	O
linked	O
syndrome	O
,	O
as	O
well	O
as	O
immune	BP
dysregulation-24	IP
polyendocrinopathy	O
autoimmune	O
enteropathy	O
X	O
-	O
linked	O
-	O
like	O
forms	O
of	O
Autoimmune	BP
enteropathy-36	IP
,	O
which	O
are	O
FOXP3-40	BG
independent	O
.	O

PS2031	O
Germline	O
mutations	O
in	O
the	O
human	BG
E	IG
-	IG
cadherin-8	IG
gene	O
,	O
CDH1-11	BG
,	O
are	O
initiating	O
events	O
in	O
cases	O
of	O
human	O
hereditary	O
diffuse	O
gastric	O
cancer	O
indicating	O
that	O
human	BG
E	IG
-	IG
cadherin-29	IG
is	O
a	O
tumor	O
suppressor	O
.	O

PS2032	O
Microdeletions	O
are	O
predominantly	O
maternal	O
in	O
origin	O
and	O
arise	O
by	O
unequal	O
crossover	O
between	O
misaligned	BP
Neurofibromatosis-14	IP
type	O
1REP	O
paralogous	O
sequence	O
blocks	O
which	O
flank	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-26	IG
.	O

PS2034	O
In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
presence	O
of	O
pathogenic	O
mutations	O
in	O
the	O
LKB1-14	BG
/	O
STK11-16	BG
gene	O
in	O
46	O
unrelated	O
Peutz	O
-	O
Jeghers	O
syndrome	O
families	O
,	O
and	O
also	O
carried	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
regard	O
of	O
the	O
development	O
of	O
cancer-40	BP
in	O
170	O
Peutz	O
-	O
Jeghers	O
syndrome	O
patients	O
belonging	O
to	O
these	O
families	O
.	O

PS2035	O
Genotype	O
-	O
phenotype	O
analysis	O
did	O
not	O
yield	O
any	O
significant	O
differences	O
between	O
patients	O
carrying	O
mutations	O
in	O
LKB1-16	BG
/	O
STK11-18	BG
versus	O
those	O
without	O
mutations	O
,	O
even	O
with	O
respect	O
to	O
primary	BP
biliary	IP
adenocarcinoma-30	IP
.	O

PS2036	O
This	O
study	O
presents	O
the	O
molecular	O
characterization	O
and	O
cancer-8	BP
occurrence	O
of	O
a	O
large	O
cohort	O
of	O
Peutz	O
-	O
Jeghers	O
syndrome	O
patients	O
,	O
increases	O
the	O
mutational	O
spectrum	O
of	O
LKB1-26	BG
/	O
STK11-28	BG
allelic	O
variants	O
worldwide	O
,	O
and	O
provides	O
a	O
new	O
insight	O
useful	O
for	O
clinical	O
diagnosis	O
and	O
genetic	O
counseling	O
of	O
Peutz	O
-	O
Jeghers	O
syndrome	O
families	O
.	O

PS2038	O
This	O
study	O
analyzes	O
the	O
mutation	O
spectrum	O
in	O
Spain-8	BG
,	O
remarks	O
the	O
importance	O
of	O
genetic	O
diagnosis	O
of	O
Familial	O
hypercholesterolemia-18	BP
patients	O
,	O
as	O
well	O
as	O
the	O
cascade	O
screening	O
,	O
and	O
shows	O
how	O
it	O
is	O
being	O
carried	O
out	O
in	O
Spain	O
.	O

PS2047	O
We	O
studied	O
278	O
subjects	O
with	O
non	O
-	O
insulin-8	BG
-	O
dependent	O
diabetes	O
mellitus	O
from	O
the	O
population	O
of	O
Penne	O
,	O
Italy	O
.	O

PS2049	O
Preliminary	O
data	O
on	O
53	O
children	O
with	O
insulin	BP
-	IP
dependent	IP
diabetes	IP
mellitus-11	IP
from	O
Sardinia	O
seem	O
to	O
confirm	O
the	O
relationship	O
between	O
RH	O
and	O
Hb	BG
A	IG
(	IG
1c	IG
)-26	IG
observed	O
in	O
non	O
-	O
insulin-31	BP
-	IP
dependent	IP
diabetes	IP
mellitus	IP
.	O

PS2051	O
Four	O
mutations	O
,	O
85T	BG
>	IG
C-6	IG
(	O
DPYD	BG
*	IG
9A-10	IG
)	O
,	O
1627A	O
>	O
G	O
(	O
DPYD	O
*	O
5	O
)	O
,	O
1896T	O
>	O
C	O
and	O
2194G	O
>	O
A	O
(	O
DPYD	O
*	O
6	O
)	O
,	O
were	O
found	O
in	O
the	O
142	O
cancer-40	BP
patients	O
.	O

PS2052	O
The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
frequency	O
of	O
mutations	O
in	O
SH2D1A-14	BG
in	O
X	O
-	O
linked	O
lymphoproliferative	BP
disease-20	IP
and	O
the	O
role	O
of	O
SH2D1A-25	BG
mutations	O
and	O
Epstein	O
-	O
Barr	O
virus	O
infection	O
in	O
determining	O
the	O
phenotype	O
and	O
outcome	O
of	O
patients	O
with	O
X	O
-	O
linked	O
lymphoproliferative	O
disease	O
.	O

PS2055	O
These	O
results	O
add	O
two	O
phenotypes	O
to	O
the	O
phenotypic	O
spectrum	O
caused	O
by	O
GLI3-12	BG
mutations	O
:	O
the	O
combined	O
polydactyly-17	BP
type	O
-	O
A	O
/	O
B	O
and	O
preaxial	BP
polydactyly-25	IP
type	O
-	O
IV	O
.	O

PS2057	O
Children	O
with	O
Silver	O
-	O
Russell	O
syndrome	O
and	O
an	O
11p15	O
epimutation	O
have	O
IGF	BG
-	IG
binding	IG
protein	IG
-	IG
3-17	IG
excess	O
and	O
show	O
endocrine	O
characteristics	O
suggesting	O
IGF	BG
-	IG
I-26	IG
insensitivity	O
,	O
whereas	O
children	O
with	O
Silver	O
-	O
Russell	O
syndrome	O
and	O
Uniparental	BP
disomy-38	IP
of	O
chromosome	O
7	O
were	O
not	O
different	O
from	O
nonsyndromic	O
short	O
children	O
born	O
small	O
for	O
gestational	BP
age-53	IP
.	O

PS2058	O
We	O
present	O
a	O
phenotype	O
-	O
genotype	O
correlation	O
analysis	O
in	O
12	O
patients	O
with	O
cystic	BP
fibrosis-14	IP
carrying	O
the	O
mutation	O
R334W	O
in	O
the	O
cystic	BG
fibrosisTR	IG
gene-23	IG
.	O

PS2061	O
The	O
CYP1B1-2	BG
mutation	O
spectrum	O
of	O
Kuwaiti	O
primary	O
congenital	O
glaucoma-9	BP
patients	O
is	O
similar	O
to	O
that	O
detected	O
in	O
the	O
neighboring	O
countries	O
.	O

PS2063	O
The	O
panel	O
of	O
heterogeneous	O
ARG1-5	BG
mutations	O
that	O
cause	O
Hyperargininemia-9	BP
was	O
expanded	O
,	O
nevertheless	O
a	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
not	O
observed	O
in	O
our	O
series	O
.	O

PS2065	O
Approximately	O
10	O
-	O
15	O
%	O
of	O
human	O
cancers-8	BP
do	O
not	O
show	O
evidence	O
of	O
telomerase-14	BG
activity	O
,	O
and	O
a	O
subset	O
of	O
these	O
maintain	O
telomere	O
lengths	O
by	O
a	O
recombination	O
-	O
based	O
mechanism	O
termed	O
alternative	O
lengthening	O
of	O
telomeres	O
.	O

PS2070	O
The	O
presence	O
of	O
two	O
most	O
common	O
mutations	O
associated	O
with	O
Arylsulfatase	BG
A	IG
-	IG
PD-13	IG
was	O
analyzed	O
in	O
56	O
patients	O
with	O
diagnosis	O
of	O
relapsing	O
-	O
remitting	O
multiple	BP
sclerosis-26	IP
,	O
by	O
polymerase	O
chain	O
reaction	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
.	O

PS2072	O
regulatory	O
subunit	O
of	O
the	O
cAMP	BG
-	IG
dependent	IG
protein	IG
kinase	IG
A-10	IG
,	O
in	O
which	O
the	O
index	O
patient	O
presented	O
with	O
Adrenocortical	BP
cancer-20	IP
.	O

PS2074	O
We	O
performed	O
a	O
clinical	O
,	O
biochemical	O
,	O
and	O
genetic	O
study	O
in	O
16	O
patients	O
from	O
11	O
families	O
with	O
adult	O
-	O
onset	O
acid	BG
maltase	IG
deficiency-23	IP
.	O

PS2076	O
To	O
study	O
the	O
clinical	O
,	O
pathologic	O
,	O
and	O
genetic	O
features	O
of	O
thymic	O
carcinoids	O
in	O
the	O
setting	O
of	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1-22	IG
and	O
to	O
study	O
means	O
for	O
detection	O
and	O
prevention	O
of	O
this	O
tumor	O
in	O
patients	O
with	O
multiple	O
endocrine	O
neoplasia-39	BP
type	O
1	O
.	O

PS2077	O
Mutation	O
analysis	O
was	O
performed	O
on	O
the	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene-12	IG
in	O
families	O
with	O
clusterings	O
of	O
the	O
tumor	O
to	O
look	O
for	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS2078	O
Mutation	O
analysis	O
of	O
the	O
families	O
with	O
clustering	O
revealed	O
mutations	O
in	O
different	O
exons	O
/	O
introns	O
of	O
the	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene-22	IG
.	O

PS2081	O
Electron	O
microscopic	O
analysis	O
of	O
immature	O
ears	O
indicated	O
early	BP
abnormalities-9	IP
in	O
the	O
arrangement	O
of	O
stereocilia	O
and	O
the	O
inner	O
and	O
outer	O
hair	O
cell	O
cuticular	O
plates	O
,	O
stereocilia	O
rootlets	O
,	O
and	O
the	O
actin-30	BG
meshwork	O
within	O
the	O
cuticular	O
plate	O
.	O

PS2082	O
Methylmalonic	BP
aciduria-2	IP
and	O
homocystinuria-4	BP
,	O
cblC-6	BG
type	O
,	O
is	O
the	O
most	O
common	O
inborn	O
error	O
of	O
vitamin	O
B	O
(	O
12	O
)	O
(	O
cobalamin	O
)	O
metabolism	O
.	O

PS2086	O
Among	O
lung	O
cancer-3	BP
patients	O
,	O
the	O
frequency	O
of	O
homozygous	O
rare	O
allele	O
of	O
P450IA1	BG
gene-14	IG
was	O
found	O
to	O
be	O
about	O
3	O
-	O
fold	O
higher	O
than	O
that	O
among	O
healthy	O
population	O
,	O
and	O
this	O
difference	O
was	O
statistically	O
significant	O
.	O

PS2089	O
The	O
knowledge	O
of	O
this	O
MEN1	BG
gene-6	IG
germline	O
defect	O
,	O
may	O
be	O
used	O
for	O
presymptomatic	O
identification	O
of	O
Multiple	O
endocrine	O
neoplasia-19	BP
type	O
1	O
disease	O
gene	O
-	O
carriers	O
among	O
family	O
-	O
members	O
of	O
this	O
proband	O
.	O

PS2101	O
We	O
have	O
therefore	O
assessed	O
the	O
prevalence	O
of	O
15	O
RYR1	O
mutations	O
currently	O
used	O
in	O
the	O
genetic	O
diagnosis	O
of	O
Malignant	O
hyperthermia-19	BP
in	O
a	O
sample	O
of	O
over	O
500	O
unrelated	O
European	O
Malignant	BP
hyperthermia-29	IP
susceptible	O
individuals	O
and	O
have	O
recorded	O
the	O
frequency	O
of	O
RYR1	BG
genotype-39	IG
/	O
in	O
vitro	O
contracture	O
test	O
phenotype	O
discordance	O
.	O

PS2102	O
These	O
data	O
represent	O
the	O
most	O
comprehensive	O
assessment	O
of	O
RYR1-9	BG
mutation	O
prevalence	O
and	O
genotype	O
/	O
phenotype	O
correlation	O
analysis	O
and	O
highlight	O
the	O
possible	O
limitations	O
of	O
Malignant	BP
hyperthermia-25	IP
screening	O
methods	O
.	O

PS2104	O
To	O
find	O
genes	O
for	O
insulin	BP
resistance-6	IP
it	O
is	O
necessary	O
to	O
assess	O
insulin	BP
action-13	IP
in	O
large	O
populations	O
.	O

PS2105	O
We	O
have	O
previously	O
measured	O
insulin-5	BG
action	O
in	O
a	O
large	O
cohort	O
of	O
subjects	O
(	O
Insulin	BP
Resistance-15	IP
and	O
Atherosclerosis	O
Study	O
[	O
IRAS	O
]	O
Family	O
Study	O
)	O
using	O
the	O
minimal	O
model	O
approach	O
.	O

PS2106	O
In	O
this	O
study	O
,	O
we	O
compare	O
sensitivity	O
from	O
the	O
minimal	O
model	O
(	O
insulin-13	O
sensitivity	O
index	O
[	O
S	O
(	O
I	O
)	O
]	O
)	O
with	O
the	O
measure	O
of	O
insulin	BP
resistance-28	IP
emanating	O
from	O
the	O
homeostasis	O
model	O
assessment	O
(	O
homeostasis	O
model	O
assessment	O
)	O
approach	O
.	O

PS2107	O
To	O
address	O
this	O
issue	O
,	O
we	O
conducted	O
a	O
statistical	O
genetic	O
analysis	O
of	O
serum	O
concentrations	O
of	O
bone	O
-	O
specific	O
alkaline	BG
phosphatase-20	IG
(	O
bone	BG
-	IG
specific	IG
alkaline	IG
phosphatase-26	IG
)	O
,	O
a	O
highly	O
specific	O
marker	O
of	O
osteoblast	O
function	O
that	O
is	O
elevated	O
in	O
persons	O
with	O
conditions	O
like	O
osteoporosis-44	BP
characterized	O
by	O
excessive	O
bone	O
turnover	O
or	O
rapid	O
bone	O
loss	O
.	O

PS2113	O
The	O
GSTM1-2	BG
null	O
genotype	O
confrs	O
a	O
moderately	O
increased	O
risk	O
of	O
smoking	O
-	O
related	O
lung	O
cancer-15	BP
,	O
however	O
.	O

PS2116	O
To	O
analyse	O
the	O
influence	O
of	O
HLA	BG
-	IG
DR-8	IG
,	O
DQ	O
and	O
corresponding	O
DQA1-13	BG
and	O
DQB1	BG
promoter	IG
alleles-17	IG
(	O
QAP-19	BG
and	O
QBP-21	BG
)	O
on	O
the	O
anti	O
-	O
Ro	O
alone	O
autoantibody	O
response	O
in	O
systemic	BP
lupus	IP
erythematosus-34	IP
.	O

PS2118	O
The	O
allelic	O
frequencies	O
of	O
anti	BG
-	IG
Ro-7	IG
alone	O
-	O
positive	O
and	O
anti	O
-	O
Ro	O
-	O
negative	O
systemic	BP
lupus	IP
erythematosus-19	IP
patients	O
and	O
healthy	O
controls	O
were	O
compared	O
using	O
the	O
chi	O
(	O
2	O
)	O
test	O
or	O
Fisher	O
'	O
s	O
exact	O
test	O
as	O
appropriate	O
.	O

PS2120	O
The	O
above	O
-	O
mentioned	O
alleles	O
may	O
contribute	O
to	O
the	O
presence	O
or	O
absence	O
of	O
anti	BG
-	IG
Ro-16	IG
alone	O
autoantibodies	O
in	O
systemic	BP
lupus	IP
erythematosus-22	IP
patients	O
.	O

PS2121	O
With	O
direct	O
sequence	O
analysis	O
of	O
Ornithine	BG
transcarbamylase	IG
gene-8	IG
of	O
26	O
unrelated	O
Korean	O
patients	O
with	O
Ornithine	BG
transcarbamylase	IG
deficiency-17	IP
,	O
23	O
different	O
mutations	O
were	O
identified	O
.	O

PS2123	O
Carriers	O
of	O
a	O
RET	BG
mutation-5	IG
are	O
at	O
risk	O
of	O
medullary	O
thyroid	BP
carcinoma-12	IP
,	O
pheochromocytoma-14	BP
,	O
and	O
primary	O
hyperparathyroidism-18	BP
.	O

PS2124	O
However	O
for	O
rare	O
mutations	O
in	O
the	O
RET	BG
proto	IG
-	IG
oncogene-10	IG
there	O
is	O
insufficient	O
evidence	O
to	O
provide	O
guidance	O
as	O
to	O
the	O
risk	O
of	O
medullary	O
thyroid	BP
carcinoma-25	IP
.	O

PS2130	O
The	O
results	O
suggest	O
that	O
haploinsufficiency	O
of	O
SHOX	O
is	O
primarily	O
responsible	O
for	O
the	O
borderline	O
short	BP
stature-15	IP
,	O
and	O
that	O
the	O
deletion	O
of	O
the	O
PAR1-23	BG
may	O
result	O
in	O
spermatogenic	BP
failure-28	IP
due	O
to	O
defective	O
X	BG
-	IG
Y-34	IG
pairing	O
and	O
recombination	O
in	O
the	O
PAR1-40	BG
.	O

PS2132	O
The	O
results	O
suggest	O
that	O
haploinsufficiency	O
of	O
SHOX	O
is	O
primarily	O
responsible	O
for	O
the	O
borderline	O
short	BP
stature-15	IP
,	O
and	O
that	O
the	O
deletion	O
of	O
the	O
PAR1-23	BG
may	O
result	O
in	O
spermatogenic	BP
failure-28	IP
due	O
to	O
defective	O
X	BG
-	IG
Y-34	IG
pairing	O
and	O
recombination	O
in	O
the	O
PAR1-40	BG
.	O

PS2133	O
Chromosomal	O
studies	O
on	O
the	O
boy	O
and	O
his	O
father	O
revealed	O
a	O
very	O
small	O
Y	O
chromosome	O
in	O
both	O
cases	O
,	O
probably	O
due	O
to	O
loss	O
of	O
the	O
heterochromatic	BG
long	IG
arm	IG
segment-28	IG
.	O

PS2136	O
The	O
F8	BG
gene-3	IG
mutation	O
of	O
all	O
46	O
carriers	O
was	O
determined	O
,	O
and	O
family	O
history	O
of	O
haemophilia-16	BP
was	O
recorded	O
.	O

PS2138	O
We	O
conclude	O
that	O
RET-4	BG
variants	O
are	O
present	O
in	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-12	IP
patients	O
yet	O
show	O
no	O
significant	O
statistical	O
association	O
with	O
the	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-25	IP
phenotype	O
,	O
suggesting	O
at	O
best	O
an	O
adjuvant	O
role	O
for	O
RET-35	BG
in	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-40	IP
.	O

PS2139	O
Pyruvate	BG
dehydrogenase	IG
deficiency-3	IP
and	O
cytochrome	BG
c	IG
oxidase-7	IG
deficiency	O
are	O
common	O
metabolic	O
disturbances	O
in	O
this	O
syndrome	O
.	O

PS2140	O
A	O
principal	O
-	O
component	O
score	O
composed	O
of	O
the	O
subtests	O
of	O
the	O
WISC	BG
-	IG
R-14	IG
,	O
PPVT-16	BG
,	O
WRAT-18	BG
,	O
and	O
MAT	O
represented	O
each	O
twin	O
'	O
s	O
cognitive	BP
ability-28	IP
.	O

PS2144	O
The	O
New	O
Zealand	O
Black	O
Lbw2	O
locus	O
(	O
lupus	O
New	O
Zealand	O
Black	O
x	O
New	O
Zealand	O
White	O
(	O
NZW	O
)	O
2	O
locus	O
)	O
was	O
previously	O
linked	O
to	O
mortality	O
and	O
glomerulonephritis-28	BP
,	O
but	O
not	O
to	O
IgG	BG
autoantibodies-34	IG
,	O
suggesting	O
that	O
it	O
played	O
a	O
role	O
in	O
a	O
later	O
disease	O
stage	O
.	O

PS2145	O
Lack	O
of	O
the	O
New	O
Zealand	O
Black	O
Lbw2	O
indeed	O
reduced	O
mortality	O
and	O
glomerulonephritis-12	BP
,	O
but	O
not	O
serum	O
levels	O
of	O
total	O
and	O
anti	BG
-	IG
DNA	IG
IgG-24	IG
Abs	O
.	O

PS2148	O
Some	O
genotype	O
-	O
phenotype	O
correlations	O
exist	O
,	O
for	O
example	O
,	O
homozygosity	O
for	O
one	O
G6PC	BG
mutation-15	IG
,	O
G188R-17	BG
,	O
seems	O
to	O
be	O
associated	O
with	O
a	O
glycogen	O
storage	O
disease	O
type	O
I	O
non	O
-	O
a	O
phenotype	O
and	O
homozygosity	O
for	O
the	O
727G	O
>	O
T	O
mutation	O
may	O
be	O
associated	O
with	O
a	O
milder	O
phenotype	O
but	O
an	O
increased	O
risk	O
for	O
hepatocellular	BP
carcinoma-55	IP
.	O

PS2149	O
Clinical	O
assessment	O
,	O
haematological	O
studies	O
,	O
and	O
globin	BG
gene-9	IG
mapping	O
were	O
performed	O
in	O
21	O
Greek	O
subjects	O
with	O
haemoglobin	BG
H	IG
disease-20	IG
.	O

PS2150	O
For	O
deletion	O
genotypes	O
of	O
haemoglobin	BG
H	IG
disease-7	IP
,	O
the	O
value	O
of	O
antenatal	O
diagnosis	O
is	O
questionable	O
.	O

PS2153	O
Homozygous	O
deletion	O
of	O
exons	O
7	O
and	O
8	O
of	O
SMN1-9	BG
has	O
been	O
detected	O
in	O
approx	O
85	O
%	O
of	O
Spanish	O
spinal	BP
muscular	IP
atrophy-21	IP
patients	O
regardless	O
of	O
their	O
phenotype	O
.	O

PS2154	O
A	O
history	O
of	O
cardiac	O
events	O
was	O
present	O
in	O
50	O
%	O
(	O
14	O
/	O
28	O
)	O
,	O
including	O
9	O
with	O
syncope-20	BP
,	O
2	O
with	O
sudden	O
death	O
and	O
occurred	O
in	O
the	O
absence	O
of	O
beta	BG
-	IG
blocker-34	IG
.	O

PS2155	O
However	O
,	O
25	O
%	O
of	O
patients	O
affected	O
with	O
severe	O
haemophilia-10	BP
,	O
develop	O
factor	BG
VIII	IG
antibodies-15	IG
against	O
the	O
concentrate	O
substituted	O
.	O

PS2156	O
This	O
study	O
was	O
conducted	O
to	O
determine	O
whether	O
there	O
is	O
a	O
genotype	O
/	O
phenotype	O
correlation	O
between	O
aspects	O
of	O
cognitive	O
,	O
neurologic	O
,	O
and	O
ovarian	O
outcome	O
in	O
patients	O
with	O
galactosemia-28	BP
and	O
the	O
Q188R	O
mutation	O
of	O
the	O
galactose	BG
-	IG
1	IG
-	IG
phosphate	IG
uridyltransferase	IG
gene-41	IG
.	O

PS2157	O
In	O
one	O
family	O
,	O
the	O
disease	O
did	O
not	O
segregate	O
with	O
the	O
polymorphic	O
markers	O
of	O
PKD1	BG
-	IG
locus-17	IG
,	O
thus	O
excluding	O
any	O
possibility	O
that	O
a	O
mutation	O
in	O
this	O
locus	O
was	O
the	O
cause	O
of	O
the	O
autosomal	O
dominant	O
polycystic	BP
kidney	IP
disease-38	IP
.	O

PS2158	O
A	O
correlation	O
was	O
discovered	O
between	O
the	O
positive	O
echographic	O
diagnosis	O
and	O
the	O
genotype	O
in	O
the	O
PKD1-15	BG
-	O
dependent	O
patients	O
with	O
autosomal	O
dominant	O
polycystic	BP
kidney-23	IP
disease	O
.	O

PS2159	O
The	O
most	O
commonly	O
reported	O
phenotypes	O
described	O
in	O
patients	O
with	O
PTEN-10	BG
mutations	O
are	O
Bannayan	O
-	O
Riley	O
-	O
Ruvalcaba	O
syndrome	O
,	O
with	O
childhood	O
onset	O
,	O
macrocephaly-24	BP
,	O
lipomas-26	BP
and	O
developmental	BP
delay-29	IP
,	O
and	O
Cowden	O
Syndrome	O
,	O
an	O
adult	O
-	O
onset	O
condition	O
recognised	O
by	O
mucocutaneous	O
signs	O
,	O
with	O
a	O
risk	O
of	O
cancers-49	BP
,	O
in	O
particular	O
those	O
of	O
the	O
thyroid	O
and	O
breast	O
.	O

PS2161	O
The	O
present	O
study	O
sought	O
to	O
determine	O
the	O
clinical	O
characteristics	O
,	O
penetrance	O
and	O
prognosis	O
of	O
hypertrophic	O
cardiomyopathy-16	BP
with	O
an	O
identical	O
mutation	O
in	O
MYBPC3-22	BG
.	O

PS2163	O
The	O
potential	O
for	O
drug	O
-	O
drug	O
interactions	O
that	O
may	O
affect	O
the	O
efficacy	O
of	O
anticancer-14	BP
treatment	O
is	O
high	O
,	O
and	O
a	O
major	O
source	O
of	O
such	O
interactions	O
is	O
competition	O
for	O
the	O
drug	O
-	O
metabolizing	O
enzymes	O
,	O
cytochromes	BG
P450-36	IG
(	O
P450s-38	BG
)	O
.	O

PS2164	O
We	O
have	O
examined	O
a	O
series	O
of	O
20	O
drugs	O
commonly	O
prescribed	O
to	O
cancer-12	BP
patients	O
to	O
look	O
for	O
potential	O
interactions	O
via	O
CYP2D6-20	BG
.	O

PS2167	O
We	O
have	O
screened	O
55	O
untreated	O
phenylketonuria-6	BP
patients	O
from	O
42	O
families	O
for	O
common	O
mutations	O
of	O
the	O
phenylalanine	BG
hydroxylase	IG
gene-18	IG
and	O
determined	O
both	O
causative	O
alleles	O
in	O
12	O
families	O
.	O

PS2168	O
Genotyping	BG
N	IG
-	IG
acetyltransferase	IG
2-5	IG
is	O
of	O
high	O
relevance	O
for	O
individualized	O
dosing	O
of	O
antituberculosis	O
drugs	O
and	O
bladder	BP
cancer-18	IP
epidemiology	O
.	O

PS2169	O
Mutations	O
in	O
the	O
LEMD3	BG
gene-5	IG
were	O
recently	O
incriminated	O
in	O
Buschke	O
-	O
Ollendorff	O
syndrome	O
and	O
osteopoikilosis-15	BP
,	O
with	O
or	O
without	O
melorheostosis-20	BP
.	O

PS2170	O
We	O
investigated	O
LEMD3-3	BG
in	O
a	O
two	O
-	O
generation	O
Buschke	O
-	O
Ollendorff	O
syndrome	O
family	O
showing	O
an	O
extremely	O
variable	O
expression	O
of	O
the	O
disease	O
,	O
in	O
a	O
sporadic	O
patient	O
with	O
skin	O
features	O
of	O
Buschke	O
-	O
Ollendorff	O
syndrome	O
,	O
and	O
in	O
an	O
additional	O
subject	O
with	O
isolated	O
melorheostosis-43	BP
.	O

PS2172	O
Duchenne	O
and	O
Becker	O
muscular	BP
dystrophy-5	IP
(	O
DMD	O
and	O
BMD	O
,	O
respectively	O
)	O
are	O
allelic	O
disorders	O
with	O
different	O
clinical	O
presentations	O
and	O
severity	O
determined	O
by	O
mutations	O
in	O
the	O
gene	O
DMD	O
,	O
which	O
encodes	O
the	O
sarcolemmal	BG
protein	IG
dystrophin-35	IG
.	O

PS2174	O
About	O
60	O
%	O
of	O
both	O
Duchenne	O
'	O
s	O
muscular	BP
dystrophy-10	IP
and	O
Becker	O
'	O
s	O
muscular	BP
dystrophy-16	IP
is	O
due	O
to	O
deletions	O
of	O
dystrophin	BG
gene-23	IG
.	O

PS2176	O
These	O
data	O
demonstrate	O
that	O
SLC7A9-5	BG
is	O
the	O
main	O
non	O
-	O
Type	O
I	O
cystinuria-13	BP
gene	O
.	O

PS2178	O
These	O
data	O
demonstrate	O
that	O
SLC7A9-5	BG
is	O
the	O
main	O
non	O
-	O
Type	O
I	O
cystinuria-13	BP
gene	O
.	O

PS2180	O
In	O
this	O
study	O
the	O
role	O
of	O
genetically	O
determined	O
individual	O
N	BG
-	IG
acetyltransferase1-12	IG
and	O
N	BG
-	IG
acetyltransferase2	IG
genotypes-17	IG
,	O
haplotypes	O
and	O
haplotype	O
combinations	O
in	O
the	O
predisposition	O
to	O
head	O
and	O
neck	O
cancer-30	BP
was	O
investigated	O
.	O

PS2181	O
Polymorphic	O
regions	O
of	O
the	O
N	BG
-	IG
acetyltransferase1-7	IG
and	O
N	BG
-	IG
acetyltransferase2	IG
genes-12	IG
were	O
analyzed	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer-21	BP
and	O
healthy	O
individuals	O
by	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
.	O

PS2182	O
No	O
association	O
was	O
observed	O
between	O
the	O
N	BG
-	IG
acetyltransferase1	IG
*	IG
3-11	IG
,	O
N	BG
-	IG
acetyltransferase1	IG
*	IG
10-17	IG
,	O
N	BG
-	IG
acetyltransferase1	IG
*	IG
11-23	IG
,	O
N	BG
-	IG
acetyltransferase2	IG
*	IG
5-29	IG
and	O
N	BG
-	IG
acetyltransferase2	IG
*	IG
6-35	IG
genotypes	O
and	O
risk	O
of	O
head	O
and	O
neck	O
cancer-43	BP
.	O

PS2183	O
A	O
significant	O
association	O
was	O
observed	O
between	O
the	O
fast	O
acetylator	BG
N	IG
-	IG
acetyltransferase2	IG
*	IG
4	IG
/	IG
N	IG
-	IG
acetyltransferase1-18	IG
*	O
10	O
diplotype	O
and	O
risk	O
of	O
head	O
and	O
neck	O
cancer-28	BP
.	O

PS2186	O
A	O
total	O
of	O
86	O
unrelated	O
patients	O
with	O
familial	BP
hypercholesterolemia-9	IP
were	O
selected	O
on	O
clinical	O
grounds	O
,	O
and	O
complete	O
DNA	O
analysis	O
of	O
the	O
low	BG
-	IG
density	IG
lipoprotein	IG
-	IG
receptor-27	IG
and	O
apolipoprotein	O
B	O
genes	O
by	O
DGGE	O
and	O
DNA	O
-	O
sequencing	O
was	O
performed	O
.	O

PS2187	O
However	O
,	O
the	O
22	O
patients	O
with	O
a	O
mutation	O
had	O
significantly	O
more	O
xanthomas-12	BP
and	O
a	O
higher	O
incidence	O
of	O
coronary	O
heart	O
disease	O
and	O
levels	O
of	O
low	BG
-	IG
density	IG
lipoproteins-27	IG
were	O
also	O
significantly	O
different	O
.	O

PS2191	O
Mevalonate	BG
kinase-2	IG
deficiency	O
is	O
an	O
autosomal	O
recessive	O
autoinflammatory	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
MVK	BG
gene-16	IG
resulting	O
in	O
deficient	O
activity	O
of	O
mevalonate	O
kinase	O
.	O

PS2193	O
We	O
analyzed	O
the	O
MVK	BG
gene-5	IG
in	O
57	O
patients	O
with	O
Mevalonate	BG
kinase	IG
deficiency-12	IP
and	O
found	O
39	O
different	O
mutations	O
including	O
15	O
novel	O
mutations	O
,	O
expanding	O
the	O
total	O
mutational	O
spectrum	O
of	O
Mevalonate	BG
kinase-30	IG
deficiency	O
to	O
63	O
mutations	O
.	O

PS2194	O
To	O
get	O
more	O
insight	O
into	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Mevalonate	BG
kinase	IG
deficiency-14	IP
,	O
we	O
studied	O
the	O
effect	O
of	O
selected	O
missense	O
mutations	O
on	O
mevalonate	O
kinase	O
protein	O
stability	O
and	O
activity	O
in	O
various	O
patient	O
fibroblast	O
cell	O
lines	O
.	O

PS2195	O
When	O
fibroblasts	O
of	O
Mevalonate	BG
kinase-5	IG
deficiency	O
patients	O
were	O
cultured	O
under	O
conditions	O
known	O
to	O
promote	O
a	O
more	O
controlled	O
protein	O
folding	O
,	O
all	O
cell	O
lines	O
of	O
patients	O
with	O
the	O
hyper	O
-	O
IgD-30	BG
and	O
periodic	O
fever-33	BP
syndrome	O
phenotype	O
and	O
few	O
cell	O
lines	O
of	O
patients	O
with	O
the	O
mevalonic	O
aciduria	O
phenotype	O
showed	O
an	O
increase	O
in	O
the	O
residual	O
mevalonate	O
kinase	O
activity	O
.	O

PS2196	O
The	O
finding	O
that	O
the	O
residual	O
activity	O
in	O
Mevalonate	BG
kinase	IG
deficiency-10	IP
can	O
be	O
manipulated	O
by	O
environmental	O
conditions	O
may	O
offer	O
therapeutic	O
options	O
to	O
alleviate	O
or	O
prevent	O
the	O
clinical	O
symptoms	O
associated	O
with	O
Mevalonate	BG
kinase	IG
deficiency-32	IP
.	O

PS2197	O
We	O
standardized	O
conformation	O
sensitive	O
gel	O
electrophoresis	O
method	O
to	O
detect	O
mutations	O
in	O
ABCD1	BG
gene-13	IG
in	O
twenty	O
Indian	O
patients	O
with	O
X	O
-	O
linked	O
Adrenoleukodystrophy-22	BP
.	O

PS2202	O
Mutations	O
in	O
ALOXE3-3	BG
and	O
ALOX12B-5	BG
on	O
chromosome	O
17p13	O
,	O
which	O
code	O
for	O
two	O
different	O
epidermal	BG
lipoxygenases-16	IG
,	O
were	O
recently	O
found	O
in	O
patients	O
with	O
ichthyosiform	O
erythroderma-25	BP
from	O
Turkey	O
,	O
France	O
,	O
and	O
North	O
Africa	O
.	O

PS2203	O
Here	O
we	O
describe	O
molecular	O
and	O
clinical	O
findings	O
in	O
17	O
families	O
with	O
Autosomal	O
-	O
recessive	O
congenital	BP
ichthyosis-16	IP
originating	O
from	O
Central	O
Europe	O
,	O
Turkey	O
,	O
and	O
the	O
Indian	O
subcontinent	O
,	O
with	O
mutations	O
in	O
ALOXE3-32	BG
or	O
ALOX12B-34	BG
.	O

PS2205	O
Accumulation	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
is	O
important	O
for	O
better	O
understanding	O
of	O
SPG4-13	BG
-	O
linked	O
hereditary	O
spastic	BP
paraplegia-18	IP
.	O

PS2206	O
To	O
perform	O
a	O
clinical	O
and	O
genetic	O
study	O
of	O
families	O
with	O
Autosomal	O
dominant	O
hereditary	O
spastic	BP
paraplegia-15	IP
and	O
to	O
perform	O
the	O
functional	O
analysis	O
of	O
the	O
founder	O
mutation	O
discovered	O
in	O
the	O
SPG4	BG
gene-30	IG
.	O

PS2209	O
Factor	BG
XI	IG
deficiency-3	IP
has	O
a	O
more	O
variable	O
bleeding	O
tendency	O
than	O
haemophilia	O
A	O
or	O
B	O
.	O

PS2210	O
Two	O
mutations	O
are	O
responsible	O
for	O
most	O
factor	BG
XI	IG
deficiency-9	IP
in	O
the	O
Ashkenazi	O
population	O
,	O
but	O
a	O
number	O
of	O
other	O
mutations	O
have	O
now	O
been	O
reported	O
in	O
other	O
racial	O
groups	O
.	O

PS2211	O
Individuals	O
with	O
factor	BG
XI	IG
deficiency-5	IP
may	O
need	O
specific	O
therapy	O
for	O
surgery	O
,	O
accidents	O
,	O
and	O
dental	O
extractions	O
.	O

PS2212	O
The	O
SPAST	O
gene	O
encoding	O
for	O
spastin-6	BG
plays	O
a	O
central	O
role	O
in	O
the	O
genetically	O
heterogeneous	O
group	O
of	O
diseases	O
termed	O
hereditary	O
spastic	BP
paraplegia-21	IP
.	O

PS2213	O
Furthermore	O
,	O
we	O
used	O
a	O
previously	O
generated	O
structural	O
model	O
of	O
spastin-11	BG
as	O
a	O
framework	O
to	O
classify	O
the	O
missense	O
mutations	O
in	O
the	O
associated	O
with	O
diverse	O
cellular	O
activities	O
domain	O
from	O
the	O
hereditary	O
spastic	BP
paraplegia-32	IP
patients	O
into	O
different	O
structural	O
/	O
functional	O
groups	O
.	O

PS2214	O
Background	O
:	O
Deficiency	O
of	O
21	O
-	O
hydroxylase-7	BG
is	O
present	O
in	O
90	O
-	O
95	O
%	O
cases	O
of	O
congenital	BP
adrenal	IP
hyperplasia-19	IP
(	O
CAH	O
)	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
.	O

PS2215	O
Earlier	O
studies	O
reporting	O
a	O
protective	O
effect	O
of	O
bilirubin	O
on	O
stroke-10	BP
have	O
not	O
included	O
analysis	O
of	O
UGT1A1	BG
*	IG
28-18	IG
.	O

PS2221	O
The	O
lack	O
of	O
consistent	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Congenital	O
erythropoietic	BP
porphyria-12	IP
suggests	O
a	O
contribution	O
to	O
phenotype	O
from	O
other	O
factors	O
,	O
such	O
as	O
environment	O
,	O
patients	O
'	O
photoprotective	O
behaviour	O
and	O
genes	O
other	O
than	O
uroporphyrinogen	BG
III	IG
synthase-36	IG
.	O

PS2222	O
The	O
isolation	O
of	O
cystic	O
fibrosis	O
gene	O
at	O
the	O
cystic	O
fibrosis	O
locus	O
assigned	O
to	O
the	O
long	O
arm	O
of	O
chromosome	O
7	O
band	O
q31	O
and	O
definition	O
of	O
its	O
protein	O
product	O
named	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-33	IG
permits	O
to	O
understand	O
the	O
basic	O
defect	O
in	O
this	O
inherited	O
disorder	O
known	O
as	O
cystic	BP
fibrosis-47	IP
or	O
mucoviscidosis-49	BP
.	O

PS2225	O
We	O
reviewed	O
recorded	O
medical	O
data	O
from	O
1975	O
to	O
2001	O
on	O
patients	O
with	O
Multiple	O
endocrine	O
neoplasia-15	BP
type	O
1	O
and	O
compared	O
specific	O
types	O
and	O
locations	O
of	O
MEN1	BG
gene-26	IG
mutations	O
with	O
manifestations	O
of	O
the	O
syndrome	O
.	O

PS2230	O
We	O
found	O
no	O
apparent	O
relationship	O
between	O
the	O
ACE	BG
genotype-9	IG
(	O
of	O
either	O
donor	O
or	O
recipient	O
)	O
and	O
systemic	O
hypertension-19	BP
(	O
absolute	O
measurements	O
and	O
the	O
number	O
or	O
dose	O
of	O
antihypertensive	O
agents	O
used	O
)	O
.	O

PS2232	O
Moreover	O
,	O
the	O
evidence	O
of	O
a	O
clinical	O
myopathy-8	BP
in	O
the	O
patient	O
with	O
higher	O
amounts	O
of	O
cytochrome	BG
-	IG
c	IG
oxidase-19	IG
-	O
negative	O
ragged	O
red	O
fibers	O
bolsters	O
the	O
concept	O
that	O
a	O
differential	O
distribution	O
of	O
mutant	O
mitochondrial	O
DNAs	O
at	O
the	O
cellular	O
level	O
may	O
have	O
effects	O
on	O
the	O
clinical	O
involvement	O
of	O
individual	O
tissues	O
.	O

PS2234	O
To	O
assess	O
the	O
clinical	O
phenotype	O
in	O
a	O
Swedish	O
family	O
with	O
X	O
-	O
linked	O
retinitis	BP
pigmentosa-15	IP
resulting	O
from	O
a	O
novel	O
splice	O
defect	O
in	O
the	O
RPGR	BG
gene-25	IG
.	O

PS2235	O
RPGR-1	BG
mutation	O
analysis	O
was	O
performed	O
in	O
one	O
family	O
with	O
X	O
-	O
linked	O
retinitis-13	BP
pigmentosa	O
,	O
and	O
several	O
individuals	O
from	O
the	O
family	O
were	O
examined	O
clinically	O
.	O

PS2238	O
Based	O
on	O
a	O
case	O
series	O
of	O
130	O
gastric	BP
cancers-9	IP
that	O
covered	O
both	O
early	O
(	O
70	O
cases	O
)	O
and	O
advanced	O
(	O
60	O
cases	O
)	O
stages	O
and	O
that	O
represented	O
most	O
histological	O
types	O
and	O
structural	O
patterns	O
,	O
this	O
study	O
investigated	O
(	O
1	O
)	O
microsatellite	O
instability	O
and	O
p53	BG
gene-45	IG
mutation	O
by	O
means	O
of	O
PCR	O
-	O
based	O
molecular	O
techniques	O
and	O
(	O
2	O
)	O
p53	BG
protein-60	IG
accumulation	O
or	O
tumor	O
cell	O
immunophenotype	O
by	O
means	O
of	O
immunoperoxidase-69	BG
procedures	O
.	O

PS2240	O
Mixed	O
cancers-2	BP
,	O
namely	O
,	O
those	O
in	O
which	O
glandular	O
admixed	O
with	O
diffuse	O
growths	O
,	O
showed	O
scarce	O
microsatellite	O
instability	O
at	O
all	O
stages	O
,	O
whereas	O
prominent	O
p53	BG
gene-26	IG
mutation	O
and	O
p53	BG
protein-30	IG
accumulation	O
was	O
limited	O
to	O
the	O
advanced	O
stage	O
alone	O
.	O

PS2241	O
It	O
is	O
concluded	O
that	O
at	O
least	O
two	O
genetically	O
distinct	O
subsets	O
of	O
glandular	O
cancer-13	BP
,	O
one	O
with	O
microsatellite	O
instability	O
and	O
the	O
other	O
with	O
p53-23	BG
lesions	O
,	O
should	O
be	O
separated	O
both	O
from	O
purely	O
diffuse	O
cancer-33	BP
and	O
,	O
at	O
least	O
in	O
the	O
advanced	O
stage	O
,	O
from	O
mixed	O
cancer-45	BP
.	O

PS2243	O
Approximately	O
75	O
%	O
of	O
patients	O
with	O
classical	O
form	O
of	O
congenital	BP
adrenal	IP
hyperplasia-12	IP
have	O
severe	O
impairment	O
of	O
21	BG
-	IG
hydroxylase-19	IG
activity	O
.	O

PS2245	O
However	O
,	O
the	O
panoply	O
of	O
cancer-6	BP
phenotypes	O
associated	O
with	O
mutations	O
of	O
genes	O
other	O
than	O
in	O
BRCA1-16	BG
is	O
yet	O
to	O
be	O
fully	O
characterised	O
;	O

PS2247	O
METHODS	O
:	O
Eighty	O
-	O
five	O
unrelated	O
primary	O
congenital	O
glaucoma-9	BP
patients	O
and	O
their	O
family	O
members	O
of	O
South	O
Korean	O
origin	O
were	O
screened	O
for	O
mutations	O
in	O
the	O
CYP1B1-25	BG
and	O
myocilin	BG
genes-28	IG
by	O
sequencing	O
with	O
the	O
PCR	O
.	O

PS2253	O
The	O
clinical	O
profile	O
of	O
this	O
family	O
was	O
similar	O
to	O
that	O
of	O
previously	O
described	O
SCA1-14	BG
and	O
non	O
-	O
SCA1-18	BG
families	O
,	O
except	O
that	O
dementia-23	BP
was	O
observed	O
in	O
2	O
out	O
of	O
6	O
patients	O
.	O

PS2254	O
Moreover	O
,	O
the	O
molecular	O
studies	O
of	O
four	O
patients	O
(	O
two	O
Italians	O
,	O
one	O
Iranian	O
,	O
and	O
one	O
Australian	O
)	O
affected	O
by	O
Holocarboxylase	BG
synthetase	IG
deficiency-24	IP
are	O
here	O
reported	O
.	O

PS2256	O
BAMBI	O
regulates	O
colorectal	BP
cancer-4	IP
metastasis	O
by	O
connecting	O
the	O
Wnt-9	BG
/	O
beta	BG
-	IG
catenin-13	IG
and	O
transforming	BG
growth	IG
factor	IG
-	IG
beta-19	IG
-	O
signaling	O
pathways	O
.	O

PS2257	O
It	O
is	O
now	O
generally	O
accepted	O
that	O
primary	O
CD30	BG
+-9	IG
cutaneous	O
lymphomas	O
comprise	O
a	O
clinical	O
and	O
morphologic	O
spectrum	O
in	O
which	O
a	O
clear	O
distinction	O
between	O
lymphomatoid	O
papulosis	O
and	O
lymphoma-27	BP
cannot	O
always	O
be	O
made	O
.	O

PS2258	O
Germline	O
mutations	O
in	O
highly	O
penetrant	O
autosomal	O
dominant	O
genes	O
explain	O
about	O
5	O
%	O
of	O
all	O
breast	BP
cancer-16	IP
,	O
and	O
heritable	O
mutations	O
in	O
the	O
BRCA1-23	BG
breast	BG
and	IG
ovarian	IG
cancer	IG
susceptibility	IG
gene-29	IG
account	O
for	O
2	O
-	O
3	O
%	O
of	O
breast	BP
cancer-38	IP
in	O
the	O
general	O
population	O
.	O

PS2260	O
Thirteen	O
germline	O
truncating	O
/	O
splicing	O
mutations	O
in	O
BRCA1-8	BG
were	O
found	O
in	O
33	O
%	O
(	O
6	O
/	O
18	O
)	O
of	O
the	O
breast	O
-	O
ovarian	O
cancer-24	BP
families	O
and	O
in	O
17	O
%	O
(	O
7	O
/	O
42	O
)	O
of	O
breast	BP
cancer-37	IP
only	O
families	O
.	O

PS2262	O
We	O
conclude	O
that	O
,	O
in	O
our	O
population	O
,	O
the	O
10	O
-	O
methylenetetrahydrofolate	O
reductase	BG
C677T	IG
mutation-15	IG
is	O
rather	O
common	O
,	O
but	O
it	O
does	O
not	O
appear	O
to	O
be	O
associated	O
per	O
se	O
to	O
coronary	BP
artery	IP
disease-33	IP
.	O

PS2263	O
The	O
SCA7	BG
mutation-3	IG
has	O
been	O
found	O
in	O
54	O
patients	O
and	O
7	O
at	O
-	O
risk	O
subjects	O
from	O
17	O
families	O
who	O
have	O
autosomal	O
dominant	O
cerebellar	O
ataxia	O
II	O
with	O
progressive	BP
pigmentary	IP
maculopathy-29	IP
.	O

PS2264	O
Analysis	O
of	O
the	O
clinical	O
features	O
in	O
the	O
patients	O
with	O
SCA7-10	BG
confirmed	O
that	O
the	O
most	O
frequently	O
associated	O
features	O
are	O
pigmentary	BP
maculopathy-20	IP
,	O
pyramidal	O
tract	O
involvement	O
,	O
and	O
slow	O
saccades	O
.	O

PS2266	O
In	O
phenylketonuria-2	BP
,	O
genotype	O
at	O
the	O
phenylalanine	BG
hydroxylase	IG
locus-9	IG
appears	O
to	O
explain	O
the	O
biochemical	O
phenotype	O
,	O
but	O
not	O
the	O
intellectual	O
status	O
.	O

PS2267	O
Phenotypic	O
discordance	O
in	O
sickle	O
cell	O
anemia-6	BP
and	O
beta	O
-	O
thalassemia	O
has	O
been	O
associated	O
with	O
the	O
co	O
-	O
inheritance	O
of	O
genes	O
for	O
hereditary	O
persistence	O
of	O
fetal	O
hemoglobin-26	BG
.	O

PS2268	O
Detection	O
of	O
disease	O
causing	O
mutations	O
in	O
the	O
Neurofibromatosis	BG
type	IG
1	IG
gene-11	IG
allows	O
presymptomatic	O
and	O
prenatal	O
diagnosis	O
,	O
but	O
is	O
complex	O
and	O
time	O
-	O
consuming	O
due	O
to	O
the	O
large	O
size	O
of	O
the	O
gene	O
,	O
the	O
existence	O
of	O
pseudogenes	O
,	O
the	O
lack	O
of	O
clustering	O
of	O
the	O
mutations	O
in	O
a	O
particular	O
region	O
of	O
the	O
gene	O
,	O
and	O
the	O
variability	O
of	O
clinical	O
findings	O
.	O

PS2270	O
Three	O
different	O
missense	O
mutations	O
have	O
been	O
detected	O
in	O
the	O
coding	O
region	O
of	O
BIGH3	BG
gene-14	IG
,	O
R555Q-16	BG
,	O
in	O
16	O
corneal	BP
dystrophy-21	IP
of	O
Bowman	O
layer	O
type	O
2	O
patients	O
,	O
R555W	O
in	O
8	O
granular	O
CD	O
patients	O
,	O
and	O
R124C	O
in	O
5	O
lattice	O
CD	O
type	O
I	O
patients	O
.	O

PS2271	O
Mutations	O
in	O
SDCCAG8-3	BG
(	O
NPHP10-5	BG
)	O
were	O
described	O
recently	O
in	O
patients	O
with	O
nephronophthisis-13	BP
and	O
retinal	O
degeneration	O
(	O
Senior	O
-	O
Loken	O
syndrome	O
;	O
SLS	O
)	O
.	O

PS2273	O
Typical	O
substrates	O
for	O
Cytochrome	BG
P4502D6-5	IG
are	O
largely	O
lipophilic	O
bases	O
and	O
include	O
some	O
antidepressants	O
,	O
antipsychotics-15	BP
,	O
antiarrhythmics	O
,	O
antiemetics	O
,	O
beta	BG
-	IG
adrenoceptor-23	IG
antagonists	O
(	O
beta	O
-	O
blockers	O
)	O
and	O
opioids	O
.	O

PS2275	O
Frontometaphyseal	BP
dysplasia-2	IP
belongs	O
to	O
a	O
group	O
of	O
overlapping	O
skeletal	O
dysplasias	O
,	O
the	O
common	O
molecular	O
basis	O
of	O
which	O
are	O
mutations	O
of	O
FLNA	O
,	O
the	O
gene	O
encoding	O
filamin	BG
A-27	IG
.	O

PS2276	O
In	O
a	O
second	O
family	O
with	O
Frontometaphyseal	BP
dysplasia-7	IP
,	O
we	O
identified	O
a	O
known	O
mutation	O
(	O
S1186L-15	BG
)	O
in	O
a	O
mother	O
and	O
her	O
son	O
.	O

PS2279	O
We	O
first	O
compared	O
27	O
BRCA1-5	BG
-	O
associated	O
breast	BP
cancers-9	IP
from	O
14	O
families	O
with	O
4	O
,	O
461	O
cases	O
from	O
an	O
administrative	O
district	O
registry	O
and	O
242	O
cases	O
from	O
a	O
hospital	O
-	O
based	O
registry	O
,	O
matching	O
for	O
grade	O
and	O
constitutive	O
elements	O
,	O
and	O
then	O
considered	O
their	O
repartition	O
in	O
families	O
.	O

PS2285	O
One	O
particular	O
mutant	O
was	O
found	O
that	O
caused	O
progressive	O
opacity-9	BP
and	O
was	O
referred	O
to	O
as	O
Aey2-15	BG
.	O

PS2286	O
One	O
particular	O
mutant	O
was	O
found	O
that	O
caused	O
progressive	O
opacity-9	BP
and	O
was	O
referred	O
to	O
as	O
Aey2-15	BG
.	O

PS2287	O
Dystrophic	O
epidermolysis	BP
bullosa	IP
pruriginosa-4	IP
is	O
a	O
rare	O
variant	O
of	O
dystrophic	O
epidermolysis	O
bullosa	O
due	O
to	O
dominant	O
or	O
recessive	O
mutations	O
in	O
the	O
COL7A1	BG
gene-22	IG
.	O

PS2288	O
More	O
than	O
40	O
mutations	O
in	O
COL7A1-6	BG
have	O
been	O
described	O
in	O
Dystrophic	O
epidermolysis	BP
bullosa	IP
pruriginosa-14	IP
.	O

PS2291	O
Laboratory	O
tests	O
revealed	O
inappropriately	O
normal	O
parathyroid	BG
hormone-7	IG
concentrations	O
and	O
relative	BP
hypercalciuria-11	IP
typical	O
of	O
autosomal	O
dominant	O
hypocalcemia	O
.	O

PS2294	O
In	O
order	O
to	O
investigate	O
a	O
possible	O
phenotype	O
-	O
genotype	O
correlation	O
and	O
to	O
further	O
define	O
the	O
predictive	O
value	O
of	O
nuclear	O
receptor	O
binding	O
SET	O
-	O
Domain	O
1	O
mutations	O
,	O
we	O
performed	O
mutational	O
analysis	O
of	O
the	O
nuclear	BG
receptor	IG
binding	IG
SET	IG
-	IG
Domain	IG
1	IG
gene-41	IG
in	O
20	O
patients	O
and	O
one	O
familial	O
case	O
with	O
Sotos	O
syndrome	O
,	O
five	O
patients	O
with	O
Weaver	O
syndrome	O
,	O
six	O
patients	O
with	O
unclassified	O
overgrowth	O
/	O
mental	BP
retardation-66	IP
,	O
and	O
six	O
patients	O
with	O
macrocephaly-72	BP
/	O
mental	O
retardation	O
.	O

PS2295	O
In	O
this	O
report	O
we	O
analyse	O
ESR1-6	BG
and	O
ESR2	BG
gene-9	IG
single	O
nucleotide	O
polymorphisms	O
for	O
association	O
with	O
obesity-16	BP
.	O

PS2301	O
Multiple	O
endocrine	O
neoplasia-3	BP
type	O
1	O
and	O
type	BG
2-8	IG
(	O
MEN2-10	BG
)	O
are	O
major	O
genetic	O
disorders	O
carrying	O
a	O
high	O
risk	O
of	O
endocrine	O
tumor	O
development	O
.	O

PS2302	O
The	O
mutated	O
genes	O
were	O
identified	O
in	O
1993	O
(	O
MEN2	BG
-	IG
RET-11	IG
)	O
and	O
1997	O
(	O
Multiple	O
endocrine	O
neoplasia-18	BP
type	O
1	O
)	O
,	O
enabling	O
genetic	O
testing	O
and	O
functional	O
studies	O
.	O

PS2304	O
We	O
also	O
briefly	O
describe	O
the	O
genetic	O
basis	O
of	O
three	O
other	O
inherited	O
states	O
predisposing	O
individuals	O
to	O
endocrine	O
tumors	O
,	O
namely	O
Carney	O
'	O
s	O
syndrome	O
,	O
hyperparathyroidism-25	BP
type	O
2	O
and	O
familial	O
isolated	O
pituitary	O
adenoma	O
,	O
which	O
are	O
related	O
to	O
inactivating	O
mutations	O
in	O
the	O
PRKAR1	BG
-	IG
alpha-44	IG
,	O
hyperparathyroidism	BG
type	IG
2-48	IG
and	O
AIP	BG
genes-51	IG
,	O
respectively	O
.	O

PS2305	O
He	O
had	O
a	O
complete	O
form	O
of	O
idiopathic	O
hypogonadotropic	BP
hypogonadism-9	IP
,	O
with	O
descended	O
testes	O
and	O
severe	O
oligospermia-16	BP
but	O
little	O
response	O
to	O
exogenous	O
gonadotropins-22	BG
.	O

PS2306	O
Exogenous	BG
gonadotropin-2	IG
therapy	O
may	O
not	O
be	O
as	O
beneficial	O
for	O
increasing	O
sperm	O
concentration	O
in	O
older	O
men	O
with	O
idiopathic	O
hypogonadotropic	BP
hypogonadism-19	IP
.	O

PS2308	O
Genotype	O
/	O
phenotype	O
correlations	O
were	O
observed	O
with	O
cutaneous	O
severity	O
,	O
growth	O
retardation-12	BP
,	O
skin	BP
infection-15	IP
,	O
stratum	O
corneum	O
protease	O
activities	O
,	O
and	O
KLK-23	BG
levels	O
in	O
the	O
stratum	O
corneum	O
.	O

PS2309	O
It	O
has	O
been	O
suggested	O
that	O
not	O
only	O
the	O
position	O
but	O
also	O
the	O
nature	O
of	O
the	O
mutations	O
of	O
the	O
ret	BG
protooncogene-20	IG
strongly	O
correlate	O
with	O
the	O
clinical	O
manifestation	O
of	O
the	O
multiple	O
endocrine	O
neoplasm-31	BP
type	O
2	O
syndrome	O
.	O

PS2311	O
In	O
all	O
but	O
1	O
of	O
59	O
families	O
with	O
multiple	O
endocrine	O
neoplasm-11	BP
type	O
2A	O
,	O
germline	O
mutations	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
ret	BG
protein-24	IG
were	O
found	O
.	O

PS2312	O
In	O
all	O
but	O
1	O
of	O
27	O
familial	O
medullary	O
thyroid	BP
carcinoma-10	IP
families	O
,	O
mutations	O
were	O
detected	O
in	O
1	O
of	O
4	O
cysteines	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
ret	BG
protooncogene-28	IG
.	O

PS2313	O
Mutations	O
outside	O
of	O
codon	O
634	O
occurred	O
more	O
often	O
in	O
Fmedullary	O
thyroid	BP
carcinoma-12	IP
families	O
than	O
in	O
multiple	O
endocrine	BG
neoplasm	IG
type	IG
2A	IG
families-21	IG
.	O

PS2314	O
For	O
this	O
study	O
,	O
mice	O
of	O
the	O
Fv	BG
-	IG
1n	IG
/	IG
n-12	IG
,	O
Fv	BG
-	IG
1b	IG
/	IG
b-18	IG
,	O
or	O
Fv	BG
-	IG
1n	IG
/	IG
b	IG
genotype-26	IG
were	O
inoculated	O
with	O
stocks	O
of	O
defective	O
Murine	O
AIDS	O
virus	O
pseudotyped	O
with	O
N	O
-	O
tropic	O
,	O
B	O
-	O
tropic	O
,	O
or	O
NB	O
-	O
tropic	O
helper	O
murine	O
leukemia-52	BP
virus	O
,	O
respectively	O
.	O

PS2315	O
Isolated	O
growth	BG
hormone-3	IG
deficiency	O
may	O
be	O
congenital	O
,	O
often	O
due	O
to	O
genetic	O
mutations	O
,	O
or	O
acquired	O
as	O
a	O
result	O
of	O
other	O
factors	O
such	O
as	O
cranial	O
irradiation	O
.	O

PS2316	O
Rarely	O
,	O
Isolated	BG
growth	IG
hormone	IG
deficiency-6	IP
may	O
be	O
caused	O
by	O
mutations	O
in	O
transcription	O
factors	O
(	O
HESX1-16	BG
,	O
SOX3-18	BG
,	O
OTX2-20	BG
)	O
or	O
be	O
the	O
first	O
presentation	O
before	O
the	O
development	O
of	O
other	O
pituitary	BG
hormone-33	IG
deficiencies	O
.	O

PS2318	O
The	O
leanness	O
of	O
Fto-4	BG
-	O
deficient	O
mice	O
develops	O
as	O
a	O
consequence	O
of	O
increased	O
energy	O
expenditure	O
and	O
systemic	O
sympathetic	O
activation	O
,	O
despite	O
decreased	O
spontaneous	O
locomotor	O
activity	O
and	O
relative	BP
hyperphagia-28	IP
.	O

PS2320	O
It	O
is	O
helpful	O
to	O
screen	O
MYBPC3	BG
gene-7	IG
mutation	O
in	O
late	O
-	O
onset	O
hypertrophic	BP
cardiomyopathy-14	IP
patients	O
with	O
mild	O
symptoms	O
.	O

PS2321	O
It	O
has	O
been	O
suggested	O
that	O
Hypomagnesemia-6	BP
with	O
secondary	O
hypocalcemia-9	BP
is	O
genetically	O
heterogeneous	O
,	O
but	O
only	O
one	O
causative	O
gene	O
,	O
TRPM6-20	BG
,	O
on	O
chromosome	O
9	O
has	O
so	O
far	O
been	O
isolated	O
.	O

PS2324	O
To	O
elicit	O
correlations	O
of	O
polymorphic	O
markers	O
of	O
GNB3	O
(	O
C825T	O
)	O
,	O
AGTR1-13	BG
(	O
A1166C-15	BG
)	O
,	O
ACE-18	BG
(	O
A2350G-20	BG
and	O
I	BG
/	IG
D-24	IG
)	O
genes	O
with	O
arterial	O
pressure	O
,	O
left	O
ventricular	O
hypertrophy	O
and	O
blood	O
concentrations	O
of	O
proinflammatory	O
cytokines	O
in	O
hypertensive	O
patients	O
with	O
diabetes	BP
mellitus-45	IP
type	O
2	O
.	O

PS2327	O
In	O
this	O
study	O
we	O
analyzed	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
a	O
group	O
of	O
Becker	O
muscular	BP
dystrophy-16	IP
patients	O
with	O
deletions	O
affecting	O
the	O
proximal	O
part	O
of	O
dystrophin	BG
gene-26	IG
,	O
encompassing	O
exons	O
3	O
-	O
13	O
.	O

PS2330	O
We	O
have	O
used	O
two	O
heterologous	O
in	O
vitro	O
expression	O
systems	O
(	O
a	O
mammalian	O
cell	O
-	O
free	O
transcription	O
-	O
translation	O
system	O
and	O
the	O
pET	O
system	O
of	O
Escherichia	O
coli	O
)	O
to	O
examine	O
34	O
mutations	O
that	O
have	O
been	O
associated	O
with	O
Phenylalanine	BG
hydroxylase	IG
deficiency-39	IP
in	O
the	O
Danish	O
population	O
.	O

PS2331	O
A	O
particular	O
mutation	O
in	O
Ecuadorian	O
families	O
that	O
truncates	O
the	O
intermediate	O
filament	O
-	O
binding	O
site	O
of	O
desmoplakin-16	BG
results	O
in	O
a	O
variant	O
of	O
Naxos	O
disease	O
with	O
predominantly	O
left	O
ventricular	O
involvement	O
,	O
early	O
morbidity	O
and	O
clinical	O
overlapping	O
with	O
dilated	BP
cardiomyopathy-37	IP
(	O
Carvajal	O
syndrome	O
)	O
.	O

PS2335	O
Patients	O
receiving	O
HLA	BG
-	IG
A30-5	IG
and	O
HLA	BG
-	IG
DR7	IG
antigens-10	IG
,	O
and	O
elderly	O
patients	O
are	O
at	O
higher	O
risk	O
of	O
developing	O
Posttransplantation	O
diabetes	BP
mellitus-23	IP
.	O

PS2337	O
We	O
present	O
a	O
patient	O
lacking	O
the	O
typical	O
symptoms	O
of	O
XLP	BG
-	IG
1-12	IG
,	O
but	O
experiencing	O
a	O
severe	O
unusual	O
skin	O
condition	O
encompassing	O
features	O
of	O
dermatosclerosis-24	BP
and	O
vesiculobullous	O
skin	O
disease	O
.	O

PS2346	O
The	O
most	O
common	O
enzyme	O
defect	O
causing	O
Congenital	BP
adrenal	IP
hyperplasia-9	IP
is	O
steroid	BG
21	IG
-	IG
hydroxylase-14	IG
deficiency	O
.	O

PS2351	O
The	O
R337H	BG
p53-3	IG
mutation	O
was	O
inherited	O
from	O
one	O
of	O
the	O
parents	O
of	O
the	O
patients	O
,	O
and	O
there	O
was	O
no	O
association	O
between	O
the	O
presence	O
of	O
this	O
mutation	O
and	O
tumor	O
malignancy-29	BP
in	O
children	O
.	O

PS2352	O
Certain	O
sequences	O
present	O
in	O
the	O
hypervariable	O
region	O
of	O
human	BG
leucocyte	IG
antigen-11	IG
-	O
DRB1	O
known	O
as	O
the	O
shared	O
epitope	O
are	O
hypothesised	O
to	O
increase	O
the	O
risk	O
of	O
rheumatoid	BP
arthritis-27	IP
,	O
whereas	O
alleles	O
encoding	O
aspartic	O
acid	O
at	O
position	O
70	O
(	O
D70	O
alleles	O
)	O
may	O
have	O
a	O
protective	O
effect	O
.	O

PS2363	O
Total	O
area	O
of	O
geographic	BP
atrophy-5	IP
in	O
18	O
affected	O
individuals	O
with	O
the	O
peripherin-12	BG
/	O
RDS	BG
Arg172Trp-15	IG
substitution	O
was	O
measured	O
from	O
retinal	O
photographs	O
and	O
plotted	O
as	O
a	O
function	O
of	O
age	O
.	O

PS2365	O
Among	O
the	O
patients	O
with	O
these	O
two	O
clinical	O
entities	O
,	O
those	O
with	O
a	O
homozygous	O
HTRA1	BG
rs11200638-15	IG
risk	O
allele	O
had	O
larger	BP
choroidal	IP
neovascular-21	IP
lesions	O
.	O

PS2366	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
search	O
for	O
large	O
pathogenic	O
deletions	O
and	O
/	O
or	O
duplications	O
in	O
the	O
FBN1	O
,	O
TGF	BG
beta	IG
R1-23	IG
,	O
and	O
TGF	BG
beta	IG
R2	IG
genes-29	IG
using	O
multiplex	O
-	O
ligation	O
dependent	O
probe	O
amplification	O
in	O
patients	O
with	O
aortopathy-40	BP
,	O
in	O
whom	O
no	O
mutations	O
in	O
the	O
FBN1	O
,	O
TGF	BG
beta	IG
R1-52	IG
,	O
and	O
TGF	BG
beta	IG
R2	IG
genes-58	IG
were	O
identified	O
by	O
sequencing	O
.	O

PS2367	O
Our	O
findings	O
expand	O
the	O
number	O
of	O
large	O
FBN1-8	BG
deletions	O
,	O
and	O
emphasize	O
the	O
importance	O
of	O
screening	O
for	O
large	O
genomic	O
deletions	O
in	O
connective	O
tissue	O
disorders	O
featuring	O
aortopathies-26	BP
,	O
especially	O
for	O
those	O
with	O
classic	O
Marfan	O
phenotype	O
.	O

PS2370	O
The	O
epistasis	O
between	O
CYP11B2-4	BG
and	O
NOS3-6	BG
and	O
its	O
correlation	O
with	O
varied	O
clinical	O
and	O
biochemical	O
parameters	O
signify	O
its	O
possible	O
contribution	O
in	O
the	O
complex	O
etiology	O
of	O
hypertension-25	BP
.	O

PS2371	O
A	O
single	O
base	O
substitution	O
(	O
C	O
-	O
-	O
>	O
T	O
)	O
in	O
exon	O
II	O
of	O
the	O
Bbeta	BG
fibrinogen	IG
gene-19	IG
resulting	O
in	O
an	O
Arg14	O
-	O
-	O
>	O
Cys	O
replacement	O
was	O
identified	O
in	O
a	O
young	O
woman	O
with	O
a	O
history	O
of	O
recurrent	O
thrombotic	O
stroke-41	BP
.	O

PS2374	O
We	O
studied	O
the	O
disorder	O
at	O
various	O
levels	O
in	O
a	O
group	O
of	O
six	O
patients	O
with	O
Adenylosuccinate	BG
lyase	IG
deficiency-17	IP
.	O

PS2376	O
We	O
studied	O
the	O
disorder	O
at	O
various	O
levels	O
in	O
a	O
group	O
of	O
six	O
patients	O
with	O
Adenylosuccinate	BG
lyase	IG
deficiency-17	IP
.	O

PS2377	O
Somatic	O
VHL	O
mutations	O
and	O
hypermethylation	O
of	O
the	O
VHL	BG
gene-9	IG
are	O
found	O
in	O
some	O
75	O
-	O
80	O
%	O
of	O
sporadic	O
clear	O
cell	BP
renal	IP
carcinomas-23	IP
.	O

PS2378	O
About	O
20	O
%	O
of	O
clear	O
cell	BP
renal	IP
carcinomas-8	IP
show	O
neither	O
VHL	BG
gene-12	IG
mutation	O
or	O
hypermethylation	O
.	O

PS2380	O
Here	O
,	O
leaf	O
and	O
spike	O
(	O
flower	O
cluster	O
)	O
alternative	O
oxidase-11	BG
protein	O
content	O
and	O
spike-15	BP
/	O
floral	O
reflectance	O
of	O
genotypes	O
from	O
European	O
Plantago	O
lanceolata	O
populations	O
found	O
in	O
regions	O
differing	O
in	O
reproductive	O
season	O
temperatures	O
were	O
measured	O
.	O

PS2381	O
To	O
investigate	O
the	O
phenotype	O
of	O
primary	O
open	O
-	O
angle	O
glaucoma-10	BP
in	O
Brazilian	O
families	O
with	O
mutation	O
in	O
exon	O
3	O
of	O
TIGR-20	BG
/	O
MYOC-22	BG
.	O

PS2382	O
Seventy	O
-	O
eight	O
primary	O
open	O
-	O
angle	O
glaucoma-8	BP
patients	O
with	O
a	O
positive	O
family	O
history	O
and	O
eighteen	O
unrelated	O
patients	O
with	O
primary	O
open	O
-	O
angle	O
glaucoma-24	BP
were	O
screened	O
by	O
automated	O
DNA	O
sequencing	O
for	O
mutations	O
in	O
exon	O
3	O
of	O
the	O
TIGR-38	BG
/	O
MYOC	BG
gene-41	IG
.	O

PS2383	O
Cys433Arg	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
TIGR-8	BG
/	O
MYOC	BG
gene-11	IG
is	O
related	O
to	O
juvenile	O
-	O
onset	O
primary	O
open	O
-	O
angle	O
glaucoma-22	BP
in	O
Brazilian	O
families	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O

PS2387	O
Sixty	O
-	O
five	O
patients	O
suffering	O
from	O
autosomal	BG
dominant	IG
cerebellar	IG
ataxia	IG
-	IG
I-12	IG
(	O
ADCA	BG
-	IG
1-16	IG
)	O
were	O
subjected	O
genotype	O
phenotype	O
correlation	O
analysis	O
using	O
molecular	O
genetic	O
assignment	O
to	O
the	O
spinocerebellar	BG
ataxia	IG
type	IG
1	IG
,	IG
2	IG
or	IG
3-37	IG
(	O
SCA1-39	BG
,	O
-	O
2	O
or	O
-	O
3	O
)	O
locus	O
,	O
clinical	O
examination	O
,	O
eye	O
movement	O
recording	O
and	O
morphometric	O
analysis	O
of	O
MRIs	O
.	O

PS2388	O
Pyramidal	O
tract	O
signs	O
,	O
pale	O
discs	O
and	O
dysphagia-8	BP
were	O
more	O
frequent	O
in	O
SCA1-13	BG
compared	O
SCA2-15	BG
and	O
SCA3-17	BG
patients	O
.	O

PS2389	O
Spinocerebellar	BP
ataxia-2	IP
type	O
I	O
falls-5	BP
into	O
an	O
intermediate	O
range	O
that	O
overlaps	O
with	O
both	O
SCA2-14	BG
and	O
SCA3-16	BG
.	O

PS2391	O
Recently	O
,	O
genotypes	O
have	O
been	O
defined	O
for	O
some	O
of	O
them	O
,	O
such	O
as	O
X	O
-	O
linked	O
severe	O
combined	O
immunodeficiency-19	BP
and	O
CD3-21	BG
deficiencies	O
(	O
or	O
hyper	O
IgM-26	BG
syndrome	O
)	O
.	O

PS2392	O
The	O
"	O
complex	O
of	O
myxomas	O
,	O
spotty	O
skin	O
pigmentation-9	BP
,	O
and	O
endocrine	O
overactivity	O
,	O
"	O
or	O
"	O
Carney	O
complex	O
"	O
,	O
is	O
caused	O
by	O
inactivating	O
mutations	O
of	O
the	O
regulatory	O
subunit	O
type	O
1A	O
of	O
the	O
cAMP	BG
-	IG
dependent	IG
protein	IG
kinase-39	IG
(	O
PRKAR1A-41	BG
)	O
gene	O
and	O
as	O
yet	O
unknown	O
defect	O
(	O
s	O
)	O
in	O
other	O
gene	O
(	O
s	O
)	O
.	O

PS2393	O
Patients	O
with	O
a	O
PRKAR1A-4	BG
mutation	O
were	O
more	O
likely	O
to	O
have	O
pigmented	O
skin	O
lesions	O
,	O
myxomas-15	BP
,	O
and	O
thyroid	O
and	O
gonadal	O
tumors	O
;	O

PS2394	O
We	O
investigated	O
NOS1	O
through	O
sequencing	O
of	O
the	O
complete	BG
NOS1-9	IG
coding	O
region	O
in	O
DNA	O
from	O
43	O
patients	O
with	O
Infantile	O
hypertrophic	O
pyloric	BP
stenosis-21	IP
compared	O
the	O
genotype	O
frequencies	O
to	O
47	O
controls	O
using	O
the	O
Cochran	O
-	O
Armitage	O
trend	O
or	O
Fisher	O
exact	O
tests	O
.	O

PS2396	O
Adults	O
with	O
the	O
same	O
enzyme	O
deficiency	O
,	O
alternatively	O
named	O
acid	BG
maltase-11	IG
deficiency	O
,	O
were	O
reported	O
to	O
have	O
slowly	O
progressive	O
skeletal	BP
muscle	IP
weakness-22	IP
and	O
respiratory	O
problems	O
,	O
but	O
no	O
cardiac	O
involvement	O
.	O

PS2397	O
Genotyping	O
for	O
CARD15-3	BG
(	O
R702W-5	BG
,	O
G908R-7	BG
,	O
3020insC-9	BG
)	O
,	O
IL23R-12	BG
(	O
rs1004819-14	BG
,	O
rs7517847-16	BG
,	O
rs11209026-18	BG
,	O
rs10889677-20	BG
,	O
rs1495965-22	BG
)	O
,	O
and	O
ATG16L1-26	BG
(	O
rs2241880-28	BG
)	O
was	O
performed	O
in	O
187	O
children	O
and	O
adults	O
with	O
Crohn	BP
'	IP
s	IP
disease-41	IP
and	O
255	O
healthy	O
ethnically	O
matched	O
controls	O
.	O

PS2399	O
Eighty	O
-	O
six	O
Chinese	O
Han	O
HSP	O
patients	O
were	O
investigated	O
for	O
spastic	BP
paraplegia-12	IP
type	O
6	O
mutations	O
by	O
direct	O
sequencing	O
of	O
the	O
NIPA1	BG
gene-22	IG
.	O

PS2401	O
The	O
data	O
substantiate	O
the	O
reliability	O
of	O
the	O
novel	O
strategy	O
for	O
a	O
fast	O
(	O
5	O
day	O
)	O
quantitative	O
evaluation	O
of	O
HIV	BG
-	IG
1-22	IG
phenotype	O
to	O
protease	O
inhibitors	O
,	O
and	O
indicate	O
that	O
this	O
method	O
may	O
contribute	O
to	O
the	O
understanding	O
of	O
mechanisms	O
of	O
virus	BP
resistance-42	IP
to	O
protease	O
inhibitors	O
.	O

PS2402	O
With	O
regard	O
to	O
the	O
latter	O
,	O
there	O
has	O
been	O
a	O
recent	O
shift	O
from	O
the	O
"	O
common	O
variant	O
"	O
to	O
the	O
"	O
rare	O
variant	O
"	O
paradigm	O
,	O
since	O
rare	O
variants	O
of	O
TNFAIP3-31	BG
and	O
TREX1-33	BG
with	O
large	O
effect	O
sizes	O
have	O
recently	O
been	O
discovered	O
in	O
Systemic	BP
lupus	IP
erythematosus-45	IP
.	O

PS2405	O
In	O
the	O
discovery	O
sample	O
,	O
we	O
observed	O
that	O
all	O
tested	O
TNFAIP3-11	BG
variants	O
were	O
in	O
linkage	O
disequilibrium	O
and	O
were	O
associated	O
with	O
systemic	O
sclerosis-22	BP
and	O
various	O
systemic	O
sclerosis	O
subsets	O
,	O
including	O
the	O
polyautoimmune	BP
phenotype-32	IP
.	O

PS2406	O
The	O
present	O
findings	O
establish	O
the	O
TNFAIP3	BG
locus-7	IG
as	O
a	O
susceptibility	O
factor	O
for	O
the	O
subset	O
of	O
systemic	O
sclerosis-17	BP
with	O
a	O
polyautoimmune	BP
phenotype-21	IP
.	O

PS2410	O
The	O
prevalence	O
of	O
KRT5-4	BG
/	O
KRT14-6	BG
mutations	O
and	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
the	O
largest	O
tissue	O
-	O
confirmed	O
Epidermolysis-20	BP
bullosa	O
simplex	O
population	O
is	O
investigated	O
.	O

PS2411	O
Insulin	BP
resistance-2	IP
,	O
obesity-4	BP
,	O
dyslipidemia-6	BP
,	O
and	O
high	O
blood	O
pressure	O
characterize	O
the	O
metabolic	O
syndrome	O
.	O

PS2412	O
Ichthyosis-1	BP
vulgaris	O
is	O
a	O
genetic	O
disorder	O
with	O
a	O
prevalence	O
of	O
1	O
:	O
250	O
-	O
1000	O
caused	O
by	O
filaggrin-18	BG
mutations	O
,	O
which	O
also	O
predispose	O
to	O
atopic	O
diseases	O
.	O

PS2413	O
We	O
evaluated	O
a	O
cohort	O
of	O
26	O
German	O
patients	O
with	O
Ichthyosis	BP
vulgaris-11	IP
,	O
established	O
an	O
Ichthyosis	O
vulgaris	O
severity	O
score	O
and	O
analysed	O
epidermal	O
ultrastructure	O
,	O
histology	O
,	O
filaggrin-26	BG
and	O
CD1a	BG
antigens-29	IG
.	O

PS2414	O
Interestingly	O
,	O
CD1a-3	BG
cell	O
counts	O
showed	O
a	O
significant	O
difference	O
between	O
nonatopic	O
and	O
atopic	O
Ichthyosis	O
vulgaris	O
patients	O
both	O
with	O
eczema-19	BP
and	O
without	O
eczema	O
.	O

PS2415	O
To	O
determine	O
which	O
of	O
the	O
N	BG
-	IG
acetyltransferase-8	IG
alleles	O
[	O
monomorphic	O
(	O
N	BG
-	IG
acetyltransferase1-15	IG
)	O
or	O
polymorphic	O
(	O
N	BG
-	IG
acetyltransferase2-22	IG
)	O
]	O
are	O
expressed	O
in	O
the	O
target	O
cells	O
for	O
arylamine	BP
carcinogenesis-33	IP
,	O
namely	O
normal	O
human	O
uroepithelial	O
cells	O
,	O
cDNA	O
was	O
prepared	O
from	O
cellular	O
RNA	O
and	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
,	O
using	O
upstream	O
primer	O
1	O
comprising	O
the	O
5	O
'	O
end	O
(	O
nt	O
47	O
-	O
68	O
)	O
and	O
either	O
downstream	O
primers	O
2	O
(	O
nt	O
908	O
-	O
889	O
)	O
or	O
3	O
(	O
nt	O
953	O
-	O
931	O
)	O
corresponding	O
with	O
the	O
3	O
'	O
end	O
.	O

PS2418	O
In	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
myophosphorylase	BG
deficiency-9	IP
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
polymorphic	O
variants	O
in	O
either	O
myoadenylate	O
deaminase	O
or	O
angiotensin	BG
-	IG
converting	IG
enzyme-26	IG
could	O
act	O
as	O
modulators	O
of	O
phenotype	O
expression	O
.	O

PS2420	O
In	O
patients	O
with	O
juvenile	O
polyposis-5	BP
syndrome	O
the	O
frequency	O
of	O
large	O
genomic	O
deletions	O
in	O
the	O
SMAD4-15	BG
and	O
BMPR1A	BG
genes-18	IG
was	O
unknown	O
.	O

PS2422	O
In	O
22	O
%	O
of	O
the	O
23	O
unrelated	O
SMAD4	BG
mutation-9	IG
carriers	O
,	O
hereditary	O
hemorrhagic	BP
telangiectasia-14	IP
was	O
also	O
diagnosed	O
clinically	O
.	O

PS2423	O
Both	O
polycystic	BP
kidney-3	IP
disease	O
'	O
s	O
forms	O
have	O
a	O
pathogeny	O
and	O
similar	O
clinic	O
,	O
but	O
in	O
the	O
patients	O
with	O
mutation	O
in	O
PKD2-22	BG
,	O
the	O
clinical	O
manifestations	O
appear	O
later	O
and	O
the	O
progression	O
to	O
end	O
stage	O
renal	BP
failure-36	IP
happens	O
10	O
years	O
later	O
than	O
in	O
the	O
patients	O
with	O
mutation	O
in	O
PKD1-48	BG
.	O

PS2424	O
In	O
this	O
work	O
,	O
we	O
present	O
the	O
results	O
of	O
the	O
mutational	O
analysis	O
of	O
the	O
PKD2	BG
gene-16	IG
in	O
18	O
patients	O
diagnosed	O
with	O
autosomal	O
dominant	O
polycystic	BP
kidney-25	IP
disease	O
.	O

PS2426	O
The	O
copy	O
number	O
variations	O
contained	O
in	O
the	O
HLA	BG
locus-9	IG
region	O
in	O
patients	O
with	O
the	O
novel	O
phenotype	O
of	O
chronic	O
cerebrospinal	BP
venous	IP
insufficiency-21	IP
/	O
VM	O
and	O
Multiple	O
sclerosis	O
were	O
mapped	O
in	O
detail	O
,	O
demonstrating	O
a	O
significant	O
correlation	O
between	O
the	O
number	O
of	O
known	O
copy	O
number	O
variations	O
found	O
in	O
the	O
HLA	BG
region-48	IG
and	O
the	O
number	O
of	O
chronic	O
cerebrospinal	O
venous	O
insufficiency	O
-	O
VMs	O
identified	O
in	O
patients	O
.	O

PS2428	O
Previous	O
analysis	O
of	O
data	O
from	O
92	O
families	O
,	O
ascertained	O
through	O
a	O
parent	O
with	O
asthma-14	BP
,	O
showed	O
evidence	O
for	O
recessive	O
inheritance	O
of	O
high	O
IgE-23	BG
levels	O
with	O
linkage	O
to	O
chromosome	O
5q	O
.	O

PS2430	O
(	O
LTA	O
)	O
,	O
galectin	BG
-	IG
2-7	IG
(	O
LGALS2-9	BG
)	O
,	O
and	O
proteasome	O
subunit	O
a	O
type	O
6	O
genes	O
as	O
genetic	O
risk	O
factors	O
for	O
myocardial	BP
infarction-25	IP
.	O

PS2432	O
To	O
undertake	O
mutation	O
screening	O
of	O
cytochrome	BG
P4501B1-7	IG
and	O
myocilin-9	BG
genes	O
in	O
Egyptian	O
and	O
Saudi	O
Arabian	O
patients	O
with	O
primary	O
congenital	O
glaucoma-20	BP
.	O

PS2434	O
Hereditary	O
hemorrhagic	BP
telangiectasia-3	IP
is	O
a	O
genetically	O
heterogeneous	O
vascular	O
dysplasia	O
with	O
multiple	O
telangiectases	O
and	O
arteriovenous	O
malformations	O
and	O
it	O
is	O
caused	O
by	O
mutations	O
in	O
endoglin	BG
gene-24	IG
(	O
hemorrhagic	O
telangiectasia1	O
)	O
and	O
activin	BG
A	IG
receptor	IG
type	IG
II	IG
-	IG
like	IG
1	IG
gene-38	IG
(	O
activin	BG
A	IG
receptor	IG
type	IG
II	IG
-	IG
like	IG
1	IG
gene-48	IG
)	O
(	O
hemorrhagic	O
telangiectasia2	O
)	O
.	O

PS2436	O
A	O
rare	O
,	O
recessive	O
form	O
of	O
bilateral	O
periventricular	O
nodular	O
heterotopia	O
with	O
microcephaly-12	BP
and	O
severe	O
delay	O
is	O
associated	O
with	O
mutations	O
of	O
the	O
ADP	BG
-	IG
ribosylation	IG
factor	IG
guanine	IG
nucleotide	IG
-	IG
exchange	IG
factor	IG
-	IG
2-32	IG
gene	O
,	O
required	O
for	O
vesicle	O
and	O
membrane	O
trafficking	O
from	O
the	O
trans	O
-	O
Golgi	O
.	O

PS2437	O
We	O
performed	O
mutation	O
analysis	O
of	O
Filamin	BG
A	IG
gene-8	IG
in	O
120	O
patients	O
,	O
of	O
whom	O
72	O
(	O
60	O
%	O
)	O
had	O
classical	O
bilateral	O
periventricular	O
nodular	O
heterotopia-25	BP
and	O
48	O
(	O
40	O
%	O
)	O
other	O
Periventricular	O
heterotopia	O
phenotypes	O
,	O
and	O
identified	O
25	O
mutations	O
in	O
40	O
individuals	O
.	O

PS2438	O
Congenital	BP
adrenal	IP
hyperplasia-3	IP
due	O
to	O
21	O
-	O
hydroxylase-8	BG
deficiency	O
is	O
one	O
of	O
the	O
most	O
common	O
autosomal	O
recessive	O
hereditary	O
diseases	O
.	O

PS2439	O
In	O
patients	O
with	O
classic	O
Congenital	O
adrenal	O
hyperplasia	O
obesity-8	BP
,	O
hyperinsulinaemia-10	BP
,	O
insulin	BP
resistance-13	IP
,	O
and	O
hyperleptinaemia-16	BP
are	O
more	O
often	O
seen	O
than	O
in	O
the	O
general	O
population	O
.	O

PS2441	O
Phenotypic	O
characteristics	O
were	O
examined	O
in	O
melanoma-6	BP
-	O
prone	O
southern	O
Swedish	O
CDKN2A-11	BG
(	O
p16	BG
-	IG
113insArg-15	IG
/	O
p14ARF	BG
-	IG
128insSer-19	IG
)	O
mutation	O
families	O
,	O
in	O
relation	O
to	O
the	O
CDKN2A	BG
genotype-29	IG
,	O
nevi-31	BP
,	O
clinically	O
atypical	O
nevi	O
and	O
melanoma-37	BP
.	O

PS2442	O
29	O
invasive	O
melanomas-3	BP
in	O
16	O
patients	O
were	O
recorded	O
,	O
all	O
in	O
the	O
38	O
verified	O
CDKN2A	BG
mutation-16	IG
carriers	O
.	O

PS2445	O
Patients	O
affected	O
by	O
the	O
multiple	O
endocrine	O
neoplasia-7	BP
type	O
I	O
syndrome	O
(	O
MEN1-12	BG
)	O
display	O
a	O
high	O
incidence	O
of	O
pituitary	BP
adenomas-20	IP
,	O
though	O
it	O
is	O
still	O
unknown	O
whether	O
these	O
pituitary	O
tumors	O
have	O
specific	O
pathologic	O
features	O
that	O
would	O
distinguish	O
them	O
from	O
sporadic	BP
pituitary	IP
adenomas-42	IP
.	O

PS2446	O
MEN1	O
patients	O
with	O
large	BP
pituitary	IP
tumors-6	IP
(	O
grade	O
IV	O
)	O
were	O
younger	O
than	O
non	O
-	O
MEN1-16	BG
patients	O
.	O

PS2448	O
Somatotroph	O
hyperplasia-2	BP
,	O
with	O
or	O
without	O
a	O
microadenoma-8	BP
was	O
found	O
in	O
only	O
3	O
MEN1	O
patients	O
,	O
with	O
growth	BG
hormone	IG
-	IG
releasing	IG
hormone-22	IG
hypersecretion	O
by	O
a	O
pancreatic	O
tumor	O
in	O
2	O
of	O
them	O
.	O

PS2452	O
We	O
found	O
(	O
a	O
)	O
no	O
significant	O
marker	O
associations	O
with	O
small	O
cell	BP
lung	IP
carcinoma-14	IP
,	O
(	O
b	O
)	O
rare	O
surfactant	O
protein	O
-	O
A2	O
(	O
1A9	O
)	O
and	O
surfactant	O
protein	O
-	O
A1	O
(	O
6A11	O
)	O
alleles	O
associate	O
with	O
Nsmall	O
cell	O
lung	O
carcinoma	O
risk	O
when	O
compared	O
with	O
population	O
control	O
,	O
(	O
c	O
)	O
the	O
same	O
alleles	O
(	O
1A9	O
,	O
6A11	O
)	O
associate	O
with	O
risk	O
for	O
adenocarcinoma	O
when	O
compared	O
with	O
population	O
(	O
6A11	O
)	O
or	O
clinical	O
control	O
(	O
1A9	O
)	O
,	O
and	O
(	O
d	O
)	O
the	O
surfactant	BG
protein	IG
-	IG
A1	IG
-	IG
6A4	IG
allele-90	IG
(	O
found	O
in	O
approximately	O
10	O
%	O
of	O
the	O
population	O
)	O
associates	O
with	O
squamous	BP
cell	IP
carcinoma-105	IP
,	O
when	O
compared	O
with	O
population	O
or	O
clinical	O
control	O
.	O

PS2453	O
Although	O
some	O
authors	O
did	O
not	O
find	O
an	O
association	O
with	O
the	O
premature	O
ovarian	BP
failure-13	IP
manifestation	O
,	O
others	O
suggest	O
that	O
the	O
severity	O
of	O
FMR1-22	BG
premutation	O
-	O
associated	O
phenotypes	O
may	O
be	O
related	O
to	O
this	O
X	O
-	O
inactivation	O
ratio	O
.	O

PS2454	O
Mutations	O
of	O
FOXL2-3	BG
are	O
responsible	O
for	O
the	O
Blepharophimosis	O
-	O
Ptotsis	O
-	O
Epicantus	O
-	O
inversus	O
Syndrome	O
,	O
involving	O
complex	O
eyelid	O
malformations	O
often	O
associated	O
with	O
premature	O
ovarian	BP
failure-26	IP
.	O

PS2455	O
Here	O
,	O
we	O
dissect	O
the	O
molecular	O
and	O
functional	O
effects	O
of	O
10	O
FOXL2	BG
mutants-13	IG
,	O
known	O
to	O
induce	O
Blepharophimosis	O
-	O
Ptotsis	O
-	O
Epicantus	O
-	O
inversus	O
Syndrome	O
associated	O
with	O
premature	O
ovarian	BP
failure-30	IP
or	O
not	O
.	O

PS2457	O
If	O
the	O
common	O
pathway	O
of	O
these	O
conditions	O
is	O
the	O
hypoglycosyation	O
of	O
alpha	BG
-	IG
dystroglycan-14	IG
,	O
one	O
would	O
expect	O
a	O
correlation	O
between	O
clinical	O
severity	O
and	O
the	O
extent	O
of	O
hypoglycosylation-28	BP
.	O

PS2458	O
46	O
,	O
XX	O
individuals	O
with	O
classical	O
congenital	BP
adrenal	IP
hyperplasia-9	IP
due	O
to	O
deficiency	O
of	O
the	O
enzyme	O
,	O
21	BG
-	IG
hydroxylase-19	IG
,	O
show	O
variable	O
degrees	O
of	O
masculinization	O
of	O
body	O
and	O
behavior	O
due	O
to	O
excess	O
adrenal	O
androgen	O
production	O
.	O

PS2461	O
To	O
identify	O
the	O
distribution	O
and	O
the	O
frequency	O
of	O
the	O
MEFV	BG
gene-11	IG
mutations	O
in	O
Syrian	O
Familial	O
Mediterranean	O
fever-17	BP
patients	O
and	O
population	O
and	O
perform	O
a	O
genotype	O
/	O
phenotype	O
correlation	O
in	O
the	O
patients	O
'	O
cohort	O
.	O

PS2464	O
Guanidinoacetate	BG
methyltransferase-2	IG
deficiency	O
is	O
an	O
autosomal	O
recessive	O
error	O
of	O
creatine	O
synthesis	O
characterized	O
by	O
cerebral	O
creatine	O
deficiency	O
,	O
accumulation	O
of	O
guanidinoacetate	O
,	O
mental	BP
retardation-23	IP
,	O
epilepsy-25	BP
and	O
extrapyramidal	O
signs	O
.	O

PS2465	O
Our	O
results	O
showed	O
that	O
standard	O
functional	O
tests	O
provide	O
sufficient	O
information	O
only	O
for	O
severe	O
androgen	BG
receptor-15	IG
mutations	O
,	O
whereas	O
for	O
androgen	BG
receptor-21	IG
mutations	O
found	O
in	O
mild	O
androgen	O
insensitivity	O
syndrome	O
patients	O
with	O
male	BP
infertility-32	IP
,	O
only	O
an	O
extensive	O
analysis	O
with	O
different	O
in	O
vitro	O
systems	O
,	O
and	O
in	O
particular	O
with	O
PEM	O
promoter	O
,	O
can	O
give	O
information	O
on	O
the	O
functionality	O
of	O
the	O
androgen	BG
receptor-60	IG
and	O
therefore	O
on	O
the	O
pathogenicity	O
of	O
the	O
mutations	O
and	O
on	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

PS2467	O
No	O
definitive	O
genotype	O
-	O
phenotype	O
correlation	O
has	O
been	O
established	O
between	O
these	O
clinical	O
forms	O
and	O
multiple	O
endocrine	BG
neoplasia	IG
type	IG
1	IG
gene-20	IG
mutations	O
.	O

PS2468	O
We	O
previously	O
demonstrated	O
that	O
mutant	O
menin	O
proteins	O
associated	O
with	O
multiple	O
endocrine	O
neoplasia-12	BP
type	O
1	O
are	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin-20	BG
-	O
proteasome	O
pathway	O
.	O

PS2471	O
To	O
perform	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
and	O
delineate	O
the	O
region	O
involved	O
in	O
growth	BG
hormone	IG
deficiency-17	IP
,	O
we	O
carried	O
out	O
a	O
molecular	O
characterization	O
of	O
the	O
18p	O
deletions	O
,	O
in	O
three	O
patients	O
with	O
midline	O
defects	O
.	O

PS2472	O
Two	O
unrelated	O
children	O
,	O
a	O
7	O
-	O
month	O
-	O
old	O
girl	O
and	O
a	O
2	O
-	O
month	O
-	O
old	O
boy	O
had	O
del	O
(	O
18p	O
)	O
syndrome	O
and	O
growth	BG
hormone	IG
deficiency-29	IP
.	O

PS2473	O
These	O
findings	O
suggest	O
that	O
the	O
distal	O
region	O
on	O
18p	O
is	O
involved	O
in	O
the	O
main	O
clinical	O
features	O
,	O
and	O
growth	BG
hormone	IG
deficiency-21	IP
,	O
in	O
18p	O
deletions	O
.	O

PS2474	O
X	O
-	O
linked	O
dilated	BP
cardiomyopathy-5	IP
represents	O
a	O
well	O
known	O
genetic	BP
disease-11	IP
,	O
allelic	O
to	O
Duchenne	O
and	O
Becker	O
muscular	BP
dystrophies-19	IP
and	O
caused	O
by	O
dystrophin	BG
gene-24	IG
mutations	O
.	O

PS2475	O
We	O
measured	O
the	O
perioperative	O
endotoxemia	O
and	O
TNF	BG
-	IG
alpha-9	IG
production	O
and	O
the	O
TNF	BG
-	IG
alpha-15	IG
production	O
capacity	O
of	O
each	O
patient	O
in	O
a	O
whole	O
-	O
blood	O
stimulation	O
assay	O
using	O
blood	O
drawn	O
before	O
anesthesia-32	BP
,	O
using	O
various	O
LPS	O
concentrations	O
,	O
in	O
patients	O
undergoing	O
elective	O
cardiac	O
surgery	O
.	O

PS2477	O
Haematologically	O
,	O
the	O
anaemia-4	BP
was	O
more	O
severe	O
and	O
there	O
were	O
higher	O
bilirubin	O
levels	O
,	O
reticulocyte	O
counts	O
,	O
Hb	BG
H-19	IG
levels	O
,	O
and	O
percentage	O
of	O
red	O
blood	O
cells	O
with	O
inclusion	O
bodies	O
.	O

PS2481	O
The	O
goal	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
relationship	O
between	O
individual	O
PAH	BG
locus-14	IG
mutations	O
and	O
biochemical	O
and	O
metabolic	O
phenotypes	O
in	O
phenylketonuria-22	BP
and	O
mild	O
hyperphenylalaninemia-25	BP
patients	O
.	O

PS2483	O
It	O
has	O
been	O
proposed	O
that	O
truncations	O
of	O
the	O
C	BG
-	IG
terminal	IG
Eya	IG
domain	IG
cause-14	IG
DFNA10-15	BG
whereas	O
upstream	O
truncations	O
of	O
the	O
N	O
-	O
terminal	O
variable	O
region	O
cause	O
hearing	BP
loss-28	IP
with	O
dilated	BP
cardiomyopathy-31	IP
.	O

PS2484	O
These	O
are	O
the	O
first	O
definitive	O
cardiac	O
evaluations	O
of	O
DFNA10-9	BG
hearing	O
loss	O
to	O
support	O
a	O
correlation	O
of	O
eyes	O
absent	O
4	O
mutation	O
position	O
with	O
the	O
presence	O
or	O
absence	O
of	O
dilated	BP
cardiomyopathy-29	IP
.	O

PS2485	O
To	O
identify	O
the	O
underlying	O
molecular	O
defects	O
causing	O
retinal	BP
degeneration-9	IP
in	O
seven	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
)	O
induced	O
mutant	O
alleles	O
of	O
the	O
Pde6b	BG
gene-34	IG
and	O
to	O
analyze	O
the	O
timescale	O
of	O
retinal	O
degeneration	O
in	O
these	O
new	O
models	O
of	O
retinitis	BP
pigmentosa-49	IP
.	O

PS2489	O
The	O
frequency	O
of	O
HLA	BG
-	IG
DR	IG
antigens-7	IG
,	O
as	O
well	O
as	O
the	O
prevalence	O
of	O
islet	O
cell	O
insulin-17	BG
autoantibodies	O
and	O
other	O
autoimmunity	BP
disorders-22	IP
,	O
were	O
investigated	O
in	O
Tunisian	O
patients	O
with	O
insulin-30	BP
-	IP
dependent	IP
diabetes	IP
mellitus-34	IP
and	O
were	O
compared	O
with	O
family	O
members	O
(	O
sibs	O
)	O
and	O
healthy	O
control	O
subjects	O
.	O

PS2492	O
A	O
good	O
correlation	O
between	O
HLA-5	BG
-	O
DR3-7	BG
/	O
DR4-9	BG
heterozygous	O
phenotypes	O
and	O
the	O
presence	O
of	O
islet	O
cell	O
autoantibodies	O
in	O
patients	O
with	O
insulin-22	BG
-	O
dependent	O
diabetes	BP
mellitus-26	IP
and	O
their	O
unaffected	O
sibs	O
was	O
observed	O
in	O
the	O
Tunisian	O
population	O
.	O

PS2498	O
To	O
determine	O
the	O
frequency	O
of	O
mutations	O
in	O
these	O
genes	O
among	O
patients	O
with	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
or	O
a	O
related	O
peripheral	O
neuropathy-23	BP
,	O
we	O
identified	O
153	O
unrelated	O
patients	O
who	O
enrolled	O
prior	O
to	O
the	O
availability	O
of	O
clinical	O
testing	O
,	O
79	O
had	O
a	O
17p12	O
duplication	O
(	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease1A	O
duplication	O
)	O
,	O
11	O
a	O
connexin	O
32	O
mutation	O
,	O
5	O
a	O
myelin	O
protein	O
zero	O
mutation	O
,	O
5	O
a	O
peripheral	O
myelin	BG
protein	IG
22	IG
mutation	IG
,	IG
1-76	IG
an	O
early	BG
growth	IG
response	IG
factor	IG
2	IG
mutation	IG
,	IG
1	IG
a	IG
periaxin-87	IG
mutation	O
,	O
0	O
a	O
myotubularin	BG
related	IG
protein	IG
2	IG
mutation	IG
,	IG
1	IG
a	IG
neurofilament	IG
light	IG
chain-102	IG
mutation	O
,	O
and	O
50	O
had	O
no	O
identifiable	O
mutation	O
;	O

PS2500	O
Identification	O
of	O
an	O
association	O
between	O
IRF5	BG
rs2004640-7	IG
and	O
systemic	O
sclerosis	O
has	O
highlighted	O
a	O
key	O
role	O
for	O
type	BG
1	IG
interferon-19	IG
.	O

PS2501	O
Case	O
-	O
control	O
studies	O
of	O
single	O
markers	O
revealed	O
an	O
association	O
between	O
IRF5	BG
rs3757385-13	IG
,	O
rs2004640-15	BG
,	O
and	O
rs10954213	O
variants	O
and	O
systemic	O
sclerosis-22	BP
.	O

PS2504	O
Although	O
ATP7A-2	BG
mutations	O
are	O
typically	O
associated	O
with	O
severe	O
Menkes	O
disease	O
or	O
its	O
milder	O
allelic	O
variant	O
,	O
occipital	O
horn	O
syndrome	O
,	O
we	O
demonstrate	O
here	O
that	O
certain	O
missense	O
mutations	O
at	O
this	O
locus	O
can	O
cause	O
a	O
syndrome	O
restricted	O
to	O
progressive	O
distal	O
motor	O
neuropathy	O
without	O
overt	O
signs	O
of	O
systemic	BP
copper	IP
deficiency-47	IP
.	O

PS2509	O
This	O
confirms	O
previous	O
observations	O
in	O
Danish	O
and	O
German	O
Phenylketonuria-9	BP
patients	O
that	O
disease	O
phenotype	O
is	O
a	O
consequence	O
of	O
the	O
nature	O
of	O
the	O
mutations	O
at	O
the	O
phenylalanine	BG
hydroxylase	IG
locus-27	IG
and	O
not	O
significantly	O
influenced	O
by	O
other	O
loci	O
.	O

PS2510	O
Correlation	O
of	O
genotype	O
with	O
phenotype	O
in	O
haemogloblin	BG
H	IG
disease-9	IP
is	O
important	O
for	O
genetic	O
counselling	O
,	O
especially	O
in	O
the	O
antenatal	O
setting	O
.	O

PS2512	O
More	O
than	O
90	O
%	O
of	O
individuals	O
with	O
a	O
JAG1-9	BG
mutation	O
or	O
Alagille	O
syndrome	O
have	O
cardiovascular	BP
anomalies-16	IP
,	O
with	O
branch	O
PA	O
stenosis	O
the	O
most	O
common	O
abnormality	O
.	O

PS2513	O
A	O
potential	O
molecular	O
marker	O
associated	O
with	O
cancer-7	BP
susceptibility	O
as	O
well	O
as	O
metastasis	O
,	O
prognosis	O
and	O
adverse	O
survival	O
,	O
is	O
the	O
L	BG
-	IG
myc	IG
gene-24	IG
.	O

PS2516	O
However	O
,	O
a	O
higher	O
frequency	O
of	O
L	BG
-	IG
myc	IG
S	IG
allele-11	IG
in	O
the	O
squamous	BP
cell	IP
carcinoma-16	IP
compared	O
to	O
other	O
histological	O
groups	O
was	O
found	O
,	O
although	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

PS2520	O
Study	O
of	O
the	O
clinical	O
,	O
radiographic	O
,	O
and	O
morphological	O
features	O
of	O
the	O
seven	O
cases	O
supports	O
evidence	O
for	O
a	O
phenotypic	O
continuum	O
between	O
achondrogenesis	O
II	O
-	O
hypochondrogenesis	O
and	O
lethal	BP
spondyloepiphyseal	IP
dysplasia-29	IP
congenita	O
and	O
suggests	O
a	O
relationship	O
between	O
the	O
amount	O
of	O
type	BG
I	IG
collagen-41	IG
in	O
the	O
cartilage	O
and	O
the	O
severity	O
of	O
the	O
phenotype	O
.	O

PS2521	O
They	O
also	O
confirm	O
that	O
the	O
extremely	O
high	O
phenotypic	O
heterogeneity	O
observed	O
in	O
patients	O
with	O
hypophosphatasia-14	BP
was	O
due	O
mainly	O
to	O
variable	O
residual	O
enzymatic	O
activities	O
allowed	O
by	O
missense	O
mutations	O
found	O
in	O
the	O
human	BG
TNSALP	IG
gene-32	IG
.	O

PS2522	O
The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
correlation	O
between	O
the	O
beta	BG
-	IG
fibrinogen	IG
gene	IG
-	IG
148C-18	IG
/	O
T-20	BG
and	O
-	O
455G	O
/	O
A	O
polymorphisms	O
and	O
susceptibility	O
to	O
coronary	BP
artery	IP
disease-32	IP
in	O
the	O
Chinese	O
population	O
using	O
a	O
meta	O
-	O
analytic	O
approach	O
.	O

PS2524	O
Criteria	O
for	O
classification	O
into	O
the	O
salt	O
-	O
wasting	O
phenotype	O
included	O
history	O
of	O
a	O
salt	O
-	O
losing	O
crisis	O
with	O
documented	O
hyponatremia-20	BP
,	O
hyperkalemia-22	BP
,	O
and	O
markedly	O
elevated	O
plasma	BG
renin-28	IG
activity	O
.	O

PS2533	O
To	O
investigate	O
further	O
the	O
genetic	O
epidemiology	O
of	O
hereditary	O
non	O
-	O
polyposis	O
colon	O
cancer-13	BP
syndrome	O
and	O
the	O
nature	O
and	O
frequency	O
of	O
germline	O
mutations	O
in	O
this	O
disorder	O
,	O
we	O
studied	O
17	O
English	O
hereditary	O
non	O
-	O
polyposis	O
colon	O
cancer-36	BP
syndrome	O
kindreds	O
for	O
germline	O
mutations	O
in	O
MSH2-43	BG
and	O
MLH1-45	BG
.	O

PS2534	O
A	O
previous	O
genetic	O
linkage	O
study	O
had	O
suggested	O
that	O
most	O
English	O
hereditary	BG
non	IG
-	IG
polyposis	IG
colon	IG
cancer	IG
syndrome	IG
families-18	IG
will	O
have	O
mutations	O
in	O
one	O
of	O
these	O
genes	O
.	O

PS2535	O
Age	O
related	O
risks	O
for	O
colorectal	O
and	O
uterine	O
cancer-8	BP
were	O
similar	O
for	O
MSH2-12	BG
and	O
MLH1-14	BG
mutations	O
.	O

PS2537	O
In	O
addition	O
,	O
tumour	O
tissues	O
of	O
liver	O
(	O
n	O
=	O
59	O
)	O
were	O
obtained	O
from	O
the	O
studied	O
hepatocellular	BP
carcinoma-19	IP
patients	O
for	O
measurement	O
of	O
miR	BG
-	IG
196a-26	IG
expression	O
levels	O
.	O

PS2538	O
The	O
frequency	O
of	O
the	O
CC	O
genotype	O
among	O
hepatocellular	BP
carcinoma-9	IP
patients	O
was	O
higher	O
than	O
that	O
in	O
the	O
control	O
group	O
,	O
implying	O
that	O
the	O
cirrhotic	O
patients	O
with	O
the	O
CC	O
genotype	O
or	O
C	BG
allele-31	IG
containing	O
genotypes	O
(	O
CT	O
and	O
CC	O
)	O
may	O
have	O
a	O
higher	O
risk	O
of	O
hepatocellular	BP
carcinoma-46	IP
.	O

PS2539	O
Our	O
results	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
miR	O
-	O
196a2	O
polymorphism	O
may	O
contribute	O
to	O
cirrhosis	O
-	O
related	O
hepatocellular	BP
carcinoma-22	IP
susceptibility	O
in	O
Chinese	O
patients	O
through	O
influencing	O
mature	O
miR	BG
-	IG
196a-32	IG
expression	O
.	O

PS2541	O
The	O
risk	O
of	O
severe	O
neonatal	BP
alloimmune	IP
thrombocytopenia-7	IP
due	O
to	O
anti	BG
-	IG
HPA	IG
-	IG
1a	IG
antibodies-15	IG
is	O
correlated	O
to	O
maternal	O
ABO	O
types	O
,	O
and	O
this	O
study	O
indicates	O
that	O
the	O
observation	O
is	O
due	O
to	O
genetic	O
properties	O
on	O
the	O
maternal	O
side	O
.	O

PS2544	O
We	O
performed	O
logistic	O
regression	O
analysis	O
for	O
the	O
effect	O
of	O
endothelial	BG
nitric	IG
oxide	IG
synthase-13	IG
intron	O
4	O
polymorphism	O
and	O
other	O
coronary	O
risk	O
factors	O
on	O
multi	O
-	O
vessel	O
coronary	BP
artery	IP
disease-28	IP
and	O
endothelial	O
function	O
.	O

PS2546	O
To	O
determine	O
whether	O
the	O
different	O
distribution	O
of	O
AAT	BG
globules-9	IG
within	O
neoplastic-11	BP
and	O
non	O
-	O
neoplastic	O
hepatocytes	O
is	O
the	O
result	O
of	O
a	O
self	O
-	O
induced	O
correction	O
of	O
the	O
genetic	O
defect	O
.	O

PS2547	O
Two	O
HCV	O
-	O
positive	O
patients	O
with	O
alpha	BG
-	IG
1	IG
-	IG
antitrypsin-11	IG
deficiency	O
-	O
associated	O
hepatocellular	BP
carcinoma-16	IP
were	O
studied	O
.	O

PS2553	O
The	O
emergence	O
of	O
cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-8	IG
-	O
assist	O
therapies	O
may	O
potentially	O
play	O
a	O
future	O
role	O
in	O
the	O
treatment	O
of	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
-	O
mutation	O
associated	O
pancreatitis-30	BP
.	O

PS2555	O
To	O
understand	O
the	O
basis	O
for	O
the	O
clinical	O
heterogeneity	O
of	O
phenylalanine	BG
hydroxylase	IG
deficiency-12	IP
among	O
Portuguese	O
hyperphenylalaninemic	O
patients	O
,	O
genotype	O
-	O
phenotype	O
correlations	O
were	O
established	O
.	O

PS2559	O
A	O
family	O
with	O
neurological	O
findings	O
similar	O
to	O
hereditary	O
sensory	O
and	O
autonomic	BP
neuropathy-12	IP
type	O
V	O
having	O
a	O
point	O
mutation	O
in	O
the	O
nerve	BG
growth	IG
factor	IG
beta-24	IG
gene	O
was	O
recently	O
described	O
.	O

PS2561	O
Eighty	O
-	O
four	O
healthy	O
Chinese	O
male	O
control	O
subjects	O
derived	O
from	O
an	O
occupation	O
-	O
based	O
case	O
-	O
control	O
study	O
of	O
bladder	BP
cancer-21	IP
were	O
evaluated	O
for	O
hepatic	BG
N	IG
-	IG
acetyltransferase-28	IG
activity	O
by	O
dapsone	O
and	O
for	O
NAT2	BG
genotype-35	IG
using	O
allele	O
-	O
specific	O
amplification	O
of	O
peripheral	O
leukocyte	O
DNA	O
by	O
the	O
polymerase	O
chain	O
reaction	O
.	O

PS2563	O
In	O
one	O
family	O
,	O
a	O
4684insA	O
mutation	O
led	O
to	O
a	O
mild	O
polyposis	O
associated	O
with	O
early	O
inherited	O
osteomas-17	BP
and	O
,	O
in	O
the	O
family	O
bearing	O
the	O
double	O
mutation	O
(	O
Z1625H	BG
+	IG
4897delC-30	IG
)	O
,	O
the	O
phenotype	O
was	O
obviously	O
a	O
3	O
'	O
attenuated	O
type	O
.	O

PS2572	O
The	O
most	O
frequent	O
indications	O
for	O
DNA	O
analysis	O
were	O
hepatopathy	O
of	O
unknown	O
ethiology	O
,	O
liver	BP
cirrhosis-15	IP
,	O
diabetes	BP
mellitus-18	IP
,	O
bronze	O
skin	O
pigmentation-22	BP
in	O
connection	O
with	O
high	O
serum	O
iron	O
concentration	O
,	O
elevated	O
transferrin-32	BG
saturation	O
and	O
elevated	O
serum	O
ferritin-37	BG
levels	O
.	O

PS2573	O
Several	O
studies	O
examining	O
the	O
molecular	O
basis	O
for	O
Dihydropyrimidine	BG
dehydrogenase	IG
deficiency-10	IP
have	O
identified	O
over	O
30	O
sequence	O
variations	O
in	O
the	O
DPYD	BG
gene-20	IG
(	O
which	O
codes	O
for	O
the	O
Dihydropyrimidine	BG
dehydrogenase	IG
enzyme-28	IG
)	O
.	O

PS2574	O
We	O
conclude	O
that	O
(	O
a	O
)	O
lethal	O
toxicity	O
can	O
occur	O
in	O
partially	O
Dihydropyrimidine	BG
dehydrogenase-14	IG
-	O
deficient	O
individuals	O
after	O
administration	O
of	O
5	O
-	O
fluorouracil	O
and	O
is	O
not	O
exclusive	O
to	O
profoundly	O
Dihydropyrimidine	BG
dehydrogenase-31	IG
-	O
deficient	O
individuals	O
as	O
suggested	O
previously	O
,	O
(	O
b	O
)	O
the	O
complicated	O
heterozygote	O
genotype	O
seen	O
in	O
these	O
patients	O
,	O
combined	O
with	O
Dihydropyrimidine	BG
dehydrogenase	IG
deficiency-55	IP
being	O
an	O
autosomal	O
codominant	O
inherited	O
syndrome	O
,	O
precludes	O
the	O
use	O
of	O
simple	O
genotyping	O
assays	O
that	O
identify	O
only	O
one	O
or	O
two	O
mutations	O
as	O
a	O
method	O
for	O
identifying	O
Dihydropyrimidine	BG
dehydrogenase-83	IG
-	O
deficient	O
individuals	O
;	O

PS2575	O
Others	O
included	O
a	O
case	O
of	O
Leber	O
congenital	O
amaurosis	O
and	O
genetically	O
confirmed	O
cases	O
of	O
cone	O
or	O
cone	O
-	O
rod	O
dystrophy	O
(	O
GUCA1A-21	BG
,	O
retinitis	BG
pigmentosaGR-24	IG
,	O
RIMS1-26	BG
)	O
,	O
"	O
cone	O
dystrophy	O
with	O
supernormal	O
rod	O
electroretinography	O
"	O
(	O
KCNV2-38	BG
)	O
and	O
X	O
-	O
linked	O
retinoschisis	O
(	O
RS1	O
)	O
.	O

PS2578	O
Long	O
-	O
term	O
clinical	O
follow	O
-	O
up	O
demonstrated	O
low	O
levels	O
of	O
secretory	BG
immunoglobulin	IG
A-14	IG
on	O
several	O
occasions	O
and	O
likely	O
related	O
to	O
the	O
patient	O
'	O
s	O
recurrent	O
respiratory	BP
infections-28	IP
,	O
a	O
main	O
clinical	O
feature	O
of	O
the	O
trisomy	O
5p	O
syndrome	O
.	O

PS2579	O
Long	O
-	O
term	O
clinical	O
follow	O
-	O
up	O
demonstrated	O
low	O
levels	O
of	O
secretory	BG
immunoglobulin	IG
A-14	IG
on	O
several	O
occasions	O
and	O
likely	O
related	O
to	O
the	O
patient	O
'	O
s	O
recurrent	O
respiratory	BP
infections-28	IP
,	O
a	O
main	O
clinical	O
feature	O
of	O
the	O
trisomy	O
5p	O
syndrome	O
.	O

PS2581	O
Cystic	BP
fibrosis-2	IP
disease	O
severity	O
is	O
characterized	O
by	O
a	O
broad	O
variability	O
that	O
has	O
been	O
attributed	O
,	O
in	O
addition	O
to	O
the	O
Cystic	BG
fibrosis	IG
transmembrane	IG
conductance	IG
regulator-24	IG
genotype	O
,	O
to	O
modulating	O
factors	O
such	O
as	O
Cystic	BG
fibrosisTR-33	IG
-	O
mediated	O
residual	O
chloride	O
secretion	O
.	O

PS2584	O
We	O
screened	O
51	O
unrelated	O
individuals	O
with	O
anophthalmia-7	BP
/	O
microphthalmia-9	BP
and	O
identified	O
SOX2	BG
mutations-13	IG
in	O
the	O
coding	O
region	O
of	O
the	O
gene	O
in	O
10	O
individuals	O
.	O

PS2585	O
Among	O
the	O
SOX2-3	BG
-	O
positive	O
cases	O
,	O
seven	O
patients	O
had	O
bilateral	O
anophthalmia-12	BP
/	O
microphthalmia-14	BP
and	O
mutations	O
resulting	O
in	O
premature	O
termination	O
of	O
the	O
normal	O
protein	O
sequence	O
(	O
7	O
/	O
38	O
;	O
18	O
%	O
of	O
all	O
bilateral	O
cases	O
)	O
,	O
one	O
patient	O
had	O
bilateral	O
anophthalmia-43	BP
/	O
microphthalmia-45	BP
associated	O
with	O
a	O
single	O
amino	O
acid	O
insertion	O
(	O
1	O
/	O
38	O
;	O
3	O
%	O
of	O
bilateral	O
cases	O
)	O
,	O
and	O
the	O
final	O
two	O
patients	O
demonstrated	O
unilateral	O
anophthalmia-72	BP
/	O
microphthalmia	O
associated	O
with	O
missense	O
mutations	O
(	O
2	O
/	O
13	O
;	O
15	O
%	O
of	O
all	O
unilateral	O
cases	O
)	O
.	O

PS2586	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
glaucoma-6	BP
-	O
causing	O
mutant	BG
myocilin	IG
proteins-11	IG
are	O
misfolded	O
and	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
of	O
cells	O
.	O

PS2587	O
Generally	O
,	O
there	O
is	O
an	O
inverse	O
relationship	O
between	O
the	O
degree	O
of	O
mutant	BG
myocilin-13	IG
secretion	O
at	O
30	O
degrees	O
C	O
and	O
the	O
severity	O
of	O
the	O
associated	O
glaucoma-25	BP
phenotype	O
.	O

PS2592	O
Because	O
Hirschsprung	BP
disease-3	IP
is	O
a	O
multifactorial	O
and	O
multigene	O
disorder	O
,	O
the	O
higher	O
mutation	O
rate	O
of	O
10	O
%	O
for	O
short	O
-	O
segment	O
Hirschsprung	BP
disease-23	IP
suggests	O
the	O
important	O
role	O
that	O
the	O
EDNRB	BG
gene-31	IG
plays	O
in	O
the	O
pathogenesis	O
of	O
short	O
-	O
segment	O
Hirschsprung	BP
disease-41	IP
in	O
Taiwan	O
.	O

PS2593	O
Hypocalciuria-1	BP
is	O
generally	O
believed	O
to	O
be	O
a	O
pathognomonic	O
finding	O
of	O
Na	BG
-	IG
Cl	IG
cotransporter-14	IG
malfunction	O
.	O

PS2595	O
We	O
examined	O
2	O
patients	O
with	O
POMT1-6	BG
-	O
associated	O
alpha	O
-	O
dystroglycanopathy-11	BP
,	O
1	O
displaying	O
a	BP
limb	IP
girdle	IP
muscular	IP
dystrophy2K-19	IP
and	O
1	O
with	O
a	O
Walker	O
-	O
Warburg	O
syndrome	O
phenotype	O
.	O

PS2596	O
Our	O
results	O
suggest	O
that	O
dermal	O
fibroblasts	O
can	O
be	O
applied	O
to	O
facilitate	O
the	O
diagnostic	O
analysis	O
of	O
dystroglycanopathy-16	BP
patients	O
as	O
well	O
as	O
to	O
study	O
the	O
pathogenic	O
mechanism	O
of	O
POMT-27	BG
mutations	O
.	O

PS2598	O
Of	O
the	O
cases	O
where	O
the	O
calpain	BG
3	IG
gene-8	IG
was	O
not	O
affected	O
,	O
approximately	O
20	O
%	O
were	O
diagnosed	O
as	O
LGMD2I	O
muscular	BP
dystrophy-21	IP
,	O
while	O
facioscapulohumeral	O
muscular	BP
dystrophy-26	IP
was	O
uncommon	O
in	O
this	O
sample	O
.	O

PS2600	O
In	O
this	O
study	O
we	O
examined	O
the	O
fibroblast	BG
growth	IG
factor	IG
receptor	IG
3	IG
gene-12	IG
for	O
the	O
previously	O
described	O
hypochondroplasia	O
mutations	O
and	O
the	O
phenotype	O
of	O
23	O
probands	O
with	O
clinically	O
and	O
radiologically	O
diagnosed	O
hypochondroplasia-30	BP
.	O

PS2603	O
A	O
phosphate	O
-	O
poor	O
diet	O
markedly	O
increases	O
survival	O
of	O
NPP1-10	BG
null	O
mice	O
,	O
a	O
model	O
of	O
generalized	BP
arterial	IP
calcification-19	IP
of	O
infancy	O
.	O

PS2605	O
DNA	O
samples	O
from	O
220	O
mutation	O
-	O
positive	O
Hereditary	O
nonpolyposis	O
colorectal	BP
cancer-11	IP
participants	O
(	O
86	O
Australian	O
and	O
134	O
Polish	O
)	O
were	O
genotyped	O
for	O
single	O
nucleotide	O
polymorphisms	O
in	O
CYP1A1-27	BG
,	O
GSTM1-29	BG
,	O
GSTT1-31	BG
,	O
GSTP1-33	BG
,	O
and	O
NAT2-36	BG
.	O

PS2606	O
The	O
Hereditary	O
nonpolyposis	O
colorectal	BP
cancer-5	IP
population	O
displays	O
a	O
significant	O
difference	O
in	O
the	O
genotype	O
frequency	O
distribution	O
between	O
colorectal	O
cancer-18	BP
patients	O
and	O
unaffected	O
mismatch	O
repair	O
gene	O
mutation	O
carriers	O
for	O
the	O
CYP1A1-29	BG
single	O
nucleotide	O
polymorphisms	O
where	O
the	O
colorectal	BP
cancer-36	IP
patients	O
harbor	O
more	O
of	O
the	O
mutant	O
genotype	O
.	O

PS2608	O
To	O
assess	O
better	O
the	O
link	O
between	O
congenital	O
bilateral	O
absence	O
of	O
the	O
vas	O
deferens	O
and	O
cystic	BP
fibrosis-16	IP
,	O
we	O
compared	O
sweat	O
chloride	O
values	O
,	O
analysis	O
of	O
the	O
cystic	BG
fibrosisTR	IG
intron	IG
8-30	IG
poly	O
(	O
T	O
)	O
tract	O
length	O
and	O
analysis	O
of	O
10	O
exons	O
in	O
a	O
population	O
of	O
38	O
patients	O
with	O
congenital	BP
bilateral	IP
absence-51	IP
of	O
the	O
vas	O
deferens	O
.	O

PS2609	O
All	O
mutant	O
pvon	O
Hippel	O
-	O
Lindau	O
proteins	O
restored	O
proper	O
hypoxic	O
regulation	O
of	O
hypoxia	BG
inducible	IG
factor1alpha-15	IG
,	O
although	O
one	O
von	O
Hippel	O
-	O
Lindau	O
mutation	O
displayed	O
impaired	O
binding	O
to	O
Elongin	BG
C-29	IG
.	O

PS2610	O
This	O
mutation	O
also	O
failed	O
to	O
restore	O
hypoxia	BG
inducible	IG
factor2alpha-9	IG
regulation	O
.	O

PS2611	O
Surprisingly	O
,	O
teratomas	O
expressing	O
the	O
von	BG
Hippel	IG
-	IG
Lindau-9	IG
(	O
Y112H-11	BG
)	O
mutant	O
protein	O
displayed	O
a	O
growth	O
disadvantage	O
,	O
despite	O
restoring	O
hypoxia	BG
inducible	IG
factoralpha	IG
regulation-25	IG
.	O

PS2616	O
A	O
common	O
variant	O
of	O
the	O
angiotensinogen	BG
gene-7	IG
(	O
T235	O
)	O
predicts	O
elevated	O
levels	O
of	O
circulating	O
angiotensinogen-16	BG
,	O
and	O
polymorphisms	O
of	O
this	O
gene	O
have	O
been	O
linked	O
to	O
physiologic	O
responses	O
and	O
to	O
the	O
risk	O
of	O
cardiovascular	BP
disease-35	IP
.	O

PS2617	O
The	O
angiotensin-2	BG
-	O
converting	O
-	O
enzyme	O
gene	O
insertion	O
/	O
deletion	O
polymorphism	O
,	O
although	O
not	O
considered	O
functional	O
,	O
has	O
been	O
associated	O
with	O
physiologic	O
responses	O
and	O
disease	O
risk	O
in	O
hypertension-28	BP
and	O
diabetes	O
.	O

PS2618	O
The	O
biochemical	O
hallmark	O
of	O
glutaric	BP
aciduria-6	IP
type	O
I	O
due	O
to	O
glutaryl	BG
-	IG
CoA	IG
dehydrogenase-14	IG
deficiency	O
is	O
the	O
accumulation	O
of	O
glutaric	O
acid	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
of	O
3	O
-	O
hydroxyglutaric	O
and	O
glutaconic	O
acids	O
.	O

PS2620	O
Neonatal	O
onset	O
of	O
carnitine	BG
palmitoyltransferase	IG
II-6	IG
deficiency	O
is	O
an	O
autosomal	O
recessive	O
,	O
often	O
lethal	O
disorder	O
of	O
the	O
mitochondrial	O
beta	O
-	O
oxidation	O
of	O
long	O
-	O
chain	O
fatty	BP
acids-27	IP
.	O

PS2622	O
All	O
lethal	O
neonatal-3	BP
carnitine	O
palmitoyltransferase	BG
II	IG
deficiency-7	IP
patients	O
previously	O
described	O
presented	O
severe	O
symptoms	O
during	O
the	O
first	O
week	O
of	O
life	O
,	O
although	O
this	O
was	O
not	O
the	O
case	O
in	O
our	O
patient	O
,	O
who	O
remained	O
stable	O
and	O
without	O
apparent	O
vital	O
risk	O
during	O
the	O
first	O
11	O
days	O
of	O
life	O
.	O

PS2623	O
A	O
recent	O
study	O
reported	O
associations	O
of	O
a	O
series	O
of	O
single	O
nucleotide	O
polymorphisms	O
within	O
PTPN22-14	BG
,	O
including	O
rs2476601	O
,	O
with	O
rheumatoid	BP
arthritis-21	IP
.	O

PS2624	O
These	O
data	O
suggest	O
that	O
the	O
association	O
of	O
single	O
nucleotide	O
polymorphisms	O
within	O
the	O
PTPN22-13	BG
region	O
differs	O
between	O
autoimmune	BP
diseases-18	IP
,	O
occurring	O
individually	O
and	O
/	O
or	O
as	O
part	O
of	O
a	O
haplotype	O
,	O
indicating	O
that	O
the	O
mechanisms	O
by	O
which	O
PTPN22-37	BG
confers	O
susceptibility	O
to	O
Graves	O
'	O
disease	O
may	O
,	O
in	O
part	O
,	O
be	O
disease	O
specific	O
.	O

PS2625	O
The	O
ryanodine	BG
receptor-3	IG
(	O
RYR1-5	BG
)	O
encoding	O
the	O
major	O
Ca	O
(	O
2	O
+	O
)	O
release	O
channel	O
in	O
the	O
skeletal	O
muscle	O
sarcoplasmic	O
reticulum	O
has	O
been	O
shown	O
to	O
be	O
mutated	O
in	O
a	O
number	O
of	O
Malignant	O
hyperthermia-34	BP
pedigrees	O
.	O

PS2627	O
The	O
high	O
number	O
of	O
discordants	O
observed	O
using	O
the	O
standardized	O
diagnostic	O
cut	O
-	O
off	O
points	O
is	O
likely	O
to	O
reflect	O
the	O
presence	O
of	O
a	O
second	O
Malignant	BG
hyperthermiaS	IG
susceptibility	IG
locus-27	IG
in	O
the	O
pedigree	O
.	O

PS2628	O
Our	O
results	O
provide	O
new	O
information	O
about	O
the	O
correlation	O
of	O
the	O
GUSB	BG
genotype-12	IG
to	O
phenotype	O
and	O
establish	O
a	O
novel	O
canine	O
model	O
for	O
mucopolysaccharidosis-22	BP
VII	O
.	O

PS2629	O
This	O
study	O
describes	O
the	O
mutations	O
at	O
the	O
phenylalanine	BG
hydroxylase-9	IG
locus	O
in	O
patients	O
with	O
the	O
diagnosis	O
of	O
classic	O
PKU	O
(	O
n	O
=	O
18	O
)	O
,	O
hyperphenylalaninemia-25	BP
variant	O
(	O
n	O
=	O
9	O
)	O
and	O
benign	O
persistent	O
hyperphenylalaninemia-35	BP
(	O
n	O
=	O
13	O
)	O
who	O
were	O
identified	O
by	O
the	O
Texas	O
Newborn	O
Screening	O
Program	O
.	O

PS2641	O
Therefore	O
,	O
mismatch	O
repair	O
may	O
play	O
a	O
role	O
in	O
the	O
breast	BP
carcinogenesis-12	IP
and	O
the	O
Gly322Asp	O
polymorphism	O
of	O
the	O
hMSH2	BG
gene-20	IG
may	O
be	O
considered	O
as	O
a	O
potential	O
marker	O
in	O
breast	BP
cancer-30	IP
.	O

PS2642	O
These	O
human	O
porphyrias-3	BP
can	O
be	O
modelled	O
in	O
iron	O
-	O
loaded	O
mice	O
exposed	O
to	O
hexachlorobenzene	O
,	O
in	O
which	O
C57BL-18	BG
/	O
10ScSn-20	BG
is	O
a	O
prototype	O
susceptible	O
strain	O
whereas	O
DBA	O
/	O
2	O
mice	O
are	O
extremely	O
resistant	O
.	O

PS2643	O
The	O
keratin	BG
5-3	IG
and	O
keratin	BG
14	IG
genes-7	IG
encode	O
proteins	O
that	O
form	O
the	O
primary	O
structural	O
components	O
of	O
the	O
basal	O
epidermal	O
keratinocytes	O
,	O
mutations	O
in	O
either	O
of	O
these	O
genes	O
can	O
cause	O
epidermolysis	BP
bullosa	IP
simplex-32	IP
.	O

PS2646	O
We	O
have	O
screened	O
54	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
Type	O
1	O
patients	O
,	O
of	O
variable	O
clinical	O
severity	O
,	O
and	O
25	O
Hereditary	O
neuropathy-22	BP
with	O
liability	O
to	O
pressure	O
palsies	O
patients	O
from	O
Turkey	O
,	O
with	O
no	O
duplication	O
or	O
deletion	O
,	O
for	O
mutations	O
in	O
the	O
Point	O
mutations	O
in	O
peripheral	O
myelin	BG
gene	IG
22-48	IG
and	O
connexin	BG
32	IG
genes-52	IG
.	O

PS2647	O
No	O
correlation	O
was	O
observed	O
between	O
the	O
rs2075876	BG
genotype-8	IG
and	O
quantitative	O
traits	O
reflecting	O
the	O
progression	O
of	O
Rheumatoid	BP
arthritis-17	IP
.	O

PS2652	O
Compared	O
with	O
the	O
mutations	O
in	O
patients	O
with	O
classical	O
manifestations	O
,	O
F453S	O
in	O
the	O
patient	O
with	O
regular	O
menses	O
,	O
occasional	O
hypertension-20	BP
,	O
and	O
hypokalemia-23	BP
showed	O
a	O
partially	O
reduced	O
17alpha	BG
-	IG
hydroxylase-30	IG
(	O
29	O
%	O
of	O
those	O
of	O
wild	O
type	O
)	O
and	O
a	O
minor	O
protein	O
conformational	O
change	O
.	O

PS2654	O
The	O
frequency	O
of	O
p53	BG
mutations-5	IG
has	O
been	O
reported	O
to	O
be	O
significantly	O
higher	O
in	O
the	O
gemistocytic	O
variant	O
as	O
compared	O
with	O
other	O
astrocytomas-21	BP
.	O

PS2655	O
Our	O
data	O
confirm	O
that	O
the	O
frequency	O
of	O
p53	BG
mutations-9	IG
is	O
significantly	O
higher	O
(	O
approximately	O
twofold	O
)	O
in	O
gemistocytic	O
astrocytomas-19	BP
as	O
compared	O
with	O
other	O
astrocytoma-24	BP
subtypes	O
.	O

PS2657	O
Phenylalanine	BG
hydroxylase	IG
deficiency-3	IP
is	O
a	O
trait	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
pattern	O
;	O

PS2659	O
Forty	O
-	O
two	O
unrelated	O
patients	O
affected	O
by	O
juvenile	O
polyposis-9	BP
syndrome	O
were	O
analyzed	O
for	O
germline	O
alterations	O
in	O
the	O
BMPR1A-18	BG
and	O
SMAD4	BG
genes-21	IG
,	O
and	O
for	O
clinical	O
and	O
histological	O
features	O
.	O

PS2663	O
The	O
classic	O
form	O
of	O
Ataxia	BP
telangiectasia-6	IP
results	O
from	O
the	O
presence	O
of	O
two	O
truncating	O
ATM	O
mutations	O
,	O
leading	O
to	O
total	O
loss	O
of	O
the	O
ATM	BG
protein-24	IG
,	O
a	O
protein	O
kinase	O
.	O

PS2668	O
Mutations	O
in	O
the	O
ATP7B	BG
gene-5	IG
cause	BP
failure-7	IP
of	O
copper	O
excretion	O
into	O
the	O
bile	O
and	O
a	O
defective	O
incorporation	O
of	O
copper	O
into	O
ceruloplasmin-21	BG
.	O

PS2669	O
Here	O
we	O
use	O
polychromatic	O
flow	O
cytometry	O
to	O
show	O
that	O
differences	O
in	O
surface	O
expression	O
of	O
the	O
human	BG
interleukin	IG
-	IG
2-19	IG
receptor	O
alpha	O
(	O
IL2RA-23	BG
,	O
or	O
CD25-26	BG
)	O
protein	O
are	O
restricted	O
to	O
particular	O
immune	O
cell	O
types	O
and	O
correlate	O
with	O
several	O
haplotypes	O
in	O
the	O
IL2RA	O
region	O
that	O
have	O
previously	O
been	O
associated	O
with	O
two	O
autoimmune	BP
diseases-53	IP
,	O
type	O
1	O
diabetes	O
and	O
multiple	O
sclerosis-60	BP
.	O

PS2670	O
Mucopolysaccharidosis	BG
type	IG
I-3	IG
(	O
MPS	BG
-	IG
I	IG
orMPS1-8	IG
)	O
is	O
an	O
autosomal	O
recessive	O
condition	O
characterized	O
by	O
a	O
broad	O
range	O
of	O
clinical	O
symptoms	O
.	O

PS2673	O
A	O
synthetic	O
probe	O
set	O
for	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
was	O
developed	O
to	O
confirm	O
and	O
characterize	O
NR0B1-19	BG
deletions	O
in	O
patients	O
with	O
adrenal	BP
hypoplasia-25	IP
congenita	O
and	O
to	O
correlate	O
their	O
genotypes	O
with	O
their	O
divergent	O
phenotypes	O
.	O

PS2674	O
In	O
2	O
patients	O
,	O
isolated	O
adrenal	BP
hypoplasia-7	IP
congenita	O
was	O
confirmed	O
,	O
while	O
a	O
patient	O
at	O
risk	O
for	O
metabolic	O
crisis	O
was	O
revealed	O
as	O
the	O
deletion	O
extends	O
to	O
the	O
GK	BG
gene-29	IG
.	O

PS2675	O
A	O
deletion	O
extending	O
to	O
IL1RAPL1-5	BG
was	O
confirmed	O
in	O
both	O
patients	O
showing	O
mental	BP
retardation-13	IP
.	O

PS2676	O
Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
is	O
a	O
valuable	O
tool	O
to	O
detect	O
NR0B1-14	BG
and	O
contiguous	O
gene	O
deletions	O
in	O
patients	O
with	O
adrenal	BP
hypoplasia	IP
congenita-24	IP
.	O

PS2677	O
It	O
is	O
especially	O
helpful	O
for	O
IL1RAPL1-6	BG
deletion	O
detection	O
as	O
no	O
clinical	O
markers	O
for	O
mental	BP
retardation-15	IP
are	O
available	O
.	O

PS2678	O
Furthermore	O
,	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
has	O
the	O
advantage	O
to	O
identify	O
female	O
carriers	O
that	O
,	O
depending	O
on	O
the	O
deletion	O
extension	O
,	O
have	O
a	O
high	O
risk	O
of	O
giving	O
birth	O
to	O
children	O
with	O
mental	BP
retardation-35	IP
,	O
adrenal	BG
hypoplasia	IG
congenita-39	IG
,	O
glycerol	BG
kinase	IG
deficiency-43	IP
and	O
Duchenne	O
muscular	BP
dystrophy-47	IP
.	O

PS2682	O
We	O
report	O
on	O
two	O
unrelated	O
families	O
with	O
EEC	O
syndrome	O
(	O
ectrodactyly	O
,	O
ectodermal	BP
dysplasia-14	IP
,	O
cleft	O
lip	O
/	O
palate	O
)	O
,	O
each	O
with	O
an	O
Arg227Gln	BG
TP63	IG
gene	IG
mutation-28	IG
,	O
where	O
the	O
phenotype	O
overlapped	O
extensively	O
with	O
the	O
allelic	O
disorder	O
,	O
limb	O
-	O
mammary	O
syndrome	O
.	O

PS2691	O
Two	O
cases	O
had	O
Alport	O
manifestations	O
including	O
deafness	O
,	O
nephritis-9	BP
,	O
and	O
cataracts-12	BP
and	O
had	BG
R1165C-15	IG
and	O
E1841K-17	BG
mutations	O
,	O
respectively	O
.	O

PS2692	O
MtSNPscore	O
predicted	O
possible	O
role	O
of	O
eight	O
and	O
79	O
novel	O
variations	O
in	O
ataxia-12	BP
and	O
mtSNP	BG
datasets-15	IG
,	O
respectively	O
,	O
in	O
disease	O
etiology	O
.	O

PS2693	O
Transgenic	O
mice	O
,	O
expressing	O
DHCR7	BG
driven-6	IG
by	O
murine	BG
nestin	IG
promoter-10	IG
,	O
were	O
bred	O
onto	O
Dhcr7	O
knock	O
-	O
out	O
(	O
Dhcr7	BG
(	IG
-	IG
1	IG
-	IG
)-25	IG
)	O
background	O
and	O
resulted	O
in	O
a	O
partial	O
rescue	O
of	O
neonatal	O
lethality-36	BP
in	O
11	O
of	O
91	O
(	O
12	O
%	O
)	O
of	O
transgene	O
-	O
positive	O
Dhcr7	O
(	O
-	O
1	O
-	O
)	O
pups	O
.	O

PS2694	O
As	O
in	O
most	O
weeds	O
,	O
triazine	BP
resistance-7	IP
is	O
conferred	O
by	O
a	O
point	O
mutation	O
in	O
the	O
chloroplast	BG
psbA	IG
gene-18	IG
that	O
negatively	O
affects	O
the	O
fitness	O
of	O
its	O
carrier	O
.	O

PS2696	O
An	O
overlapping	O
phenotypic	O
presentation	O
with	O
its	O
biological	O
counterpart	O
AFG3L2	O
,	O
which	O
when	O
mutated	O
causes	O
spinocerebellar	BP
ataxia-16	IP
type	O
28	O
,	O
is	O
apparent	O
and	O
possibly	O
suggests	O
that	O
abnormal	O
levels	O
of	O
the	O
SPG7	BG
protein-31	IG
impact	O
the	O
function	O
of	O
the	O
mitochondrial	O
ATPases-38	BG
associated	O
with	O
diverse	O
cellular	O
activities	O
-	O
protease	O
complex	O
(	O
formed	O
by	O
SPG7-50	BG
and	O
AFG3L2-52	BG
)	O
in	O
the	O
cerebellum	O
.	O

PS2697	O
In	O
addition	O
,	O
a	O
missense	O
mutation	O
in	O
exon	O
10	O
resulted	O
in	O
predominant	O
optical	O
nerve	O
atrophy	O
,	O
which	O
might	O
suggest	O
deleterious	O
interactions	O
of	O
this	O
SPG7	BG
variant-25	IG
with	O
its	O
substrate	O
OPA1-29	BG
,	O
the	O
mutated	O
gene	O
product	O
in	O
optic	BP
atrophy-37	IP
type	O
1	O
.	O

PS2700	O
We	O
genotyped	O
195	O
patients	O
with	O
heart	BP
failure-7	IP
and	O
systolic	O
left	O
ventricular	O
dysfunction	O
(	O
ejection	O
fraction	O
<	O
40	O
%	O
)	O
for	O
angiotensin	BG
-	IG
converting	IG
enzyme-24	IG
insertion	O
(	O
I	O
)	O
/	O
deletion	O
(	O
D	O
)	O
and	O
chymase	BG
-	IG
1-37	IG
(	O
-	O
1903G	O
/	O
A	O
)	O
polymorphisms	O
.	O

PS2705	O
The	O
clinical	O
diagnosis	O
of	O
Friedreich	O
'	O
s	O
ataxia-8	BP
was	O
afterwards	O
confirmed	O
in	O
all	O
patients	O
by	O
the	O
appropriate	O
DNA	O
investigation	O
which	O
showed	O
markedly	O
increased	O
amounts	O
of	O
GAA	O
repeats	O
on	O
both	O
alleles	O
of	O
the	O
frataxin	BG
gene-34	IG
.	O

PS2707	O
First	O
,	O
a	O
search	O
for	O
candidate	O
genes	O
was	O
performed	O
focusing	O
on	O
rhodopsin-12	BG
,	O
peripherin-14	BG
/	O
RDS-16	BG
,	O
and	O
phosducin	BG
genes-20	IG
,	O
using	O
non	O
-	O
radioisotopic	O
SSCP	O
and	O
genomic	O
DNA	O
samples	O
obtained	O
from	O
387	O
Japanese	O
patients	O
with	O
retinitis	BP
pigmentosa-38	IP
,	O
including	O
56	O
families	O
of	O
the	O
autosomal	O
dominant	O
type	O
(	O
ADRP	O
)	O
.	O

PS2710	O
The	O
results	O
indicate	O
a	O
significant	O
modification	O
of	O
the	O
phenotype	O
of	O
familial	O
hypercholesterolemia-12	BP
with	O
the	O
defective	O
LDL	BG
receptor	IG
gene	IG
allele-19	IG
,	O
by	O
growth	BG
hormone	IG
receptor	IG
Leu-25	IG
variation	O
in	O
the	O
kindred	O
studied	O
.	O

PS2712	O
The	O
results	O
indicate	O
a	O
significant	O
modification	O
of	O
the	O
phenotype	O
of	O
familial	O
hypercholesterolemia-12	BP
with	O
the	O
defective	O
LDL	BG
receptor	IG
gene	IG
allele-19	IG
,	O
by	O
growth	BG
hormone	IG
receptor	IG
Leu-25	IG
variation	O
in	O
the	O
kindred	O
studied	O
.	O

PS2714	O
Most	O
patients	O
with	O
protocadherin19	BG
gene-5	IG
mutations	O
exhibit	O
a	O
distinctive	O
electroclinical	O
pattern	O
of	O
focal	O
seizures-14	BP
with	O
affective	O
symptoms	O
,	O
suggesting	O
an	O
epileptogenic	O
dysfunction	O
involving	O
the	O
frontotemporal	O
limbic	O
system	O
.	O

PS2715	O
Management	O
is	O
also	O
different	O
given	O
that	O
Neurofibromatosis-7	BP
type	O
1	O
results	O
from	O
loss	O
of	O
function	O
of	O
tumour	BG
suppressor	IG
gene-18	IG
.	O

PS2716	O
To	O
determine	O
whether	O
variations	O
in	O
the	O
pol	O
gene	O
sequence	O
correlated	O
with	O
virus	O
infectivity	O
,	O
we	O
sequenced	O
and	O
phenotypically	O
tested	O
pol	BG
genes-21	IG
from	O
a	O
variety	O
of	O
human	O
T	O
-	O
cell	O
leukemia-30	BP
virus	O
type	O
1	O
isolates	O
derived	O
from	O
primary	O
sources	O
,	O
transformed	O
cell	O
lines	O
,	O
and	O
molecular	O
clones	O
.	O

PS2718	O
These	O
data	O
suggest	O
that	O
the	O
UGT1A1	BG
TATAA-7	IG
box	O
polymorphism	O
plays	O
a	O
role	O
in	O
an	O
individual	O
'	O
s	O
overall	O
ability	O
to	O
detoxify	O
benzo	O
(	O
a	O
)	O
pyrene	O
and	O
in	O
cancer-29	BP
risk	O
.	O

PS2720	O
The	O
primary	O
goal	O
of	O
this	O
work	O
was	O
the	O
detailed	O
study	O
of	O
the	O
different	O
allele	O
combinations	O
and	O
the	O
metabolic	O
phenotypes	O
in	O
Spanish	O
phenylketonuria	O
patients	O
in	O
order	O
to	O
understand	O
better	O
the	O
clinical	O
heterogeneity	O
of	O
phenylalanine	BG
hydroxylase	IG
deficiency-35	IP
in	O
our	O
population	O
.	O

PS2722	O
Overall	O
,	O
20	O
of	O
23	O
sporadic	O
patients	O
with	O
a	O
COL2A1-10	BG
mutation	O
had	O
either	O
a	O
cleft	BP
palate-16	IP
or	O
retinal	O
detachment	O
with	O
vitreous	O
anomalies	O
.	O

PS2723	O
The	O
presence	O
of	O
vitreous	O
anomalies	O
,	O
retinal	BP
tears-8	IP
or	O
detachments	O
,	O
cleft	BP
palate-13	IP
and	O
a	O
positive	O
family	O
history	O
were	O
shown	O
to	O
be	O
good	O
indicators	O
for	O
a	O
COL2A1-27	BG
defect	O
.	O

PS2726	O
Although	O
a	O
clinical	O
overlap	O
between	O
patients	O
with	O
dominant	O
and	O
recessive	O
RYR1	BG
mutations-12	IG
exists	O
,	O
in	O
most	O
cases	O
with	O
recessive	O
mutations	O
the	O
pattern	O
of	O
muscle	BP
weakness-25	IP
is	O
remarkably	O
different	O
from	O
that	O
observed	O
in	O
dominant	O
central	O
core	O
disease	O
.	O

PS2728	O
Protein	O
expression	O
studies	O
in	O
nine	O
cases	O
suggested	O
a	O
correlation	O
between	O
specific	O
mutations	O
,	O
RyR1	BG
protein-15	IG
levels	O
and	O
resulting	O
phenotype	O
:	O
in	O
particular	O
,	O
whilst	O
patients	O
with	O
dominant	O
or	O
recessive	O
mutations	O
associated	O
with	O
typical	O
central	O
core	O
disease	O
phenotypes	O
appeared	O
to	O
have	O
normal	O
RyR1-42	BG
expression	O
,	O
individuals	O
with	O
more	O
generalized	O
weakness-49	BP
,	O
multi	O
-	O
minicores	O
and	O
external	BP
ophthalmoplegia-56	IP
had	O
a	O
pronounced	O
depletion	O
of	O
the	O
RyR1	BG
protein-64	IG
.	O

PS2729	O
Our	O
data	O
represent	O
the	O
most	O
extensive	O
study	O
of	O
RYR1-9	BG
-	O
related	O
myopathies-12	BP
and	O
indicate	O
complex	O
genotype	O
-	O
phenotype	O
correlations	O
associated	O
with	O
mutations	O
differentially	O
affecting	O
assembly	O
and	O
function	O
of	O
the	O
RyR1	BG
calcium	IG
release	IG
channel-33	IG
.	O

PS2730	O
Increased	O
gal4-2	BG
dosage	O
correlated	O
with	O
accumulation	O
of	O
insoluble	O
GAL4-9	BG
,	O
suggesting	O
that	O
the	O
cascade	O
of	O
events	O
leading	O
to	O
apoptosis-19	BP
might	O
be	O
triggered	O
by	O
protein	O
deposits	O
of	O
either	O
GAL4-28	BG
or	O
protein	O
intermediates	O
.	O

PS2731	O
In	O
uveal	BP
melanoma-3	IP
,	O
different	O
predictors	O
of	O
poor	O
prognosis	O
have	O
been	O
identified	O
,	O
including	O
monosomy	O
of	O
chromosome	O
3	O
,	O
HLA-20	BG
expression	O
,	O
and	O
the	O
presence	O
of	O
infiltrating	O
leukocytes	O
and	O
macrophages	O
.	O

PS2735	O
Analysis	O
of	O
DNA	O
obtained	O
by	O
chorionic	O
villus	O
sampling	O
in	O
early	O
pregnancy	O
permits	O
prenatal	O
diagnosis	O
and	O
treatment	O
of	O
21	O
-	O
hydroxylase-20	BG
deficiency	O
Congenital	BP
adrenal	IP
hyperplasia-24	IP
.	O

PS2743	O
Our	O
results	O
suggest	O
that	O
PTEN-5	BG
plays	O
a	O
critical	O
role	O
in	O
cancer-11	BP
development	O
,	O
and	O
genetic	O
background	O
may	O
influence	O
the	O
onset	O
,	O
the	O
spectrum	O
,	O
and	O
the	O
progression	O
of	O
tumorigenesis	O
caused	O
by	O
Pten	O
mutation	O
.	O

PS2746	O
Hypertrophic	BP
cardiomyopathy-2	IP
patients	O
with	O
the	O
malignant	O
Arginine719Trp	BG
mutation-8	IG
have	O
more	O
extensive	O
hypertrophy	O
than	O
those	O
with	O
the	O
benign	O
Leu606Valine	O
mutation	O
.	O

PS2748	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
disease	O
,	O
23	O
patients	O
with	O
early	O
-	O
onset	O
disease	O
and	O
no	O
mutations	O
in	O
Bruton	BG
tyrosine	IG
kinase-23	IG
,	O
the	O
gene	O
responsible	O
for	O
X	O
-	O
linked	O
agammaglobulinemia-32	BP
,	O
were	O
selected	O
and	O
analyzed	O
by	O
direct	O
sequencing	O
of	O
candidate	O
genes	O
.	O

PS2749	O
The	O
albumin-2	BG
/	O
creatinine	O
ratio	O
in	O
a	O
random	O
urine	O
sample	O
was	O
used	O
as	O
a	O
measure	O
of	O
albuminuria-17	BP
.	O

PS2750	O
Rheumatoid	BP
arthritis-2	IP
is	O
a	O
chronic	O
inflammatory	O
disease	O
in	O
which	O
tumour	BG
necrosis	IG
factor	IG
-	IG
alpha-14	IG
plays	O
an	O
important	O
role	O
.	O

PS2756	O
We	O
found	O
that	O
induced	O
sputum	O
samples	O
of	O
patients	O
with	O
bronchial	O
asthma-11	BP
contained	O
elevated	O
levels	O
of	O
Baculoviral	BG
IAP	IG
repeat	IG
containing	IG
5	IG
mRNA-21	IG
compared	O
with	O
healthy	O
subjects	O
and	O
its	O
level	O
was	O
in	O
correlation	O
with	O
sputum	O
eosinophil	O
percentages	O
.	O

PS2760	O
Laboratory	O
data	O
showed	O
hypocalcemia-4	BP
,	O
low	O
urine	O
calcium	O
,	O
hypophosphatemia-10	BP
,	O
high	O
serum	BG
alkaline	IG
phosphatase-15	IG
,	O
elevated	BG
PTH-18	IG
,	O
and	O
low	O
serum	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D	O
(	O
3	O
)	O
.	O

PS2761	O
Ninety	O
-	O
three	O
individuals	O
(	O
78	O
families	O
)	O
with	O
an	O
undetermined	O
leukodystrophy	O
were	O
selected	O
on	O
MRI	O
-	O
based	O
criteria	O
of	O
childhood	O
ataxia-22	BP
with	O
central	O
hypomyelination	O
/	O
vanishing	O
white	O
matter	O
for	O
EIF2B	BG
genes-32	IG
analysis	O
.	O

PS2762	O
Eighty	O
-	O
nine	O
percent	O
of	O
individuals	O
with	O
MRI	O
criteria	O
of	O
childhood	O
ataxia-12	BP
with	O
central	O
hypomyelination	O
/	O
vanishing	O
white	O
matter	O
have	O
a	O
mutation	O
in	O
one	O
of	O
the	O
eucaryotic	BG
initiation	IG
factor	IG
2B	IG
beta-31	IG
to	O
epsilon	O
subunits	O
.	O

PS2764	O
BRCA1-1	BG
and	O
BRCA2-3	BG
have	O
now	O
been	O
isolated	O
and	O
a	O
large	O
number	O
of	O
families	O
characterized	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
these	O
breast	BP
cancer-23	IP
susceptibility	O
genes	O
.	O

PS2765	O
For	O
example	O
,	O
studies	O
of	O
large	O
,	O
extensively	O
affected	O
families	O
suggest	O
that	O
45	O
%	O
of	O
inherited	O
breast	BP
cancer-18	IP
is	O
due	O
to	O
BRCA1-22	BG
mutations	O
,	O
while	O
similar	O
studies	O
in	O
individuals	O
ascertained	O
from	O
breast	BP
cancer-33	IP
risk	O
evaluation	O
clinics	O
suggest	O
that	O
the	O
attributable	O
risk	O
is	O
only	O
15	O
%	O
-	O
20	O
%	O
.	O

PS2767	O
Total	O
RNA	O
from	O
194	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
embedded	O
prostate	BP
cancer-13	IP
samples	O
obtained	O
by	O
radical	O
prostatectomy	O
was	O
subjected	O
to	O
reverse	O
-	BG
transcriptase	IG
polymerase	IG
chain-26	IG
reaction	O
to	O
detect	O
the	O
common	BG
TMPRSS2-32	IG
:	O
ERG	BG
T1	IG
-	IG
E4-37	IG
and	O
T1	BG
-	IG
E5	IG
fusion	IG
transcripts-43	IG
and	O
five	O
other	O
non	O
-	O
TMPRSS2-49	BG
:	O
ERG-51	BG
fusion	O
transcripts	O
.	O

PS2768	O
To	O
exclude	O
the	O
possibility	O
that	O
Japanese	O
prostate	BP
cancer-8	IP
displays	O
novel	O
TMPRSS2	O
:	O
ERG	O
transcript	O
variants	O
or	O
has	O
unique	O
5	O
'	O
fusion	O
partners	O
for	O
the	O
ETS	BG
genes-26	IG
,	O
we	O
performed	O
5	O
'	O
RACE	O
using	O
fresh	O
-	O
frozen	O
prostate	BP
cancer-38	IP
samples	O
.	O

PS2769	O
Genes	O
deregulated	O
at	O
the	O
DNA	O
and	O
mRNA	O
level	O
included	O
well	O
-	O
known	O
cancer-13	BP
genes	O
partly	O
already	O
linked	O
to	O
melanoma-19	BP
(	O
RAS	BG
genes-22	IG
,	O
PTEN-24	BG
,	O
AURKA-26	BG
,	O
MAPK-28	BG
inhibitors	O
Sprouty	O
/	O
Spred	O
)	O
,	O
but	O
also	O
novel	O
candidates	O
like	O
SIPA1-40	BG
(	O
a	O
Rap1GAP-43	BG
)	O
.	O

PS2774	O
We	O
believe	O
that	O
portals	O
such	O
as	O
ROCK-7	BG
will	O
not	O
only	O
afford	O
researchers	O
rapid	O
access	O
to	O
profiling	O
data	O
,	O
but	O
also	O
aid	O
the	O
integration	O
of	O
different	O
data	O
types	O
,	O
thus	O
enhancing	O
the	O
discovery	O
of	O
novel	O
targets	O
and	O
biomarkers	O
for	O
breast	BP
cancer-40	IP
.	O

PS2775	O
Congenital	O
deficiency	O
of	O
carnitine	BG
palmitoyltransferase	IG
II-6	IG
has	O
been	O
known	O
for	O
at	O
least	O
30	O
years	O
now	O
,	O
and	O
its	O
phenotypic	O
variability	O
remains	O
fascinating	O
.	O

PS2776	O
The	O
introduction	O
of	O
mass	O
spectrometry	O
to	O
analyze	O
blood	O
acylcarnitine	O
profiles	O
has	O
revolutionized	O
the	O
diagnosis	O
of	O
fatty	O
acid	O
oxidation	O
disorders	O
including	O
carnitine	O
palmitoyltransferase	BG
II	IG
deficiency-24	IP
.	O

PS2777	O
Herein	O
,	O
we	O
present	O
a	O
new	O
case	O
of	O
lethal	O
perinatal	O
carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-14	IP
with	O
a	O
rare	O
missense	O
mutation	O
,	O
R296Q	O
(	O
907G	O
>	O
A	O
)	O
associated	O
with	O
a	O
previously	O
described	O
25	O
-	O
bp	O
deletion	O
on	O
the	O
second	O
allele	O
.	O

PS2778	O
We	O
review	O
the	O
clinical	O
features	O
,	O
the	O
diagnostic	O
protocol	O
including	O
expanded	O
neonatal	O
screening	O
,	O
the	O
treatment	O
,	O
and	O
the	O
biochemical	O
and	O
molecular	O
basis	O
of	O
carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-28	IP
.	O

PS2779	O
Congenital	O
deficiency	O
of	O
carnitine	BG
palmitoyltransferase	IG
II-6	IG
has	O
been	O
known	O
for	O
at	O
least	O
30	O
years	O
now	O
,	O
and	O
its	O
phenotypic	O
variability	O
remains	O
fascinating	O
.	O

PS2780	O
The	O
introduction	O
of	O
mass	O
spectrometry	O
to	O
analyze	O
blood	O
acylcarnitine	O
profiles	O
has	O
revolutionized	O
the	O
diagnosis	O
of	O
fatty	O
acid	O
oxidation	O
disorders	O
including	O
carnitine	O
palmitoyltransferase	BG
II	IG
deficiency-24	IP
.	O

PS2781	O
Herein	O
,	O
we	O
present	O
a	O
new	O
case	O
of	O
lethal	O
perinatal	O
carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-14	IP
with	O
a	O
rare	O
missense	O
mutation	O
,	O
R296Q	O
(	O
907G	O
>	O
A	O
)	O
associated	O
with	O
a	O
previously	O
described	O
25	O
-	O
bp	O
deletion	O
on	O
the	O
second	O
allele	O
.	O

PS2782	O
We	O
review	O
the	O
clinical	O
features	O
,	O
the	O
diagnostic	O
protocol	O
including	O
expanded	O
neonatal	O
screening	O
,	O
the	O
treatment	O
,	O
and	O
the	O
biochemical	O
and	O
molecular	O
basis	O
of	O
carnitine	BG
palmitoyltransferase	IG
II	IG
deficiency-28	IP
.	O

PS2784	O
Data	O
on	O
lung	O
cancer-4	BP
and	O
CYP1A1	BG
gene-7	IG
polymorphism	O
indicate	O
that	O
carriers	O
of	O
genotypes	O
associated	O
with	O
CYP1A1-16	BG
inducibility	O
are	O
at	O
higher	O
risk	O
for	O
cancer-23	BP
,	O
but	O
that	O
,	O
at	O
least	O
for	O
Caucasians	O
,	O
the	O
recognized	O
mutations	O
probably	O
identify	O
only	O
a	O
fraction	O
of	O
the	O
inducible	O
individuals	O
.	O

PS2786	O
In	O
the	O
case	O
of	O
CYP2E1-5	BG
,	O
some	O
studies	O
indicate	O
a	O
relationship	O
between	O
lung	O
cancer-14	BP
and	O
the	O
occurrence	O
of	O
a	O
rare	O
allele	O
,	O
although	O
future	O
research	O
is	O
needed	O
in	O
order	O
to	O
establish	O
a	O
significant	O
relationship	O
.	O

